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1 Abstract
The global burden of human renal diseases continually increased in the last decades. To lower
associated mortality and morbidity rates, early diagnosis as well as improved understanding
of underlying biological mechanisms are essential. Here, metabolic investigations of biofluids
by means of nuclear magnetic resonance (NMR) spectroscopy in the context of nephrology are
presented to facilitate earlier detection and to enable new insights into renal disease manifes-
tation.
The detection of novel low-molecular-weight factors for improved early diagnosis and patient
treatment in the context of acute kidney injury (AKI) was successfully conducted in a prospec-
tive study of 85 adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB)
use. One-dimensional (1D) 1H NMR spectral data sets of filtered ethylenediaminetetraacetic
acid (EDTA) plasma specimens collected 24 h after surgery were subjected to Random Forests
based classification with t-test based feature filtering to prognosticate AKI. An average overall
prognostication accuracy of 80 ± 0.9% with a corresponding area under the receiver-operating
characteristic curve of 0.87 ± 0.01 could be obtained with, on average, 24 ± 2.8 spectral fea-
tures. The set of discriminative ions and molecules included Mg2+, lactate and the glucuronide
conjugate of propofol, an anesthetic agent which had been administered to all patients during
surgery. In AKI patients, increased levels of propofol-glucuronide seem to be a surrogate marker
for reduced glomerular filtration, whereas an elevation of Mg2+ levels might be explained by
its use for the treatment of cardiac arrythmias, and ischemic injury as well as systemic hy-
poperfusion present in this group might be linked to elevated lactate levels. Furthermore, this
thesis presents a novel endogenous biomarker panel consisting of absolutely quantified EDTA
plasma concentrations of Mg2+, creatinine, and lactate, which would offer a reliable and swift
diagnostic tool for the early detection of AKI after cardiac surgery with CPB use only requiring
easily implementable point-of-care technologies. This biomarker panel was further employed
to derive a novel Acute Kidney Injury Network (AKIN) index score, which illustrated that the
metabolic profile of patients diagnosed with mildest renal injury was very similar to that of
patients not developing AKI.
This study was further utilized to elucidate the importance of appropriate data normalization
prior to statistical analysis, which proofed to be crucial for correct data interpretation.
The second part of this thesis presents first statistical data analysis results of 1D 1H NMR
spectra of EDTA plasma or urine specimens, respectively, from two large-scale clinical trials
on chronic kidney disease (CKD). The German Chronic Kidney Disease (GCKD) study in-
cludes the currently world-wide largest cohort of patients suffering from CKD, which will be
prospectively followed in the next ten years, and the Trial to Reduce Cardiovascular Events
with Aranesp® Therapy (TREAT) study comprises a large, homogeneous cohort of patients
suffering from CKD, type-2 diabetes mellitus, and concomitant anemia. Distinct differences
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in metabolic fingerprints between various leading renal diseases, such as diabetic nephropathy
and glomerulonephritis, in the GCKD study, or associated with adverse patient outcome in the
TREAT study could be detected by t-tests in concordance with standard clinical pathologies of
CKD. Additionally, the prediction of future kidney performance, which is crucial for improved
patient care, with regression models based on either NMR derived EDTA plasma metabolic
fingerprints or clinical parameters both assessed two years before was conducted within the
GCKD study. Here, multiple regression models based on NMR fingerprints did not outper-
form simple regression models based on respective baseline clinical parameters. This probably
reflects the fact that the renal function of most investigated CKD patients was fairly stable
within these two years.
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2 Zusammenfassung
Innerhalb der letzten Jahrzehnte nahm die globale Belastung aufgrund von Nierenerkrankun-
gen im Menschen kontinuierlich zu. Um damit verbundene Sterblichkeits- und Morbiditätsraten
zu verringern, sind frühe Diagnose sowie verbesserte Einsichten in zugrundeliegende biologis-
che Mechanismen entscheidend. Diese Doktorarbeit präsentiert metabolische Untersuchungen
von Körperflüssigkeiten mittels der Kernspinresonanzspektroskopie innerhalb der Nephrologie,
um frühere Detektion sowie neue Erkenntnisse bezüglich klinischer Manifestation der Nieren-
erkrankung zu ermöglichen.
Der Nachweis neuer Komponenten mit niedrigem Molekulargewicht zur verbesserten Früherken-
nung und Patientenbehandlung im Kontext akuten Nierenversagens (AKI) wurde erfolgreich in
einer prospektiven Studie mit 85 erwachsenen Patienten, die sich einer Herzoperationen mit Ver-
wendung der Herz-Lungen-Maschine unterzogen hatten, durchgeführt. Eindimensionale (1D)
1H Kernspinresonanzspektren gefilterter Ethylendiamintetraacetat (EDTA) Plasmaproben, die
24 Stunden nach der Operation abgenommen worden waren, wurden mittels Random Forests
inklusive t-Test basierender Featureauswahl klassifiziert, um AKI zu prognostizieren. Bezogen
auf die Gesamtkohorte, konnten mit Hilfe von, im Durchschnitt, 24 ± 2.8 spektraler Features,
im Mittel 80 ± 0.9 % der Patienten richtig klassifiziert werden, was einer Fläche unter der
Beobachterkennlinie von 0.87 ± 0.01 entspricht. Mg2+, Laktat, und das Glucuronid-Konjugat
des Propofols, das allen Patienten während der Operation als Anästhetikum verabreicht worden
war, befanden sich unter den diskriminierenden Ionen und Molekülen. In AKI Patienten scheint
ein erhöhter Propofol-Glukuronid-Spiegel ein surrogater Marker für reduzierte glomeruläre Fil-
tration zu sein, wobei ein erhöhter Mg2+ Spiegel durch die Administration von Magnesium
zur Behandlung von Herzrythmusstörungen erklärt werden könnte, und Ischämie sowie sys-
temische Hypoperfusion in dieser Patientengruppe mit erhöhten Laktatspiegeln in Verbindung
gebracht werden könnten. Außerdem präsentiert diese Doktorarbeit ein neues Set an endoge-
nen Biomarkern bestehend aus absoluten EDTA Plasmakonzentrationen von Mg2+, Kreatinin
und Laktat, welches ein zuverlässiges und schnelles Diagnosewerkzeug zur AKI Früherkennung
nach Herzoperationen mit Herz-Lungen-Maschine darstellen könnte. Des weiteren wurde dieses
Biomarker-Set zur Ableitung eines neuen Acute Kidney Injury Network (AKIN) Scores benutzt,
der die Tatsache illustrierte, dass Patienten mit geringster Nierenschädigung ein metabolisches
Profil aufweisen, das sich nur gering vom metabolischen Profil von Patienten ohne AKI unter-
scheidet.
Zusätzlich wurde diese Studie dazu genutzt um die Bedeutung angemessener Datennormal-
isierung im Vorfeld von statistischen Analysen zu illustrieren, was sich als ausschlaggebend zur
korrekten Dateninterpretation erwies.
Der zweite Teil dieser Doktorarbeit präsentiert erste statistische Datenauswertungen von 1D
1H Kernspinresonanzspektren von EDTA Plasma- beziehungsweise Urinproben zweier großan-
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gelegter klinischer Studien über chronisches Nierenversagen (CKD). Die German Chronic Kid-
ney Disease (GCKD) Studie umfasst die derzeit weltweit größte Kohorte an Patienten mit
CKD, die prospektiv über die nächsten zehn Jahre verfolgt wird, und die Trial to Reduce
Cardiovascular Events with Aranesp® Therapy (TREAT) Studie schließt eine große, homo-
gene Kohorte an Patienten mit CKD, Typ-2 Diabetes Mellitus, und begleitender Anämie ein.
Ausgeprägte Unterschiede in metabolischen "Fingerprints" konnten mittels t-Tests zwischen
verschiedenen führenden Nierenerkrankungen, z.B. diabetische Nephropathie und Glomeru-
lonephritis, in der GCKD Studie, oder in Verbindung mit widrigem Krankheitsausgang in der
TREAT Studie nachgewiesen werden. Diese unterschiedlichen metabolischen "Fingerprints"
stimmen mit klinischen Standard-Pathogenesen chronischen Nierenversagens überein. Außer-
dem wurde im Rahmen der GCKD Studie die Vorhersage zukünftigen Nierenversagens, was
ausschlaggebend für eine verbesserte Patientenversorgung ist, mit Regressionsmodellen en-
tweder basierend auf metabolischen "Fingerprints" der Kernspinresonanzspektren der EDTA
Plasmaproben oder basierend auf klinischen Parametern durchgeführt, wobei sowohl EDTA
Plasmaproben als auch klinische Parameter zwei Jahre zuvor erhoben worden waren. Hier-
bei erzielten multiple Regressionsmodelle basierend auf Kernspinresonanz-"Fingerprints" keine
besseren Ergebnisse im Vergleich zu einfachen Regressionsmodellen basierend auf entsprechen-
den klinischen Baseline-Parametern. Möglicherweise reflektiert dies die Tatsache, dass die
Nierenfunktion der meisten untersuchten CKD Patienten innerhalb dieser zwei Jahre eher stabil
war.
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3.1 Motivation: The global burden of kidney disease
The kidney is one of the vital organs in the human body due to its regulatory functions [Dörner
2013]. Maintenance of the homeostatic condition of the body is one of its main tasks [Treuting
and Kowalewska 2012,Arastéh et al. 2009].
Consequently, the study and cure of kidney diseases, the primary aspect of nephrology, are of
great importance for decreasing mortality and morbidity rates across the globe [O’Toole and
Sedor 2014,Eckardt et al. 2013]. In the process, a large range of different illnesses is covered,
mostly revealing an either acute (≤3 months) or chronic (>3 months) deterioration of the kid-
ney’s performance [Eckardt et al. 2013,Kuhlmann et al. 2003].
Acute kidney injury (AKI), which is characterized by an abrupt (within one week) reduc-
tion in renal function [Eckardt et al. 2013,Mehta et al. 2007], is a subgroup of acute kidney
diseases [Eckardt et al. 2013]. It comprises the whole spectrum of acute renal failure (ARF),
caused by various factors including nephrotoxic drugs and complicated surgeries [Mehta et al.
2007]. The incidence of AKI constantly increased in the last decade due to, for example, aug-
mented risk factors as well as improved diagnosis and documentation of the disease [Siew and
Davenport 2015,Lameire et al. 2013].
AKI is a significant complication after cardiac surgery, leading to an increased risk of mor-
tality and morbidity [Chawla et al. 2014, Eckardt et al. 2013,Mariscalco et al. 2011,Rosner
and Okusa 2006]. Its occurrence in patients undergoing cardiac surgery approaches 30% with
about 1 - 6% requiring dialysis [Mariscalco et al. 2011, Rosner and Okusa 2006]. For AKI
patients requiring dialysis, the mortality rate amounts to 54% [Mariscalco et al. 2011]. More-
over, already a small decrease of renal function indicated by a reduction of the postoperative
glomerular filtration rate (GFR) of equal or more than 30% is associated with a 5.9% mortality
rate [Mariscalco et al. 2011]. A GFR decline of less than 30% is still associated with a mortality
rate of 0.4% [Mariscalco et al. 2011]. Furthermore, a link between AKI and increased risk of
long-term mortality has been reported [Hobson et al. 2009,Engoren et al. 2014]. Hence, AKI
after cardiac surgery leads to increases in cost of care and length of stay in the intensive care
unit (ICU) [Mariscalco et al. 2011]. The demand for early diagnosis of AKI is consequently
eminent for improved patient care [Wyckoff and Augoustides 2012,Shaw 2012,Mariscalco et al.
2011].
The most common classification and staging scheme, the KDIGO (Kidney Disease: Improv-
ing Global Outcomes) criteria, make use of increases in serum creatinine (SCr) levels and
decreases in GFR and urine output (UO) for diagnosis of AKI [KDIGO workgroup 2012]. Nev-
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ertheless, SCr is not the ideal biomarker for AKI due to its relatively late alteration following
surgery [Shaw 2012] and its modulation by nonrenal factors [Macedo and Mehta 2013,Wyckoff
and Augoustides 2012,Star 1998]. Consequently, the search for alternative biomarkers is an im-
portant field in nephrology [Mariscalco et al. 2011,Parikh et al. 2011,Endre et al. 2011,Haase
et al. 2010a),Haase et al. 2010b),Haase et al. 2009].
To date, none of the novel biomarkers reported for the diagnosis of AKI after cardiac surgery, e.g.
neutrophil-gelatinase-associated lipocalin (NGAL) and serum cystatin C (CysC), has proven
to be sufficiently predictive in heterogeneous patient cohorts with comorbidities [Endre et al.
2011,Lameire et al. 2011]. Moreover, in a clinically relevant setting, these biomarkers do not
seem to clearly add any new information to the traditional approach [Lameire et al. 2011], still
leaving the desire for improved diagnosis unsatisfied.
AKI is tightly connected to chronic kidney disease (CKD), with CKD being the most im-
portant risk factor for common AKI [Chawla et al. 2014,Lameire et al. 2013]. Moreover, even
mild cases of AKI are associated with new-onset as well as progression to advanced stages of
CKD [Chawla et al. 2014,Jha et al. 2013,Eckardt et al. 2013,Lameire et al. 2013].
CKD imposes an even larger burden on the world’s health system [Jha et al. 2013], with global
occurrence exceeding 10% [O’Toole and Sedor 2014,Eckardt et al. 2013] and 50% in high-risk
subpopulations [Eckardt et al. 2013]. Its incidence is strongly linked to increasing age, with
more than 20% of the population older than 60 years and more than 35% older than 70 years at
the time of diagnosis of CKD [Eckardt et al. 2013]. In general, CKD is associated with a reduced
GFR and increased albuminuria, irrespective of the cause of diminished renal function [Eckardt
et al. 2013]. Along its progression, CKD leads to a large number of adverse clinical symptoms,
finally ending in complete renal failure, called end-stage renal disease (ESRD) [Kuhlmann et
al. 2003]. It is linked to elevated all-cause and cardiovascular mortality, AKI, cognitive decline,
anemia (hemoglobin (Hb) deficiency), mineral and bone disorders, and fractures [Jha et al.
2013,KDIGO workgroup 2013,Eckardt et al. 2012,Kuhlmann et al. 2003]. Actually, CKD was
ranked 18th in the list of causes of total number of worldwide deaths in 2010 [Jha et al. 2013].
It is also a comorbidity of numerous chronical illnesses, e.g. cardiovascular disease, hyperten-
sion, obesity, and diabetes [Chawla et al. 2014,O’Toole and Sedor 2014,Eckardt et al. 2013],
further worsening patient’s prognosis [Eckardt et al. 2013]. In fact, type-2 diabetes mellitus
is the leading cause of ESRD in developed countries [Jha et al. 2013,Kuhlmann et al. 2003].
Moreover, the presence of anemia in patients with type-2 diabetes mellitus and CKD further
increases the rates of cardiovascular and renal events [Pfeffer et al. 2009a)].
With regard to the demanding adverse outcomes of CKD, the need for early detection is of prime
interest [Eckardt et al. 2013,Jha et al. 2013]. In general, the underlying mechanisms as well as
the pathophysiological and clinical consequences of CKD are still poorly understood [Eckardt
et al. 2012]. Moreover, due to the overall heterogenity of CKD ethiology and pathomechanism,
an urging demand for clinical studies in specific subpopulations is given [O’Toole and Sedor
2014,Eckardt et al. 2013].
The German Chronic Kidney Disease (GCKD) study was designed as a national prospective ob-
servational cohort study, involving study centers throughout Germany [Eckardt et al. 2012]. It
comprises about 5000 CKD patients with a moderately reduced GFR and/or overt proteinuria
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at enrollment, receiving comparable medical care [Eckardt et al. 2012]. The major goals are
the characterization of burden and course of CKD patients, the identification and validation of
novel risk factors and biomarkers for CKD manifestation, progression and complications as well
as the achievement of an advanced understanding of the underlying pathophysiology [Eckardt
et al. 2012]. Study participants are seen annually for up to ten years [Eckardt et al. 2012] and
biomaterial, including urine, serum, and plasma specimens, is collected for every other year.
The large size of the GCKD study cohort, which is well-characterized, and the long observation
period facilitate the investigation of various hypotheses in a statistically meaningful manner.
In contrast to the GCKD study, the Trial to Reduce Cardiovascular Events with Aranesp®
Therapy (TREAT) study was a randomized, multicenter, double-blind placebo-controlled, clin-
ical trial [Pfeffer et al. 2009a), Pfeffer et al. 2009b)]. It comprised about 4000 patients with
CKD, type-2 diabetes mellitus and anemia, which develops in most CKD patients as the dis-
eased kidneys produce increasingly less erythropoietin (EPO) [Rao and Pereira 2003], and was
designed to test whether the administration of darbepoetin alfa, an erythropoiesis-stimulating
agent (ESA), would reduce the rates of death, cardiovascular events and ESRD [Pfeffer et al.
2009a), Pfeffer et al. 2009b)]. The large size and homogeneity of this cohort offer excellent
opportunities to detect novel biomarkers associated with adverse outcomes as well as to gain
novel insights into course of renal disease progression and complications in this specific patient
group.
3.2 Objective: Metabolomics in the context of nephrology
Systems biology studies the behavior and development of a specific biological system under
the influence of a particular perturbation [Ideker et al. 2001]. High-throughput and high-
dimensional data sets are evaluated employing computational bioinformatic methods [Ideker
et al. 2001]. Associated disciplines, the so-called ‘omics’-sciences, comprise, among others,
genomics, transcriptomics, proteomics, and metabolomics [Joyce and Palsson 2006].
The principal aim of metabolomics is the study of all small organic compounds, denoted as
metabolites, present in a biological specimen [Tzoulaki et al. 2014,Kosmides et al. 2013,Nichol-
son and Lindon 2008,Nicholson 2006]. Their flow through bioenergetic and biosynthetic path-
ways is investigated in a quantitative manner [Tzoulaki et al. 2014]. Hence, the metabolome
comprises the whole range of metabolites present or produced by a biological system, e.g. an
organism at a defined time-point under a given set of conditions [Tzoulaki et al. 2014,Kosmides
et al. 2013].
The application of metabolomics in the context of nephrology seems to be highly suitable.
The kidneys’ major functions comprise the excretion and also tubular secretion of metabolic
waste products from the blood into the urine as well as reabsorption of essential nutritive
substances [Treuting and Kowalewska 2012,Arastéh et al. 2009]. Consequently, metabolic in-
vestigations of urine, serum, and plasma specimens are predestined to facilitate new insights into
pathomechanism and detection of novel biomarkers of renal diseases [Zhang et al. 2014,Weiss
et al. 2011]. Moreover, changes in the metabolome due to an alteration of the renal function
should be more significant and more detectable than elaborate changes in the renal proteome
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or transcriptome [Wishart 2008].
Major analytical methods used in the field of metabolomics are nuclear magnetic resonance
(NMR) spectroscopy and mass spectrometry (MS) [Tzoulaki et al. 2014]. Thereby, both meth-
ods facilitate the simultaneous detection as well as absolute quantification of a large range of
metabolites in a specimen [Nicholson and Lindon 2008]. Hence, in comparison to the traditional,
targeted approach, usually conducted in clinical studies, an untargeted approach is facilitated by
measuring a so-called ‘metabolic fingerprint’ of the investigated specimen [Tzoulaki et al. 2014].
However, the complexity of the metabolism itself and the investigated ‘metabolic fingerprint’
of the sample require sophisticated bioinformatic strategies for data interpretation [Nicholson
and Lindon 2008].
NMR spectroscopy, in comparison to MS spectrometry, is non-destructive, highly repeatable
and requires minimum sample preparation [Tzoulaki et al. 2014,Nicholson and Lindon 2008],
hence being especially well suited for the analysis of large biomaterial collections comprising
several hundred to thousands of specimens. On the downside, it offers lower sensitivity as well
as lower spectral resolution in comparison to MS [Tzoulaki et al. 2014,Weiss et al. 2011,Nichol-
son and Lindon 2008].
Biomedical studies in the field of metabolomics usually investigate biofluids, e.g. urine and
blood, which are easily obtained [Tzoulaki et al. 2014]. Their clinical objectives are diverse,
including detection of novel diagnostic biomarkers and determination of distinct metabolic pro-
files for specific clinical conditions (‘metabolic fingerprinting’) [Kosmides et al. 2013,Dettmer
and Hammock 2004]. Consequently, they can facilitate improved or individualized patient
treatment, the goal of personalized medicine [Weiss et al. 2011]. Several metabolic studies
already proved the capability of NMR spectroscopy for detection of novel disease biomarkers in
such diverse areas as, e.g. autosomal dominant polycystic kidney disease (ADPKD) [Gronwald
et al. 2011], diary cow metabolism [Klein et al. 2012,Bertram et al. 2011,Klein et al. 2010],
as well as various metabolic and renal diseases [Elliott et al. 2015,Dawiskiba et al. 2014,Deja
et al. 2013,Neild et al. 1997,Holmes et al. 1997].
With regard to the diverse research questions, still pending in the field of nephrology, as de-
picted in section 3.1, I have formulated three specific aims concerning metabolic investigations
of renal diseases by means of NMR spectroscopy for this thesis. This analytical method was
selected due to its especially high suitability for the comprehensive analysis of large specimen
collections as it is required here.
My first aim is the detection of metabolic biomarkers in the context of various renal diseases
as alternatives to traditional clinical approaches. My second aim comprises the prediction
of future kidney performance based on baseline metabolic fingerprints derived by NMR spec-
troscopy. General method developments and additions for NMR based metabolomics with
regard to appropriate data normalization, absolute low-molecular-weight compound quantifi-
cation, and NMR measurements of unfiltered plasma specimens are the third aim of my Ph.D.
thesis.
The first aim of this Ph.D. thesis is the detection of metabolic biomarkers for both acute
and chronic kidney diseases as alternatives to traditional clinical approaches.
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In the setting of AKI diagnosis after cardiac surgery, the search and evaluation of earlier or
alternative biomarkers is pursued by NMR spectroscopic fingerprinting of urine and plasma
specimens collected from a heterogeneous group of AKI and non-AKI patients. Here, the de-
tection of AKI after cardiac surgery by means of urinary biomarkers collected before, at 4 and
24 h after surgery as well as by means of plasma biomarkers collected 24 h after surgery is
pursued. Furthermore, the performance of different plasma biomarker sets is evaluated and
compared to each other as well as to traditional diagnostic tools. These novel metabolic mark-
ers could offer the chance of an earlier AKI detection after cardiac surgery than by monitoring
changes in SCr levels or UO.
Furthermore, several thousand different plasma specimens collected at the baseline time-point
of the GCKD study are measured by means of NMR spectroscopy and specific metabolic fin-
gerprints for the discrimination of different leading renal diseases are searched and evaluated.
These investigations can provide new insights into the metabolic characteristics of specific renal
diseases such as vascular or glomerulonephritis.
For the generation of new insights into CKD progression and corresponding Hb responsiveness,
novel biomarkers for several different clinical outcomes are scanned and appraised. About 1100
different urine specimens collected from TREAT study participants are measured by NMR
spectroscopy and the following hypotheses are tested: (1) no difference exists between patients
dying from any cause, and patients not dying, under the restriction that all patients within
both subcohorts do not progress to ESRD, (2) no difference exists between patients progressing
and not progressing to ESRD under the restriction that all patients within both subcohorts do
not die and (3) no difference exists between patients with various stages of Hb responsiveness
at two different time-points, respectively, whereas four different subcohorts treated with darbe-
poetin alfa with various stages of Hb responsiveness and one subcohort treated with a placebo
compound are investigated.
The second aim, the prediction of future kidney performance based on baseline metabolic
fingerprints derived by NMR spectroscopy was conducted in order to give further insights into
kidney disease development and progression.
The correlation of NMR metabolic fingerprints derived from the baseline plasma specimen co-
hort of the GCKD study with the estimated GFR and specific renal performance markers, such
as SCr and serum CysC, as well as their associated predictive performance are investigated.
Here, multiple regression analyses between baseline NMR metabolic fingerprints and these clin-
ical parameters, determined at the baseline as well as at the second follow-up time-point two
years after inclusion into the study, were performed. Moreover, simple linear regression with
baseline clinical parameters, i.e. SCr, serum CysC, as well as eGFR, with respect to second
follow-up clinical parameters, i.e. SCr, serum CysC, as well as eGFR, respectively, were con-
ducted. The prediction of present and future kidney performance based on these measures will
be of great importance for timely interventions and improved patient care in this patient cohort.
My third aim covers method developments and improvements for NMR based metabo- lomics.
Proper NMR data normalization is crucial for correct interpretation of metabolomic investiga-
tions. However, common normalization techniques, such as Quantile or Variance Stabilization
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normalization, can lead to erroneous results if different investigated cohorts do not exhibit ap-
proximately equal shares of up- and down-regulated features. This thesis reports a prominent
case of inappropriate NMR data normalization and provides, as well as evaluates alternative
normalization methods.
The absolute quantification of the metal ions calcium and magnesium in plasma specimens by
NMR spectroscopy is an addition to NMR based metabolomic methods. Here, their absolute
quantification via ethylenediaminetetraacetic acid (EDTA) complexes is implemented and val-
idated for the AKI plasma data set.
Moreover, the acquisition of 1D 1H NMR spectra of unfiltered EDTA plasma specimens implies
several challenges with regard to the traditional NMR reference substance 3-trimethylsilyl-
2,2,3,3-tetradeuteropropionate (TSP). These challenges are reported and easily implementable
solutions are presented in the context of the GCKD study.
This Ph.D. thesis has in parts already been published in [Zacharias 2012, Zacharias et al.
2013a), Zacharias et al. 2013b), Zacharias et al. 2015, Hochrein et al. 2015] and was funded
by the Bavarian Genome Network (BayGene), the German Federal Ministry of Education and
Research (BMBF Grant no. 01 ER 0821), the German Research Foundation (KFO 262), and
the intramural funding program of the Regensburg School of Medicine.
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4.1 Introduction to nephrology
4.1.1 Renal structure and physiology
The human kidneys are the most important organs for maintaining the homeostatic balance
in the body [Eckardt et al. 2013,Dörner 2013]. They are bean-shaped organs, located in the
retroperitoneum [Arastéh et al. 2009].
The kidney’s principal anatomy is depicted in Figure 4.1a). It is surrounded by a thin fibrous
capsule and the renal parenchyma can be subdivided into the cortex and the medulla [Treuting
and Kowalewska 2012,Arastéh et al. 2009]. The medulla itself consists of so-called pyramids,
which form a broad base towards the cortex and a cone end, denoted as papilla, extending
into the sinus [Treuting and Kowalewska 2012,Arastéh et al. 2009]. The spaces between the
pyramids are filled by cortex tissue and are termed renal columns (of Bertin) [Treuting and
Kowalewska 2012,Arastéh et al. 2009]. Each of the papillae ends in a minor calyx, whereas
two to three of the minor calyces unite to form one major calyx [Treuting and Kowalewska
2012,Arastéh et al. 2009]. The major calices themselves are discharged into the renal pelvis,
located at the renal sinus [Treuting and Kowalewska 2012,Arastéh et al. 2009]. The formed
urine is conducted from the renal pelvis via the ureter to the bladder [Treuting and Kowalewska
2012,Arastéh et al. 2009]. The kidney’s blood supply is managed by the renal artery, the fil-
tered blood is removed by the renal vein [Treuting and Kowalewska 2012,Arastéh et al. 2009].
The structure of the basic functional unit of the kidney, the nephron [Eckardt et al. 2013,Tre-
uting and Kowalewska 2012, Arastéh et al. 2009], is given in Figure 4.1b). A single kidney
comprises about one million nephrons. Every nephron can be further subdivided into a fil-
trating body, the glomerulus, and different tubule segments [Eckardt et al. 2013,Treuting and
Kowalewska 2012,Arastéh et al. 2009], compare to Fig. 4.1b). The glomeruli are only located
in the renal cortex, whereas the tubuli can additionally be found in the medulla [Treuting and
Kowalewska 2012,Arastéh et al. 2009]. In the glomerulus, which is imbedded into the Bowman’s
capsule, incoming blood transported by the afferent arteriole, a branch from the arcuate artery,
is ultrafiltrated to form the so-called primary urine or ultrafiltrate [Eckardt et al. 2013,Arastéh
et al. 2009]. About 180-200 l of ultrafiltrate are generated daily, usually containing sodium,
potassium, chloride, phosphate, water, glucose, amino acids, urea and proteins with a mass
below 60-70 kDa [Eckardt et al. 2013,Arastéh et al. 2009]. The ultrafiltrate is released from
the Bowman’s capsule into the proximal tubule, whereas the filtered blood is discharged by the
efferent arteriole [Eckardt et al. 2013,Arastéh et al. 2009]. During the ultrafiltrate’s propaga-
tion along the proximal tubule, about 80% of the fluid is being reabsorbed into the peritubular
capillaries, including about two-thirds of filtered water and salt, 100% of filtered glucose and
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amino acids, as well as proteins [Eckardt et al. 2013,Arastéh et al. 2009]. At the end of the
proximal tubule, organic molecules and drug metabolites are secreted into the filtrate [Eckardt
et al. 2013]. The loop of Henle, subdivided into the descending and ascending limb, is respon-
sible for concentrating the filtrate [Eckardt et al. 2013]. The associated mechanisms, namely
reabsorption of water and removal of sodium from the filtrate, take place in the descending
and ascending limb, respectively [Eckardt et al. 2013,Arastéh et al. 2009]. The tubular NaCl
concentration is monitored at the junction between the ascending limb of the loop of Henle
and the distal nephron, the macula densa [Eckardt et al. 2013,Arastéh et al. 2009]. Thereby,
the glomerular blood flow is tightly autoregulated by the so called tubuloglomerular feedback
mechanism [Eckardt et al. 2013,Arastéh et al. 2009]. The distal nephron, comprising the distal
tubule and the collecting duct at the renal papilla, reabsorbs approximately 5% of the total
amount of filtered sodium and responds to the hormons aldosterone and vasopressin, hence
controlling the composition and concentration of the final urine [Eckardt et al. 2013,Treuting
and Kowalewska 2012,Arastéh et al. 2009].
The main functions of the human kidney can be summarized as follows. The secretion of
metabolic waste products from the blood into the urine with the possibility of an effective
reabsorption mechanism enables the elimination of potentially toxic products without loosing
vital nutrients [Treuting and Kowalewska 2012,Arastéh et al. 2009]. Its central role in home-
ostasis is furthermore reflected by the regulation of the acid-base and osmolality balance as
well as the blood pressure [Treuting and Kowalewska 2012,Arastéh et al. 2009]. Finally, the
human kidney produces important hormones like renin, calcitriol, the activated form of vita-
min D, and EPO, which stimulates the production of red blood cells [Treuting and Kowalewska
2012,Arastéh et al. 2009].
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Figure 4.1: a) Principal anatomy of the human right kidney. b) Structure of a
nephron, the basic functional unit of the kidney. a) The human kidney
is surrounded by a fibrous capsule and can be further divided into the cortex and
the medulla, comprising the pyramids. Their tips, the papillae, point towards the
minor calices. The minor calices join in order to form the major calices, which end
into the renal pelvis at the renal sinus. The renal pelvis is connected to the ureter.
The cortex fills up the space between the pyramids, which is called the renal column
(of Bertin) [Treuting and Kowalewska 2012,Arastéh et al. 2009]. Reprinted with
permission from [Treuting and Kowalewska 2012]. b) Blood plasma, supplied by
the afferent arteriole, a branch of the arcuate artery, is filtered by the glomerulus in
the Bowman’s capsule. The ultrafiltrate is modified along its propagation through
the proximal tubule, the loop of Henle and the distal tubule until it is secreted into
the collecting duct, where a final adjustment of the urine takes place [Eckardt et al.
2013,Arastéh et al. 2009]. Reprinted with permission from [Eckardt et al. 2013].
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4.1.2 Clinical diagnostic tools for assessment of renal performance
With the human kidney executing essential tasks for maintaining body’s homeostasis, compare
to section 4.1.1, a deterioration of its performance can have hazardous consequences, as depicted
in section 3.1. Therefore, monitoring renal function is vital for detection and supervision of all
renal complications. As the filtration of blood and the formation of urine is strongly regulated
by the kidney (compare to section 4.1.1), the study of their composition is predestined to offer
comprehensive insights into renal performance.
In clinical practice, the most commonly used diagnostic methods for the detection of kidney
malfunctions are based on alterations of the following parameters.
The glomerular filtration rate (GFR) is considered to be the best indicative reference for renal
performance [KDIGO workgroup 2013,Stevens and Levey 2009,Stevens et al. 2006]. However,
its exact determination by measuring the urinary or plasma clearance of exogenous filtration
markers, e.g. inulin or EDTA, is considered to be too cumbersome and expensive for routine ap-
plication [KDIGO workgroup 2013,Macedo and Mehta 2013, Stevens and Levey 2009, Stevens
et al. 2006]. Therefore, the GFR is usually estimated from levels of endogenous filtration
markers such as SCr, and consequently denoted as estimated GFR (eGFR) [KDIGO work-
group 2013, Cravedi and Remuzzi 2013, Jha et al. 2013, Stevens and Levey 2009]. An ideal
filtration marker would be a substance that is freely filtered at the glomeruli, neither reab-
sorbed, secreted, synthesized, or metabolized by the tubuli, and that does not change renal
function [Stevens and Levey 2009]. Various equations can be employed for the determination
of eGFR, e.g. the Modification of Diet in Renal Disease (MDRD) Study or the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation [KDIGO workgroup 2013, Cravedi
and Remuzzi 2013, Jha et al. 2013, Stevens and Levey 2009]. However, these equations still
perform poorly in comparison to direct measurement of the GFR in various critically ill patient
cohorts [Bragadottir et al. 2013,Cravedi and Remuzzi 2013].
In general, SCr is well suited as an endogenous filtration marker, as it is almost completely
removed from the blood by glomerular filtration and proximal tubular secretion, compare to sec-
tion 4.1.1, and only marginally reabsorbed, e.g. in healthy newborns or elderly people [Dörner
2013,Arastéh et al. 2009,Musso et al. 2009]. SCr levels, however, are significantly influenced
by age, sex, race, muscle mass, chronic illnesses, diet, and medications of the monitored pa-
tient [Stevens and Levey 2009,Curhan 2005]. Consequently, in order to ascertain, for example,
an acute impairment of the renal function, only the alteration of the SCr level in comparison
to the individual baseline level is meaningful [Stevens et al. 2006]. In healthy subjects, SCr
values range between 74-110 µmol/l (0.84-1.25mg/dl) in white men and 58-96 µmol/l (0.66-
1.09mg/dl) in white women [Dörner 2013]. The eGFR determined by estimating equations
additionally takes age, sex, and certain races into account [KDIGO workgroup 2013, Stevens
and Levey 2009, Arastéh et al. 2009, Stevens et al. 2006] and is typically adjusted for body
surface area [Stevens and Levey 2009,Stevens et al. 2006], with eGFR values in young healthy
whites of about 130 ml/min per 1.73m2 for men and 120 ml/min per 1.73m2 for women [Stevens
and Levey 2009,Stevens et al. 2006].
However, the detection of renal impairment based on alterations of SCr levels and/or eGFRSCr
can be erroneous because of several major drawbacks. First, a rise in SCr levels due to impaired
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glomerular filtration does not take place until about 50% of the kidney function is already lost,
hampering early detection of impaired glomerular filtration [Dörner 2013,Macedo and Mehta
2013]. Second, under non-steady state conditions, as often presented in critically ill patients,
alterations in SCr levels and therefore in the eGFRSCr might reflect the magnitude and direc-
tion of the change in GFR, but do not accurately reflect its exact level [Macedo and Mehta
2013, Stevens and Levey 2009]. Additionally, in patients with a chronic impairment of the re-
nal function, the kidney might adapt to the loss of nephrons and no change in the SCr levels
or eGFRSCr is detectable, hence obscuring disease progression [Macedo and Mehta 2013]. In
healthy subjects, about 10-20% of overall excreted creatinine is secreted by the proximal tubuli,
but in patients with impaired glomerular filtration, up to 50% can be eliminated by proximal
tubular secretion [Macedo and Mehta 2013,Curhan 2005]. This can lead to an overestimation
of the eGFR based on SCr levels, which needs to be overcome by drug administration [Macedo
and Mehta 2013]. Moreover, clinical measurements of SCr levels are not absolutely precise and
therefore require a change in creatinine of at least 10% to exhibit significant results [Macedo
and Mehta 2013]. The accurate determination of SCr levels in critically ill patients is further
hampered by positive fluid balance, which leads to diluted SCr concentrations [Macedo and
Mehta 2013].
An alternative to determination of eGFR by assessing SCr clearance is the measurement of
serum cystatin C (SCysC) levels [Macedo and Mehta 2013, Stevens et al. 2006,Curhan 2005].
CysC is supposed to be constantly produced by all nucleated cells, it is filtered in the glomeruli,
and taken up as well as degraded by the proximal tubular cells [Curhan 2005]. CysC is less
affected by age, sex, muscle mass, and race of the monitored patient in comparison to SCr
and faster mirrors changes in GFR [Macedo and Mehta 2013]. However, it is still significantly
influenced by non-renal factors like smoking status, glucocorticoids use, and C-reactive pro-
tein (CRP) [Macedo and Mehta 2013, Stevens et al. 2006], it can be altered in specific health
states such as diabetes, cancer, obesity, liver disease, and thyroid status [Macedo and Mehta
2013,Curhan 2005], and its concentration can also be affected by positive fluid balance [Macedo
and Mehta 2013]. Nevertheless, CysC is also considered to be a biomarker for inflammation and
a predictor of cardiovascular events and death independent of kidney function [Curhan 2005].
In healthy adults, SCysC values range between 0.54-0.94 mg/l in men and 0.48-0.82 mg/l in
women [Dörner 2013].
A deterioration of the renal function is, in general, often accompanied with diminished urinary
output (UO) [Dörner 2013]. Therefore, monitoring the state of UO can illustrate the renal per-
formance in a sensitive and non-invasive way [Dörner 2013,KDIGO workgroup 2012,Macedo et
al. 2011]. Daily UO for healthy adults ranges between 800-1800 ml for men and 600-1600 ml for
women [Dörner 2013]. Oliguria and anuria in adults are defined as a daily UO below 400-500 ml
or 100 ml, respectively [Dörner 2013,Arastéh et al. 2009]. However, the determination of UO
over a fixed period of time, mostly ranging between 6-24 hrs, can be challenging and prone to
errors [Dörner 2013,Macedo et al. 2011]. Moreover, the urine flow can be affected by non-renal
factors, e.g. fluid intake and drug administration [Macedo et al. 2011], and oliguria or anuria
can also be induced by urinary tract obstruction and total arterial or venous occlusion, dimin-
ishing their specificity for detection of renal damage [KDIGO workgroup 2012]. Furthermore,
UO is usually normalized to body weight and the non-consistent use of body weight might lead
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to an underestimation of UO in obese patients [KDIGO workgroup 2012].
In the course of clinical urinalysis in nephrology, several additional important parameters are
assessed, e.g. the urinary protein content [Dörner 2013,Arastéh et al. 2009]. Healthy individ-
uals usually excrete less than 150mg of protein per day into the urine [Dörner 2013,Arastéh et
al. 2009], with 10-15% thereof being represented by albumin, a large-molecular-weight protein
of about 67kDa [Arastéh et al. 2009]. Proteinuria is defined as a protein excretion of more than
150mg per day [Dörner 2013,Arastéh et al. 2009]. An increase of urinary protein content may
be caused by elevated permeability of the glomeruli for large-molecular-weight proteins (so-
called albuminuria or glomerular proteinuria), insufficient reabsorption of low-molecular-weight
proteins in the tubuli (so-called tubular proteinuria) or higher concentration of low-molecular-
weight proteins in the filtered plasma (so-called overproduction proteinuria) [KDIGO workgroup
2013]. With albumin representing the major part of urinary protein in most renal diseases, the
assessment of urinary albumin content mainly substitutes the diagnosis of proteinuria in clinical
practice [KDIGO workgroup 2013]. Drawbacks of albuminuria as a biomarker for detection and
progression of impaired renal function include lack of standardized laboratory assays [Jha et
al. 2013] and unreleability due to clinical treatment of albuminuria as, for example, included
in clinical interventions to improve CKD outcome [Fassett et al. 2011].
The detection of increased excretion of low-molecular-weight proteins into the urine can be uti-
lized to specify tubular dysfunction [Del Palacio et al. 2012]. These "tubular proteins" include
neutrophil gelatinase-associated lipocalin (NGAL), β-2-microglobulin, retinol-binding protein,
urinary CysC, and N-acetyl-β-D-glucosamini- dase (NAG) [Del Palacio et al. 2012]. Other
biomarkers for tubular injury comprise glutathione S-transferases, liver-type fatty acid binding
protein, kidney injury molecule-1 (KIM-1), and interleucin-18 (IL-18) [Del Palacio et al. 2012].
Kidney biopsies are one of the most specific diagnostic tools for renal malfunctions, how-
ever exhibit various drawbacks associated with the required invasive procedure [Arastéh et
al. 2009,Kuhlmann et al. 2003].
In addition to the aforementioned clinical tools to monitor renal performance, numerous other
parameters are typically assessed in nephrology, e.g. blood pressure, blood and urinary glucose
content, urinary pH, urinary leukocyte content, urinary urea content, blood electrolyte con-
tent, etc. [Dörner 2013, Arastéh et al. 2009,Kuhlmann et al. 2003], and imaging techniques
like sonography, computer tomography, or magnetic resonance imaging are applied in clinical
practice [Arastéh et al. 2009,Kuhlmann et al. 2003].
4.1.3 Basic concepts of acute kidney injury after cardiac surgery
Acute kidney injury (AKI) is basically described as an abrupt decrease of the renal perfor-
mance [Eckardt et al. 2013,KDIGO workgroup 2012,Mehta et al. 2007]. The most commonly
used diagnostic and staging systems for AKI are the Risk Injury Failure Loss End-Stage Renal
Disease (RIFLE) [Bellomo et al. 2004], the Acute Kidney Injury Network (AKIN) [Mehta et
al. 2007], and the Kidney Disease: Improving Global Outcomes (KDIGO) [KDIGO workgroup
2012] criteria [Ostermann 2014], which are summarized in Table 4.1. They are all based on
alterations in SCr levels and UO over certain periods of time, whereas the RIFLE criteria also
consider changes in the GFR [Ostermann 2014,KDIGO workgroup 2012,Mehta et al. 2007,Bel-
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lomo et al. 2004]. These are common clinical parameters assessed in nephrology, as elaborately
discussed in section 4.1.2. RIFLE and AKIN criteria exhibit certain differences, compare to
Table 4.1, whereas the KDIGO criteria merge both into a uniform staging system for AKI [Os-
termann 2014]. One has to notice that although initiation of renal replacement therapy (RRT)
is explicitly excluded in the AKIN criteria as a staging criterion for AKI [Mehta et al. 2007],
patients treated with RRT are commonly classified as AKIN-stage 3 irrespective of their AKI
stage at RRT initiation [Ostermann 2014].
AKI after cardiac surgery mostly arises due to different, interconnected, pathophysiological
mechanisms, and main causes are patient-related factors and the use of cardiopulmonary by-
pass (CPB) before, during, and after the surgery [Mariscalco et al. 2011].
CPB use leads to unavoidable changes in blood flow by ischemia-reperfusion injury, low cardiac
output, renal vasoconstriction, hemodilution and loss of the pulsatile blood flow [Mariscalco
et al. 2011]. This leads to an imbalanced oxygen supply/demand of the kidney, whose blood
circulation is usually tightly regulated, compare to section 4.1.1, resulting into significant cel-
lular injury [Mariscalco et al. 2011]. Moreover, AKI after cardiac surgery also seems to result
from hypothermia, systemic inflammatory response, cell lysis, and embolization caused by CPB
use [Mariscalco et al. 2011].
Patient-related risk factors include type of surgery, sex, age, genetic AKI susceptibility, conges-
tive heart failure, anemia, diabetes mellitus, chronic obstructive pulmonary disease, emergency
status, nephrotoxic drugs and contrast agents, blood transfusions, post-surgical low cardiac
output, use of post-operative intraaortic balloon pump, occurrence of sepsis after the surgery,
and baseline renal performance [Mariscalco et al. 2011], with CKD, in general, being strongly
associated with AKI incidence [Chawla et al. 2014,Lameire et al. 2013].
The AKI pathology is usually divided into several clinical phases [Mariscalco et al. 2011]. The
early phase is determined by a vasomotor nephropathy with alterations in vasoreactivity and
renal perfusion [Mariscalco et al. 2011]. Consequently, AKI is initiated and the early AKI
phase is characterized by prerenal azotemia, cellular adenosine triphosphate depletion and ox-
idative injury [Mariscalco et al. 2011]. The extension of these symptoms in the next clinical
phase leads to the activation of bone-marrow derived and endothelial cells with a subsequent
proinflammatory state [Mariscalco et al. 2011]. These inflammatory cells adhere to the acti-
vated endothelium in the peritubular capillaries of the outer medulla with medullary congestion
and hypoxic injury of the proximal tubule [Mariscalco et al. 2011]. The final clinical phase is
characterized by a proliferation to the tubule cells and the renal function is reconstructed after
their redifferentiation and repolarization [Mariscalco et al. 2011].
A typical symptom of post-operative AKI is acute tubular necrosis including urinary granular
casts [Mariscalco et al. 2011].
Due to the significantly negative outcomes of AKI after cardiac surgery, as discussed in section
3.1, its prevention and/or early treatment is crucial to improve patient outcome [KDIGO work-
group 2012,Wyckoff and Augoustides 2012, Shaw 2012,Mariscalco et al. 2011]. With the use
of CPB being the most important cause of AKI, its employment should be adapted in order
to prevent AKI [Mariscalco et al. 2011]. In this context, pulsatile CPB proved to be superior
to standard linear CPB and in general, CPB flow rates of 1.8 - 2.2 l·min−1·m−2 (only refers to
cerebral flow) with a mean arterial pressure > 50 - 60 mmHg are recommended [Mariscalco et
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al. 2011]. Furthermore, cardiac surgeries should be delayed beyond 24hrs of the patient’s ex-
posure to nephrotoxic contrast agents and their use should be limited [Mariscalco et al. 2011].
Moreover, drugs, which increase the renal blood flow, e.g. fenoldopam, show renal protective
effects and could therefore prevent AKI [Mariscalco et al. 2011].
The detection of AKI based on SCr levels, UO, and GFR, usually takes place within 48hrs
after the surgery when applying the AKIN and KDIGO criteria or within seven days after the
surgery when applying the RIFLE criteria [Ostermann 2014,KDIGO workgroup 2012,Cruz et
al. 2009,Mehta et al. 2007,Bellomo et al. 2004].
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4.1.4 Basic concepts of chronic kidney disease
Chronic kidney disease (CKD) in adults is broadly defined as abnormalities of the renal struc-
ture or function, which are present for more than three months and exhibit certain implications
for health [KDIGO workgroup 2013]. These implications or CKD criteria are a decreased GFR
<60ml/min per 1.73m2, presence of proteinuria/albuminuria (albumin excretion rate (AER)
≥30mg for 24hrs; urinary albumin-creatinine ratio (ACR) ≥30mg/g [≥3mg/mmol]), urine sed-
iment abnormalities, electrolyte and other abnormalities due to tubular disorders or detected
by histology and imaging [KDIGO workgroup 2013]. One or more of these criteria should
be present for more than three months in order to confirm CKD [KDIGO workgroup 2013].
Patients with a history of kidney transplantation are automatically defined as CKD patients,
irrespective of their GFR level or presence of markers for renal damage [KDIGO workgroup
2013].
CKD patients with reduced GFR in general exhibit three significant types of complications, i.e.
increased drug toxicity, metabolic and endocrine complications, e.g. anemia, acidosis, malnutri-
tion, bone and mineral disorders, and increased risk of CVD and death [Jha et al. 2013,KDIGO
workgroup 2013,Eckardt et al. 2012,Kuhlmann et al. 2003]. Other complications include in-
fections, cognitive impairment, frailty, etc. [Jha et al. 2013,KDIGO workgroup 2013,Eckardt
et al. 2012,Kuhlmann et al. 2003]. CKD renal outcomes can be generally summarized as GFR
decline, albuminuria rise, AKI, and chronic kidney failure (equal to ESRD) defined as a GFR
<15ml/min per 1.75m2 [KDIGO workgroup 2013].
The classification system of CKD is called CGA (Cause, GFR, and Albuminuria) staging as
it is based on cause as well as GFR and albuminuria levels [KDIGO workgroup 2013]. With
CKD being broadly defined and not being a diagnosis per se, the assignment of its cause is
crucial for prognostication and patient treatment [KDIGO workgroup 2013]. This assignment
is based on the presence or absence of underlying systemic disease, and the location of observed
or presumed pathologic-anatomic findings within the kidney [KDIGO workgroup 2013]. Con-
sequently, CKD can be, in general, categorized into glomerular, tubulointerstitial, vascular, or
cystic and congenital diseases [KDIGO workgroup 2013]. The GFR and albuminuria categories
for CKD, are summarized in Table 4.2. To predict the prognosis of CKD in general, its cause
and other risk factors and comorbid conditions are considered [KDIGO workgroup 2013]. How-
ever, these risk categories still differ for individual outcomes, highlighting the importance of
supplementary research [KDIGO workgroup 2013,Eckardt et al. 2012].
Consequently, GFR and albuminuria should be assessed in CKD patients at least annually in
order to monitor disease progression [KDIGO workgroup 2013]. Factors associated with CKD
progression include, among others, cause of CKD, level of GFR and albuminuria, age, sex,
race/ethnicity, elevated blood pressure, hyperglycemia, dyslipidemia, smoking, obesity, history
of CVD, and ongoing exposure to nephrotoxic agents [KDIGO workgroup 2013].
Due to the complexity of CKD causes and comorbidities, treatment strategies are diverse and
need to be tailored to the individual patient [Eckardt et al. 2013]. General treatment strategies
to slow progression of CKD and reduce risk of mortality associated with CVD comprise blood
pressure and glycemic control, especially in CKD patients with diabetes, as well as change
of diet and/or lifestyle [KDIGO workgroup 2013, Jha et al. 2013]. Furthermore, with CKD
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patients exhibiting an increased risk of developing AKI, appropriate precautions should be con-
sidered to prevent AKI incidence [KDIGO workgroup 2013], as, for example, outlined in section
4.1.3 in the context of cardiac surgery. Even with appropriate patient treatment to slow down
CKD progression, CKD patients classified in stage G5 according to the GFR criteria (compare
to Table 4.2) have established chronic kidney failure or ESRD, and the only option to avoid
hazardous consequences is timed application of RRT [Kuhlmann et al. 2003]. RRT include
hemodialysis and kidney transplantation [Kuhlmann et al. 2003], with favorable long-term
results for transplant recipients [Purnell et al. 2013,Tonelli et al. 2011,Weitz et al. 2006].
Additionally, elaborate treatment options for CKD complications, e.g. hypertension and ane-
mia, exist [KDIGO workgroup 2013]. Anemia in CKD patients older than 15 years is defined
as a Hb concentration <13.0g/dl in males and <12.0g/dl in females [KDIGO workgroup 2013].
It represents a serious complication in CKD patients with increased risk of adverse cardiovas-
cular and renal events [KDIGO workgroup 2013,Pfeffer et al. 2009a)]. In CKD patients, the
production of EPO is mainly reduced due to impaired renal function [Rao and Pereira 2003]
and resulting anemia is commonly treated by administration of ESAs, e.g. darbepoetin alfa,
or iron therapy [KDIGO workgroup 2013, Pfeffer et al. 2009a)]. However, significant contro-
versies exist regarding the target Hb concentration achieved by ESA treatment [Pfeffer et al.
2009a), Phrommintikul et al. 2007,Drüeke et al. 2006, Singh et al. 2006], as high Hb target
levels are consistently associated with increased cardiovascular mortality [Strippoli et al. 2007].
Furthermore, an increased stroke risk is reported for CKD patients with diabetes mellitus 2
treated with darbepoetin alfa in the TREAT study [Skali et al. 2011]. In this context [KDIGO
workgroup 2013,Singh 2010] recommend no ESA treatment for patients with mild to moderate
anemia or with active or recent history of malignancy, the target Hb concentration achieved
with ESA treatment should not exceed 11.5g/dl and in general, blood transfusion or treatment
with short course of ESAs is only recommended as a rescue therapy for patients with Hb <9g/dl.
For transplant candidates or patients with severe anemia (Hb <9g/dl) requiring regular blood
transfusions, a long-term treatment with ESAs should be considered [Singh 2010].
4.1.5 Clinical study design in nephrology
Patient-oriented clinical trials are, in general medical science as well as in the specific field of
nephrology, conducted in order to establish guidelines for clinical decision making [Palmer et al.
2011]. They can be subdivided into two major categories according to the investigator’s role:
interventional and observational studies [Thiese 2014, Palmer et al. 2011]. These categories
both comprise three basic steps of research, i.e. definition and assessment of exposure in two
or more patient groups, outcome measurement in these groups, and statistical analysis in order
to make inferences about possible relationships between exposure and outcome [Thiese 2014].
In interventional or experimental trials, the investigator acts upon the study participants as
part of the study design [Thiese 2014]. This offers the opportunity to investigate the effect
of therapeutic interventions, e.g. preventive drugs [Thiese 2014]. Several different types of
interventional studies exist, e.g. pre-post, non-randomized controlled, crossover randomized
controlled, and randomized controlled trials, whereas the latter is commonly considered to be
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GFR categories of CKD
G1 normal or high ≥90ml/min/1.73m2
G2 mildly decreased 60-89ml/min/1.73m2
G3a mildly to moderately decreased 45-59ml/min/1.73m2
G3b moderately to severely decreased 30-44ml/min/1.73m2
G4 severely decreased 15-29ml/min/1.73m2
G5 kidney failure <15ml/min/1.73m2
Albuminuria categories of CKD
A1 normal to mildly increased <30mg/mmol
A2 moderately increased 3-30mg/mmol
A3 severely increased >30mg/mmol
Table 4.2: CKD staging system based on GFR and albuminuria criteria. Abbrevia-
tions: GFR, glomerular filtration rate. Modified from [KDIGO workgroup 2013].
the gold standard [Thiese 2014,Concato 2013].
In randomized controlled trials, a homogeneous group of study participants is randomly split
into two or more separate groups with, therefore, equal characteristics and confounders [Thiese
2014]. Then, one group is left untreated, the so-called control group, whereas a therapy is
administered to the other(s) [Thiese 2014]. The analysis of differences between the treated
group(s) and the control offers the possibility of making inferences about the therapy’s impact
on the treated group(s) [Thiese 2014]. The vigorousness of randomized controlled trials com-
prises balanced baseline characteristics due to randomization, collection of pertinent data due
to a "prospective" infrastructure, and mainly straightforward analytical evaluation of differences
between treated and control group(s) [Concato 2013]. On the other hand, different randomized
controlled trials on the same topic often show contradictory results due to, e.g. differences
concerning technical issues, inclusion and baseline criteria, etc., as well as comparisons between
meta-analyses, i.e. combined statistical analysis of several small independent studies [Fisher
and Wood 2007], and large randomized controlled trials [Concato 2013]. Furthermore, random-
ized controlled trials have limited generalizability due to strict inclusion criteria, can be very
expensive and time consuming, often demand complex administration, and patient recruitment
can be challenging [Concato 2013,Fisher and Wood 2007].
The study design of a randomized controlled trial can be enhanced by following further guide-
lines: Allocation concealment, guaranteed for both study participants and involved researchers,
should theoretically prevent biased randomization [Thiese 2014]. In comparison, blinding rep-
resents the concealment of the group membership from the study participants and involved
researchers by, e.g. treating the control group with a placebo medication [Thiese 2014]. It
assures equal treatment for the control and the treated group(s) and consequently minimizes
biases [Thiese 2014]. By measuring the compliance of study participants and potentially adjust-
ing for differences in intervention adherence between control and treated group(s), erroneous
results of the statistical analysis can be avoided [Thiese 2014]. Co-interventions, which might
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have a different impact on the outcome than the primary treatment of the study, should be
either excluded or statistically adjusted in order to prevent wrong deductions about the treat-
ment effect [Thiese 2014]. The number of study participants, who drop out of a trial, should
be counted and considered while interpreting the study results [Thiese 2014]. Deviations from
random allocation can be regulated by an intention-to-treat analysis, where the data from study
participants is analysed based solely on their allocated intervention, i.e. regardless whether they
actually received a treatment or not [Thiese 2014]. It consequently allows deductions about
the randomization benefits, but relies on data completeness [Thiese 2014]. Finally, data should
be collected from each group at the same time-point and in the same way in order to reduce
substantial bias [Thiese 2014].
In observational studies, also called epidemiological studies, the investigator does not perform
any interventions on the study participants, but solely observes exposure, e.g. disease, therapy,
etc., and outcome [Thiese 2014]. They can be, based on their measures of disease and risk as
well as temporality, further subdivided into ecological, proportional mortality, case-crossover,
cross-sectional, case-control, as well as retrospective and prospective cohort studies [Thiese
2014]. The gold standard for observational studies are prospective cohort studies [Thiese 2014].
For cohort studies, study participants are classified according to their exposure status and
are either followed through time in order to determine their outcome (prospective) or their
health data, which has been recorded prior to outcome development, is retrospectively eval-
uated [Thiese 2014]. Cohort studies allow the determination of incidence, point and period
prevalence, as well as numerous risk measures [Thiese 2014,Fisher and Wood 2007].
In general, diagnostic accuracy studies, where a new diagnostic method is compared to the
current "gold standard" in a cross-section of both diseased and healthy study participants, are
also classified as observational studies, although they could be seen as a unique category [Thiese
2014].
Even though randomized controlled trials are often stated to be superior to observational stud-
ies [Fisher and Wood 2007], the latter still offer certain advantages [Concato 2013]. They
can be further improved by restricted eligibility criteria and well-defined time-points of last
interventions [Concato 2013]. Moreover, observational studies and corresponding randomized
controlled trials proved to show similar results, and the conclusions derived from observational
studies seem to be trustworthy [Concato 2013]. Additionally, observational cohort studies seem
to offer greater generalizability than randomized controlled trials due to broader patient pop-
ulations [Fisher and Wood 2007, Jager et al. 2007]. However, observational studies usually
exhibit imbalanced baseline characteristics, the quality of the data collected with regard to the
research question can be variable and therefore introduce bias, and the analytical methods can
be very complex and obscure [Concato 2013].
Alternative categorization schematas for clinical trials are based on the temporal nature of
the study, i.e. retrospective or prospective, the usability of the study results, i.e. basic or ap-
plied, the investigator’s aim, i.e. descriptive or analytical, or the study purpose, i.e. prevention,
diagnosis, or treatment [Thiese 2014].
Retrospective studies, where data on past exposures and outcomes is collected based on medi-
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cal records or the participants’ memories, do not offer easy deductions about temporality and
can be prone to several biases depending on the record quality [Thiese 2014]. In comparison,
prospective trials, where study participants are monitored forward through time, are less prone
to biases and deductions about causality are easier achieved due to determined time-frames for
exposure and outcome [Thiese 2014].
Which study design is to be chosen for an actual trial, crucially depends on the research ques-
tion and practical aspects, e.g. costs, available infrastructure, etc. [Fisher and Wood 2007].
The clinical trials included in this thesis both comprise interventional, e.g. TREAT, and ob-
servational, e.g. GCKD, studies and the individual study designs are briefly introduced in the
respective Introduction parts of section 5.
4.2 Fundamentals of nuclear magnetic resonance
spectroscopy
4.2.1 The theory of nuclear magnetic resonance spectroscopy
This introduction approaches NMR spectroscopy in a classical way and does not go into quan-
tum mechanics or quantum electro dynamics. Quantum mechanical background can be found
in [Cavanagh et al. 1996,Ernst et al. 1987].
The spin angular momentum, in general, is a fundamental, quantum-mechanical property of
particles such as protons, neutrons, and electrons, and can be described mathematically as a
vector [Ernst et al. 1987].
The principle of NMR spectroscopy is based on the presence of a nuclear spin angular momen-
tum ~I for certain nuclei and the corresponding nuclear magnetic moment ~µ [Cavanagh et al.
1996]. The magnitude of ~I is given by
|~I|2 = ~2[I(I + 1)]. (4.1)
I is the angular momentum quantum number and ~ = 1.055 · 10−34Js is Planck’s constant
divided by 2pi. Nuclei with odd mass numbers possess half-integer angular momentum quantum
numbers, the most important nuclei with I = 12 are
1H, 13C, 15N, 19F, and 31P [Cavanagh et al.
1996]. Nuclei with an even mass and an even charge number have angular momentum quantum
numbers equal to zero and are therefore NMR-inactive [Cavanagh et al. 1996]. Nuclei with
an even mass number and an odd charge number have integer angular momentum quantum
numbers, whereas the most important nuclei with I = 1 are 2H and 14N [Cavanagh et al. 1996,
Ernst et al. 1987]. As nuclei with I > 12 additionally possess electric quadrupole moments due
to nonspherical nuclear charge distributions, the lifetimes for their magnetic states in solution
are usually much shorter than for nuclei with I = 12 [Cavanagh et al. 1996]. Consequently,
NMR resonance lines of such quadrupolar nuclei are broader and more difficult to resolve than
resonance lines for nuclei with I = 12 [Cavanagh et al. 1996].
Due to quantum mechanical restrictions, only one Cartesian component of ~I, usually Iz, can be
measured simultaneously with ~I2 [Cavanagh et al. 1996], and the magnitude of the nuclear spin
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angular momentum ~I is always greater than its z-component Iz [Ernst et al. 1987,Cavanagh
et al. 1996]:
Iz = ~m, |~I|2 > I2z , (4.2)
where m defines the magnetic quantum number with m = (−I,−I + 1, ..., I − 1, I). Corre-
spondingly, Iz possesses 2I + 1 possible values and the orientation of the nuclear spin angular
momentum ~I in space is quantized [Cavanagh et al. 1996].
Nuclei with a non-zero nuclear spin angular momentum ~I also have a magnetic moment ~µ,
defined by [Cavanagh et al. 1996]
~µ = γ~I, µz = γIz = γ~m, (4.3)
with γ being the gyromagnetic ratio, a characteristic constant for a given nucleus. The recep-
tivity of a nucleus in NMR spectroscopy depends, in part, on the magnitude of γ, as illustrated
below [Cavanagh et al. 1996]. In the absence of external fields, the quantum states of an iso-
lated spin corresponding to 2I + 1 different values of m have the same energy and the nuclear
spin angular momentum ~I and therefore the magnetic moment ~µ have no preferred orienta-
tion [Cavanagh et al. 1996].
In presence of an external static magnetic field ~B0, the spin quantum states of the nucleus
possess the following discrete energies [Cavanagh et al. 1996]:
Em = −~µ · ~B0. (4.4)
In case of ~B0 || eˆz, as usually postulated in an NMR spectrometer, one obtains [Cavanagh et
al. 1996]
Em = −µzBz = −γIzBz = −m~γBz, (4.5)
in which Bz is the static magnetic field strength. The minimum energy E0 equals zero, corre-
sponding to a magnetic quantum number of m = 0 [Cavanagh et al. 1996].
Consequently, 2I+1 different energy levels exist, the so called Zeeman levels, all separated from
each other by equal spaces [Cavanagh et al. 1996]. The transition condition equals ∆m = ±1
and the energy gap ∆E between two neighboring Zeeman levels is [Cavanagh et al. 1996]
∆E = γ~Bz. (4.6)
This energy gap ∆E corresponds, according to Planck’s law to a frequency ν0 of electromagnetic
radiation required to excite a transition [Cavanagh et al. 1996],
ν0 =
∆E
h
= γBz2pi , ω0 = 2piν0 = γBz, (4.7)
where h = 6.63 · 10−34 Js denotes Planck’s constant.
With |~I|2 > I2z and ~µ and ~I being collinear, ~µ and ~B0 are not collinear [Ernst et al. 1987].
This leads to a precession of ~µ around ~B0 with the so-called Larmor frequency ω0 [Ernst et al.
1987], as, for example, depicted in Figure 4.2a) for a single nucleus with an angular momentum
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quantum number I = 12 and nuclear spin angular momentum ~I. The Larmor frequency ω0
is equal to the required excitation frequency given in equation (4.7). ~I can be either parallel
oriented to an external magnetic field ~B0, the so-called spin-up state with the energy level α,
corresponding to a magnetic quantum number m = +12 [Ernst et al. 1987]. Or ~I can be ori-
ented anti-parallel to ~B0, the so-called spin-down state, corresponding to m = −12 and a higher
energy level β [Ernst et al. 1987].
In a bulk material with millions of nuclei, all magnetic moments of the single nuclei need
to be added up as vectors in order to calculate the macroscopic magnetization ~M [Cavanagh
et al. 1996]. At thermal equilibrium, the number of nuclei Nα in the spin-up state at the lower
energy level, is slightly higher than the number of nuclei Nβ in the spin-down state [Cavanagh
et al. 1996]. This population difference can be calculated as [Ernst et al. 1987]
Nα −Nβ
Nα +Nβ
= 1− exp
−∆E/kBT
1 + exp−∆E/kBT ≈
∆E
2kBT
= γ~Bz2kBT
. (4.8)
Here, kB = 1.38 · 10−23 JK−1 represents Boltzmann’s constant and T the temperature. The
longitudinal macroscopic magnetization ~M is therefore parallel oriented to the external static
magnetic field ~B0 and precesses with Larmor frequency ω0 around the z-axis [Cavanagh et
al. 1996,Ernst et al. 1987]. Note that only the population difference between energy state α
and β as calculated in (4.8) contributes to the macroscopic magnetization and to the detected
NMR signal [Ernst et al. 1987], as illustrated in Figure 4.2b). This population difference
depends on the nucleus type and the applied static magnetic field strength as well as the
temperature [Cavanagh et al. 1996] and is usually on the order of 1 in 105 for 1H spins for
static magnetic field strengths of about 11T at room temperature [Cavanagh et al. 1996].
Hence, NMR spectroscopy is quite insensitive in comparison to other spectroscopic techniques
like visible or ultraviolet spectroscopy [Cavanagh et al. 1996]. Its sensitivity can be increased
by choosing higher static magnetic field strengths [Ernst et al. 1987,Cavanagh et al. 1996].
If a radio frequency (rf) pulse with frequency νrf equal to the Larmor frequency ν0 is irradiated
onto the bulk material, the orientation of ~M can be altered [Ernst et al. 1987,Cavanagh et al.
1996]. ~Brf (t) is the magnetic field component of this induced electromagnetic field and is, for
example, linearly polarized along the x-axis [Ernst et al. 1987]. It can be fractionized into two
circularly polarized magnetic fields, which rotate around the z-axis in opposite directions [Ernst
et al. 1987]. ~M can only significantly interact with the component of ~Brf rotating in the same
sense as itself [Ernst et al. 1987]. It starts to perform an additional rotation around ~Brf , i.e.
around the x-axis, and moves away from the z-axis towards the x-y-plane [Ernst et al. 1987].
At the same time, ~M(t) still rotates around the z-axis due to the external static magnetic field
~B0 leading to a helical line movement [Ernst et al. 1987]. This process is illustrated in Figure
4.3a). In the considered case of a 90° rf pulse, the rf-field is switched off when ~M(t) reaches
the x-y-plane [Ernst et al. 1987]. ~M(t), now called transversal magnetization, rotates in the
x-y-plane with angular frequency ω0 = γBz [Ernst et al. 1987]. It induces, due to electro-
magnetic induction, the NMR signal in the receiver coil (represented as an eye), located in the
x-y-plane [Bloch 1946,Ernst et al. 1987], as illustrated in Figure 4.3b). The NMR spectrometer,
employed for this thesis, uses a magnetic field strength Bz of 14.1 T and consequently works
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Figure 4.2: Illustration of two different energy levels α (spin-up state) and β (spin-
down state) for the nuclear spin represented by the spin angular momen-
tum ~I with an angular momentum quantum number I = 12 in an external
magnetic field ~B0. a) shows a single nucleus in an external magnetic field ~B0
and b) illustrates the longitudinal macroscopic magnetization ~M in bulk material
at thermal equilibrium. More nuclei are in the energy state α than in the energy
state β. The longitudinal macroscopic magnetization ~M is parallel oriented to the
external magnetic field ~B0. The x- and y-fractions of ~I and ~µ, respectively, which
rotate with Larmor frequency ω0, compensate each other. Taken from [Zacharias
2012].
with a resonance frequency for protons of approximately 600 MHz. The time for recording the
NMR signal is called the acquisition period and the signal itself is called the free induction
decay (FID) [Ernst et al. 1987], compare to Figure 4.3c). The time-dependent FID, whose
data points are not continually recorded, but only in distinctive time intervals facilitated by
the Nyquist theorem, is transformed into the corresponding NMR spectrum as a function of
frequency ν using, in most cases, a fast Fourier transformation [Ernst et al. 1987,Cavanagh et
al. 1996].
Two different relaxation effects of the macroscopic magnetization ~M occur, which are mainly
induced by interactions with surrounding electromagnetic fields [Bloch 1946,Ernst et al. 1987].
The longitudinal relaxation, also called T1-relaxation, arises from spin-lattice-interaction and
leads to a reorientation of the transversal magnetization back to a longitudinal orientation par-
allel to ~Bz carried out in the time period T1, see Figure 4.4a) [Bloch 1946,Ernst et al. 1987]. T1
depends on the mobility of the lattice and determines the waiting time between two acquisition
periods [Ernst et al. 1987].
The transverse relaxation or T2-relaxation describes the dephasing of the transversal magneti-
zation due to intramolecular spin-spin or dipole-dipole-interaction in the time period T2 [Bloch
39
4 Background
Figure 4.3: A 90° rf pulse irradiates on a bulk material with macroscopic magne-
tization ~M parallel oriented to ~B0. a) The rf pulse with the magnetic field
component ~Brf (t) causes an additional rotation of ~M around the x-axis leading to
a helical line movement of ~M . b) ~M rotates in the x-y-plane with angular frequency
ω0 and induces an electrical potential in the receiver coil (represented as an eye),
which is the measured NMR signal. c) During the acquisition period, the FID, a
superposition of different sine and cosine waves, is recorded as the NMR signal. It
declines exponentially due to spin-spin relaxation, indicated by the time constant
for inhomogeneous magnetic fields T ∗2 [Ernst et al. 1987]. Taken from [Zacharias
2012].
1946, Ernst et al. 1987], see Figure 4.4b). T2 depends consequently on the molecule’s size,
on the density of the interacting nuclei, the viscosity of the solvent, and the temperature and
determines the useful maximum acquisition period [Ernst et al. 1987]. Taking into account
local inhomogeneities of the magnetic field Bz, which arise from fluctuations of the magnetic
susceptibility, one considers the effective transversal time constant T ∗2 as presented in Figure
4.3c) [Homans 1995].
These two relaxation processes are mathematically described in the phenomenological Bloch
equations [Ernst et al. 1987].
The energy gap ∆E, as described in (4.6), depends on the effective magnetic field at the
nucleus [Cavanagh et al. 1996]. Local changes of the magnetic field at a nucleus can arise due
to magnetic shielding effects caused by its electronic environment in a molecule [Cavanagh et
al. 1996]. Hence, the Larmor frequency ω0 of the electromagnetic radiation required to excite
a transition between different spin states of a nucleus, as given in (4.7), is shifted and now
denoted as ωlocal [Cavanagh et al. 1996]. In general, this shift is given as the chemical shift δ
in ppm and is independent of the applied static magnetic field B0 [Cavanagh et al. 1996,Ernst
et al. 1987]
δ = ωlocal − ωref
ω0
× 106. (4.9)
ωref denotes the offset resonance frequency of a reference substance, the so called internal
standard compound, for example tetramethylsilan (TMS; Si(CH3)4) or 3-trimethylsilyl-2,2,3,3-
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Figure 4.4: Illustration of T1 and T2 relaxation. a) Due to spin-lattice-interaction, the
transversal magnetization relaxes back to the original longitudinal relaxation in
the time period T1. b) Due to spin-spin- or dipole-dipole-relaxation, the transver-
sal magnetization dephases in the x-y-plane in the time period T2. Taken from
[Zacharias 2012].
tetradeuteropropionate (TSP), and can be calculated using quantum mechanics or the chemical
shift increment system.
With the resonance frequency and consequently the chemical shift δ of a nucleus in a cer-
tain molecular surrounding being distinct, NMR spectroscopy enables the identification and
validation of compounds in an investigated substance. The NMR spectrum can be seen as a
molecular fingerprint of different molecular structures present in biological fluids. However, it
is important to consider the influence of the solvent, the salt concentration, the pH value, the
temperature and other environmental impacts of the investigated specimen on the chemical
shift.
For a nucleus A with nuclear spin angular momentum ~IA, which is located near a second
nucleus X with nuclear spin angular momentum ~IX , possible coupling effects need to be consid-
ered [Ernst et al. 1987]. One possible coupling mechanism is called scalar or J-coupling, also
called indirect dipole-dipole coupling, which is mediated by the electrons of the chemical bonds
between these two nuclei [Ernst et al. 1987]. J is the coupling constant for such a two spin
system and its magnitude depends on the number and types of bonds between nuclei A and X,
as well as, if applicable, the dihedral angles between them [Ernst et al. 1987,Homans 1995]. It
is therefore a distinct constant for the considered spin system with fixed dihedral angle [Ernst
et al. 1987]. The J-coupling mechanism changes the energy levels of a non-coupled two spin
system, as illustrated in Figure 4.5. A two spin system has four possible energy levels E in a
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molecular surrounding, depending on the orientation of the two nuclear spin angular momenta
~IA and ~IX with respect to the static magnetic field [Cavanagh et al. 1996]. In the presence of
scalar coupling conveyed by the chemical bonds between the two nuclei, the energy levels are
shifted [Ernst et al. 1987,Cavanagh et al. 1996], as illustrated in Figure 4.5b). Consequently,
the two original NMR lines reflecting transitions between E1 and E3, as well as E2 and E4
or transitions between E1 and E2, as well as E3 and E4 (compare to Figure 4.5c)) are now
split into two lines, respectively, each of them reflecting one of the four possible transitions
(compare to Figure 4.5d)) [Cavanagh et al. 1996,Ernst et al. 1987]. Note that the resulting
resonance lines all have the same intensity, as the small population difference between spin-up
and spin-down state is neglected in this case [Ernst et al. 1987]. However, this is only true for
the so-called high-field or weak coupling approximation, which assumes that the J couplings are
much smaller than the chemical shifts between resonances of the coupled nuclei [Homans 1995].
Depending on the magnitude of the coupling constant J as well as the presence of additional
neighboring nuclei, the resonance line pattern of a nucleus in a molecular surrounding becomes
even more complex [Ernst et al. 1987]. If the magnitude of J approximates the value of the
chemical shift difference between the two nuclei, the weak coupling approximation becomes in-
valid and one refers to strong coupling [Homans 1995]. The resulting resonance lines in Figure
4.5d) become distorted, also known as roofing-effect [Ernst et al. 1987, Homans 1995]. For
magnetically equivalent nuclei, i.e. nuclei with the same chemical environment and only one
coupling constant to the neighboring nuclei, no line splitting is observed [Ernst et al. 1987].
Another coupling mechanism is dipolar coupling, which is based on direct interaction between
different nuclei through space [Ernst et al. 1987]. It is independent of the chemical bonds
between the two nuclei, but depends on the angle between the static magnetic field and the
vector connecting the two nuclei [Ernst et al. 1987]. In isotropic solution, where molecules can
move freely, this angle continually changes and the dipolar coupling is averaged to zero [Ernst
et al. 1987]. Therefore, line splitting due to dipolar coupling effects are, in general, not vis-
ible in the NMR spectrum [Ernst et al. 1987]. However, fast rotation of the molecules and
intra-molecular motions give rise to fluctuations of their magnetic fields [Ernst et al. 1987].
A fluctuating field of one nucleus can lead to longitudinal and transversal relaxation of the
neighboring nuclei [Ernst et al. 1987]. This is, in case of longitudinal relaxation, called cross
relaxation [Ernst et al. 1987] and described by the Solomon equations [Solomon 1955].
Scalar or dipolar coupling mechanisms can be employed in order to transfer magnetization be-
tween different nuclei populations [Ernst et al. 1987]. This property can be utilized to transfer
magnetization from nuclei, which are sensitive to external rf pulses (e.g. 1H nuclei), to in-
sensitive nuclei (e.g. 13C nuclei), and vice versa, as realized, for example, in two-dimensional
(2D) heteronuclear NMR experiments [Ernst et al. 1987]. An important example is the in-
direct measurement of 13C spectra via 1H spectra [Ernst et al. 1987]. 2D NMR spectra offer
the possibility of effectively reducing the excessive signal overlap present in 1D NMR spectra
of complex biofluids, e.g. urine, and can illustrate correlations between different nuclei in a
molecule [Ernst et al. 1987]. 2D NMR experiments can usually be subdivided into four differ-
ent parts, namely preparation, evolution characterized by a variable time interval t1, mixing,
and acquisition characterized by the time interval t2 [Cavanagh et al. 1996,Ernst et al. 1987].
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Figure 4.5: The effect of J-coupling on the energy levels of a two-spin system. a) A
two-spin system in the absence of J-coupling has four different energy levels. The
differences between energy levels 1 and 2 and energy levels 3 and 4 are equivalent,
the corresponding transitions give rise to one line in the NMR spectra (same holds
true for differences between energy levels 1 and 3 and energy levels 2 and 4), as
illustrated in c) [Cavanagh et al. 1996]. b) In the presence of J-coupling, the four
energy levels of a two-spin system are shifted, and the previous two NMR lines are
split into four [Cavanagh et al. 1996], as illustrated in d) under the assumption of
weak coupling. Modified from [Cavanagh et al. 1996].
By increasing t1 m-times in a step-wise manner and thereby executing the pulse sequence and
recording an FID of n digitized data points for each increment, one obtains an m × n data
matrix [Cavanagh et al. 1996]. A double Fourier transformation consequently yields a 2D
spectrum as a function of two frequency variables [Cavanagh et al. 1996,Ernst et al. 1987].
4.2.2 General data acquisition
This section comprises a general overview of the different data acquisition steps performed for
this thesis. Details and modifications specific for certain projects are explicitly addressed in
the respective Materials and Methods parts of section 5.
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4.2.2.1 Sample characteristics and preparation
The main biofluids measured for this thesis are human urine and plasma. A general overview
of the sample characteristics and preparation procedures for these two fluids is given here.
Urine is the most popular biofluid for metabolomic investigations [Emwas et al. 2014]. It
comprises a large range of metabolites and reflects the most metabolic processes, which take
place throughout the body [Emwas et al. 2014]. As urine is not constantly released by the
body, but rather stored in the bladder until excretion, it represents a "time-averaged" profile of
whole-body homeostasis [Kosmides et al. 2013,Maher et al. 2007]. With the kidney being re-
sponsible for its creation, compare to section 4.1.1, the urine composition can excellently reflect
the renal performance, as it is utilized in traditional clinical monitoring described in section
4.1.2. Moreover, urine specimens are easily obtained in a non-invasive way and are usually
available in large volume [Emwas et al. 2014]. Furthermore, in comparison to, for example,
blood, urine contains fewer protein complexes and lipids [Emwas et al. 2014], whose broad
NMR signals need to be attenuated in order to obtain well resolved spectra.
However, the metabolic concentration in a urine specimen of an individual crucially depends
on the person’s fluid intake, adding to overall data variance [Dieterle et al. 2011]. This effect
is usually addressed by employing appropriate scaling and normalization techniques, which are
discussed in section 4.3.1.
Further individual-related factors contributing to significant variation of the urinary metabolic
concentrations are diet, age and gender effects, metabolic phenotypes, gut microflora effects,
comorbidities, drug administration, and physical activity, which can be interconnected [Emwas
et al. 2014]. These effects can be overcome by appropriate matching of the compared patient
groups and by applying various normalization techniques, as described in section 4.3.1.
Factors related to specimen collection and storage are different sample collection time-points,
presence of human or bacterial cells that might break open, different sample storage conditions,
and repeated thawing and freezing [Emwas et al. 2014]. Human or bacterial cells present in
urine are usually removed by a short centrifugation step prior to sample freezing [Emwas et al.
2014,Zacharias et al. 2013b)], as applied in this thesis. Differences in sample storage conditions
were avoided by employing unified storage conditions for all biofluid specimens belonging to
one project. The number of thawing and freezing cycles was minimized.
Furthermore, the individual pH value of the specimens as well as differences in osmolality of
the specimens, ionic strength or metal ion composition lead to chemical shift changes [Emwas
et al. 2014,Zacharias et al. 2013b),Ross et al. 2007]. The individual pH value of each sample
was adjusted to 7.0 by adding an appropriate buffer volume [Zacharias et al. 2013b)], as de-
scribed below, and general differences in chemical shifts were compensated by spectral binning,
compare to section 4.2.2.3.
The second most prominent biofluid for metabolomic investigations is blood plasma or serum
[Kosmides et al. 2013]. For this thesis, only plasma samples were investigated. Plasma is the
liquid carrier of the blood cells and is usually obtained by adding anti-coagulants, e.g. EDTA,
to the blood, centrifuging it and subsequently decanting the remaining liquid [Psychogios et al.
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2011].
Blood circulates around and inside every tissue and organ of the body and carries all molecules
that are secreted, excreted, or discarded during the bodies metabolism [Psychogios et al. 2011].
Therefore, the composition of blood/plasma is strongly affected by organ dysfunctions, tissue
lesions, and pathological states of the body, justifying its prominent role in clinical tests [Psy-
chogios et al. 2011]. In comparison to urine, plasma metabolic profiles rather represent an
"instantaneous" picture of the whole-body homeostasis [Kosmides et al. 2013, Maher et al.
2007]. As the kidney serves as a filter for blood/plasma in the body, compare to section 4.1.1,
alterations of the blood/plasma composition are strong indications of modified renal function.
Consequently, traditional clinical monitoring of the renal performance is also based on the as-
sessment of blood/plasma composition, as depicted in section 4.1.2. In general, blood/plasma
is easily accessed by employing a minimally invasive procedure [Psychogios et al. 2011].
In comparison to urine, however, plasma specimens contain large amounts of macromolecules,
especially proteins, which give rise to broad and unspecific NMR signals [Zacharias et al.
2013b)]. Therefore, macromolecules should be removed from plasma specimens prior to NMR
data acquisition by, e.g. ultrafiltration, or their NMR signals should be attenuated employing,
for instance, the Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence [Zacharias et al. 2013b)],
as introduced in section 4.2.2.2. For ultrafiltration, Millipore Amicon Ultra-4 (Millipore, Bil-
lerica, MA, USA) cellulose filter devices with a molecular weight cutoff of 10 kDa were used in
this thesis.
1 Filters were prewashed with 3 ml of distilled water and centrifuged at 4000 × g in a swing-
bucket rotor at 22°C for 30 min in order to remove filter-preserving substances like glycerol and
triethylene glycol. Spectra of blank samples of rinsing water were acquired and compared to
spectra of filtered biofluid to detect and exclude signals from filter residues in subsequent data
analysis. 1000 µl of plasma were placed into the filter device and centrifuged at 4000 × g at
4°C for 60 min.
Although the metabolite composition and concentration of plasma is usually tightly controlled
and therefore not significantly influenced by individual fluid intake [Warrack et al. 2008], cer-
tain other patient-related factors can affect its composition, e.g. diet, age, sex, comorbidities,
and drug administration, which also need to be addressed appropriately. Like urine, plasma
composition can be influenced by collection and storing conditions. These collection and stor-
ing conditions were unified for all plasma specimens belonging to one project for this thesis.
Furthermore, the number of thawing and freezing cycles was also minimized for plasma samples.
All biofluid specimens measured for this thesis were either immediately stored at -80°C or
put on ice after collection and stored at -80°C as soon as possible until measurement. Prior
to sample preparation, biofluid specimens were thawed at room temperature. Then, usually
400 µl of each biofluid sample (i.e. either urine, filtered or unfiltered plasma) was placed in an
individual 5 mm NMR tube (Bruker BioSpin GmbH, Rheinstetten, Germany, or Norell Inc.,
Marion, USA) mixed with 200 µl of 0.1 mol/l phosphate buffer at pH 7.4 and 50 µl of 0.75%
1The following description of the filtering procedure was similarly published in [Zacharias et al. 2013b)].
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(w) of the sodium salt of TSP (Sigma-Aldrich, Taufkirchen, Germany), solved in deuterium
oxide (D2O), as recommended in [Zacharias et al. 2013b)]. TSP serves as an internal standard
and provides the reference signal, the phosphate buffer is added in order to stabilize the pH
value of the biofluid samples at 7.0 and D2O is used as a reference for the internal lock signal
of the spectrometer [Zacharias et al. 2013b)]. Moreover, the buffer contained 30 mg boric acid
(3.9 mmol/l) in order to inhibit bacterial growth [Zacharias et al. 2013b)]. Further informa-
tion about alternative internal standards or buffer solutions is given in [Zacharias et al. 2013b)].
4.2.2.2 Experimental setup of the employed NMR spectrometer
All NMR experiments for this thesis were carried out on a 600 MHz Bruker Avance III (Bruker
BioSpin GmbH, Rheinstetten, Germany) employing a triple-resonance (1H, 13C, 31P, 2H lock)
cryogenic probe equipped with z-gradients and an automatic cooled sample changer (SampleJet,
Bruker BioSpin GmbH, Rheinstetten, Germany). The spectrometer’s operating frequency of
600 MHz for protons corresponds to a magnetic field strength of 14.1 T. This magnetic field is
generated by a superconducting magnet, which is cooled by liquid helium at 4 K, whereas the
helium Dewar itself is cooled by liquid nitrogen at about 77.35 K [Butler 2002]. This magnet is
surrounded by a shielding superconducting magnet of inverse polarization, also located in the
Dewar, to minimize the magnetic field outside the spectrometer. The probe head contains the
emitter/receiver coils for the frequencies of the 1H, 13C, and 31P nuclei and a separate coil for
locking purposes. They are cooled by helium gas. Presaturation of the large water signal is
enhanced by an additional coil generating magnetic field gradients along the z-axis. A picture
of the used spectrometer is given in Figure 4.6.
The prepared samples were placed in the sample changer at 4°C. A robotic arm inserted an
individual sample into the static magnetic field of the superconducting magnet through the
bore. Before starting the measurements, each sample was allowed to equilibrate for 300 s in the
magnet at 298 K (25°C), as recommended in [Zacharias et al. 2013b)]. The temperature unit
had been previously calibrated using a deuterated methanol sample [Zacharias et al. 2013b)].
For each inserted specimen, the following steps were, if not indicated elsewise, performed au-
tomatically, employing the automated acquisition suite ICON-NMR (Bruker BioSpin GmbH,
Rheinstetten, Germany) included in the TopSpin program (latest version: TopSpin 3.1) (Bruker
BioSpin GmbH, Rheinstetten, Germany). First, the cryogenic probe head was "tuned and
matched" by a "wobble" routine, i.e. it was correctly tuned to the observe frequency of the in-
serted sample, which depends on the solvent of the specimen, and the impedance of the network
was correctly matched [Butler 2002]. Then, the probe head was locked onto the resonance fre-
quency of D2O, which had been previously added to the sample as described in section 4.2.2.1,
employing an independent coil [Butler 2002]. This allowed a monitoring of possible variations
of the static magnetic field strength during the measurement, which can be corrected accord-
ingly [Butler 2002]. The automated shimming procedure ensures maximum field homogeneity,
which is crucial for optimal signal resolution and sensitivity [Butler 2002]. Thereby, the cur-
rents of a set of shim coils, the so-called shim system, were adjusted to eliminate any magnetic
field strength gradients along the sample [Butler 2002] starting from a standard shim file op-
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Figure 4.6: Experimental NMR setup. a) Console with amplifier and digital receiver unit.
b) 600 MHz Bruker Avance III NMR spectrometer with cooled sample changer,
superconducting magnet, and probe head. Taken from [Zacharias 2012].
timized for the respective sample matrix [Zacharias et al. 2013b)]. Finally, the pulse lengths
were calibrated automatically [Zacharias et al. 2013b)]. A detailed description of the actual
procedures performed for an automated tuning and matching, locking, and shimming of the
probe head are beyond the scope of this thesis and can be found in [Butler 2002].
After these adjustments, the actual FIDs were recorded employing the respective pulse se-
quences, as detailed separately in the Materials and Methods part of each project.
In the following, some popular one-dimensional (1D) and 2D NMR experiments are briefly
introduced, which were applied for this thesis.
The nuclear Overhauser enhancement spectroscopy (NOESY) experiment is very popular in
NMR based metabolomic investigations of complex biofluids [Zacharias et al. 2013b),McKay
2011]. It utilizes the nuclear Overhauser effect (NOE), which describes the transfer of mag-
netization between different nuclei populations via cross relaxation through space [Kumar et
al. 1980]. The NOE manifests itself in a fractional change in intensity of one NMR line when
another resonance is perturbed [Kumar et al. 1980]. Consequently, by saturating one spin reso-
nance, the resonance of a neighboring spin can be enhanced and the corresponding sensitivity is
improved [McKay 2011]. This phenomenon is employed to effectively suppress the solvent, i.e.
water, signal [McKay 2011]. Furthermore, NOESY experiments allow inference of the spatial
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arrangement of nuclei in a molecule [Kumar et al. 1980]. Measurement of the first increment
of the 2D NOESY pulse sequence yields a well resolved 1D spectrum with efficient water signal
suppression in addition to presaturation [McKay 2011].
The Carr-Purcell-Meiboom-Gill (CPMG) [Carr and Purcell 1954,Meiboom and Gill 1958] ex-
periment offers an effective method for the suppression of broad NMR signals arising from
spins in macromolecules such as proteins [Zacharias et al. 2013b), Beckonert et al. 2007]. It
employs differences in the relaxation properties of spins in macromolecules and low-molecular
weight metabolites [Zacharias et al. 2013b)]. In fact, the transversal or T2 relaxation of protons
in macromolecules is faster than the T2 relaxation of protons in small molecules due to more
possible spin-spin interactions [Beckonert et al. 2007]. Consequently, after the magnetization
has been transferred to the x - y - plane by an initial 90° pulse, the magnetization of pro-
tons in macromolecules and the magnetization of protons in small molecules start to dephase
with different rates. During the application of appropriate 180° pulses in order to refocus the
chemical shifts, the wanted magnetization of spins in small molecules relaxes with a smaller
rate than the unwanted magnetization of spins in macromolecules. Consequently, the FID, ac-
quired after an appropriate filter period, does not reflect rf signals from spins in macromolecules.
The heteronuclear single quantum coherence (HSQC) experiment correlates a nucleus with its
directly attached heteronucleus via scalar coupling [Ernst et al. 1987]. Thereby, magnetization
is usually transferred from sensitive 1H nuclei to insensitive 13C heteronuclei by scalar cou-
pling, a process called insensitive nuclei enhanced by polarization transfer (INEPT) [Ernst et
al. 1987]. The preparation period is used to establish a maximum amount of magnetization
for the 13C heteronuclei by employing INEPT [Ernst et al. 1987]. During the evolution period
t1, the chemical shifts of the 13C heteronuclei evolve [Ernst et al. 1987]. In the mixing period,
the 13C magnetization is brought back to the 1H nucleus by scalar coupling, which is called a
reversed INEPT [Ernst et al. 1987]. The resulting 1H magnetization is now recorded in the
acquisition period with time t2. During the acquisition period, the J-coupling between protons
and heteronuclei is removed by applying decoupling pulses, which are longer and less powerful
than excitation pulses, to avoid splitting of the acquired 1H signals [Ernst et al. 1987,Butler
2002]. By varying t1, a second time/frequency dimension is created [Ernst et al. 1987], and
the resulting 2D HSQC spectrum usually shows cross peaks of the excited 1H nucleus, whose
resonance frequency is commonly displayed on the x-axis, and its scalar coupled 13C nucleus,
whose resonance frequency is commonly displayed on the y-axis [Ernst et al. 1987]. The great
signal dispersion of about 140ppm in the indirect 13C dimension without an increased number
of signals in the 2D 1H-13C HSQC spectra in comparison to 1D 1H spectra supports efficient
metabolite identification [Zacharias et al. 2013b)].
The heteronuclear multiple bond correlation (HMBC) experiment usually transfers magnetiza-
tion from sensitive 1H nuclei to insensitive 13C heteronuclei, which are separated from each other
by more than one chemical bond [Berger and Braun 2004]. Consequently, the 1H frequency of
the direct proton is correlated with the 13C frequency of the indirect nucleus usually separated
by two to three chemical bonds [Berger and Braun 2004], similar to the HSQC experiment. Its
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application for this thesis was limited to providing supplemental information about molecular
structures for the identification of unknown metabolites.
The total correlation spectroscopy (TOCSY) experiment is closely related to the correlation
spectroscopy (COSY) experiment. In a COSY experiment, directly coupled nuclei as well as nu-
clei coupled through multiple couplings are correlated with each other by scalar coupling [Berger
and Braun 2004]. Cross-peaks in COSY spectra usually provide information about nuclei sepa-
rated from each other by two to three chemical bonds and deductions about connectivities and
even about the chemical structure of the investigated molecules can be made [Berger and Braun
2004]. In TOCSY spectra, all connected nuclei within the same spin system can be correlated
via scalar coupling under the restriction that nuclei are not separated from each other by more
than three bonds, since otherwise, the interactions between the nuclei become too weak to be
detected [Ernst et al. 1987]. In complex biofluids like urine or plasma, compare to section
4.2.2.1, severe signal overlap is present in 1H 1H TOCSY spectra [Zacharias et al. 2013b)].
Therefore, 1H 1H TOCSY spectra have only been used as a complementary tool for metabolite
identification in combination with 1D NOESY and 2D HSQC spectra in this thesis (compare
to section 4.3.2).
4.2.2.3 Data preprocessing
The acquired FID is automatically Fourier transformed to yield the frequency dependent
NMR spectrum employing the TopSpin program (latest version: TopSpin 3.1) (Bruker BioSpin
GmbH, Rheinstetten, Germany). Prior to this, an exponential filter function with a line broad-
ening of 0.3 Hz and zero filling to 131072 points was automatically applied for zero order phase
correction for the 1D spectra [Zacharias et al. 2013b)]. For 2D HSQC spectra, squared sine
functions were used as window functions for both dimensions with a shift of 90° between them.
For 1D spectra, the first points of the FID were corrected using the baseopt option of Top-
Spin (latest version: TopSpin 3.1) (Bruker BioSpin GmbH, Rheinstetten, Germany) in order
to obtain a flat baseline prior to Fourier transformation and to avoid first order phase dis-
tortions [Zacharias et al. 2013b)]. In the rare case of phase errors, usually by 180° mostly
for highly diluted samples, spectra were manually phase corrected. Additionally, an auto-
matic baseline correction with fifth-degree polynomial was applied employing a readily avail-
able Python script [Klein 2011]. 2D spectra were also preprocessed using a readily available
Python script [Klein 2011]. Each 2D spectrum was manually phase corrected and a fifth-order
polynomial baseline correction was applied in both dimensions [Klein 2011].
For subsequent statistical data analysis, as described in section 4.3.1, NMR-derived fingerprints
were employed, which usually exploit variations in NMR signal position due to differences in
pH, salt concentration, and/or temperature [Zacharias et al. 2013b)]. The following passage
describes a procedure to account for these differences and has already been published in a
slightly modified version in [Zacharias et al. 2013b)].
A widely used and robust method to compensate for the previously described effects is called
binning or bucketing, whereby a spectrum is split into a number of segments called bins, buck-
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ets, or features. Equal-sized buckets were used throughout this thesis, albeit other schemes
such as adaptive binning have been proposed. Data points inside every bucket were summed
up. The whole spectrum is then represented as a vector of bucket integrals, which are used for
statistical data analysis.
The bucketing procedure for this thesis was carried out employing Amix VIEWER (latest ver-
sion: Amix Viewer 3.9.13) (Bruker BioSpin GmbH, Rheinstetten, Germany). Furthermore,
the region around the water artifact and the broad urea signal were excluded for both urinary
and plasma NMR data. The water artifact, still remaining despite accurate water suppression,
obscures all neighboring signals and might further vary across different spectra depending on
the quality of the applied water suppression [Dieterle et al. 2011]. Urea, both present in urine
and plasma specimens [Bouatra et al. 2013,Psychogios et al. 2011], rapidly exchanges protons
with the surrounding water solvent and therefore exhibits a very broad NMR signal [Dieterle
et al. 2011,Klein 2011].
Exact details about the used parameters for bucketing and NMR signal exclusion are given
explicitly for each project in the respective Materials and Methods parts in section 5.
4.3 Data analysis
4.3.1 Statistical data analysis
All statistical data analyses described in this section and in section 5 were carried out with the
freely available statistical analysis software R [R Core Team 2014], if not stated elsewise. R is
highly accepted in the biostatistics community and provides a large range of software packages
for statistical computing and graphics [James et al. 2013].
A step-by-step R-Code for the statistical data analysis performed for this thesis has been
developed and is given in a general form in Appendix I section 7.1. The following paragraphs
will provide the statistical background and refer to the specific R-Code in Appendix I section
7.1.
4.3.1.1 Data normalization
As already highlighted in section 4.2.2.1, metabolic fingerprints derived from urine or plasma
specimens exhibit, in general, data variance across the sample cohort from three major sources:
technical variation, non-intended biological variation, and intended biological variation [Zacharias
et al. 2013b),Maher et al. 2007,van den Berg et al. 2006].
Technical variations, e.g. differences in sample storage, were avoided or kept to a minimum in
this thesis, as outlined in section 4.2.2.1.
Investigations of the intended biological variation, i.e. disease status of the biofluid donors, are
the main objectives of this thesis, as described in section 3.2. Therefore, multivariate statistics
were employed, which utilize the joint distribution of the data including the variance of indi-
vidual features and their joint covariance structure [Zacharias et al. 2013b),Kohl et al. 2012].
Non-intended biological variation, e.g. differences in fluid intake across investigated urine spec-
imens, comorbidities, etc., but also inevitable measurement noise need to be appropriately
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addressed as they can obscure statistical analysis of the intended biological variation [Zacharias
et al. 2013b),Kohl et al. 2012,van den Berg et al. 2006]. Moreover, several-order-of-magnitude
differences between metabolite concentrations of a biological specimen can lead to erroneous
inferences by statistical data analyses, as the high abundance of metabolites is not necessar-
ily proportional to their biological importance [Kohl et al. 2012, van den Berg et al. 2006].
Additionally, technical and non-intended biological variation is usually heteroscedastic, leading
to secondary data structures [Kohl et al. 2012, van den Berg et al. 2006]. To overcome these
confounding effects, adequate scaling and normalization techniques can be applied, which are
briefly introduced in this section.
The actual scaling and/or normalization method including the respective parameters employed
for the individual projects are given in the respective Materials and Methods parts in section
5. A detailed mathematical description of the available normalization and scaling techniques
was omitted, as it lies beyond the scope of this thesis. It can be found in [Kohl et al. 2012,van
den Berg et al. 2006].
Differences in urinary metabolic concentrations across a sample cohort due to individual fluid
intake are usually overcome by a scaling of the metabolite concentrations/bucket intensities
of a sample to the respective creatinine concentration [Zacharias et al. 2013b), Kohl et al.
2012,Klein 2011]. As the creatinine excretion into urine is normally constant over time [Dörner
2013], this is also general practice in traditional clinical approaches [Dörner 2013].
For this thesis, this scaling method was usually performed during the bucketing procedure,
compare to section 4.2.2.3, employing Amix VIEWER (latest version: Amix Viewer 3.9.13)
(Bruker BioSpin GmbH, Rheinstetten, Germany). However, note that scaling of bucket inten-
sities to urinary creatinine is only applicable if there exist no overall differences in creatinine
concentrations between the intended biological groups.
Previously, various normalization methods for NMR-based metabolomic data had been sys-
tematically compared utilizing two different urinary data sets by [Kohl et al. 2012]. With
regard to overall results for classification of specimens, bias reduction, and correct detection of
fold changes, Quantile [Bolstad et al. 2003], Variance Stabilization [Huber et al. 2002], and
Cubic-Spline [Workman et al. 2002] normalization performed best [Zacharias et al. 2013b),Kohl
et al. 2012]. For this thesis, only Quantile and Variance Stabilization normalization were em-
ployed and are briefly discussed here.
Quantile normalization removes unwanted sample-to-sample variation of metabolites/bucket in-
tensities by introducing an equal distribution of feature intensities across all spectra [Zacharias
et al. 2013b),Kohl et al. 2012]. In brief, for each spectrum, the individual buckets are sorted
according to their feature intensities in ascending order [Kohl et al. 2012]. Then, the mean
value for each quantile, i.e., for example, the bucket with the highest feature intensity in one
spectrum, is calculated across all spectra [Kohl et al. 2012]. Now, each bucket intensity is
set to the corresponding mean value of its respective quantile [Kohl et al. 2012]. Finally, the
individual buckets with new values of feature intensities are brought back to the original order
of the respective spectrum [Kohl et al. 2012]. Consequently, each spectrum of the normalized
data cohort now exhibits the same set of feature intensities, although individually distributed
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across the features/buckets [Kohl et al. 2012]. In this thesis, Quantile normalization was car-
ried out utilizing the R package affy [Gautier et al. 2004], and the corresponding R-code can
be found in section 7.1.3.2.
Variance Stabilization normalization (VSN) performs an inverse hyperbolic sine transformation
of the data, which has logarithmic character for large, and linear character for small values [Hu-
ber et al. 2002,Kohl et al. 2012]. For unnormalized data, the coefficient of variation, i.e. the
variance divided by the corresponding mean, fairly stays constant for strong and medium feature
intensities under the assumption that the standard deviation is proportional to the mean [Kohl
et al. 2012]. However, for small feature intensities, the variance rather stays constant, resulting
into an increasing coefficient of variation for decreasing feature intensities [Kohl et al. 2012].
Consequently, after applying the VSN, the adjusted variance of different metabolites/bucket
intensities across the spectra becomes fairly homoscedastic [Kohl et al. 2012]. In this thesis,
VSN was carried out utilizing the R package vsn [Huber et al. 2002] and the corresponding
R-code can be found in section 7.1.3.3. Note that the vsn package, in addition, linearly maps
all spectra to the first spectrum [Kohl et al. 2012].
It has to be noted that Quantile and VS normalization are only applicable if a relatively small
proportion of metabolites/feature intensities is regulated in approximately equal shares up and
down between the intended biological groups [Hochrein et al. 2015,Kohl et al. 2012].
4.3.1.2 Unsupervised statistical data analysis
2 For unsupervised statistical data analysis, no information about underlying groups is used.
Therefore, group separations observed are purely data-driven. This renders these approaches,
in contrast to supervised statistical data analysis, as described in section 4.3.1.3, insensitive to
overfitting in case of small sample numbers. Unsupervised statistical data analyses are often
employed initially to check for group separation prior to classification of data, in cases where
too few samples are available for classification with rigid cross-validation, or if the group iden-
tities are unknown.
The following paragraphs briefly introduce the unsupervised algorithms utilized in this the-
sis without a detailed mathematical description, which can be found in [Abdi and Williams
2010,Eisen et al. 1998].
Principal component analysis (PCA) is a widely used unsupervised approach for easy visu-
alization of experimental data. In case of binned NMR spectra, the data of each spectrum
can be considered as one point in a multidimensional space, with each bucket representing one
dimension and the bucket intensity representing the value in that dimension. PCA performs a
data transformation by defining a new coordinate system within this space. The newly defined
dimensions are referred to as Principal Components (PCs). The first PC is aligned along the
direction of maximum variance in the data. The second PC is chosen to be orthogonal to PC1
and to have maximum variance, again. According to this scheme, PCs are defined either until a
fixed number of PCs is reached or until the PCs variance exceeds a certain amount of the total
2This section was published in [Zacharias et al. 2013b)] in a slightly altered version.
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variance of all original dimensions, e.g. 95%. Mathematically speaking, the whole procedure
is based on matrix diagonalization. When plotting the spectra in the reduced PC space, e.g.
showing PC1 versus PC2, a considerable amount of the variance present in the data set is
visualized allowing an easy inspection of the data such as the identification of distinct groups
of samples or the detection of batch effects.
In this thesis, PCA was carried out with the R intern PCA algorithm [Venables and Ripley
2002,Mardia et al. 1979, Becker et al. 1988], and the package missMDA [Husson and Josse
2013]. The corresponding R-code can be found in section 7.1.4.1.
The general goal of clustering algorithms is to combine observations into groups or clusters
based on a distance measure, by minimizing the distances within a cluster as compared to
the distances between clusters. For this, both hierarchical and non-hierarchical algorithms are
used.
Hierarchical clustering is an intriguingly simple method for finding similarities between spectra.
All spectra are arranged in groups called clusters. At the beginning, each cluster contains ex-
actly one spectrum. Using a distance matrix of pairwise distances, such as Euclidean distance,
Manhattan distance, Pearson’s correlation coefficient, or Spearman’s correlation coefficient, be-
tween clusters, with bucket values serving as coordinates in a multidimensional space, similar
clusters are merged to form a new, larger cluster. This procedure is repeated iteratively, i.e. a
new distance matrix is calculated, the closest clusters are joined, and so on. In case a cluster
contains more than one sample, an overall coordinate for the cluster has to be defined. In
average linkage, for example, the average of all data of a cluster is used. The choice of distance
measure and linkage type exerts a decisive effect on the final clustering result. In the end, all
spectra are contained in one cluster. Taking all intermediate steps into account, a hierarchy of
clusters has been created that can be visualized as a cluster dendrogram. This tree will reveal
groups of similar spectra. Ideally, spectra from predefined groups (e.g. healthy and diseased
groups) should end up in different clusters. This will only work if the inter-spectra differences
are dominated by intended group differences rather than noise or other disturbing factors.
Clustering in this thesis was performed by choosing the option cluster="TRUE" of the function
geneImager included in the R-package compdiagTools [Held et al. 2012], as outlined in Ap-
pendix I section 7.1.4.2. This conducts hierarchical clustering employing Euclidian distances
and the average linkage method [Eisen et al. 1998].
4.3.1.3 Supervised statistical data analysis
Several principle aims of this thesis, as outlined in section 3.2, deal with the detection of
metabolic differences between two patient groups with intended biological inter-group variance,
e.g. healthy and diseased patients. To fulfill this major objective, supervised statistical data
analysis is traditionally the method of choice [Zacharias et al. 2013b)]. It requires information
about the class labels of the individual specimen groups [Zacharias et al. 2013b)].
For the detection of metabolic differences between two predefined patient groups, the Stu-
dent’s t-test was employed in this thesis. The investigated null hypothesis H0 here represents
53
4 Background
the case that no statistically significant difference between the means of two groups exists. To
be more precise, for each feature/bucket b of the NMR data set, it is tested whether H0, i.e. that
there exists no difference between the two group means Xb1 and Xb2, is true or not [Zacharias
et al. 2013b)]. The alternative hypothesis HA represents the case that a statistically significant
difference between these two group means exists.
These hypotheses can be tested by employing a Student’s t-test under the assumption that
the continuous data, here the NMR bucket intensities, is normally distributed [Zacharias et al.
2013b),Livingston 2004]. The normal distribution had been previously tested by employing the
Kolmogorov-Smirnov test [Klein 2011]. By conducting a Student’s t-test for a specific bucket
b, the test statistic Tb is calculated in order to estimate how likely the two group means are
different [Livingston 2004]
Tb =
Xb1 −Xb2
sb
√
1
n1
+ 1
n2
. (4.10)
sb denotes the standard deviation under the assumption that both groups show the same stan-
dard deviation and n1 and n2 denote the size of the different groups, respectively, which are
the degrees of freedom of the t statistic. If |Tb| exceeds the value determined by the aimed
statistical significance, H0 is rejected [Livingston 2004]. By repeating the random drawing of
two sample sets from a normal distribution and calculating the corresponding t-values, one
obtains a normal t-value distribution described by the test statistic Tb under the assumption of
a limited sample size [Livingston 2004].
The corresponding p-values denote the probability to observe a given or even more extreme
t-value under the assumption that H0 is valid [Livingston 2004]. This is termed statistical
significance [Livingston 2004]. The p-values correspond to the area under the curve of the
Student’s t distribution from inf to the specific t-value or from − inf to −t, respectively [Liv-
ingston 2004]. Given that p-values are, by definition, uniformly distributed, p-values indicating
a rejection of H0 can also just be obtained by chance (type I error) [Casella and Berger 2002].
For a complete NMR data set, several hundred different t-tests are usually performed [Zacharias
et al. 2013b)]. Consequently, a rejection of H0 just by chance gets even more likely [Zacharias et
al. 2013b)], which is termed a multiple testing problem. Consequently, the so-called α-value is
defined as the probability of rejecting H0 when it is true or as the probability of an observed dif-
ference resulting from chance alone (type I error) [Livingston and Cassidy 2005]. In this thesis,
the multiple testing problem was overcome by applying the method of Benjamini and Hochberg
(B/H) [Benjamini and Hochberg 1995]. This method controls the false discovery rate (FDR),
i.e. the expected proportion of falsely rejected H0, at a given significance level [Zacharias et al.
2013b),Benjamini and Hochberg 1995]. Here, α was, in agreement with general practice [Liv-
ingston and Cassidy 2005], chosen to be 0.05, i.e. for the group of all buckets with a p-value
B/H adjusted below 0.05, there exists a less than 5% probability that observed differences be-
tween the two compared groups occur because of chance alone rather than because of a true
difference between the groups (i.e. chance of detecting false positives) [Livingston and Cassidy
2005]. This corresponds to an FDR below 5% [Zacharias et al. 2013b)]. Mathematical details
can be found in [Benjamini and Hochberg 1995].
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The β-value is defined as the probability of accepting H0 when it is false or as the probabil-
ity of concluding that no difference exists when one is present (type II error) [Livingston and
Cassidy 2005]. Hence, the statistical power pi = 1 − β is defined as the probability of reject-
ing H0 when it is false or as the probability of detecting a statistically significant difference
if one exists [Livingston and Cassidy 2005]. In other words, it is the probability that a true
difference between two groups is correctly detected. It can be calculated post-hoc, i.e. after
executing a Student’s t-test, and depends on the actual sample sizes of the two groups n1 and
n2, the magnitude of the measured effect, i.e. the size of the actual difference between the two
groups, here Xb1 − Xb2, the underlying variability of the outcome measurements of interest,
i.e. the standard deviation sb, and the α-value, here α = 0.05 [Livingston and Cassidy 2005].
The magnitude of the measured effect and the corresponding standard deviation together are
called the effect size [Livingston and Cassidy 2005]. Note that in clinical research, however,
one usually determines the required sample size for detecting a certain effect size (which is usu-
ally estimated based on previous studies) prior to patient recruitment [Livingston and Cassidy
2005]. The required sample size, in turn, depends on the effect size, the α-value, and the desired
statistical power pi, which is, as a general agreement, usually set to pi = 0.8 [Livingston and
Cassidy 2005]. More details about the mathematical relationship between these parameters
can be found in [Livingston and Cassidy 2005]. The statistical power pi was either calculated
employing the freely available software G*Power Version 3.1.7 [Faul et al. 2007], or with the R
package pwr [Champely 2015], whereas the corresponding effect size was calculated with the
R package compute.es [Del Re 2013]. The corresponding R-code can be found in Appendix I
section 7.1.4.2.
In this thesis, t- and p-values for two groups were calculated using the R package multtest,
which employs the so called Welch-test, a modification of the two sample t-test assuming un-
equal and unknown variances of the basic population [Pollard et al. 2005]. The corresponding
R-code is given in section 7.1.4.2.
If more than two groups were compared, a one-way analysis of variance (one-way ANOVA)
was conducted under the assumption of normally distributed continuous data [Zacharias et
al. 2013b), Casella and Berger 2002]. The one-way ANOVA additionally assumes that the
samples are independent, which implies that one sample can only belong to one group, and
that the observations within each sample were acquired independently [Motulsky 1995]. The
corresponding H0 is that the specimens of two or more groups are members of the same ba-
sic population [Motulsky 1995]. Therefore, a one-way ANOVA tests whether all investigated
groups have equal mean and variance, which is equivalent to an F -test [Motulsky 1995]. The
result of a one-way ANOVA therefore indicates the probability that at least two groups of the
data set have different means, but it does not reveal the varying groups. Therefore, additional
two sample t-tests have to be employed for all possible group comparisons [Klein 2011]. The
utilized R package limma [Smyth 2005] furthermore fits a linear model to the data, which de-
scribes the influence of each given group characteristic (a group characteristic can be, e.g., the
treatment with a specific drug or a specific sample collection time-point) on the data [Zacharias
et al. 2013b)]. The respective R-code can be found in section 7.1.4.2.
The discriminating features, identified by the two sample t-test, were displayed in heat-map
representations, which offer a convenient possibility of illustrating their respective up- and
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down-regulations in each investigated spectrum [Zacharias et al. 2013b)]. They were generated
employing the R package compdiagTools [Held et al. 2012], and the corresponding R-code is
outlined in section 7.1.4.2.
In the case of comparing categorical variables between two groups, Fisher’s exact test for 2× 2
contingency tables was employed for this thesis utilizing the R intern function "fisher.test"
[Agresti 1990,Agresti 2002,Fisher 1935,Fisher 1962,Fisher 1970,Mehta and Patel 1986,Clark-
son et al. 1993, Patefield 1981]. It assumes random sampling as well as both independent
observations and samples [Motulsky 1995].
3 Classification of an unknown sample to known classes of disease (e.g. healthy and dis-
eased) based on discriminating features offers a convenient way of estimating the strength of
a novel disease biomarker. Here, it was performed by employing supervised techniques from
machine learning.
Thus far, approaches based on Partial Least Squares Discriminant Analysis (PLS-DA) [Barker
and Rayens 2003], often in the combination with orthogonal projection to latent structures
(OPLS-DA) [Trygg and Wold 2002], have dominated the classification of NMR metabolomic
data. Dipl. Math. Jochen Hochrein compared the performance of PLS-DA to other clas-
sification approaches commonly used in genomics on various metabolite fingerprinting data
including an AKI plasma data set [Hochrein et al. 2012]. For some classifiers consistently good
performance was obtained independent of the data set in question. These classifiers included
Random Forests (RF) [Hochrein et al. 2012, Breiman 2001] and Support Vector Machines
(SVM) [Hochrein et al. 2012, Dudoit et al. 2002, Burges 1998]. The former are particularly
suited for the analysis of high-dimensional NMR data.
A RF classifier consists of a set of tree predictors, where each tree is constructed from a different
bootstrap sample of the training data. At each node of the tree the splitting in branches is
based on a random selection of the input features. The final class label given to a new sample
is the result of a majority vote over all trees. Another advantage of RFs is the provision of
different measures of variable importance, which was used for the identification of predictive
subsets of spectral features [Menze et al. 2009,Bryan et al. 2008]. A schematic representation
for an RF classifier is given in Figure 4.7a). The internal parameters of the RF classifier are
the number of grown decision trees ntree and the number of tried variables mtry, which repre-
sents the number of variables employed by the RF classifier for the splitting at each node of a
tree [Breiman 2001,Breiman 2002].
SVMs showed good performance on high- as well as low-dimensional data sets. SVM classi-
fiers are so-called large margin classifiers, in which a separating hyperplane is determined in
a way to maximize the distance between the individual classes of the training data. This hy-
perplane is constructed in a high dimensional vector space defined by the individual feature
levels [Zacharias et al. 2013b), Hochrein et al. 2012]. Therefore, SVMs map the data to a
higher-dimensional space by employing kernel-functions [Hochrein et al. 2012]. Both linear
and radial basis function kernels were used in this thesis. Figure 4.7b) illustrates the main
3The following two paragraphs were published in [Zacharias et al. 2013b)] in a slightly altered version.
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principle of a linear SVM trained on linearly separable data in a 2D space. For both linear
and radial basis function kernels, the cost parameter C, which weighs the distance between
outliers and the separating hyperplane and needs to be optimized in order to avoid over- and
underfitting [Burges 1998], is optimized as an internal parameter of the SVM classifier in the
cross-validation procedure. For a radial basis function kernel, the Kernel parameter γ, which
is an indicator for the smearing out of the data points [Varma and Simon 2006], is additionally
optimized.
Figure 4.7: Main principle of a RF and a linear SVM trained on linearly separable
data in 2D space. a) An RF consists of multiple decision trees, each of them
independently grown during training [Hochrein et al. 2012]. The classification of a
new data point with unknown group membership by the RF is based on a majority
vote of all decision trees [Hochrein et al. 2012]. Modified from [Zacharias et al.
2013b)]. b) By training an SVM, an optimal hyperplane hopt with maximal margin
δ is generated, which is capable of separating two predefined groups (blue circles
and red squares). A new data point/vector (green polygon) with unknown group
membership can now be classified. δ is defined as the maximal possible distance
to the two hyperplanes h−1 and h+1. These hyperplanes h−1 and h+1 indicate
the position of the data points (vectors) x1 and x2. As the position of hopt only
depends on the position of x1 and x2, they are called support vectors. Note that the
cost parameter C, which weighs the distance between outliers and the separating
hyperplane, is not considered in this case since only perfectly separable data is
shown. Modified from [Zacharias 2012].
Generally, classifiers or classification algorithms are trained on a training data set where a class
label for each sample is known, followed by an application of the trained algorithm on new
test data. For performance evaluation, class labels of the test data also have to be known. In
this thesis, performance evaluations were conducted within a cross-validation setting for small
specimen cohorts (number of specimens < number of features) in order to avoid overfitting,
where the complete data set was iteratively split into training and test data [Varma and Simon
2006]. For larger specimen cohorts (number of specimens > number of features), the complete
data set was once split into a training and test set, comprising 2/3 and 1/3 of the complete set,
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respectively, as recommended in [Lottaz et al. 2008]. It was ensued that no systematic differ-
ences exist between these two subcohorts. The employed classifier was subsequently trained on
this specific training set and its predictive performance was assessed on the fixed test set.
Nested cross-validation schemes where parameters relevant for feature selection and the clas-
sification algorithm are optimized within the inner loops were employed for small specimen
cohorts. This ensures that validation is not biased by training or parameter optimization. A
schematic representation of a 3-fold nested cross-validation is given in Figure 4.8. Here, the
upper bar represents the complete data set; it is split iteratively in training and test data (in-
dicated by the green and orange bars, respectively). The training data of this loop is passed
on to the middle loop, where it is again split in training and test data. The training data
of the middle loop is transferred to the innermost loop of the nested cross-validation scheme
where it is again split as described above. Here, parameters inherent to the classifier are tuned.
In the middle loop, the sparsity of the classifier, e. g. the number of used features/buckets
is optimized, while in the outmost loop validation is performed. It was ensured that all data
of a specific loop are used once for testing. It has been previously shown that with a nested
cross-validation approach an almost unbiased assessment of the true classification error is ob-
tained [Varma and Simon 2006].
Figure 4.8: General scheme of a three-fold nested cross-validation. Each line, consisting
of two bars, which represent test and training data set, respectively, represents one
loop. The training and test data set of the upmost line comprises the complete data
set. More details are given in the text. Modified from [Zacharias et al. 2013b)].
For this thesis, RF as well as SVM classification methods were combined with a t-score-based
feature filtering approach [Zacharias et al. 2013b),Hochrein et al. 2012], as it performed best
in [Hochrein et al. 2012].
For RF classification, the R package randomForest [Liaw and Wiener 2002], for SVM classifi-
cation, the R package e1071 [Dimitriadou et al. 2011] was employed. Classifier performances
were evaluated utilizing the area under the respective receiver operating characteristic (ROC)
curve, employing the R package ROCR [Sing et al. 2005]. The corresponding R-code of the
cross-validation procedures with feature selection based on t-tests was implemented by Dipl.
Math. Jochen Hochrein [Hochrein et al. 2012]. More details about the mathematical back-
ground of RFs and SVMs are given in [Burges 1998,Breiman 2001]. The specific parameters for
the classification procedures conducted for the respective projects are detailed in the particular
Materials and Methods parts in section 5.
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Correlation calculations were performed in order to estimate the linear dependence between
two variables x and y [Merziger et al. 2004]. In this thesis, Pearson’s correlation coefficient r
was calculated according to the following definition [Motulsky 1995]
r =
∑n
i=1[
(xi−x)
sx
] · [ (yi−y)
sy
]
n− 1 , (4.11)
where s denotes the standard deviation and n the number of data points [Motulsky 1995]. It
assumes that x and y values were sampled from populations which follow a Gaussian distribu-
tion [Motulsky 1995]. r can attain values over the interval [−1,+1], where r = −1 and r = 1
indicate perfect anti-correlation or correlation of two variables, respectively [Motulsky 1995].
If r = 0, no correlation exists between the compared variables [Motulsky 1995]. The square of
r is called the coefficient of determination R2, and is a measure for the proportion of variance
shared between the two variables [Motulsky 1995]. The R intern function "cor" [Becker et al.
1988] was employed.
The principle of regression analysis can be summarized as the description of a dependent vari-
able by one or more explanatory variables. Therefore, a so-called regression function or model
is computed, which can be used to predict dependent variables based on the corresponding ex-
planatory variables [Dalgaard 2008]. In this thesis, simple as well as multiple linear regression
analyses were performed. A number of explanatory or predictor variables xj are employed to
fit a linear model
yi = β0 +
p∑
j=1
βjxij + , (4.12)
where yi is the dependent or response variable, β0 is the intercept, βj the so-called regression co-
efficients, and  the disturbance parameters representing random variability, which are assumed
to be independent and N(0, σ2) [Dalgaard 2008,Hastie et al. 2001,Motulsky 1995]. β0, βj, and
σ are estimated on a training data set (x1, y1), ..., (xN , yN), where each xi = (xi1, xi2, ..., xip)T
is a vector of feature intensities for the ith case [Hastie et al. 2001]. This is conducted by em-
ploying the method of least squares, i.e. minimizing the residual sum of squares (RSS) [Hastie
et al. 2001]
RSS =
N∑
i=1
(yi − β0 −
p∑
j=1
xijβj)2. (4.13)
The derived linear regression model or equation can now be employed to predict new dependent
variables in an independent test set [James et al. 2013,Hastie et al. 2001]. By employing the
method of least squares, however, two major problems can occur [James et al. 2013]. First, if
the number of explanatory variables exceeds the number of dependent variables, the regression
model derived by the method of least squares will perfectly describe the dependent variables
of the training set [James et al. 2013]. However, this model is highly prone to overfitting and
will therefore probably not yield satisfying predictions for an independent test set [James et
al. 2013]. Second, the interpretation of such multiple regression models is not straightforward,
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because they often include variables without any association with the dependent responses
[James et al. 2013]. Especially in the case of NMR metabolomics data, where very large
numbers of explanatory variables, i.e. numbers of features/buckets, are present, often exceeding
the number of samples used for model fitting, the problems of overfitting and data interpretation
become eminent.
These drawbacks can be overcome by various methods, including subset selection and regression
coefficient shrinkage [James et al. 2013]. A prominent example for subset selection in multiple
regression analysis is the least-angle regression (LARS) [Efron et al. 2004].
The two most popular regression coefficient shrinkage methods are ridge regression [Hoerl
and Kennard 1970] and least absolute shrinkage and selection operator (LASSO) regression
[Tibshirani 1996]. An upper bound t or s, respectively, is set for the l1 or l2 norm of the
regression coefficients βj in LASSO or ridge regression, respectively [James et al. 2013,Hastie
et al. 2001]. The minimization problems can be formulated as [James et al. 2013,Hastie et al.
2001]
β̂lasso = argmin
β
N∑
i=1
(yi − β0 −
p∑
j=1
xijβj)2 subject to
p∑
j=1
|βj| ≤ t, or (4.14)
β̂ridge = argmin
β
N∑
i=1
(yi − β0 −
p∑
j=1
xijβj)2 subject to
p∑
j=1
β2j ≤ s. (4.15)
These minimization problems can be equivalently formulated following the Lagrangian formal-
ism [James et al. 2013,Hastie et al. 2001]
β̂lasso = argmin
β

N∑
i=1
(yi − β0 −
p∑
j=1
xijβj)2 + λ
p∑
j=1
|βj|
 , or (4.16)
β̂ridge = argmin
β

N∑
i=1
(yi − β0 −
p∑
j=1
xijβj)2 + λ
p∑
j=1
β2j
 . (4.17)
λ is the so-called tuning parameter [James et al. 2013], which is usually minimized in an
internal cross-validation procedure. In the case of LASSO regression, some regression coeffi-
cient estimates β̂lasso can become exactly equal to zero, which leads to the exclusion of the
corresponding explanatory variable from the regression model [James et al. 2013,Hastie et al.
2001]. In comparison, regression coefficient estimates β̂ridge are only shrunk towards zero and
all explanatory variables are always included in the regression model [James et al. 2013,Hastie
et al. 2001]. Note that a simple modification of the LARS algorithm implements the entire
solutions of the LASSO [Efron et al. 2004].
In this thesis, regression models were trained on an exclusive training set and then evaluated in
an independent test set. Both the coefficient of determination R2 between true and predicted
dependent variables as well as the mean-squared errors (mse) on training and test data are
reported.
In this thesis, the LASSO algorithm was applied using the R-package glmnet [Friedman et al.
2010]. The corresponding R-code is given in section 7.1.4.3. For simple regression analysis,
a linear model was fitted using the R function "lm" [Chambers 1992,Wilkinson and Rogers
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1973]. More details about the mathematical background of regression analysis can be found
in [James et al. 2013,Dalgaard 2008,Efron et al. 2004,Casella and Berger 2002,Hastie et al.
2001,Motulsky 1995,Tibshirani 1996,Hoerl and Kennard 1970].
4.3.2 Metabolite identification
4 The assignment of features in NMR spectra of biofluids to specific metabolites can be a labo-
rious task that is often complicated by massive signal overlap present in 1D 1H spectra. This
is especially true for the typically crowded region between 4.0 - 3.0 ppm.
As described in section 4.2.2.2, overlapping 1D signals may be resolved in a second dimension.
Consequently, NMR signal assignment in 1D spectra conducted in this thesis was verified by
corresponding 2D spectra. In case of blood samples, broad NMR peaks arising from proteins
or other macromolecules would affect peak discrimination. Therefore, proteins were either re-
moved by ultrafiltration, compare to section 4.2.2.1, or suppressed by employing the CPMG
pulse sequence, as illustrated in section 4.2.2.2.
Initial assignment of distinct NMR peaks, which discriminate between two investigated groups
according to a Student’s t-test (compare to section 4.3.1.3), to metabolites was usually per-
formed on representative 1D 1H and corresponding high-resolution 2D 1H-13C HSQC spectra.
Signals were manually identified by comparison with reference spectra of pure compounds mea-
sured ideally under the same experimental conditions. These reference spectra were downloaded
from the commercially available Bruker Biofluid Reference Compound Database BBIOREF-
CODE that includes a large amount of reference spectra of currently almost 600 mostly natu-
rally occurring metabolites acquired under various experimental conditions (e.g. different pH-
values, solvents, etc.). The NMR analysis software suite AMIX-Viewer (latest version: Amix
Viewer 3.9.13) (BrukerBioSpin GmbH, Rheinstetten, Germany) provided the interface for di-
rectly comparing acquired spectra with reference spectra from the BBIOREFCODE database.
By manually overlaying reference spectra with actual NMR spectra, a considerable number of
resonances were assigned. Despite the considerable number of reference spectra of metabolites
and pharmaceuticals stored in the BBIOREFCODE database, coverage is far from complete in
comparison to MS-based databases such as NIST [Linstrom and Mallard 2016]. Therefore, if
no clear assignment of an NMR peak to a metabolite was possible, reference spectra of pure
compounds, which potentially could be identified in the spectra, were acquired under conditions
similar to the biofluid spectra, and subsequently manually overlaid with and compared to the
biofluid NMR spectra. Additionally acquired 2D spectra further assisted in metabolite iden-
tification as well as the concomitant use of other analytical methods such as high-performing
liquid chromatography (HPLC) and MS.
More details about the actual metabolite assignment procedure are given in the respective
Materials and Methods parts in section 5.
4This section was published in [Zacharias et al. 2013b)] in a slightly altered version.
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4.3.3 Metabolite quantification
Absolute quantification of metabolites and statistical data analysis based on the absolute con-
centrations can be regarded as a targeted profiling approach [Zacharias et al. 2013b)]. For a
correct quantitative analysis of NMR spectra, two issues need to be addressed [Zacharias et al.
2013b)].
First, the complexity of biofluids, especially urine, with hundreds to thousands of different
endo- and exogenous metabolites [Holmes et al. 1997] leads to massive signal overlap especially
in 1D 1H spectra [Zacharias et al. 2013b)]. This can induce over-quantification of compounds,
whose signals are located in crowded regions, e.g. between 4.0 ppm and 3.0 ppm. A manual
inspection of each signal used for quantification, as performed in this thesis, minimizes this
problem in combination with the fact that only NMR signals not overlapping with other sig-
nals were used [Zacharias et al. 2013b)]. Moreover, quantification based on 2D NMR spectra
was applied whenever possible, as the introduction of a second dimension significantly reduces
signal overlap [Zacharias et al. 2013b),Gronwald et al. 2008].
The second issue for NMR quantification describes the fact that, in a given spectrum, two
signals of equal intensity do not necessarily imply equal concentration values [Zacharias et
al. 2013b), Klein et al. 2013]. Therefore, Dr. Matthias Klein developed the freely available
software "MetaboQuant" [Klein et al. 2013,Klein 2011], which offers a tool for automatically
calculating accurate metabolite concentrations from 1D and 2D NMR signal intensities em-
ploying individual calibration factors and different outlier detection algorithms [Klein et al.
2013,Zacharias et al. 2013b),Klein 2011]. For each NMR signal, which was used to determine
the absolute concentration of a compound, individual calibration factors had been either exper-
imentally determined by Dr. Matthias Klein and Prof. Dr. Wolfram Gronwald [Zacharias et
al. 2013b),Klein 2011,Gronwald et al. 2008] or were experimentally determined in this thesis,
as explicitly described in the respective Materials and Methods parts in section 5.
In this thesis, peak picking, fitting, and integration of 1D and 2D NMR signals were per-
formed with the Analytic Profiler of AMIX-Viewer (latest version: Amix Viewer 3.9.13) (Bruker
BioSpin GmbH, Rheinstetten, Germany) employing 1D 1H NOESY, as well as 2D 1H-13C HSQC
spectra. The Analytic Profiler compares the investigated spectrum to a real reference spectrum
and picks the best matching peak in a specified 1H range. This 1H or 13C spectral range had
been either previously determined by Dr. Matthias Klein and Prof. Dr. Wolfram Gronwald
or was determined throughout this thesis for the respective sample matrices. Afterwards, the
peak integral was calculated and the resulting integral was reported, if not stated otherwise,
relative to the known amount of the internal reference substance TSP [Zacharias et al. 2013b)].
Subsequently, the absolute concentrations were calculated employing "MetaboQuant" [Klein et
al. 2013,Klein 2011].
62
5 Biomedical Applications
5.1 Acute Kidney Injury study
5.1.1 Introduction
The first and major aim of this thesis is the detection of novel metabolic biomarkers in the
context of renal diseases. This objective was pursued in an NMR based study of acute
kidney injury after cardiac surgery in collaboration with the University Clinic of Erlangen-
Nuremberg. Small molecule markers for early diagnosis and prediction of AKI were studied in
both urine and plasma specimens and both studies have already been published in [Zacharias
et al. 2013a), Zacharias 2012] and [Zacharias et al. 2015]. I performed parts of the urine
analyses in the context of a master thesis at the Institute of Functional Genomics [Zacharias
2012]. The corresponding results are briefly summarized in this section. This study resulted in
a peer-reviewed publication [Zacharias et al. 2013a)], which was written and published during
my Ph.D. time.
Acute kidney injury has already been elaborately described as a frequent and severe com-
plication after cardiac surgery in section 3.1. Its classification and staging based on increases in
SCr levels or reduction in UO is discussed in section 4.1.2 and 4.1.3. Their drawbacks for early
detection of AKI after cardiac surgery including relatively late rise of SCr after renal injury and
affection by non-renal factors are explicitly outlined in section 4.1.2. Nevertheless, the demand
for early detection of AKI is eminent for early intervention and improved patient care, compare
to section 3.1. Consequently, the identification of urinary and/or serum biomarkers for the
early prognostication of AKI after cardiac surgery has become a prominent field in nephrol-
ogy [Mariscalco et al. 2011,Parikh et al. 2011,Endre et al. 2011,Haase et al. 2010a),Haase et
al. 2010b),Haase et al. 2009,Han et al. 2002,Westhuyzen et al. 2003,Parikh et al. 2005,Han
et al. 2009, Lameire et al. 2011]. One of the most promising biomarkers in urine and serum
was reported as NGAL, which predicted AKI as early as two hours after surgery in a cohort
of pediatric cardiac surgery patients with area under the curve of the receiver operating char-
acteristic (AUC-ROC) values above 0.90 [Haase et al. 2010a)]. Nevertheless, the individual or
combined performance of NGAL and other novel protein biomarkers including serum CysC, γ-
glutamyltranspeptidase (GGT), alkaline phosphatase (AP), kidney injury molecule-1 (KIM-1),
and interleukin-18 (IL-18) in adult patients was less powerful with AUC-ROC values around
0.80 [Kidher et al. 2014,Haase-Fielitz et al. 2009,Wagener et al. 2006].
During my master thesis, I investigated urine specimens from 106 patients that had under-
went cardiac surgery with cardiopulmonary bypass (CPB) use. Every patient had donated one
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urine specimen each before, as well as at 4 and 24 h after surgery. Thirty-four study partici-
pants had been diagnosed with post-operative AKI, compare to section 5.1.2.1. In total, 318
1D 1H NOESY urinary spectra, which had been scaled to the reference region of creatinine,
and subsequently Quantile normalized, as described in section 4.3.1.1, had been investigated.
Since urine specimens collected at three different time-points were available, I conducted a
time-course evaluation for these specimens by means of a PCA taking all NMR features into
account. The corresponding PCA plot including all urine specimens is shown in Appendix II
section 7.2.4 Figure 7.1a). It revealed a clear separation of urine specimens collected before
and at 4 h after surgery, whereas the specimens collected 24 h after surgery fall between the
earlier time-points. Further analysis of the corresponding loadings (data not shown) indicated
that spectral differences were mainly due to the presence of D-mannitol in urine collected at 4
h after surgery, presumably caused by the pre-filling of the tubes of the CPB machine with 500
ml of D-mannitol solution, as described in the CPB protocol in Appendix II section 7.2.2. This
up-regulation of D-mannitol at 4 h was also apparent by visual inspection of representative
urinary 1D 1H spectra collected at 0 h pre-op, 4 h post-op and 24 h post-op, respectively, as
depicted in Appendix II section 7.2.4 Figure 7.1c).
For each of the three urine collection time-points, I conducted classification analyses of the
34 AKI patients versus the 72 non-AKI patients using an SVM with radial basis function
kernel on the 1D 1H NMR data as described in section 4.3.1.3. Results were averaged over
five cross-validation runs where each run started from a different random splitting of test and
training data. For urine specimens collected before surgery, no satisfactory classification of
patients with or without AKI could be obtained. For urine specimens collected at 4 h after
surgery, a group separation was achieved with an overall prediction accuracy of 72.2 ± 2.8 %
and a corresponding AUC-ROC of 0.79 ± 0.02. To obtain these results, on average, 47.4 ±
2.7 features were employed, most of which could not be assigned unambiguously to a specific
solute. Exceptions were hippuric acid and 4-hydroxyhippuric acid. Hippuric acid is a conjugate
of glycine and benzoic acid, which is eliminated by active tubular secretion [Geng and Pang
1999]. Benzoic acid originates mostly from the gut microbial catabolism of dietary polyphenols
contained in fruits, vegetables, wine, tea, extra virgin olive oil, chocolate and other cocoa prod-
ucts [Selma et al. 2009]. Benzoic acid is also a common component of plasticizers, and it is
added to pharmaceuticals, foods, beverages, and cleaning agents because of its anti-microbial
and anti-fungal properties. The simultaneous increase in excretion of 4-hydroxyhippuric acid,
the glycine conjugate of 4-hydroxybenzoic acid, which also mostly originates from dietary in-
take and is a major metabolite of parabens commonly found in pharmaceutical, cosmetic and
nutritional products [Harvey and Everett 2004], makes it the more likely that the increased
urinary levels of hippuric acid in AKI patients are due to the delayed elimination of exogenous
benzoic acid in the proximal tubule, which is particularly prone to ischemia/reperfusion injury
following cardiac surgery with CPB use. However, it cannot be ruled out entirely that other
factors account for or contribute to the increased urinary levels of hippuric acid observed in AKI
patients 4 h after surgery. Cardiac surgery with CPB use, as well as AKI may be accompanied
by metabolic acidosis. Indeed, a study conducted on healthy human volunteers has found that
acidification increases both synthesis of hippuric acid in liver and kidney and its subsequent
excretion [Dzúrik et al. 2001].
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Results of the classification analysis for the 24 h urine specimens showed an improved predictive
performance with an overall accuracy of 76.0 ± 1.9 % and a corresponding AUC-ROC of 0.83
± 0.02. These results were accomplished with an average number of 2.4 ± 0.5 features. The
overall sensitivity and specificity amounted to 57.1 ± 3.7 and 88.6 ± 1.2 %, respectively. Data
indicate a reliable prediction of non-AKI patients, whereas the prediction accuracy of AKI pa-
tients strongly depended on the final stage of the disease. In fact, the worse the AKIN-staging
of the patient the better the prediction accuracy of the trained classifier became. Additionally
performed permutation tests [Mukherjee et al. 2003, Zacharias 2012], as described in section
5.1.2.7, proved that the observed classification accuracies based on 24 h urinary NMR finger-
prints had not been obtained by chance.
Moreover, spectral differences distinguishing AKI and non-AKI urinary NMR fingerprints at 24
h after surgery were investigated according to a Welch-test as described in section 4.3.1.3. The
three most significant features were used by the SVM classification algorithm and included car-
nitine (Padj = 5.0e−8), a feature representing at least in part 2-oxoglutaric acid (Padj = 5.0e−8),
and tranexamic acid (Padj = 9.2e−6). Tranexamic acid, which is a synthetic derivative of lysine,
had been administered to approximately 96 % of all patients enrolled at the time of operation
as an antifibrinolytic agent. On average, 1,489 ± 710 and 1,450 ± 546 mg of tranexamic acid
were administered to patients with and without AKI, respectively (P = 0.76), compare to the
CPB protocol given in Appendix II section 7.2.2. To investigate whether the classification
results obtained were critically dependent on the differential excretion of tranexamic acid, I
repeated tests after exclusion of all spectral regions corresponding to tranexamic acid. Results
revealed an average prediction accuracy of 78.1 % and an area under the ROC curve of 0.84,
indicating that the prediction accuracy does not diminish upon exclusion of tranexamic acid
from analysis.
An up-regulation of tranexamic acid in urine specimens collected at 24 h from AKI patients
in comparison to non-AKI patients appears to indicate reduced glomerular filtration in these
patients, as tranexamic acid is eliminated by glomerular filtration with neither tubular secre-
tion nor adsorption taking place [Eriksson et al. 1974]. This delayed excretion of exogenous
compounds is further reflected in the PCA shown in Appendix II section 7.2.4 Figure 7.1a),
where at 24 h the urinary specimens of the non-AKI patients (marked in red) are located closer
to the specimens collected preoperatively than the specimens of the AKI patients (marked in
orange).
Aside from tranexamic acid, the prediction of AKI at 24 h after surgery rested mainly on
carnitine. The main function of carnitine is the transport of long-chain fatty acids into the
mitochondria for subsequent beta-oxidation [Arduini et al. 2008]. In addition, carnitine is
also used to transport peroxisomal β-oxidation products to the mitochondria, to export ac-
cumulating acyl-groups, and to modulate the level of free coenzyme A in different subcellular
compartments. In mammals, carnitine homeostasis is maintained by endogenous synthesis from
the amino acids lysine and methionine, absorption from dietary sources, and efficient (> 95%)
renal tubular reabsorption [Vaz and Wanders 2002,Lohninger et al. 2005]. Hence, this finding of
increased urinary concentrations of free carnitine in the non-AKI group did come as a surprise,
as it appears to indicate reduced tubular reabsorption by the high-affinity sodium dependent
carnitine cotransporter OCTN2 (SLC22A5), which is expressed in the brush-border membrane
65
5 Biomedical Applications
of the proximal tubule. Damage of the proximal tubule is a hallmark of ischemic kidney injury.
However, if renal tubular dysfunctions were the cause of increased urinary levels of free carni-
tine, one would expect to observe markedly higher levels in the AKI group, in which carnitine
levels remained interestingly near physiological levels [Ciba-Geigy 1983] with an average value
of 0.040 ± 0.073 mmol/mmolcrea, while the average value in the non-AKI group [0.083 ± 0.099
mmol/mmolcrea] was significantly higher (P = 0.014). In comparison, in the specimens collected
before and at 4 h after surgery average urinary carnitine levels of <0.020 mmol/mmolcrea were
obtained for both groups, which is in line with values reported in the literature for healthy
subjects. Other reasons for reduced renal carnitine absorption include reduced urinary sodium
levels or direct inhibition of OCTN2 by drugs such as β-lactam antibiotics and the calcium
channel blocker verapamil [Diao et al. 2010,Ganapathy et al. 2000]. However, there were no
differences in medication administered to AKI and non-AKI patients. Animal studies of AKI
have reported conflicting changes in carnitine levels: In a rat model of ischemia/reperfusion-
induced AKI, reduced serum carnitine levels were observed [Liu et al. 2012], while a rat model
of gentamicin-induced AKI yielded increased levels of urinary carnitine [Al-Shabanah et al.
2010]. Interestingly, the treatment of rats subjected to renal ischemia/reperfusion injury with
carnitine has been shown to improve energy metabolism as evidenced by increased tissue ATP
levels in comparison to untreated animals and to reduce tissue damage [Idrovo et al. 2012].
Hence, the observation of increased urinary levels of carnitine in the non-AKI group may repre-
sent a successful protective response against ischemic injury, whereby carnitine helps to restore
fatty acid oxidation and facilitates the export of the accumulated long-chain acylcarnitines.
Support for this hypothesis comes from the reported significant increase in urinary levels of
hepcidin, a small cysteine-rich peptide that plays an important role in iron homeostasis, as
early as 6 h after cardiac surgery in patients not developing AKI, whereas hepcidin levels re-
mained unchanged for AKI patients [Haase-Fielitz et al. 2011]. Increased renal expression of
hepcidin as an adaptive response to limit ischemia and reperfusion injury caused by CPB was
discussed as a possible mechanism to explain its increased excretion in non-AKI patients.
More detailed information about NMR data acquisition, preprocessing, and statistical analysis
of the urinary spectral data can be found in [Zacharias et al. 2013a), Zacharias 2012]. An
excessive discussion of the presented results can be found in [Zacharias et al. 2013a)].
In the last months of my master thesis, the University Clinic of Erlangen-Nuremberg pro-
vided us with plasma specimens obtained from the same patient cohort. Eight of these plasma
specimens had been, in the context of my master thesis, prepared for and measured by NMR
spectroscopy [Zacharias 2012]. The remaining plasma specimens were prepared for and mea-
sured by NMR spectroscopy at the beginning of my Ph.D. thesis.
Encouraged by the promising prognostic performance of the urinary biomarkers for AKI investi-
gated in my master thesis [Zacharias 2012], I extended the investigation of metabolic alterations
in the context of AKI after cardiac surgery on plasma specimens obtained from the same pa-
tient cohort in my Ph.D. thesis. Moreover, I complemented the NMR study based on urine
specimens with additional statistical data analyses in order to respond to suggestions from peer
reviewers during the publication procedures for [Zacharias et al. 2013a)]. Consequently, this
section mainly focuses on the investigation of plasma specimens by means of NMR spectroscopy
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in the context of AKI after cardiac surgery, but also presents novel results for the urine speci-
men study as performed for my master thesis.
Parts of the plasma analyses were performed by M.Sc. Franziska Vogl. Moreover, several
important method developments and improvements were conducted for this study jointly to-
gether with Dipl. Math. Jochen Hochrein. They have already been published in [Hochrein
et al. 2012] and [Hochrein et al. 2015], and are also part of the Ph.D. thesis of Dipl. Math.
Jochen Hochrein [Hochrein 2016].
5.1.2 Materials and Methods
5.1.2.1 Patient selection and sample collection
1 In total, 106 patients undergoing cardiac surgery with CPB use at the University Clinic of
Erlangen-Nuremberg from July 2009 to August 2010 were included in this study. Operative
procedures included coronary artery bypass grafting (CABG), aortic and/or mitral valve surgery
(replacement and repair), combinations of CABG and heart valve surgery, and thoracic aortic
surgery. The CPB protocol is given in Appendix II section 7.2.2. For the determination of
SCr levels, serum specimens were collected for each patient on the day before surgery and daily
thereafter at 6:00 am. For patient classification according to the AKIN-criteria, SCr levels until
the second day after surgery were taken into account. Of the 106 patients, 34 were diagnosed
with AKI following surgery. In all five patients that required post-operative RRT, treatment
was initiated more than 24 h after surgery. Hence, RRT did not affect metabolite levels in
the simultaneously collected urine and plasma specimens. Detailed clinical characteristics,
administered medication and outcome are given in Table 5.1 and Appendix II section 7.2.1
Table 7.1. Written declarations of consent had been obtained from all study participants
before inclusion. Spot urine samples were collected on the day before surgery, and at 4 and
24 h after surgery. Urine was centrifuged at 1,500 rpm for 5 min and the clear supernatant
was immediately frozen and stored at -80°C until NMR analysis. At 24 h, an additional EDTA
plasma specimen was collected from each patient and stored at -80°C. The daily collected serum
specimens were not available for NMR spectroscopy.
For the plasma study, a subcohort of 85 patients was included for whom enough EDTA plasma
was available. Detailed information on clinical characteristics, administered medication and
outcome for this subcohort is given in Table 5.1b) and Appendix II section 7.2.1 Table 7.1b).
In total, 33 patients out of these 85 were diagnosed with post-operative AKI 48 h and 72 h after
cardiac surgery, compare to Table 5.1b). While 32 patients had reached the same stage of AKI
already after 48 h, one patient, being classified as AKIN 1 48 h after surgery was re-classified
as AKIN 3 72 h after surgery due to a dramatic increase in SCr on the third post-operative
day and was persistently classified as AKIN 3 for the purpose of the plasma analysis. This
difference in AKI-classification at 48 and 72 h after surgery does play a substantial role in the
analysis of intermediate AKI cases, i.e. patients clinically classified as AKIN-stage 1 patients,
as described in section 5.1.2.9. In fact, the different clinically staging at 48 and 72 h after
1The following section has already been published in [Zacharias et al. 2013a)] and [Zacharias et al. 2015] in a
slightly altered version.
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surgery of this particular AKI patient was first noticeable during the analysis of intermediate
AKI cases based on plasma specimens, whereas it did not fall into account during the analysis
of the corresponding urinary specimens for my master thesis [Zacharias et al. 2013a),Zacharias
2012]. Since the AKI-staging for the urine analysis was only based on the clinical staging 48 h
after surgery, this patient had been persistently classified as AKIN 1 in that study [Zacharias
et al. 2013a),Zacharias 2012].
AKIN-stage 0 1 2 3
a) Number of patients for urine study 72 26 3 5
b) Number of patients for plasma study 52 24 3 6a
Table 5.1: Classification by AKIN-criteria. a) Number of patients included in AKI urine
study [Zacharias et al. 2013a),Zacharias 2012]. AKI patients were diagnosed based
on AKIN-criteria, as elaborately described in section 4.1.3. Here, serum samples
collected until 6:00 am on the second post-operative day were taken into account
[Zacharias et al. 2013a), Zacharias 2012]. b) Number of patients included in AKI
plasma study [Zacharias et al. 2015]. aHere, 33 patients out of 85 were diagnosed
with post-operative AKI 48 h and 72 h after cardiac surgery. While 32 patients
had reached the same stage of AKI already after 48 h, one patient, who had been
originally classified as AKIN 1 48 h after surgery for the AKI urine study [Zacharias
et al. 2013a), Zacharias 2012], was re-classified as AKIN 3 72 h after the surgery
[Zacharias et al. 2015]. This re-classification reflects the dramatic increase of SCr on
the third post-operative day for this patient. Modified from [Zacharias et al. 2013a)].
5.1.2.2 NMR spectroscopy
Urine specimens were prepared for NMRmeasurements as described in section 4.2.2.1 [Zacharias
et al. 2013a)], EDTA plasma specimens were ultrafiltrated with a cut-off of 10kD and sub-
sequently prepared for NMR measurements as described in section 4.2.2.1 [Zacharias et al.
2013a), Zacharias et al. 2015]. Note that 0 h and 4 h urine specimens had been prepared by
Caridad Louis, whereas I prepared 24 h urine and a subset of eight plasma specimens in the
context of my master thesis [Zacharias 2012]. I explicitly prepared all other EDTA plasma
specimens for this thesis.
1D 1H NOESY as well as 2D 1H-13C HSQC spectra were measured for all specimens according
to the standard protocols described in section 4.2.2. All urine as well as eight plasma specimens
had been measured in the context of my master thesis [Zacharias 2012], whereas the remaining
plasma specimens were measured during my Ph.D. thesis. For each 1D 1H NOESY spectrum,
128 scans were collected into 65536 data points employing the pulse program noesygppr1d.comp
(BrukerBioSpin GmbH, Rheinstetten, Germany) with water suppression by presaturation dur-
ing relaxation and mixing. Four dummy scans were acquired prior to measurement, the spectral
width was 20.55 ppm, the relaxation delay was 4 s, the acquisition time amounted to 2.66 s,
and the mixing time to 0.01 s, respectively. Each 2D 1H-13C HSQC spectrum was acquired
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employing the pulse program r_hsqcetgppr (BrukerBioSpin GmbH, Rheinstetten, Germany)
with water suppression by presaturation during the relaxation delay. 2048 × 128 data points
were collected using 8 scans per increment, an acquisition time of 0.14 s, a relaxation delay of 3
s, and 16 dummy scans, resulting into a total acquisition time of less than one hour. The spec-
tral widths were 12.01 ppm in the 1H, and 165.01 ppm in the 13C direction, respectively. One
representative high-resolution 2D 1H-13C HSQC spectrum from a non-AKI plasma specimen
was acquired with 2048 × 512 data points using 40 scans per increment, and a spectral width
of 12.01 ppm in the 1H, and 200.00 ppm in the 13C direction, respectively, in the context of my
Ph.D. thesis. For the same plasma specimen, one 2D 1H 1H TOCSY spectrum was acquired
during my Ph.D. thesis using the pulse program mlevgpphw5 (BrukerBioSpin GmbH, Rhein-
stetten, Germany) with 2048 × 512 data points, 16 scans per increment, an acquisition time of
0.14 s, 32 dummy scans, a relaxation delay of 3 s, a mixing time of 60 ms, and a spectral width
of 12.07 ppm. The total acquisition times of the high-resolution 2D 1H-13C HSQC and 2D 1H
1H TOCSY spectrum amounted to approximately 19.6 h and 13 h, respectively. Furthermore,
a 2D 1H-13C HMBC spectrum was acquired for this plasma specimen during my Ph.D. thesis
with 2048 × 1024 data points using 32 scans per increment. Spectral widths amounted to 13.02
ppm in the 1H, and 200.00 ppm in the 13C direction, respectively. The pulse program hmbcgplp-
ndprqf (BrukerBioSpin GmbH, Rheinstetten, Germany) was employed with 16 dummy scans,
an acquisition time of 0.13 s, a relaxation delay of 1.5 s, and spectral widths of 13.02 ppm in
the 1H, and 200.00 ppm in the 13C direction, respectively. The complete measurement time of
the 2D 1H-13C HMBC spectrum amounted to approximately 14 h.
5.1.2.3 Mass spectrometry
M.Sc. Franziska Vogl diluted ultrafiltered plasma samples of five AKI and five non-AKI patients
each with deionized water (1:4) [Zacharias et al. 2015]. She performed metabolic fingerprinting
by means of high-resolution LC-QTOF-MS as previously described [Dettmer et al. 2013]. In
brief, a Thermo Scientific Dionex Ultimate 3000 UHPLC system (Idstein, Germany) coupled to
a Maxis Impact QTOF-MS (Bruker Daltonics, Bremen Germany) equiped with an electrospray
ionization (ESI) source was employed. She used a KinetexTM (Phenomenex, Aschaffenburg,
Germany) 2.6 µm C18 100 × 2.1 mm id column at 25°C utilizing 0.1% formic acid in (i)
water and in (ii) acetonitrile as mobile phase with a flow-rate of 0.3 ml/min. For elution, an
acetonitrile gradient of 0 - 40 % in 10 min, 40 - 95 % in 2 min, back to 0 % in 0.1 min, followed
by equilibration for 5 min was employed. M.Sc. Franziska Vogl operated the ESI source in
separate runs in both positive and negative mode. She set the source temperature and flow rate
of the drying nitrogen gas to 220°C and 10 l/min, respectively. The pressure of the nebulizer
nitrogen gas was set to 2.6 bar, the end plate offset to 500 V, and the capillary voltage to 4500
V. The spectral range was 50 - 1000 m/z at 5 spectra/s. M.Sc. Franziska Vogl had externally
calibrated the mass spectrometer prior to data acquisition utilizing sodium formate clusters
(10 mM in 50:50 v/v water/isopropanol) and internal recalibration was achieved by employing
sodium formate clusters injected via a six-port valve at the beginning of each run. Automated
MS/MS measurements were performed with a signal threshold of 1000 and the fragmentation
voltage was ramped from 25 - 35 eV with an isolation width of 4 - 8m/z. Feature extraction was
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achieved with the signal-to-noise threshold set to 20 in the "find molecular feature" algorithm
in CompassDataAnalysis 4.1 (Bruker Daltonics, Bremen, Germany) [Zacharias et al. 2015].
She employed the 64-bit beta version of Profile Analysis 2.1 (Bruker Daltonics) for feature
alignment over a retention time window of 0.01 - 14 min [Zacharias et al. 2015]. Reference
compounds of propofol metabolites were obtained from Toronto Research Chemicals (Toronto,
Canada) [Zacharias et al. 2015].
5.1.2.4 NMR data preprocessing
All 1D 1H NOESY and 2D 1H-13C HSQC spectra were preprocessed as described in section
4.2.2.3. Note that a subset of eight plasma specimens had been preprocessed in the context
of my master thesis [Zacharias 2012]. In order to compensate slight shifts in signal positions
across spectra due to small variations in sample pH, salt concentration and/or temperature, the
NMR spectral data was subjected to a bucketing procedure as described in section 4.2.2.3. For
plasma 1D 1H NOESY spectra, the spectral region from 9.5 - 0.5 ppm was evenly split into bins
of 0.01 ppm width [Zacharias et al. 2015]. The spectral region from 6.2 - 4.6 ppm containing
the broad urea signal and the remaining water signal, as well as the NMR signals (3.815 -
3.76 ppm, 3.68 - 3.52 ppm, 3.23 - 3.20 ppm, and 0.75 - 0.725 ppm) corresponding to residual
glycerol from the ultrafilration membrane and free EDTA, respectively, were excluded during
the bucketing procedure [Zacharias et al. 2015]. Note that the unspecific urea signal was much
smaller in the 1D 1H spectra acquired for plasma in comparison to urine specimens [Zacharias
et al. 2013a), Zacharias 2012]. A total number of 718 bins remained for each 1D 1H NOESY
plasma spectrum [Zacharias et al. 2015].
5.1.2.5 NMR data normalization
The general goal of data normalization can be described as a minimization of technical and un-
desired biological variances without reduction of the intended biological variation, as explicitly
outlined in section 4.3.1.1.
2 Prior to subsequent normalization, data of each plasma spectrum were scaled to the integral
of the reference TSP signal from 0.05 ppm to - 0.05 ppm to correct for variations in spectrom-
eter performance over time. This is especially important for larger sample sets such as the
AKI data set where acquisition time of the whole data set amounts to several days. For this
it is important that the pipetting error of the reference substance is smaller than the observed
variations in spectrometer performance. Prof. Dr. Wolfram Gronwald and Claudia Samol
analyzed this in detail by splitting a urine specimen from a healthy volunteer at the University
of Regensburg in 10 different aliquots and adding 50 µl of deuterium oxide containing 0.75%
(w/v) TSP to each sample. To simulate a realistic setting they defined 10 different runs in
which each aliquot was measured once with identical parameters, yielding a total of 100 1D 1H
spectra. Results showed that for the average pipetting error, defined as signal variations of the
TSP reference signal between aliquots, a relative standard deviation of 0.8% was obtained. For
2The following section has been published in [Hochrein et al. 2015] in a slightly altered version, and is also
part of Dipl. Math. Jochen Hochrein’s Ph.D. thesis [Hochrein 2016].
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the spectrometer performance, defined as signal variations of the TSP reference signal within
each aliquot across different measurements, an average relative standard deviation of 3.7% was
determined. As a consequence it is save to conclude that scaling relative to the TSP signal
helps reducing variations in spectrometer performance.
A subsequent log2 transformation was applied to all 1D 1H plasma spectra to minimize het-
eroscedasticity [Zacharias et al. 2015], as explicitly discussed in section 5.1.3.1. The corre-
sponding R-code can be found in Appendix I section 7.1.3.1.
5.1.2.6 Prognostication method
The predictive performance of potential plasma biomarkers was assessed by employing classi-
fication, compare to section 4.3.1.3. Dipl. Math. Jochen Hochrein systematically evaluated
the predictive performance of six different binary classification algorithms in combination with
various strategies for data-driven feature selection on five different data sets including the cur-
rent AKI plasma set [Hochrein et al. 2012]. For most data sets, a RF classification algorithm
combined with t-score-based feature filtering performed best with regard to prediction accu-
racy [Hochrein et al. 2012]. The combination of an SVM with radial basis function kernel and
t-score-based feature filtering performed best with respect to AUC-ROC values for almost all
employed data sets [Hochrein et al. 2012]. Nevertheless, the current AKI plasma set was best
classified by an RF classification with t-score-based feature filtering in terms of both prediction
accuracy and AUC-ROC values [Hochrein et al. 2012]. As a consequence, this classification
algorithm has been chosen for the prognostication of plasma 1D 1H NMR metabolic finger-
prints in this thesis. Note that, in comparison to [Hochrein et al. 2012], where the AKI plasma
data set had been VS-normalized, compare to section 4.3.1.1., the corresponding data set was
only log2-transformed in this thesis [Zacharias et al. 2015], as explicitly discussed in section
5.1.3.1. For the AKI urinary data set, an SVM algorithm with radial basis function kernel in
combination with a t-score-based feature selection had been employed since it performed best
in a preliminary classification algorithm evaluation conducted by Dipl. Math. Jochen Hochrein
during his diploma thesis [Hochrein 2011]. A performance evaluation of the RF classification
algorithm for NMR derived metabolomic data sets had not yet been taken place when the
investigation of the AKI urinary data set was performed in the context of my master the-
sis [Zacharias 2012].
3 Prognostication of plasma specimens was performed employing an RF classifier in combina-
tion with t-score-based feature filtering, as described in section 4.3.1.3. This combined strategy
allows fast subsequent identification of NMR signals driving the separation of cases. It also
keeps the computational model relatively sparse. Prognostications were accomplished within
a nested leave-five-out cross-validation scheme. To guarantee an almost unbiased estimate of
the true prognostication error [Varma and Simon 2006], two nested inner loops were included
for parameter selection. The number of selected features was optimized in the first inner loop
3The following section has already been published in a slightly modified version in [Zacharias et al. 2015]. The
classification/prognostication concept of nested cross-validation employed here was implemented by Dipl.
Math. Jochen Hochrein and is also part of his Ph.D. thesis [Hochrein 2016].
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in steps of one from a starting value of one. The internal parameters of the RF classifier such
as the number of trees (ntree) and the number of tried variables (mtry) were calibrated in the
second inner loop employing a grid search procedure, where each of the two parameters was
varied over 5 different settings leading in total to 25 combinations. The parameter ntree was
varied in steps of 100 between 100 and 500. Since the number of variables employed by Random
Forests for the splitting in each node (mtry) depends on the total number of input variables, i.e.
the number of selected features, it has been proposed [Liaw and Wiener 2002,Breiman 2001]
to start optimization of mtry at the square-root of the number of input variables (default) and
then trying 2 times default and 0.5 times default. Dipl. Math. Jochen Hochrein complemented
this sequence by 1.5 times default and 0.75 times default to cover a finer grid of the optimiza-
tion space. Assuming, for example, an output of 100 variables by the feature-filtering step, the
(floored) values of mtry to test would have been 5, 7, 10, 15, and 20, respectively. Each sample
was used once as a test-sample in each RF run.
Classification performance was evaluated by analyzing ROC plots, compare to section 4.3.1.3.
For each classification, the average prediction/prognostication accuracy given as the arithmetic
mean ± standard deviation of the individual results and the area under the ROC curve are
given. The significance of identified biomarkers that are present at different levels in AKI and
non-AKI patients was assessed by the corresponding P values. Raw P values were calculated by
a two-sided Welch t statistic assuming Gaussian distribution of the data, which was confirmed
by means of the Kolmogorov-Smirnov test, compare to section 4.3.1.3. To adjust for multiple
testing, P values were modified for controlling the FDR according to the method of Benjamini
and Hochberg, as described in section 4.3.1.3.
5.1.2.7 Permutation tests
By comparing the prognostic accuracies obtained for originally non-permuted and randomly
permuted data, the significance of the obtained classification results can be estimated [Zacharias
et al. 2013a), Zacharias et al. 2015,Mukherjee et al. 2003]. Here, the original class-labels of
the AKI patients, reflecting their clinical diagnosis of AKI/non-AKI incidence, were randomly
permuted before performing an RF classification with t-score-based feature selection, as explic-
itly described in section 5.1.2.6. For the plasma data set, the permutation test was performed
20 times [Zacharias et al. 2015], each starting with a new random permutation of the original
class-labels as well as a fresh splitting into training and test data [Zacharias et al. 2015]. The
mean values and standard deviations of the averaged total prediction accuracy, the area un-
der the ROC curve, and the sensitivity and specificity were calculated [Zacharias et al. 2015].
Moreover, the optimal ntree and mtry parameters of the RF classifier were reported [Zacharias
et al. 2015]. If the mean averaged total prediction accuracy and the mean AUC-ROC values
of the RF classification for randomly permuted class-labels are considerably lower than the
corresponding values of the RF classification for non-permuted class-labels, one can conclude
that the latter results were not obtained by chance [Mukherjee et al. 2003].
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5.1.2.8 Prognostication of AKI with selected metabolites
4 For prognostication of AKI with selected individual metabolites, the threshold for group
assignment was varied over the respective measured concentration ranges to obtain ROC curves.
For prognostication with predefined sets of known metabolites, probability estimates for group
assignment, reflected by the respective decision values, were first obtained in five runs of leave-
five-out cross-validation by means of an SVM with a linear kernel function, compare to section
4.3.1.3, thresholds were then varied over the entire range to generate ROC curves. The cost
parameter C was stepwise increased from 2−5 to 25.
5.1.2.9 Analysis of intermediate cases of AKI
5 During the evaluation of the prognostic performance of plasma biomarkers based on 1D 1H
NMR spectra, as explicitly described in section 5.1.3.3, the poor predictive performance of
the tested plasma fingerprints for AKIN-stage 1 patients became striking. Therefore, to gain
more insight into the nature of AKIN 1 disease, Dipl. Math. Jochen Hochrein adapted a
computational algorithm called "core-group extension", which was originally devised to derive
a molecular signature of Burkitt’s lymphoma from gene expression profiles [Hummel et al.
2006]. The algorithm is initially trained on a core group of certain outcome or diagnosis. Next,
the trained classifier is used to calculate scores for the intermediate cases followed by a ranking
of samples according to these scores. Here, the dataset was first separated according to the
AKIN criteria into a "stable" core group comprising the AKIN 0 non-AKI and AKIN 2 and
3 AKI cases, while the so-called "unstable" group comprised all patients assigned as AKIN
1. Using the plasma concentrations of a specific set of biomarkers, whose choice is explicitly
described in section 5.1.3.7, of the "stable" group, I optimized the cost parameter C of an SVM
algorithm capable of estimating prognostication probabilities, compare to section 4.3.1.3, in a
leave-one-out cross-validation, where the exponent of C was increased systematically from 2−40
to 2−10 at a step size of 1, to select the model with the lowest error-rate in the discrimination
of AKI from non-AKI members of the "stable" group, and recorded for this model within the
leave-one-out cross-validation the corresponding scores. The scores reflect the corresponding
prognostication probabilities. Note, as parameter optimization and determination of scores
was performed on the same data due to the small size of the AKIN 2/3 cohort (N=9), which
precluded the meaningful application of a nested cross-validation, the score obtained for the
"stable" group should be treated with care. Next, the classifier was trained using all the samples
of the "stable" group as training data and the parameter settings corresponding to the optimal
computational model to score the samples from the "unstable" group.
4The following section has been published in [Zacharias et al. 2015] in a slightly modified version. The applied
linear SVM cross-validation with optimization of the cost parameter C was slightly modified from a previous
R-code of Dipl. Math. Jochen Hochrein.
5This section has already been published in [Zacharias et al. 2015], and the presented concept as well as
the corresponding algorithm was developed by Dipl. Math. Jochen Hochrein. It is also part of his Ph.D.
thesis [Hochrein 2016].
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5.1.2.10 Metabolite quantification
Absolute metabolite quantification was performed as explicitly described in section 4.3.3.
6 For the quantification of Ca2+ and Mg2+ ions I made use of the fact that both ions form
complexes with EDTA that give rise to distinct NMR peaks in the 1D 1H and 2D 1H-13C HSQC
NMR spectra [Barton et al. 2010,Nicholson et al. 1983,Somashekar et al. 2006]. Here I used
the singlet 1H NCH2CH2N NMR signals at 2.56 ppm and 2.70 ppm for Ca-EDTA2− and Mg-
EDTA2−, respectively. For validation, spike-in experiments were performed in H2O and pooled
plasma (Appendix II section 7.2.3 Table 7.2). In water, mean recoveries of 97 ± 2.5% and
102 ± 2.1% were obtained for Ca-EDTA2− and Mg-EDTA2−, respectively, while the respective
values for ultrafiltered human plasma were 95.0 ± 6.8% and 104.0 ± 4.9%. Individual cali-
bration factors, lower limits of quantification, as well as 1H and/or 13C peak ranges (compare
to section 4.3.3) for CaEDTA2−, MgEDTA2−, and propofol-glucuronide have been determined
experimentally according to [Klein 2011].
Baseline serum creatinine concentrations prior to cardiac surgery were determined with stan-
dard techniques from clinical chemistry at the University Clinic of Erlangen-Nuremberg.
5.1.3 Results
5.1.3.1 Appropriate data normalization
7 For all investigated urine as well as eight plasma specimens, both 1D 1H and 2D 1H-13C
HSQC NMR spectra were acquired in the context of my master thesis [Zacharias 2012]. For the
remaining plasma specimens, both 1D 1H and 2D 1H-13C HSQC NMR spectra were acquired in
the context of my Ph.D. thesis. Figure 5.1 shows an exemplary subtraction spectrum obtained
by subtracting the 1D 1H NMR spectrum of a non-AKI plasma specimen from that of an AKIN
3 specimen, both of which had been collected 24 h after surgery. The subtraction of measured
spectra generates a virtual NMR spectrum that highlights those spectral features that differ
between the samples.
While investigating the AKI plasma data set, several different normalization techniques were
tested, including Variance Stabilization normalization as outlined in section 4.3.1.1. VSN pre-
processing yielded a significant (B/H adjusted P = 1.2 × 10−6) difference in the abundance
of CaEDTA2− between the AKI and the non-AKI group. However, the subsequent targeted
quantitative analysis of CaEDTA2−, compare to Table 5.3, revealed no significant difference
for the absolute concentrations of CaEDTA2− between non-AKI and AKI group (P = 0.47).
In contrast, simple scaling of spectral features to the TSP reference signal followed by log2-
transformation, confirmed for CaEDTA2− the absence of a significant intergroup difference
(B/H adjusted P = 0.67), but instead revealed MgEDTA2−, which had not been among the
discriminating features upon VSN, to be highly discriminative, compare to Appendix II section
7.2.6 Table 7.4. Since calcium levels are usually tightly regulated in the human body [Felsenfeld
6The following section has already been published in [Zacharias et al. 2015] in a slightly altered version.
7The following section has already been published in [Zacharias et al. 2015], and [Hochrein et al. 2015] in a
slightly altered version. Some of the results presented here are also part of Dipl. Math. Jochen Hochrein’s
Ph.D. thesis [Hochrein 2016].
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et al. 2013], a significant difference in the CaEDTA2−-levels of AKI and non-AKI patients is
rather unlikely, and points to an inappropriate application of VSN on 1D 1H plasma NMR data.
Significant differences in MgEDTA2− could also be confirmed by targeted quantitative analysis
(compare to Table 5.3). Note that careful manual inspection of the spectra revealed that the
bins corresponding to CaEDTA2− and MgEDTA2− at 2.56 ppm and 2.70 ppm, respectively, do
not contain contributions from citrate, although the small citrate signals are in close proximity.
Simple scaling to the TSP signal works well in this case, although it provided only a correc-
tion for differences in spectrometer performance and no adjustment for non-induced biological
variances and technical biases not related to spectrometer performance.
Figure 5.1: Exemplary 1D 1H NMR subtraction spectrum of plasma specimens col-
lected 24 h after cardiac surgery. 1D 1H NMR subtraction spectrum obtained
by the subtraction of a representative non-AKI plasma spectrum from an AKIN 3
spectrum and generated by Prof. Dr. Wolfram Gronwald. Metabolites significantly
up- and downregulated in AKI patients compared to metabolites in unaffected pa-
tients are marked in green and red, respectively. The complete list of discriminat-
ing features is given in Appendix II section 7.2.6 Table 7.4. The ratio of the total
spectral areas of the two spectra used for computing the difference in the spectra
amounts to 1.97, indicating a considerably higher overall metabolite concentration
in the specimen of the AKIN 3 case. Modified from [Zacharias et al. 2015].
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Close inspection of Figure 5.1 indicates that the total integral of spectral features upregulated
in the AKIN 3 specimen compared to that of the non-AKI specimen is much larger than that of
the downregulated features. This is mainly due to the significantly (P = 0.03) higher levels of
glucose, the most abundant plasma metabolite, in the AKI (9.72 ± 2.73 mmol/l) rather than the
non-AKI group (8.38 ± 2.83 mmol/l) (Table 5.3). As already outlined in section 4.3.1.1, VSN is
only applicable if a relatively small proportion of metabolites/feature intensities is regulated in
approximately equal shares up and down between the intended biological groups [Hochrein et
al. 2015,Kohl et al. 2012]. Therefore, significant differences in glucose levels and consequently
total spectral areas between the two biological groups prohibits the application of VSN in this
setting.
Encouraged by these results, Dipl. Math. Jochen Hochrein developed a strategy to choose
the appropriate data normalization method for the statistical analysis of an NMR data set
without explicit prior knowledge about significant inter-group inhomogeneities [Hochrein et al.
2015,Hochrein 2016]. First, the total spectral area for each NMR spectrum, excluding areas of
the solvent signal and the broad urea signal, is calculated. Then, the Shapiro-Wilk test [Shapiro
and Wilk 1965] is applied in order to test the set of total spectral areas for normal distribution.
The corresponding null hypothesis is that the total spectral areas are normally distributed
around a fixed mean, irrespective of the experimental groups. To detect single outliers within
the investigated groups that may not be detected by the Shapiro-Wilk-Test, total spectral areas
are also plotted in a histogram representation (data not shown). The corresponding R-code
can be found in Appendix I section 7.1.2.
For the AKI plasma data set, the Shapiro-Wilk test yielded a P -value of 1.6 × 10−4. This
indicates the presence of significant inter- and intra-group inhomogeneities in total spectral
areas, as caused in part by the significantly higher glucose levels in the AKI group than in the
non-AKI group. Consequently, the complete statistical analysis for the AKI plasma data set
was performed with the 1D 1H NMR bucket intensities scaled to TSP and subsequently log2
transferred.
5.1.3.2 Time-course development
8 Since the clear separation between urine specimens collected before and at 4 h after the surgery
in the PCA plot shown in Appendix II section 7.2.4 Figure 7.1a), was mainly driven by the
high concentration of the exogenous compound D-mannitol at 4 h after the surgery [Zacharias
et al. 2013a),Zacharias 2012], compare to section 5.1.1, a second PCA was conducted excluding
all spectral regions corresponding to this compound (Appendix II section 7.2.4 Fig. 7.1b)) in
the context of my Ph.D. thesis [Zacharias et al. 2013a)]. As in Appendix II section 7.2.4 Fig.
7.1a), a clear separation between the different time-points is visible. The specimens collected at
24 h after surgery are located approximately in between the two other time-points, with urine
specimens from non-AKI patients being located on average closer to the pre-surgical specimens,
whereas those of the AKI patients group closer to the 4 h specimens. The group separation is
now mainly driven by creatinine (loadings not shown).
8The following section has already been published in [Zacharias et al. 2013a)] in a slightly altered version.
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5.1.3.3 Prognostication of AKI
Encouraged by the promising classification results obtained by training an SVM classifier with
radial basis function kernel on 1D 1H NMR spectra of 106 urine specimens collected at 24 h
after cardiac surgery, compare to section 5.1.1, I performed the same task employing the cor-
responding plasma specimens collected at the same time-point, which were available for NMR
spectroscopy.
9 For RF-based prognostication of the eventual AKIN stage, log2 transformed 1D 1H NMR
plasma spectra were split into 718 evenly spaced bins or features, excluding chemical shifts
representing water, urea, glycerol and free EDTA. Subsequent analysis of the 33 AKI and 52
non-AKI cases yielded an overall prognostication accuracy of 80.0 ± 0.9 % (compare to Table
5.2) and a corresponding area under the ROC curve of 0.87 ± 0.01. On average, the RF al-
gorithm employed 24.0 ± 2.8 of the most discriminative features as selected by a t-test based
feature selection step prior to classification. As can be seen from Table 7.4 in Appendix II sec-
tion 7.2.6, the corresponding p-values of these features showed a range from 2.06e−8 to 8.55e−6.
The RF parameters mtry and ntree were optimized to 3.0 ± 0.0 and 270 ± 24.5, respectively.
The overall sensitivity and specificity amounted to 72.7 ± 1.9% and 84.6 ± 1.7%, respectively.
Considering the AKIN stages separately, the sensitivity for AKIN 2 and 3 amounted to 100.0
± 0.0% and 96.7 ± 6.7%, respectively, whereas it dropped to 63.3 ± 1.7% for AKIN 1 patients,
compare to Table 5.2.
AKIN-stage All (1-3 and 0) 1 2 3
24 h plasma prediction accuracy [%] 80.0 ± 0.9 63.3 ± 1.7 100.0 ± 0.0 96.7 ± 6.7
Table 5.2: Classification performance depending on AKIN-stage for plasma spec-
imens collected at 24 h post-surgery. Given are the prediction accuracies,
ordered according to diagnosis. Mean values and corresponding standard deviations
are obtained from five nested cross-validation runs. Modified from [Zacharias et al.
2015].
The 85 plasma samples constituted a subsample of the original study of 106 individual urine
specimens, as described in section 5.1.2.1. To allow for a fair comparison between urinary and
plasma data, the 1D 1H NMR urine spectra of the 85 patients, for whom plasma specimens
were available, were scaled to creatinine and log2 transformed before they were subjected to a
single random forest run. The obtained overall prognostication accuracy amounted to 69.4%
employing 7 features with a corresponding area under the ROC curve of 0.73.
Next, permutation tests with randomly perturbed class-labels were also performed for the AKI
plasma data set to exclude the possibility that the observed prognostication accuracies had
been obtained by chance. After an initial RF run with the complete feature set of 718 features
and permuted class-labels, which revealed 119 as the median number of selected features, the
9The following section has already been published in [Zacharias et al. 2015] in a slightly altered version. Parts
of the analysis presented here were performed by M.Sc. Franziska Vogl.
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feature selection was limited to a range of 109 to 129 features for the subsequent twenty RF
runs, each of which started with a fresh permutation of the class-labels and a random splitting
of test and training data. Over the twenty RF runs, I received an averaged total accuracy of
55.7 ± 5.1%, a mean area under the ROC curve of 0.48 ± 0.08, and a sensitivity and specificity
of 17.1 ± 7.2% and 80.2 ± 6.3%, respectively (Appendix II section 7.2.5 Table 7.3). Results
for the permuted data were in all 20 runs considerably lower than for the non-permuted data,
indicating that the results for the non-permutated data were with high probability not obtained
by chance (P < 0.05) and that the study was sufficiently powered. Two exemplary ROC curves
for the permuted and non-permuted data are given in Appendix II section 7.2.5 Figures 7.2a)
and 7.2b), respectively.
As described in section 5.1.2.6, t-statistics were used for both, feature filtering and identifica-
tion of spectral features that distinguish between AKI and non-AKI plasma NMR fingerprints.
After correction for multiple testing by controlling the FDR at 5%, 261 significantly differential
NMR features were obtained. A heat-map representation of these features is displayed in Ap-
pendix II section 7.2.6 Figure 7.3 and a list of all significant NMR features is given in Appendix
II section 7.2.6 Table 7.4. Their up- and down-regulation in the heat-map representation is
color coded in yellow and blue, respectively. The patients were arranged from left to right as
follows: 45 cases correctly prognosticated not to develop AKI, 7 cases falsely prognosticated
to develop AKI, 9 cases of AKIN 1 falsely prognosticated not to develop AKI, and 15, 3 and
6 cases each of AKIN 1, 2 and 3, respectively, correctly prognosticated. Rows were ordered
according to increasing correlation coefficients between disease status and feature intensities.
As on average 24.0 ± 2.8 of the most significant features were used by the RF algorithm, the
27 most significant NMR features are indicated with red arrows in Appendix II section 7.2.6
Figure 7.3. These NMR features could only partly be assigned to known metabolites due to
either massive signal overlap in some regions of the 1D spectra (see Figure 5.1) or insufficient
signal intensity.
The most significant plasma feature was a well-resolved singlet signal present at 7.285 ppm
(Padj=2.1e−8), which could be identified by neither database searches nor 2D 1H 1H TOCSY,
1H-13C HSQC, and 1H-13C HMBC spectra, respectively. Therefore, to facilitate assignment, M.
Sc. Franziska Vogl performed metabolic fingerprinting by means of high-resolution LC-QTOF-
MS on five plasma specimens each selected from the AKI and the non-AKI group, respectively.
A total of 531 features were observed in positive mode and 16 in negative mode. Dipl. Math.
Jochen Hochrein sorted features according to Student’s t-tests. After controlling the FDR at the
5% level according to the method of Benjamini and Hochberg, 11 significant features remained,
each of which was defined by retention time and them/z value. By means of the Smart Formula
tool (Bruker Daltonics, Bremen, Germany), M.Sc. Franziska Vogl determined molecular sum
formulas to search the HMDB [Wishart et al. 2007], METLIN [Smith et al. 2005], and ChEBI
(Chemical Entities of Biological Interest) metabolite databases [Hastings et al. 2013]. For the
most promising hits, she analyzed commercial standards to verify identification. Furthermore,
M.Sc. Franziska Vogl performed MS/MS experiments on both standards and plasma specimens
for additional verification. Among the most discriminating features, she positively identified
the propofol metabolites propofol-glucuronide and 4-hydroxy-propofol-1-OH-D-glucuronide.
I acquired 1D 1H NMR reference spectra on these compounds and unambiguously verified the
78
5.1 Acute Kidney Injury study
assignment of the NMR signal at 7.285 ppm to propofol-glucuronide. Furthermore, the presence
of 4-hydroxy-propofol-1-OH-D-glucuronide as another discriminating compound could be veri-
fied by the NMR data. NMR-based quantification of propofol-glucuronide showed significantly
increased plasma levels (0.004 ± 0.002 mmol/l vs. 0.010 ± 0.08 mmol/l, P=0.00008) in AKI
patients. However, for both the total dosage of administered propofol (2747.7 ± 1257.4 mg vs.
3313.3 ± 1896.4 mg, P=0.14) and the dosing rate (6.8 ± 3.7 mg/min vs. 5.8 ± 1.9 mg/min,
P=0.09), no significant differences between non-AKI and AKI patients could be observed. How-
ever, the two groups differed significantly with regard to the duration of propofol administration
(427.94± 185.34 min and 600.79± 360.69 for non-AKI and AKI patients, respectively, p=0.015)
and the time elapsed between termination of propofol infusion and sample collection (1138.6
± 201.7 min and 969.0 ± 362.7 min for non-AKI and AKI patients, respectively, p=0.02).
This suggested that the increased plasma levels of propofol-glucuronide in AKI patients were
a consequence of both prolonged administration and delayed excretion. This was confirmed by
re-analysis of the urinary NMR fingerprints obtained for the same patients. At 4 hours after
surgery, urinary levels of propofol-glucuronide amounted to 0.67 ± 0.30 mmol/mmolcrea and
0.63 ± 0.35 mmol/mmolcrea, respectively, for non-AKI and AKI patients (p=0.55), while at 24
hours after surgery urinary levels had dropped to 0.14 ± 0.07 mmol/mmolcrea and 0.19 ± 0.10
mmol/mmolcrea, respectively, but were significantly (p=0.02) higher in the AKI group (Table
5.3).
As can be seen from Table 7.4 in Appendix II section 7.2.6, plasma NMR features used
for prognostication correspond to compounds of both endogenous origin, such as tryptophan
(Padj=1.1e−6), myo-inositol (Padj=2.3e−6), hippurate (Padj=2.5e−6), citrate (Padj=3.2e−6), and
creatinine (Padj=3.9e−6), and exogenous origin, such as propofol-glucuronide (Padj=2.1e−8) and
the antifibrinolytic agent tranexamic acid (Padj=3.2e−6). A special case is Mg2+ (Padj=2.9e−6),
which can be of both endogenous and exogenous origin as Mg2+ is often administered for the
treatment of cardiac dissrhythmia.
To analyze the impact of tranexamic acid and other exogenous compounds such as D-mannitol,
paracetamol-sulfate, propofol-glucuronide, 4-hydroxy-propofol-1-OH-D-glucuronide and 4-hydroxy-
propofol-4-OH-D-glucuronide on plasma prognostication performance, all spectral areas corre-
sponding to known exogenous compounds were excluded prior to data analysis. In subsequent
analysis, which employed 26 features, an average prediction accuracy of 82.4% (vs. 80% includ-
ing exogenous compounds) and an area under the ROC curve of 0.87 (vs. 0.87) were obtained.
Overall sensitivity and specificity amounted to 75.8% and 86.5%, respectively, while the respec-
tive values before exclusion of exogenous compounds had amounted to 72.7% and 84.6%.
In addition, I investigated whether improved prognostication performance could be achieved by
combining the plasma data with the corresponding 24 h urine data, which had been scaled to
creatinine and also log2 transformed. The final data matrix consisted of 1419 rows representing
718 plasma and 701 urine features and 85 columns representing the 33 and 52 AKI and non-AKI
patients, respectively. One RF classification run with t-test based feature selection employing
a leave-five-out cross-validation was performed. Results showed an averaged prognostication
accuracy of 81.2% and an area under the ROC curve of 0.87, values similar to those obtained for
plasma only. Further analysis showed that prognostication was based on 25 features. Ranking
of these features according to their p-values revealed, that the first 24 features were identical
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to the first 24 plasma features listed in Appendix II section 7.2.6 Table 7.4. The most sig-
nificant urinary feature was tranexamic acid at rank 25 (Padj=1.6e−5), which explains why a
combination of urinary and plasma fingerprints did not outperform prognostication on plasma
fingerprints alone.
5.1.3.4 Investigation of CKD influence
During the review process for [Zacharias et al. 2013a)], the question arose whether pre-existing
CKD might have a significant impact on the predictive performance of urinary fingerprints
for the discrimination of AKI vs. non-AKI patients. Consequently, I investigated the CKD
influence on the AKI prognostication based on urinary NMR fingerprints in the context of my
Ph.D. thesis. Note that, in concordance with [Zacharias et al. 2013a), Zacharias 2012], here,
urinary 1D 1H NMR bucket intensities had been scaled to creatinine and subsequently Quantile
normalized as described in section 5.1.1.
10 Close inspection of Table 7.1a) in Appendix II section 7.2.1, showed that from the urine
study cohort, thirty-nine of the patients were suffering from non-dialysis CKD. However, em-
ploying a two-sided t-test, no significant differences between the preoperative urinary NMR
spectra of patients with or without CKD could be detected (data not shown). P -values were
adjusted for multiple testing by controlling the FDR at the 5% level. Furthermore, two-sided
t-tests for NMR spectra of urine specimens collected at 4 and 24 h after surgery were performed
separately for AKI and non-AKI patients, respectively, with regard to the presence or absence
of CKD. Of the four tests conducted, significant FDR-adjusted differences in spectral intensity
with an FDR < 5% were observed only between CKD and non-CKD spectra acquired for urine
specimens collected 4 h after surgery from the cohort of 34 AKI patients. Of the two significant
NMR features observed, one with a Padj = 0.03 remains to be identified, while the second one
with a Padj = 0.04 was tentatively assigned to phenylacetylglutamine. Of the two urinary amino
acid conjugates of phenylacetic acid reported in the literature, namely phenylacetylglycine and
phenylacetylglutamine, the former is typically assigned to the observed significant feature rep-
resenting the phenyl moiety in NMR studies of human urine [Kang et al. 2011]. However,
based on available literature on the conjugation of phenylacetic acid in humans, man excretes
exclusively the glutamine conjugate [James et al. 1972,Fukui et al. 2009]. Phenylacetic acid
and its glutamine conjugate are known uremic solutes, the serum concentrations of which are
increased in CKD patients due to attenuation of whole-body phenylalanine hydroxylation [Itoh
et al. 2012,van de Poll et al. 2004]. However, neither distinguished AKI from non-AKI patients
at 4 h after surgery.
In the plasma subcohort, twelve out of 52 non-AKI patients (23.1%) and 21 out of 33 AKI
patients (63.6%), respectively, suffered from CKD, with a P -value calculated by Fisher’s exact
test of 0.0003 (compare to Appendix II section 7.2.1 Table 7.1b)). To test whether results ob-
tained for AKI and non-AKI specimens had been dominated by CKD, I selected randomly 24
patients each from the AKI and non-AKI group, so that each group included 12 patients with
10The following section has already been published in [Zacharias et al. 2013a)] and [Zacharias et al. 2015] in a
slightly altered version.
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and 12 patients without CKD. A Student’s t-test yielded after correction for multiple testing
73 significant features, 72 of which had been also part of the significant features obtained when
all 85 samples were included (Appendix II section 7.2.6 Table 7.4). RF based prognostication
with leave-two-out cross-validation obtained an averaged prognostication accuracy of 72.9%, as
well as an area under the ROC curve of 0.84. On average, 17.5 features were employed by the
algorithm. Sensitivity and specificity amounted to 70.8% and 75.0%, respectively.
The corresponding permutation test was performed once, with an average total accuracy of
41.7%, an area under the ROC curve of 0.44, a sensitivity of 50.0% and a specificity of 66.7%.
As both groups contained the same number of patients with and without CKD, these results
clearly showed that CKD incidence did not exert a major effect on prognostication of AKI
based on plasma 1D 1H NMR spectra.
5.1.3.5 Quantification of metabolites
11 In addition to the analysis of the NMR fingerprints, the plasma levels of 16 organic metabo-
lites and the dications Ca2+ and Mg2+ were quantified from the 85 1D 1H NMR spectra. Mean
plasma concentrations and standard deviations for the non-AKI and AKI group, respectively, as
well as p-values based on two-sided t-tests are given in Table 5.3. Note that due to the relatively
small number of quantified metabolites no correction for multiple testing was applied. Metabo-
lites that differed significantly (P < 0.05) in concentration between non-AKI and AKI group
included propofol-glucuronide, lactic acid, valine, creatinine, D-glucose, and Mg-EDTA2−. The
statistical power (compare to section 4.3.1.3) of differences in absolute metabolite concentra-
tions between groups was, except for D-glucose (56.9%), above the threshold of 80% for all
significantly differential metabolites (Table 5.3).
11The following section has already been published in [Zacharias et al. 2015] in a slightly altered version.
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Metabolite Mean value ± Mean value ± P -value Statistical
SD [mmol/l] SD [mmol/l] power5
non-AKI AKI
13-Hydroxybutyric acid 0.65 ± 1.30 0.40 ± 0.38 0.21 18.5%6
1Acetic acid 0.19 ± 0.62 0.04 ± 0.02 0.10 27.5%6
1Acetone 0.15 ± 0.28 0.11 ± 0.10 0.31 12.1%6
1Acetoacetic acid 0.22 ± 0.34 0.12 ± 0.11 0.10 35.5%6
2Alanine 0.24 ± 0.09 0.26 ± 0.09 0.37 16.7%
1,3Ca-EDTA2− 1.97 ± 0.14 1.95 ± 0.12 0.49 10.5%6
1,4Creatinine 0.09 ± 0.03 0.14 ± 0.05 0.000005 100%6
2D-glucose 8.38 ± 2.83 9.72 ± 2.73 0.03 56.9%6
1Formic acid 0.03 ± 0.01 0.03 ± 0.01 0.94 -
2Glutamine 0.37 ± 0.06 0.42 ± 0.08 0.053 88.7%6
2Glycine 0.29 ± 0.36 0.25 ± 0.22 0.74 8.8%6
2Lactic acid 1.66 ± 0.60 2.40 ± 1.27 0.003 94.7%6
1L-isoleucine 0.05 ± 0.02 0.04 ± 0.02 0.07 60.3%6
1,3Mg-EDTA2− 1.05 ± 0.20 1.29 ± 0.23 0.00001 99.9%6
1Propofol-glucuronide 0.004 ± 0.002 0.010 ± 0.08 0.00008 100.0%6
1,7Propofol-glucuronide
(urine, 4h) 0.67 ± 0.30 0.63 ± 0.35 0.55 9.0%6
1,8Propofol-glucuronide
(urine, 24 h) 0.14 ± 0.07 0.19 ± 0.10 0.02 84.5%6
1Threonine 0.08 ± 0.02 0.08 ± 0.02 0.71 -
1Tyrosine 0.05 ± 0.01 0.05 ± 0.01 0.52 -
1Valine 0.20 ± 0.04 0.17 ± 0.05 0.007 91.5%6
Table 5.3: Plasma levels of 18 selected analytes 24 hours after surgery in addition
to the urine levels of propofol-glucuronide 4 and 24 hours after surgery,
respectively. Data were obtained from 1D 1H and 2D 1H-13C HSQC spectra. Given
are mean values and standard deviations in mmol/l for the non-AKI and the AKI
group, respectively, as well as P -values calculated by a two-sided heteroscedasti-
cal t-test employing Microsoft EXCEL and the actual power of the hypothesis test
employed. 1Determined from 1D 1H spectra. 2Determined from 2D 1H-13C HSQC
spectra. 3Note the recoveries given in Appendix II section 7.2.3 Table 7.2. 4Due
to massive signal overlap in the 1D NMR spectral region of creatinine of a non-
AKI patient, the creatinine value for this particular patient was determined from
the corresponding 2D 1H-13C HSQC spectrum. 5Statistical power was calculated
by employing G*Power 3.1.7. 6Effect size calculated according to Cohen’s d in
case of unequal variances. 7Determined in urine 4 hours past surgery, values are
normalized to urinary creatinine [mmol/mmolcrea]. 8Determined in urine 24 hours
past surgery, values are normalized to urinary creatinine [mmol/mmolcrea]. Modified
from [Zacharias et al. 2015].
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5.1.3.6 Prognostication of AKI by a small set of metabolites
12 To evaluate the feasibility of a reliable prognostication of patients by employing a small subset
of easily quantifiable metabolites only, prognostications were repeated with selected metabolites
either individually or in different combinations thereof. Selection of these metabolites was
performed according to P -values (Table 5.3). In case that more than a single metabolite was
used, a linear SVM algorithm was employed. Five runs of leave-five-out cross-validation gave for
the combination of the plasma metabolites Mg-EDTA2−, lactate and creatinine, all of which
are amenable to point-of-care-testing, an overall prediction accuracy of 77.0 ± 1.0% with a
corresponding area under the ROC curve of 0.84 ± 0.01 (Figure 5.2). The largest AUC value
of 0.94 ± 0.01 was obtained for plasma propofol-glucuronide in combination with the difference
in serum creatinine before and plasma creatinine 24 hours after surgery (Figure 5.2). Note
that serum creatinine levels prior to surgery had been determined by standard methods of
clinical chemistry. The corresponding prediction accuracy was 86.8 ± 0.9%. In addition to
the prognostication performance of the different combinations of plasma biomarkers shown in
Figure 5.2, (1) a combination of plasma creatinine obtained 24 hours past surgery, with plasma
lactic acid, plasma Mg-EDTA2−, and plasma propofol-glucuronide, (2) a combination of the
difference in pre- and postoperative (24 hours) serum/plasma creatinine with plasma lactic
acid and plasma Mg-EDTA2−, (3) a combination of the difference in pre- and postoperative
(24 hours) serum/plasma creatinine with plasma lactic acid, plasma Mg-EDTA2− and plasma
propofol-glucuronide, as well as (4) a combination of plasma creatinine obtained 24 hours past
surgery with plasma lactic acid, plasma Mg-EDTA2−, and urinary carnitine, which had been
normalized to urinary creatininine, were analyzed giving AUC values of 0.85, 0.88, 0.93, and
0.83, respectively. Urinary carnitine was chosen, because it had been identified during the
investigation of the AKI urine cohort, compare to section 5.1.1, as a highly discriminative
endogenous metabolite. Furthermore, prognostication of AKI based on total time of propofol
administration alone revealed an AUC of 0.66 (Figure 5.2). Note that the total time of propofol
administration was available for 84 out of 85 patients.
Clinical diagnosis of AKI is routinely made utilizing increases in SCr. In this study, AKI was
diagnosed according to the AKIN criteria two and three days after surgery employing SCr levels,
as outlined in section 5.1.2.1. Plasma creatinine levels for a subcohort of 85 patients have been
determined for both non-AKI and AKI patients, compare to Table 5.3, and amounted to 0.09 ±
0.03 mmol/l and 0.14 ± 0.05 mmol/l, respectively, with a corresponding P -value of 5e−6. These
data show already at 24 h after surgery a significant increase in plasma creatinine levels for
patients who were diagnosed later with AKI. However, the predictive performance of creatinine
alone was outperformed by propofol-glucuronide (AUC-ROC 0.85 vs. 0.87, compare to Figure
5.2) determined in 24 h plasma specimens.
12The following section has already been published in [Zacharias et al. 2015] in a slightly altered version.
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Figure 5.2: Prognostication by different combinations of easily quantifiable biomark-
ers. Prognostication performance was assessed by analysis of ROC curves. Prognos-
tications are based on the absolute concentrations given in mmol/l of the following
single metabolites or combinations of metabolites: plasma lactic acid, plasma Mg-
EDTA2−, plasma creatinine 24 hours past surgery, plasma propofol-glucuronide,
difference in pre- and postoperative (24 hours) serum/plasma creatinine, plasma
lactic acid + plasma Mg-EDTA2− + plasma creatinine 24 hours past surgery, dif-
ference in pre- and postoperative (24 hours) serum/plasma creatinine + plasma
propofol-glucuronide. In addition, the prognostication performance of the total
time of propofol administration was evaluated. Note that the total time of propofol
administration was available for 84 out of 85 patients. Reprinted with permission
from [Zacharias et al. 2015]. Copyright 2015 American Chemical Society.
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5.1.3.7 Analysis of intermediate cases of AKI
13 From both the prognostication results based on plasma as well as urinary biomarkers and the
heat-map representation shown in Appendix II section 7.2.6 Figure 7.3, it is obvious that the
urinary and plasma metabolic profiles of AKIN 1 patients were often not in agreement with their
respective staging according to the AKIN criteria. Therefore, I aimed at defining a scheme that
separated them more robustly into AKI and non-AKI cases. As detailed in section 5.1.2.9, Dipl.
Math. Jochen Hochrein followed a strategy originally developed by [Hummel et al. 2006] for
the classification of Burkitt’s lymphoma. Briefly, the original dataset was separated according
to the AKIN criteria forming two groups of data denoted as the "stable" and the "unstable"
group. The "stable" group comprised the AKIN 0 cases referred to as non-AKI, and the AKIN
2 and 3 cases referred to as AKI cases. The so-called "unstable" group comprised all patients
of AKIN 1. To allow for potential point-of-care-testing, I selected metabolites that all could
be obtained from a single sample and that have been shown to offer a good prognostication
performance, namely the plasma compounds creatinine, lactate and Mg2+, all determined 24
hours past surgery. Compounds of purely exogenous origin such as propofol-glucuronide were
excluded, because they are not always administered and not readily amenable to bedside testing.
Employing the samples of the "stable" group only, I optimized an SVM model with a linear
kernel, which yielded a cost parameter of 2−27. Employing this SVM model, I computed scores
for both the "unstable" and the "stable" group. Note, that the score reflects an estimate of the
probability that a specimen belongs to the AKI group.
An exemplary result for all 85 patients of the plasma subcohort is shown in Figure 5.3a). Not
unexpectedly, most patients without AKI were assigned a score below 0.5. More interestingly
the same was true for most AKIN 1 patients indicating that in these patients kidney function
was largely preserved. In contrast, all AKIN 2 and 3 patients received a score greater than
0.5. The three metabolites used are also shown in a heat-map representation in Figure 5.3b).
The up- and down-regulation of the plasma metabolites lactate, Mg-EDTA2− and creatinine
with respect to the average is color coded in yellow and blue, respectively. All samples of the
complete plasma data set, represented by the columns, are ordered according to the scores
obtained in the scoring procedure. This scoring is congruent to the data given in Figure 5.3a)
and additionally color coded in the topmost row of Figure 5.3b). A red vertical line denotes a
score of 0.5 that was used for class separation into AKI (right) and non-AKI (left) cases. For
reasons of comparison the scoring according to AKIN criteria in blue, dark-yellow, yellow, and
light-yellow for AKIN 0, 1, 2, and 3, respectively, is included in the bottom row.
13The following section has already been published in [Zacharias et al. 2015] in a slightly altered version. The
presented concept as well as the corresponding algorithm was developed by Dipl. Math. Jochen Hochrein.
It is also part of his Ph.D. thesis [Hochrein 2016].
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Figure 5.3: Analysis of intermediate cases of AKIN 1 based on a model making use of
the absolute concentrations of plasma lactate, magnesium, and creatinine
determined for the "stable" core group that comprised all non-AKI and
all AKIN 2 and 3 patients. a) Patients are listed on the x-axis as follows from
left to right: 52 non-AKI patients followed by 24 AKIN 1 patients and nine AKIN
2 and 3 patients. Corresponding scores are shown on the y-axis. The scores denote
for each sample the estimate of the probability given by the SVM to belong to
the class of AKI patients. Scores for the training group were obtained in a leave-
one-out cross-validation. Data from one SVM run is given. Note that different runs
gave very similar results. b) Heat-map representation of the investigated specimens.
Displayed are the variations in concentration of plasma lactate, plasma Mg-EDTA2−
and plasma creatinine. These values are also summarized in Table 5.3. Samples are
sorted in ascending order from left to right according to the scores obtained in the
AKI-rescoring procedure. The red vertical line marks a score threshold value of 0.5.
The first row shows the score values in a color-coded representation, while the next
three lines correspond to the concentrations of lactate, creatinine and Mg-EDTA2−
that define the used model. Their up- and down-regulation with respect to the
average is color coded in yellow and blue, respectively. The last row color-codes the
AKIN-staging in blue, dark-yellow, yellow, and light-yellow for AKIN 0, 1, 2, and
3, respectively. Modified from [Zacharias et al. 2015].
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5.1.4 Discussion
14 This study was designed to investigate metabolic differences in plasma specimens between
patients developing AKI versus patients not developing AKI after undergoing cardiac surgery
with CPB use by NMR spectroscopy in combination with statistical data analysis methods.
The use of appropriate data normalization techniques is crucial for subsequent statistical
data analysis, as illustrated here for the correct detection of fold changes of CaEDTA2− and
MgEDTA2−. The detection of possibly significant inter- and intra-group inhomogeneities in
total spectral area of an NMR data set is crucial for the subsequent choice of normalization
method and was conducted for all following studies.
To date, proteins have dominated the search for and validation of biomarkers of AKI. There are,
however, also a few published reports on metabolites potentially prognostic of the development
of AKI. The first of these metabolomic studies was performed on urine specimens obtained prior
to surgery and at 4 hours and 12 hours after surgery from 40 children that underwent CPB
surgery for correction of congenital cardiac defects [Beger et al. 2008]. Analysis of urine spec-
imens of the first twenty patients enrolled by means of reverse-phase ultra-performance liquid
chromatography (RP-UPLC) coupled to time-of-flight mass spectrometry (TOFMS) yielded
good separation of AKI from non-AKI patients in PCA for both the 4-hour and the 12-hour
urine specimens with a sensitivity and specificity of 95% each. A loading plot of PC2 versus
PC3 identified an ion with a mass-to-charge (m/z ratio) of 261.01 as a potential biomarker,
which was identified as the sulfate conjugate of homovanillic acid, a major metabolite of cate-
cholamines such as epinephrine and norepinephrine that are routinely administered as inotropic
agents after weaning from CPB to improve cardiac output [Gillies et al. 2005]. The subsequent
determination of urinary homovanillic acid sulfate in all 40 patients enrolled yielded a cut-off
value of 24 ng/µl at 12 hours after surgery that was capable of discriminating AKI from non-
AKI patients with a sensitivity and specificity of 90% and 95% (AUC of 0.95), respectively.
This was the more impressive as increases in SCr from baseline by ≥ 50% occurred as late
as 48-72 hours after surgery in 11 out of 21 patients that developed AKI, thus mimicking the
performance of NGAL. However, to date the validity of homovanillic acid sulfate as a prog-
nostic marker has been neither confirmed for an independent cohort of pediatric patients nor
demonstrated for adult patients. Almost all patients of the present study were treated with
catecholamines (Appendix II section 7.2.1 Table 7.1). However, neither homovanillic acid nor
its sulfate conjugate was detected in the 1D 1H and 2D 1H-13C NMR plasma spectra. Also
in the corresponding spectra of urine specimens collected before, 4 hours, and 24 hours after
surgery these compounds could not be detected.
The utility of drugs, respectively metabolites and conjugates thereof, in prognosticating AKI is
also demonstrated in the present study, which found the glucuronide conjugate of propofol to
be the best prognostic indicator of acute kidney injury, outperforming even creatinine (Figure
5.2). The total administration time of propofol showed only limited prognostic value (Figure
5.2). Propofol is not known to cause AKI itself and the present dataset does not indicate
otherwise. Actually, given its antioxidant and cytoprotective properties, propofol is believed
14The following section has already been published in [Zacharias et al. 2015], and [Hochrein et al. 2015] in a
slightly altered version.
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to protect the kidneys against ischemia and reperfusion injury [Snoeijs et al. 2011]. Plasma
levels of propofol-glucuronide appear to serve as a surrogate marker of general kidney function
similar to the antifibrinolytic agent tranexamic acid in the 24 h urinary NMR fingerprints as
discussed in section 5.1.1.
A second study, which gave no details on the cause of AKI, applied ultra-performance reversed-
phase liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer (UPLC
/QTOFMS) to 17 serum specimens each collected from healthy subjects and patients with
newly diagnosed AKI, whose serum creatinine levels at the time of enrollment had increased
1.5-9.6 times over their baseline levels [Sun et al. 2012]. In addition to AKI, patients suffered
from various co-morbidities including congestive heart failure, diabetes mellitus, hypertension,
coronary artery disease, hyperlipidemia, and peripheral vascular disease. Metabolites, whose
serum levels were increased in comparison to the controls, included creatinine, acylcarnitines,
methionine, homocysteine, pyroglutamate, asymmetric dimethylarginine, and phenylalanine,
while the serum levels of several lysophosphatidyl cholines and arginine were decreased. Major
limitations of that study over the present study are the lack of information on the cause of AKI,
other than the absence of an obstruction of the urinary tract, the eventual stage of disease,
and the time that had elapsed between the acute kidney injury and the collection of the serum
specimen used for analysis. Therefore, the utility of the metabolites listed for the diagnosis
and, even more so, prognostication of AKI in general and, particularly, in the context of cardiac
surgery with CPB cannot be assessed.
Other than for creatinine, there is no overlap between the discriminating metabolites identified
in serum by UPLC/QTOFMS and those found here in EDTA plasma by 1D 1H-NMR. The use
of EDTA as anticoagulant was the key to the determination of free calcium and magnesium
levels, because both yielded upon complex formation with EDTA distinct signals in 1H-NMR
spectra. While plasma calcium levels did not differ significantly between the non-AKI (1.97 ±
0.14 mmol/l) and the AKI group (1.95 ± 0.12 mmol/l), a significant increase (p = 1.0e−5) in
plasma levels of Mg2+ from an average concentration of 1.05 ± 0.24 mmol/l in the non-AKI
group to 1.29 ± 0.23 mmol/l in the AKI group was observed, most likely as a result of its use
in treating cardiac arrhythmias.
Ischemic injury and systemic hypoperfusion, known to contribute to the pathophysiology of
postoperative AKI (compare to section 4.1.3) [Rosner and Okusa 2006], may explain the sig-
nificantly (p = 3.0e−3) increased levels of plasma lactate in the AKI group. Acidosis may also
be responsible for the elevated plasma and urine levels of hippuric acid in AKI patients, as
discussed in section 5.1.1. Further, acidosis is also known to decrease renal excretion of cit-
rate [Zuckerman and Assimos 2009] and may thus explain its increased plasma levels. The
observed increase in tryptophan levels might not only be a consequence of reduced glomerular
filtration, but also of reduced albumin binding due to the accumulation of competing solutes
in plasma [Druml et al. 1994].
Prognostication based on NMR or mass spectrometric metabolite fingerprints is not feasible
in a routine intensive care setting, which requires markers amenable to modern point-of-care
testing to initiate swift therapeutic and preventive measures to treat and avoid complications
such as AKI. Plasma creatinine, plasma Mg2+, and plasma lactate are easily quantifiable by
point-of-care technologies and their combined predictive accuracy of 77.0% (AUC 0.84) is only
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slightly lower than that (80%, AUC 0.87) of the full metabolic fingerprinting dataset. For ad-
vanced stage disease, accuracy comes even close to 100%.
Regarding the analysis of intermediate cases of AKI, I trained a classifier only on data of pa-
tients where it was clear whether they had developed AKI or not, i.e. patients of AKIN stages
0, 2 and 3. Employing this classifier on data of AKIN 1 patients, Figure 5.3a) reveals that
most of these patients received a score below 0.5 indicating that their metabolic profiles are
similar to patients without AKI. This becomes also apparent by close inspection of Figure 7.3
in Appendix II section 7.2.6, which shows in the third column from the left in a heat-map rep-
resentation the metabolic profiles of AKIN 1 patients that were falsely prognosticated by the
Random Forest classifier. The metabolic profiles of these patients resemble those of patients,
who did not develop AKI. It has been reported, that even small postoperative increases in serum
creatinine of up to 0.5 mg/dl (44.2 µmol/l) are associated with a nearly threefold increase in
30-day mortality [Lassnigg et al. 2004]. For patients who suffered from AKI due to a variety
of reasons it was shown that AKIN 1 was associated with an almost twofold increased risk of
death [Bedford et al. 2014]. It remains to be investigated, whether patients with metabolic
profiles indistinguishable from those of non-AKI patients have a better postoperative outcome
than those, who were correctly classified as AKIN 1.
The most common risk factors for developing postoperative AKI include elevated preoperative
serum creatinine levels and length of CPB use, as already discussed in section 4.1.3. Inspection
of Table 7.1 in Appendix II section 7.2.1 shows, that length of CPB use (bypass time period) did
not differ significantly between AKI and non-AKI patients for both urine and plasma cohort.
Given, that prognostication of AKI based on length of CPB use yielded only an AUC of 0.55
and 0.52 for urine and plasma cohort, respectively, it is unlikely that length of CPB use was
a major contributor to the development of AKI in the present study. There was, however, a
significant difference in preoperative eGFR between AKI and non-AKI patients in both cohorts.
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5.2 German Chronic Kidney Disease study
5.2.1 Introduction
After the successful investigation of novel urinary and plasma metabolic biomarkers for the
early detection of acute kidney injury after cardiac surgery with CPB use, as detailed in sec-
tion 5.1, I focused on gaining new insights into the pathophysiology and development of chronic
kidney diseases.
As elaborately outlined in section 3.1, CKD is one of the largest burdens of global health [Jha
et al. 2013]. The heterogeneity of its disease pattern hinders effective patient care [Titze et al.
2015], and the demand for clinical trials has not been satisfied yet [Eckardt et al. 2013,Titze
et al. 2015]. Especially large-scale studies focusing on CKD patients under nephrological care
are still scarce [Titze et al. 2015], although two cohorts with about 3000 CKD patients each
have been recruited in the US (Chronic Renal Insufficiency Cohort (CRIC) Study) [Feldman et
al. 2003] and in Japan (Chronic Kidney Disease Japan Cohort (CKD-JAC)) [Imai et al. 2010],
respectively.
The German Chronic Kidney Disease (GCKD) study includes the currently worldwide largest
CKD cohort with about 5200 patients enrolled from March 2010 to March 2012 with a large
observation period of up to ten years [Titze et al. 2015]. It was designed as a national
prospective observational cohort study with nine study centers throughout Germany (DRKS
00003971) [Eckardt et al. 2012,Titze et al. 2015]. Enrolled patients were aged between 18 and
74 years and had to exhibit either an eGFR of 30-60ml/min per 1.73m2 or an eGRF above
60ml/min per 1.73m2 and ‘overt’ albuminuria/proteinuria [Titze et al. 2015], compare to sec-
tion 4.1.4. eGFR was usually determined employing the 4-variable MDRD equation [Titze et
al. 2015], compare to section 4.1.2. Here, albuminuria/proteinuria is defined by either a urinary
ACR above 300mg/g, an albuminuria of more than 300mg/day, a urinary protein/creatinine
ratio of more than 500mg/g, or a proteinuria of more than 500mg/day [Titze et al. 2015].
Patients with solid organ or bone marrow transplantation, active malignancy within 24 months
prior to screening, heart failure New York Heart Association Stage IV, i.e. patient experiences
severe cardiovascular disease including severe limitations in physical activity, legal attendance
or inability to provide consent, and/or non-Caucasian ethnicity have been excluded [Titze et
al. 2015].
Information about numerous clinical chemistry parameters, sociodemographic factors, medical
and family history, medications, quality of life, comorbidities, etc. have been collected by study
teams during the patients visit to a nephrologist’s practice or an outpatient unit of the regional
centers. More details can be found in [Titze et al. 2015,Eckardt et al. 2012].
Detailed baseline clinical and demographic characteristics are given in [Titze et al. 2015]. In
summary, the GCKD cohort comprised 60% men, the mean patient age was (60 ± 12) years,
a mean eGFR of (47 ± 17)ml/min per 1.73m2 and a median urinary ACR of 51 (9 - 392)mg/g
was reported [Titze et al. 2015]. The most frequent leading causes of CKD comprised vascular
nephropathy (23%), primary glomerulopathy (19%), and diabetic nephropathy (15%), whereas
the leading cause was unknown in up to 20% of cases. 35% of patients additionally suffered from
diabetes [Titze et al. 2015]. The prevalence of cardiovascular disease was 32% and prevalent
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risk factors were identified as smoking, obesity, as well as positive family history of diabetes,
cardiovascular and/or renal disease [Titze et al. 2015]. Although anti-hypertensive drugs were
frequently administered, almost half of the patient cohort still exhibited an office blood pressure
above 140/90mmHg [Titze et al. 2015].
Plasma, serum, blood, and spot-urine specimens were collected, processed and further dis-
tributed to the following collaborators. Synlab (Heidelberg, Germany) assessed routine clinical
chemistry parameters, Central Lab (University Hospital Erlangen, Germany) performed Hb and
glycated hemoglobin (HbA1c) measurements, and DNA extraction as well as biofluid storage
for future analyses was conducted at the Central Biobank of the University Hospital Erlan-
gen. The latter provided us with frozen aliquots of plasma specimens for metabolic analyses
performed by NMR spectroscopy as well as MS spectrometry, conducted by the group of Dr.
Katja Dettmer.
The large observation time period and the huge study population enables deductions about the
future disease development based on clinical data collected at the baseline and second follow-up
(FU2) time-point.
For this study, I aimed at the prediction of present and future kidney performance reflected by
the respective eGFR and serum creatinine/cystatin C levels by assessing multiple regression
analyses models for bucket intensities derived from 1D 1H NMR plasma spectra. The detection
of novel biomarkers of kidney function asides from SCr and SCysC, as elaborately described
in section 4.1.2, would offer improved patient care and better understanding of metabolic al-
terations in the context of evolving chronic kidney disease. Furthermore, I studied distinct
plasma metabolic profiles of different renal diseases by employing t-tests. These investigations
might again enable enhanced insights into the different pathophysiologies of these diseases and
possibly lead to revised treatment procedures.
5.2.2 Materials and Methods
5.2.2.1 Sample preparation and NMR data acquisition
In total, 5129 plastic tubes, each automatically filled by a pipetting robot with one EDTA
plasma aliquot collected at the baseline time-point, were sent to us from the University Hos-
pital Erlangen. Each plastic tube was bar-coded by a unique sample ID. Specimens had been
stored at -80°C until preparation for NMR spectroscopy.
Specimens were prepared for NMR measurements in collaboration with Claudia Samol. 400
µl of each unfiltered EDTA plasma specimen was mixed with 200 µl of 0.1 mol/l phosphate
buffer at pH 7.4 and 50 µl of 0.75% (w) of the sodium salt of TSP (Sigma-Aldrich, Taufkirchen,
Germany), solved in D2O, as detailed in section 4.2.2.1. A cost-intensive filtering of the plasma
specimens in order to remove proteins and lipids, as realized for the acute kidney injury study,
see section 5.1.2.2, was omitted due to the large specimen cohort. Since the presence of broad
protein signals might hinder the interpretation of metabolite signals, 1D 1H spectra employing
a CPMG pulse-sequence, compare to section 4.2.2.2, for the suppression of macromolecular sig-
nals were acquired for each plasma specimen. For each 1D 1H CPMG spectrum, 128 scans were
collected into 73728 data points employing the pulse program cpmgpr1d.comp (BrukerBioSpin
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GmbH, Rheinstetten, Germany) with water suppression by presaturation during relaxation.
Four dummy scans were acquired prior to measurement, the spectral width was 20.02 ppm,
the relaxation delay was 4 s and the acquisition time amounted to 3.07 s. The filtering delay
amounted to 0.08 s, resulting in a total acquisition time of about 16 min. I preprocessed every
recorded 1D 1H CPMG spectrum as described in section 4.2.2.3.
The baseline EDTA plasma specimen cohort of the GCKD study was measured by NMR
spectroscopy from August 2014 until June 2015. The long-term stability of the spectrome-
ter performance was controlled and evaluated by employing a reference plasma specimen from
a healthy volunteer. This reference plasma specimen had been split into a sufficient number of
aliquots immediately after decanting, compare to section 4.2.2.1, and stored at -80°C until mea-
surement. For each weekly GCKD NMR data acquisition, a new aliquot was thawed at room
temperature and 400 µl thereof were each filled into two NMR tubes. Again, 200 µl of 0.1 mol/l
phosphate buffer at pH 7.4 and 50 µl of 0.75% (w) of the sodium salt of TSP (Sigma-Aldrich,
Taufkirchen, Germany), solved in D2O, were added to each NMR tube. One 1D 1H CPMG
spectrum for each of these freshly prepared plasma specimens were recorded at the beginning
and end of the weekly NMR measurement period, respectively, typically spanning in total 69
h. We are aware that changes in metabolite concentration do occur for unfiltered plasma speci-
mens stored at 4°C for more than 24 h [Klein 2011]. These changes are exemplarily highlighted
for two reference plasma 1D 1H CPMG spectra measured 69 h appart from each other in Fig.
5.4. They add to overall intragroup variance of investigated datasets and consequently can
influence calculated p-values as well as statistical powers. However, no systematic differences
for specific investigated specimen groups should be present in the GCKD NMR spectral data
set, since NMR measurements were performed with thorough specimen randomization. Nev-
ertheless, NMR signals, whose chemical shifts as well as intensities are significantly influenced
by storage time, should be regarded with care.
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Figure 5.4: Exemplary spectral comparison of two reference EDTA plasma specimens
measured 69 h apart from each other. The EDTA plasma 1D 1H CPMG
spectra acquired at the beginning and end of the measurement period are plotted
in black and green, respectively. Only a small fraction of the spectra are shown
with overall largest variations in metabolite concentrations observed for illustration
purposes.
The conventional NMR reference substance TSP undergoes complex formation with plasma
macromolecules, resulting into a significant diminishment and broadening of the TSP sig-
nal [Zacharias et al. 2013b)]. In fact, the signal variation of the TSP reference signal across
all 1D 1H NMR spectra of the complete GCKD EDTA plasma cohort defined as the relative
standard deviation of the TSP integral amounted to approximateyl 15.0%. In comparison, the
technical variability, defined as the signal variation of the TSP reference signal across all 1D 1H
NMR spectra of the control EDTA plasma specimen, was only 4.7%, i.e. significantly (p-value
< 10−16) lower than the TSP signal variability across different plasma specimens. This illus-
trates the fact that the TSP signal in 1D 1H NMR spectra of unfiltered plasma is significantly
93
5 Biomedical Applications
influenced by the specific macromolecule content of the respective specimen and therefore inap-
propriate as an internal standard for the reduction of variations in spectrometer performance,
as applied for the AKI study detailed in section 5.1.2.5. Note that the technical variability here
includes both the pipetting error and the observed variations in spectrometer performance over
time, and is comparable to the pipetting error plus the spectrometer performance variability
evaluated by Prof. Wolfram Gronwald and Claudia Samol for the AKI study, see section 5.1.2.5.
As a consequence, we decided to further add 10 µl of 81.97 mmol/l formic acid as internal stan-
dard to each EDTA plasma specimen of the GCKD study cohort prior to NMR measurement.
The utilization of formic acid as an alternative internal standard for NMR measurements of
unfiltered plasma specimens has already been recommended in the literature, e.g. [Beckonert
et al. 2007].
5.2.2.2 Spectral alignment and data normalization
Overall variations in chemical shifts were observed in some 1D 1H CPMG spectra of the GCKD
study cohort. They probably result from chemical shifts of the TSP reference signal induced by
variable macromolecule content of the respective EDTA plasma specimen [Klein 2011]. Since
the TSP signal was employed as reference signal for the spectral zero point, compare to section
4.2.2.1, shifts of the TSP NMR signal lead to overall shifts of the respective spectrum. These
general shifts spanned a larger range than the usually employed bucket width of 0.01 ppm and
can therefore not be compensated by this bucketing procedure. Consequently, I decided to
eliminate these general inter-spectral offsets by aligning all investigated 1D 1H CPMG spectra
with respect to each other. This alignment procedure was automatically conducted employing
R.
First, the NMR spectral data was subjected to a bucketing procedure as described in section
4.2.2.3. The spectral region from 9.5 - 0.5 ppm was evenly split into bins of 0.001 ppm width.
As the TSP signal was significantly influenced by the specific macromolecule content of the re-
spective unfiltered EDTA plasma specimen and therefore inappropriate as an internal standard
for the reduction of variations in spectrometer performance, compare to section 5.2.2.1, I scaled
all investigated spectral data relative to the formic acid signal from 8.5 - 8.46 ppm in order
to reduce variations in spectrometer performance. Indeed, the signal variation of the formic
acid reference signal across all 1D 1H CPMG spectra acquired after the addition of formic acid
as internal standard (in total 3206 spectra) defined as the relative standard deviation of the
formic acid integral only amounted to 3.2%, in comparison to the relative standard deviation
of the TSP integral for this specimen cohort of 15.0%. For further analysis, data were imported
into R (Development Core Team 2009).
Now, for each of the 3206 with formic acid as internal standard acquired 1D 1H CPMG spectra,
the bucket with the greatest bucket intensity in the spectral region from 8.5 - 8.46 ppm, corre-
sponding to formic acid, was picked. In the next step, all 1D 1H CPMG spectra were aligned
to each other with respect to the bucket with maximum intensity corresponding to formic acid.
Fig. 5.5 depicts the formic acid singulet around 8.48 ppm as well as the alanine doublet around
1.49 ppm, which was chosen exemplarily, prior to (Fig. 5.5 a) and c), respectively) and after
bucket adjustment (Fig. 5.5 b) and d), respectively). The NMR bucket at 8.4785 ppm was, in
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most cases, i.e. 883 times, picked as the bucket with maximum intensity in the specified region.
If one assumes a typical bucket width of roughly 0.01 ppm around 8.4785 ppm, the bucket with
maximum peak intensity was picked 3120 times in the corresponding spectral region from 8.484
- 8.473 ppm. Consequently, only 86 of, in total 3206 1D 1H CPMG spectra (i.e. about 3%)
displayed an overall spectral shift greater than 0.01 ppm in comparison to the NMR spectra, for
which the formic acid bucket with maximum intensity was picked in the spectral region from
8.4835 - 8.4735 ppm. One exemplary 1D 1H CPMG spectrum for which the bucket at 8.4895
ppm was chosen as bucket with maximum intensity, one exemplary 1D 1H CPMG spectrum
with the maximum bucket intensity at 8.4785 ppm, and one exemplary 1D 1H CPMG spectrum
for which the bucket at 8.4635 ppm was chosen as bucket with maximum intensity are plotted
in Fig. 5.5 in black, red, and green, respectively. After bucket alignment, both the formic acid
singulet (Fig. 5.5 b)) as well as the alanine doublet (Fig. 5.5 d)) of all plotted spectra are
aligned to each other.
After this alignment procedure, bucket intensities across ten buckets with a bucket width of
0.001 ppm each were fused together in one bucket of 0.01 ppm width by summing up the in-
dividual bucket intensities to facilitate easier data interpretation. Note that the corresponding
bucket positions denote the middle of these fused buckets in ppm. The corresponding R-codes
of bucket alignment and fusion procedure are given in Appendix I section 7.1.4.4.
Afterwards, the spectral region from 6.5 - 4.4 ppm containing the broad urea signal and the re-
maining water signal, as well as the NMR signals (3.69 - 3.6 ppm, 3.3 - 3.2 ppm) corresponding
to free EDTA were excluded, resulting into a total number of 660 bins for each 1D 1H CPMG
spectrum.
95
5 Biomedical Applications
Figure 5.5: Exemplary results of bucketing alignment of GCKD study cohort. a)
Formic acid signal of three representative 1D 1H NMR bucket lists prior to bucket
alignment. The overall shifts of the formic acid signal span a range larger than the
usually applied bucket width of 0.01 ppm. b) Formic acid signal of three repre-
sentative 1D 1H NMR bucket lists after bucket alignment. The maximum of the
formic acid peak is now at 8.4785 ppm for all spectra. c) Alanine doublet around
1.49 ppm of three representative 1D 1H NMR bucket lists prior to bucket alignment.
The overall shifts of the alanine signals span a range larger than the usually applied
bucket width of 0.01 ppm. d) Alanine doublet of three representative 1D 1H NMR
bucket lists after bucket alignment. The alanine doublet is now between 1.50 - 1.48
ppm for all spectra. One exemplary 1D 1H CPMG spectrum for which the bucket
at 8.4895 ppm was chosen as bucket with maximum intensity, one exemplary 1D
1H CPMG spectrum with the maximum bucket intensity at 8.4785 ppm, and one
exemplary 1D 1H CPMG spectrum for which the bucket at 8.4635 ppm was chosen
as bucket with maximum intensity are plotted in black, red, and green, respectively.
96
5.2 German Chronic Kidney Disease study
5.2.2.3 Patient selection and characteristics
We received a clinical data file with sample and patient ID, clinical chemistry parameters, so-
ciodemographic factors, medical and family history information, etc. collected for 5296 patients
at the baseline, and for 4478 patients at the FU2 time-point, respectively, from the University
Hospital Erlangen. In order to collect the required patient information for statistical analysis,
the NMR sample IDs were matched with the corresponding sample IDs in the clinical data file.
During the course of sample preparation for NMR measurements and sample ID match, several
hundred EDTA plasma specimens and/or their respective NMR spectra had to be excluded
from statistical data analysis out of various reasons, as illustrated in the flow-charts of Fig. 5.6.
54 plastic tubes did not contain sufficient, i.e. at least 100 µl, specimen material, and the
respective EDTA plasma aliquots had to be excluded from NMR measurements. If plastic
tubes only contained between 100 and 400 µl of EDTA plasma (3.6% of measured EDTA
plasma specimens), the missing plasma volume was substituted with H2O and the bucket in-
tensities were multiplied with the respective dilution factors. Furthermore, 155 EDTA plasma
aliquots had to be excluded due to pipetting irregularities. Consequently, NMR sample IDs for
a total of 4920 individual EDTA plasma specimens collected at the baseline time-point could
be compared to sample IDs in the clinical data file.
Clinical data had been collected for 5296 patients at the baseline time-point, however, for
77 patients, no sample ID had been provided and I consequently excluded these patients from
the sample ID matching procedure, compare to Fig. 5.6a). By comparing the sample IDs of, in
total 4920 available NMR sample IDs, with, in total 5219 reported sample IDs in the clinical
baseline data file, I had to further exclude 64 NMR sample IDs and 363 patients in the clinical
baseline data file, respectively, due to sample ID mismatch (Fig. 5.6a)). Consequently, a total
of 4856 NMR sample IDs could be matched with their respective sample ID in the clinical base-
line data file. Only NMR spectra acquired after the addition of formic acid as internal standard
were included for the statistical analysis of this Ph.D. thesis. Therefore, I further excluded 1692
EDTA plasma specimens, for which a 1D 1H CPMG spectra after the addition of formic acid
as internal standard had not yet been available at the time-point of statistical analysis for this
Ph.D. thesis. The GCKD study baseline sample cohort consequently comprises in total 3164
patients, for whom one EDTA plasma specimen collected at the baseline time-point had been
measured with NMR spectroscopy and formic acid as internal standard, and their respective
baseline sample ID could be matched between NMR spectrum and clinical baseline data file.
Baseline patient characteristics corresponding to this sample cohort are given in Appendix III
section 7.3.1 Table 7.5.
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Figure 5.6: Flow-charts illustrating sample exclusion procedures conducted during
NMR sample preparation and sample ID match. a) GCKD study sample
cohort with clinical data collected at the baseline time-point. b) GCKD study
sample cohort with clinical data collected at the FU2 time-point. More details are
given in the text.
FU2 clinical data had been collected for, in total, 4478 patients. Consequently, a "drop-out" of
818 patients in comparison to the baseline clinical data collection has to be reported. Reasons
for this "drop-out" include death and consent withdrawal. In order to match the baseline NMR
sample IDs, I first had to match the respective patient IDs in the baseline and clinical FU2
data files, since the clinical FU2 data file did not contain the baseline sample IDs. Here, I had
to exclude 64 patients in the FU2 clinical data file due to patient ID mismatch, compare to Fig.
5.6b). By now comparing the sample IDs of the remaining 4414 patients in the FU2 clinical
data file with the 4920 baseline NMR sample IDs, I further excluded 826 NMR baseline sample
IDs and 320 patients in the clinical FU2 data file, respectively, due to sample ID mismatch (Fig.
5.6b)). Moreover, for 1397 out of the matched 4094 EDTA plasma specimens a 1D 1H CPMG
spectrum after the addition of formic acid as internal standard had not yet been available at
the time-point of statistical analysis for this Ph.D. thesis. They were consequently excluded
from statistical data analysis for this Ph.D. thesis. Therefore, the GCKD study FU2 sample
cohort comprises in total 2697 patients, for whom one EDTA plasma specimen collected at the
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baseline time-point had been measured with NMR spectroscopy and formic acid as internal
standard, and their respective baseline sample ID could be matched between NMR spectrum
and clinical FU2 data file. Baseline as well as FU2 patient characteristics corresponding to this
sample cohort are given in Appendix III section 7.3.1 Table 7.6.
5.2.2.4 Statistical data analysis
In order to guide decision making for the appropriate normalization technique, the for the AKI
study developed strategy was utilized, compare to section 5.1.3.1. The Shapiro-Wilk normality
test was applied to the GCKD study baseline and FU2 sample cohorts separately, and yielded
in both cases significant p-values < 10−16, indicating that the spectral data of both cohorts is
not normally distributed. Consequently, common data normalization methods such as Quantile
or VS normalization were not applied.
In order to investigate distinct metabolic differences between various leading renal diseases,
I employed an ANOVA and subsequently two sample t-tests as detailed in section 4.3.1.3. For
this analysis, I applied a log2 transformation to the formic acid scaled spectral bucket inten-
sities to minimize heteroscedasticity, as explicitly discussed in section 5.1.3.1. The effect size
and statistical power for all discriminating NMR features was determined with the R packages
compute.es [Del Re 2013] and pwr [Champely 2015], respectively. Here, I employed the GCKD
study baseline sample cohort. However, due to the fact that the leading renal disease of one
patient had not been assigned, compare to Appendix III section 7.3.1 Table 7.5, I excluded this
patient from the corresponding statistical analysis. For the comparison of specific leading renal
diseases, I furthermore excluded patients with no leading renal disease as well as patients suf-
fering from "other" leading renal diseases due to large group heterogenity. Note that all leading
renal disease groups, which did not include at least 100 individual patients, were summarized
in "other" leading renal diseases.
For the prediction of present and future kidney performance reflected by the patient’s serum
creatinine/cystatin C levels and the respective eGFR, I performed simple linear as well as
multiple regression analyses employing the LASSO method, as introduced in section 4.3.1.3.
The training of an individual regression model was performed employing a fixed training set
comprising 2/3 of the complete sample cohort, compare to section 4.3.1.3. Its predictive per-
formance was assessed on a fixed test set comprising the remaining 1/3 of the complete sample
cohort. Regression analyses for the prediction of baseline and FU2 SCr, SCysC, and eGFR
values were performed with the GCKD study FU2 sample cohort. Note that due to missing
clinical parameters, 205 samples had to be excluded from the GCKD study FU2 sample cohort.
The baseline as well as FU2 patient characteristics of training and test set for this sample
cohort, compare to section 5.2.2.3, are given in Appendix III section 7.3.1 Table 7.7. Note that
no significant difference of baseline and FU2 patient characteristics between training and re-
spective test sets are reported. For the determination of multiple regression models, I employed
log2 transformed bucket intensities derived from 1D 1H NMR plasma spectra in order to remove
heteroscedasticity. To preserve the linear relationship between log2 transformed bucket intensi-
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ties and the response variables, i.e. SCr, SCysC, as well as eGFR values, I furthermore applied
a log2 transformation on the respective response variables for the model training step. Note
that the predicted response variables in the testing step are also log2 transformed. Therefore,
the predicted response variables of the test set were subsequently inversely log2 transformed
and the reported mean-squared error (mse) as well as the coefficient of determination R2 are
calculated between the originally not log2 transformed true and the inversely log2 transformed
predicted response variables of the test set. Note that the mse for the training set, derived from
an internal cross-validation procedure for determining the optimal λ λmin, is also recorded, but
refers to the log2 transformed response values of the training set. In order to compare the
mse for the training set with the respective mse of the test set, I also report the mse between
the log2 transformed true and predicted response variables for the test set. For each trained
LASSO model, the number of employed NMR features with β coefficients unequal to zero is
reported and the not log2 transformed true and inversely log2 transformed predicted response
variables are plotted in a x− y - diagram, whereas a linear model fitted between these true and
predicted response variables is also given in this diagram.
For the determination of simple linear regression models based on respective baseline clinical
parameters, neither explanatory nor response variables were log2 transformed in the model
training step. The reported coefficients of determination R2 as well as the mse are calculated
between the originally not log2 transformed true and predicted response variables of the test
set. Again, a x − y - diagram with a fitted linear model is plotted between these true and
predicted response variables, as realized for the different LASSO models.
A comparison of the GFR estimation performance of the different employed estimation for-
mulas was conducted by performing Pearson’s correlation calculations, as well as applying
Bland-Altman plots [Bland and Altman 1999,Bland and Altman 1986] utilizing the R package
MethComp [Carstensen et al. 2015]. Metabolite identification was performed as detailed in sec-
tion 4.3.2. The identification of lipid functional groups was conducted with the aid of specific
peak lists provided by [Klein et al. 2011,Klein 2011].
5.2.3 Results
5.2.3.1 Data acquisition and appropriate preprocessing of 1D 1H NMR spectra of
unfiltered EDTA plasma
For 3206 unfiltered EDTA plasma specimens collected at the baseline time-point, 1D 1H NMR
spectra were acquired employing a CPMG pulse sequence to suppress broad NMR signals aris-
ing mainly from protons in proteins, whereas formic acid had been added to each investigated
specimen as internal standard. An exemplary 1D 1H CPMG spectrum of an unfiltered EDTA
plasma specimen of the GCKD study is shown in Fig. 5.7. For reasons of clarity, only a subset
of prominent compounds is assigned. The CPMG pulse sequence yields a well resolved 1D
spectrum. Although the spectrum lacks broad signals mainly arising from protons in proteins,
it still includes a number of broad NMR peaks from protons in lipids, especially in the region
from 2.5 - 0.7 ppm. Furthermore, one has to note that the signal intensities in a 1D 1H CPMG
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spectrum cannot be directly compared to corresponding signal intensities in a 1D 1H NOESY
spectrum acquired from the same specimen, since the former are, in general, smaller than the
latter due to overall NMR signal decay during the refocusing period.
As detailed in sections 5.2.2.1 and 5.2.2.2, the TSP signal proved to be inappropriate as an in-
ternal standard to account for variations in spectrometer performance due to its dependence on
the macromolecule content of the individual unfiltered EDTA plasma specimen. Consequently,
a scaling of bucket intensities to the spectral region of formic acid, which had been added as
an alternative internal standard, was applied in order to account for variations in spectrometer
performance, see section 5.2.2.2.
For about 3% of all 1D 1H CPMG spectra acquired with formic acid as internal standard,
global peak shifts larger than 0.01ppm were noticed. These shifts probably arise from off-
sets of the TSP reference signal, which was employed to denote the zero point of the spectrum.
These offsets were introduced by the binding of the TSP reference substance to macromolecules
present in the unfiltered EDTA plasma specimens, as already reported in [Klein 2011]. In order
to compensate these global peak shifts, all 3206 1D 1H NMR spectra acquired with formic
acid as internal standard were properly aligned to each other prior to further statistical data
analysis, as detailed in section 5.2.2.2.
Figure 5.7: Exemplary 1D 1H CPMG NMR spectrum of an EDTA plasma specimen
of the GCKD study collected at the baseline time-point. Some prominent
NMR signals are assigned to the corresponding compounds. Note that due to signal
overlap, only a small subset of identified compounds is exemplarily assigned in this
representative spectrum.
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5.2.3.2 Specific metabolic fingerprints of various leading renal diseases
In order to detect statistically significant differences between 6 individual leading renal dis-
eases, I performed an ANOVA including all 6 groups comprising, in total, 2305 individual 1D
1H spectral data sets, as outlined in section 5.2.2.4. To remove heteroscedasticity, the NMR
bucket intensities had been log2 transformed. The corresponding F -test yielded 403 buckets
with a B/H-adjusted p-value < 0.05. I subsequently conducted 15 individual pairwise group
comparisons by means of Student’s t-tests. Table 5.4 lists the number of significantly differen-
tiating bins (p-value B/H-adjusted < 0.05) for all conducted group comparisons. The spectral
positions, fold changes, unadjusted as well as B/H-adjusted p-values, statistical powers, IDs,
and corresponding identified metabolites for group comparisons yielding statistically significant
B/H-adjusted p-values are listed in Appendix III section 7.3.2 Tables 7.8 to 7.21.
In summary, significant differences in D-glucose concentration of EDTA plasma specimens of
patients suffering from diabetic nephropathy in comparison to patients suffering from another
leading renal disease are apparent in Appendix III section 7.3.2 Tables 7.8 to 7.12. Moreover, an
up-regulation of lipids and cholesterol in the EDTA plasma specimens of patients with glomeru-
lonephritis in comparison to patients suffering from another leading renal disease is shown in
Appendix III section 7.3.2 Tables 7.8 and 7.13 to 7.15. The EDTA plasma concentrations of
D-glucose were however down-regulated in patients suffering from glomerulonephritis in com-
parison to patients suffering from hypertensive nephropathy (see Appendix III section 7.3.2
Table 7.16). An up-regulation of lipids in the EDTA plasma specimens of patients with hyper-
tensive nephropathy is reported in comparison to patients suffering from hereditary diseases,
interstitial nephropathy as well as systemic diseases, respectively.
Note that the statistical power of all highly significant metabolites was above 80%, indicating
that the reported differences between these leading renal diseases are truly present in the general
population.
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DNa GNb Here- INd Syste- HNf
ditary mic
diseasec diseasee
DNa - 279 320 310 350 234
GNb 279 - 184 47 136 130
Here-
ditary
diseasec 320 184 - 3 3 223
INd 310 47 3 - 0 135
Syste-
mic
diseasee 350 136 3 0 - 251
HNf 234 130 223 135 251 -
Table 5.4: Numbers of significantly different NMR buckets (B/H-adjusted p-values
< 0.05 according to FDR < 5%) for group comparisons between 6 different
leading renal diseases by means of Student’s t-tests. The individual spec-
tral positions, IDs, log(Fold-changes), p-values both unadjusted and B/H-adjusted,
statistical power, as well as correspondingly identified compounds of these discrimi-
nating NMR features are listed in Appendix III section 7.3.2. aDN had been assigned
by our collaboration partners if patient suffered from diabetes mellitus or other dia-
betic nephropathies. bGN had been assigned by our collaboration partners if patient
suffered from primary glomerulonephritis. cHereditary disease had been assigned by
our collaboration partners if patient suffered from ADPKD, Fabry disease, or other
hereditary diseases. dIN had been assigned by our collaboration partners if patient
suffered from interstitial nephropathy, analgesic nephropathy, or other interstitial
nephropathies. eSystemic disease had been assigned by our collaboration partners
if patient suffered from granulomatosis with polyangiitis, microscopic polyangiitis,
systemic lupus erythematosus, scleroderma, hemolytic-uremic syndrome, thrombotic
thrombocytopenic purpura, gout, tuberculosis, amyloidosis, sarcoidosis, or other sys-
temic diseases. fHN had been assigned by our collaboration partners if patient
suffered from renal artery stenosis, nephrosclerosis, kidney infarction, or other hy-
pertensive nephropathies. Abbreviations: DN, diabetic nephropathy; GN, glomeru-
lonephritis; HN, hypertensive nephropathy; IN, interstitial nephropathy.
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5.2.3.3 Prediction of present and future kidney performance
For the prediction of baseline and FU2 kidney performance, reflected by the respective SCr,
SCysC, and the GFR values estimated employing the MDRD4 (eGFRmdrd4) [Levey et al. 1999],
the CKD-EPI crea (eGFRckdepi crea) [Levey et al. 2009, Inker et al. 2012], the CKD-EPI cys
(eGFRckdepi cys) [Inker et al. 2012], and the CKD-EPI crea cys (eGFRckdepi crea cys) [Inker et al.
2012] formula, respectively, I utilized the GCKD study FU2 sample cohort. As for 205 patients,
at least one of these clinical parameters had not been assigned in the clinical data file, compare
to Appendix III section 7.3.1 Table 7.6, I excluded these patients from the following statistical
data analysis. Consequently, the complete specimen cohort for the prediction of present and
future kidney performance comprises in total 2492 individual patients, for whom SCr, SCysC,
and eGFR values were reported at both the baseline and the FU2 time-point and 1D 1H CPMG
spectra had been acquired after the addition of formic acid as internal standard, compare to
sections 5.2.2.1, 5.2.2.2, and 5.2.2.3.
First, I compared the GFR estimation performance of the different employed estimation for-
mulas by applying Pearson’s correlation calculations, as well as Bland-Altman plots [Bland
and Altman 1999, Bland and Altman 1986]. The corresponding results, including Pearson’s
correlation coefficient r and the coefficient of determination R2 = r2 are given in Table 5.5.
x− y scatter plots of the compared eGFR values with fitted simple linear regression lines and
corresponding Bland-Altman plots are given in Appendix III section 7.3.3 Fig. 7.4.
a) Baseline eGFR values
eGFRmdrd4 eGFRckdepi crea eGFRckdepi cys eGFRckdepi crea cys
eGFRmdrd4 r = 1; R2 = 1 r = 0.987; R2 = 0.973 r = 0.767; R2 = 0.589 r = 0.922; R2 = 0.849
eGFRckdepi crea r = 0.987; R2 = 0.973 r = 1; R2 = 1 r = 0.784; R2 = 0.614 r = 0.933; R2 = 0.871
eGFRckdepi cys r = 0.767; R2 = 0.589 r = 0.784; R2 = 0.614 r = 1; R2 = 1 r = 0.953; R2 = 0.908
eGFRckdepi crea cys r = 0.922; R2 = 0.849 r = 0.933; R2 = 0.871 r = 0.953; R2 = 0.908 r = 1; R2 = 1
b) FU2 eGFR values
eGFRmdrd4 eGFRckdepi crea eGFRckdepi cys eGFRckdepi crea cys
eGFRmdrd4 r = 1; R2 = 1 r = 0.990; R2 = 0.980 r = 0.821; R2 = 0.674 r = 0.938; R2 = 0.880
eGFRckdepi crea r = 0.990; R2 = 0.980 r = 1; R2 = 1 r = 0.837; R2 = 0.700 r = 0.948; R2 = 0.899
eGFRckdepi cys r = 0.821; R2 = 0.674 r = 0.837; R2 = 0.700 r = 1; R2 = 1 r = 0.966; R2 = 0.933
eGFRckdepi crea cys r = 0.938; R2 = 0.880 r = 0.948; R2 = 0.899 r = 0.966; R2 = 0.933 r = 1; R2 = 1
Table 5.5: Method comparison of different GFR estimation equations for a) baseline,
and b) FU2 eGFR values. Given are Pearson’s correlation coefficients r and
coefficients of determination R2 = r2 for the different comparisons. Corresponding
x − y scatter plots of the compared eGFR values including equations of the fitted
simple linear regression lines and Bland-Altman plots are given in Appendix III
section 7.3.3 Fig. 7.5. Abbreviations: eGFR, estimated glomerular filtration rate;
eGFRckdepi crea, eGFR based on CKD-EPI crea formula; eGFRckdepi crea cys, eGFR
based on CKD-EPI crea cys formula; eGFRckdepi cys, eGFR based on CKD-EPI cys
formula; eGFRmdrd4, eGFR based on MDRD4 formula; FU2, second follow-up.
This method comparison for the four different GFR estimation equations indicates an almost
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perfect consensus between the MDRD4, CKD-EPI crea, and CKD-EPI crea cys formulas in-
dicated by large Pearson’s correlation coefficients around 0.9 and corresponding coefficients of
determination around 0.87 for both time-points. Furthermore, the limits of agreement shown
in the Bland-Altman plots in Appendix III section 7.3.3 Fig. 7.4 are very close to the mean
difference between the respective compared methods for the aforementioned comparisons. Es-
timating the GFR values utilizing the CKD-EPI cys formula in comparison to the MDRD4 and
the CKD-EPI crea formula, respectively, seem to, however, yield worse agreement between the
compared methods for both time-points with Pearson’s correlation coefficients only around 0.77
and 0.82, and corresponding coefficients of determination around 0.6 and 0.7 for baseline and
FU2 time-point, respectively. This apparent deviation between eGFR values either based on
SCr or SCysC values is furthermore reflected by comparable Pearson’s correlation coefficients
and coefficients of determination between SCr and SCysC values measured at the baseline (r =
0.713, R2 = 0.508) and FU2 (r = 0.804, R2 = 0.647) time-point, respectively, given in Appendix
III section 7.3.3 Fig. 7.5.
In order to assess the relationship between 1D 1H NMR data of baseline EDTA plasma spec-
imens and present kidney function, I conducted multiple regression analyses employing the
LASSO method with the complete NMR spectral feature set of 660 individual bucket intensi-
ties. The corresponding results are given in Table 5.6.
In order to illustrate the importance of creatinine as an explanatory variable in the derived
LASSO models, I further performed multiple regression analyses employing the LASSO method
after the exclusions of all creatinine buckets in the 1D 1H CPMG spectra, corresponding to the
spectral regions of 4.117 - 4.037 ppm and 3.117 - 3.017 ppm, leaving, in total, 641 individual
NMR buckets. The LASSO method was chosen since it yields, in comparison to ridge regres-
sion, rather small regression models, from which biological interpretations can be more easily
drawn, see section 4.3.1.3.
For regression analysis, I split the complete cohort of 2492 specimens into an exclusive training
and test set of 1661 and 831 specimens, respectively. The baseline and FU2 patient characteris-
tics of the training and test set are given in Appendix III section 7.3.1 Table 7.7. No significant
differences of these clinical parameters exist between training and test set.
As detailed in section 5.2.2.4, NMR feature intensities as well as response variables were log2
transformed in the model training step of the multiple regression analyses to remove het-
eroscedasticity and preserve the linear relationship between explanatory and response variables.
Since the predicted response variables in the testing step are also log2 transformed, they were
subsequently inversely log2 transformed and the reported mse as well as the R2 values are
calculated between the originally not log2 transformed true and the inversely log2 transformed
predicted response variables of the test set. Note that the mse for the training set refers to
the log2 transformed response values. For comparison, I also report the mse between the log2
transformed true and predicted response variables for the test set. For each trained LASSO
model, the number of employed NMR features with β coefficients unequal to zero is reported.
The not log2 transformed true and inversely log2 transformed predicted response variables are
plotted in scatter plots displayed in Appendix III section 7.3.3 Fig. 7.6 to 7.7, including a linear
model fitted between these true and predicted response variables.
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The LASSO regression analyses for the prediction of baseline Synlab clinical chemistry pa-
rameters including the complete set of 660 NMR buckets showed very good performance for
SCr values with a high R2 of 0.936 (mse on test set = 0.013 mg/dl) and slightly minor perfor-
mance for SCysC with R2 of 0.739 (mse on test set = 0.052 mg/l) on the independent test set.
After the exclusion of NMR creatinine signals, the coefficients of determination R2 significantly
dropped and the corresponding mse values on both training and test set significantly increased
for the prediction of baseline Synlab SCr values. Furthermore, the numbers of NMR buckets
with β coefficients significantly increased after the exclusion of NMR buckets corresponding to
creatinine. The exclusion of all NMR creatinine signals only slightly worsened the performance
of the corresponding LASSO model with respect to baseline Synlab SCysC values.
The performance of LASSO models derived from 660 individual baseline EDTA plasma 1D 1H
CPMG bucket intensities for the prediction of baseline eGFR values likewise showed good R2
values ranging from 0.727 for eGFRckdepi cys values to 0.860 for eGFRckdepi crea values. Again, the
exclusion of all NMR signals corresponding to creatinine prior to LASSO model determination
yielded significantly worse prediction performances with respect to eGFR values based on SCr
(e.g. increase of over 50% of the mse on both training and test set for both eGFRmdrd4 and
eGFRckdepi crea, respectively). For eGFRckdepi cys response variables, the exclusion of all creati-
nine signals only yielded a marginally worse performance of the new LASSO model (increase
of about 12% of the mse on both training and test set).
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Baseline response variables
R2 cv mse on mse on Number of employed
training set test set NMR bins
Synlab SCr
Multiple regression with 660 NMR bins 0.936 0.011 ± 0.002 0.013(mg/dl)2 / 131
0.012
Multiple regression with 641 NMR bins 0.677 0.059 ± 0.003 0.068(mg/dl)2 / 465
0.053
Synlab SCysC
Multiple regression with 660 NMR bins 0.739 0.043 ± 0.002 0.052(mg/l)2 / 211
0.042
Multiple regression with 641 NMR bins 0.709 0.050 ± 0.002 0.058(mg/l)2 / 231
0.048
eGFRmdrd4
Multiple regression with 660 NMR bins 0.843 0.033 ± 0.002 39.27(ml/min/1.73m2)2 / 273
0.032
Multiple regression with 641 NMR bins 0.680 0.077 ± 0.004 80.19(ml/min/1.73m2)2 / 410
0.069
eGFRckdepi crea
Multiple regression with 660 NMR bins 0.860 0.036 ± 0.002 41.92(ml/min/1.73m2)2 / 295
0.036
Multiple regression with 641 NMR bins 0.710 0.083 ± 0.004 87.00(ml/min/1.73m2)2 / 411
0.074
eGFRckdepi cys
Multiple regression with 660 NMR bins 0.727 0.080 ± 0.004 101.10(ml/min/1.73m2)2 / 233
0.079
Multiple regression with 641 NMR bins 0.698 0.090 ± 0.004 112.28(ml/min/1.73m2)2 / 286
0.086
eGFRckdepi crea cys
Multiple regression with 660 NMR bins 0.837 0.042 ± 0.002 49.08(ml/min/1.73m2)2 / 280
0.040
Multiple regression with 641 NMR bins 0.768 0.065 ± 0.004 70.28(ml/min/1.73m2)2 / 356
0.057
Table 5.6: Results of regression analyses for prediction of baseline SCr, SCysC, and eGFR values. Multiple regression
analyses employing the LASSO method with both the complete baseline NMR spectral feature set of 660 individual
bucket intensities, and with a baseline NMR spectral feature set of 641 individual bucket intensities after the exclusion
of all NMR buckets corresponding to creatinine, respectively, were conducted. More details are given in the text.
Abbreviations: cv, cross-validated; eGFR, estimated glomerular filtration rate; eGFRckdepi crea, eGFR based on CKD-
EPI crea formula; eGFRckdepi crea cys, eGFR based on CKD-EPI crea cys formula; eGFRckdepi cys, eGFR based on
CKD-EPI cys formula; eGFRmdrd4, eGFR based on MDRD4 formula; mse, mean-squared error; SCr, serum creatinine;
SCysC, serum cystatin C.
The reliable prediction of future kidney performance in the context of chronic kidney disease is of
crucial importance for sufficient patient treatment. Therefore, I repeated the aforementioned
multiple regression analyses employing either all 660 baseline NMR buckets or 641 baseline
NMR buckets after the exclusion of spectral regions belonging to creatinine, respectively, with
respect to FU2 clinical parameters. Furthermore, I performed simple linear regression analyses
with respect to FU2 clinical parameters now based on the respective baseline clinical parame-
ters. This means, that, e.g. in the case of Synlab SCr, a simple linear regression model is trained
with the baseline Synlab SCr values as explanatory variables and the FU2 Synlab SCr values as
response variables on the training set, and consequently, its predictive performance with respect
to the FU2 Synlab SCr values is assessed on the test set. Note that in this case, both explana-
tory as well as response variables were not log2 transformed during the model training step.
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The corresponding results are given in Table 5.7 and Appendix III section 7.3.3 Fig. 7.8 to 7.10.
FU2 response variables
R2 cv mse on mse on Number of employed
training set test set NMR bins
Synlab SCr
Multiple regression with 660 NMR bins 0.498 0.101 ± 0.005 0.204(mg/dl)2 / 113
0.097
Multiple regression with 641 NMR bins 0.383 0.146 ± 0.006 0.252(mg/dl)2 / 136
0.131
Simple regression with baseline 0.517 - 0.200(mg/dl)2 -
Synlab SCr concentrations
Synlab SCysC
Multiple regression with 660 NMR bins 0.492 0.103 ± 0.005 0.198(mg/l)2 / 102
0.099
Multiple regression with 641 NMR bins 0.477 0.113 ± 0.005 0.205(mg/l)2 / 254
0.108
Simple regression with baseline 0.589 - 0.158(mg/l)2 -
Synlab SCysC concentrations
eGFRmdrd4
Multiple regression with 660 NMR bins 0.586 0.153 ± 0.007 100.97(ml/min/1.73m2)2 / 84
0.122
Multiple regression with 641 NMR bins 0.437 0.201 ± 0.008 139.39(ml/min/1.73m2)2 / 155
0.155
Simple regression with baseline 0.643 - 87.94(ml/min/1.73m2)2 -
eGFRmdrd4 values
eGFRckdepi crea
Multiple regression with 660 NMR bins 0.612 0.167 ± 0.007 116.88(ml/min/1.73m2)2 / 73
0.133
Multiple regression with 641 NMR bins 0.463 0.219 ± 0.008 164.01(ml/min/1.73m2)2 / 149
0.170
Simple regression with baseline 0.670 - 99.63(ml/min/1.73m2)2 -
eGFRckdepi crea values
eGFRckdepi cys
Multiple regression with 660 NMR bins 0.585 0.190 ± 0.008 153.66(ml/min/1.73m2)2 / 103
0.174
Multiple regression with 641 NMR bins 0.522 0.205 ± 0.009 176.86(ml/min/1.73m2)2 / 260
0.194
Simple regression with baseline 0.699 - 110.4(ml/min/1.73m2)2 -
eGFRckdepi cys values
eGFRckdepi crea cys
Multiple regression with 660 NMR bins 0.633 0.164 ± 0.007 114.06(ml/min/1.73m2)2 / 109
0.140
Multiple regression with 641 NMR bins 0.532 0.195 ± 0.008 146.42(ml/min/1.73m2)2 / 184
0.163
Simple regression with baseline 0.711 - 89.80(ml/min/1.73m2)2 -
eGFRckdepi crea cys values
Table 5.7: Results of regression analyses for prediction of FU2 SCr, SCysC, and eGFR values. LASSO regression
with both 660, as well as 641 individual baseline NMR bucket intensities after the exclusion of all creatinine signals,
and simple linear regression with respective baseline clinical parameters were conducted. More details are given in the
text. Abbreviations: cv, cross-validated; eGFR, estimated glomerular filtration rate; eGFRckdepi crea, eGFR based on
CKD-EPI crea formula; eGFRckdepi crea cys, eGFR based on CKD-EPI crea cys formula; eGFRckdepi cys, eGFR based
on CKD-EPI cys formula; eGFRmdrd4, eGFR based on MDRD4 formula; FU2, second follow-up; mse, mean-squared
error; SCr, serum creatinine; SCysC, serum cystatin C.
It is apparent that simple linear regression models based on the respective baseline clinical
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parameters outperformed the respective LASSO models based on baseline NMR bucket inten-
sities for the prediction of all FU2 clinical parameters in terms of both higher R2 and lower
mse values on the test set.
The superior prediction performance of all simple linear regression models based on baseline
clinical parameters is not surprising since the majority of the included patients in this cohort
did not experience large changes in SCr, SCysC or eGFR values over the investigated time
period of two years, as illustrated in histograms displayed in Appendix III section 7.3.3 Fig.
7.11. This observation is actually reflected by the fact that the prediction of SCr, SCysC, or
eGFR differences between baseline and FU2 time-point based on LASSO models derived from
baseline EDTA plasma 1D 1H CPMG spectra did not yield any satisfactory results (data not
shown).
5.2.4 Discussion
The GCKD study comprises currently the world-wide largest cohort of patients suffering from
chronic kidney disease [Titze et al. 2015] and gives way to a new dimensionality in NMR based
metabolomic analyses. The measurement and statistical analysis of baseline EDTA plasma
fingerprints derived from 1D 1H NMR measurements of this cohort posed several challenges
on project management as well as NMR measurements. However, at the same time, it offers
sufficient sample sizes to derive meaningful statistical inferences about the total population,
e.g. by comparison of metabolite concentrations in this CKD cohort or entities thereof against
reference concentrations in healthy subjects as provided, for example, by the HMDB [Wishart
et al. 2007].
First, an effective way to suppress broad signals in 1D 1H NMR spectra arising from protons
in proteins of plasma specimens had to be chosen. Common protein removal methods like
filtering of specimens with 10kDa filters, as applied for the acute kidney injury study described
in section 5.1, or methanol aided protein precipitation are not feasible for large sample cohorts
due to cost intensive and time consuming procedures. Therefore, we decided to measure 1D
1H NMR spectra of the complete baseline EDTA plasma specimen cohort of the GCKD study
without a protein removal step by employing the CPMG pulse sequence. This enabled the ac-
quisition of well resolved 1D 1H spectra without broad signals arising from protons in proteins
in sufficiently low measurement times for high-throughput studies. However, broad, unspecific
signals arising from protons in lipids, which would have been removed by sample filtering [Klein
2011], are still present in the CPMG spectra.
Second, significant line broadening and diminishing of the TSP reference signal, which cru-
cially depended on the macromolecule content of the respective specimen, was observed. Con-
sequently, the alternative reference substance formic acid [Beckonert et al. 2007] was added to
the remaining, not yet measured NMR spectra, which were subsequently scaled to the respec-
tive signal intensity to reduce variations in spectrometer performance. Therefore, all statistical
analyses reported in this Ph.D. thesis were only conducted with 1D 1H CPMG spectra acquired
after the addition of formic acid. The remaining EDTA plasma specimens are currently mea-
sured with formic acid as internal standard and will be evaluated in the future. Moreover, data
cleaning procedures for correct matching between NMR sample IDs and corresponding sample
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IDs in the clinical data files are currently under way at the University Clinic of Erlangen. It is
therefore likely that NMR spectra, which had to be excluded from statistical data analyses due
to sample ID mismatch will be correctly matched in the future and consequently included in
statistical data analyses. Nevertheless, the two GCKD study specimen cohorts comprising 3164
and 2697 individual patients, respectively, showed baseline patient characteristics (Appendix
III section 7.3.1) comparable to overall GCKD study characteristics (section 5.2.1), except for
diabetes incidence. Moreover, statistical power calculations for the comparisons of different
leading renal diseases by means of t-tests proved that the reported analyses were conducted
with sufficient numbers of specimens. Thus, overall significant differences between the results
of the statistical analyses conducted for this Ph.D. thesis and respective analyses with the com-
plete specimen cohort of 4920 specimens are not to be expected.
Third, overall spectral shifts larger than 0.01 ppm were observed for 86 1D 1H CPMG spectra,
which would not be efficiently compensated by a bucketing procedure with a bucket width of
0.01 ppm. Here, I present a fast and sufficient method to align the complete cohort of 3206 1D
1H CPMG spectra. A manual alignment of the 86 shifted spectra was omitted, since it is prone
to human bias. Moreover, this general spectral alignment tool could also be applied to other
NMR-based data sets.
Specific metabolic fingerprints of six different leading renal diseases were determined via in-
dividual comparisons by means of t-tests. Major significant differences, characterized by a
sufficient number of NMR bins with significant B/H-adjusted p-values and correspondingly
sufficient statistical power, are reported for, in total, 11 different comparisons. A significant
up-regulation of D-glucose concentrations in EDTA plasma specimens of patients suffering
from diabetic nephropathy can be deduced from the presented analyses. These observations
are not surprising since the definition of diabetic nephropathy itself implements that the re-
spective patient significantly suffers from diabetes mellitus, which itself is characterized by
chronic hyperglycemia [Arastéh et al. 2009]. Patients in the GCKD study were diagnosed as
suffering from diabetes mellitus if either the percentaged fraction of the glycated hemoglobin
HbA1c in comparison to the total amount of hemoglobin was equal to or larger than 6.5%,
or if anti-diabetic medication was prescribed. HbA1c is a sufficient measure for the average
blood glucose concentration during the last 8 to 10 weeks, and accounts for about 4 - 6% of
total hemoglobin in people without diabetes mellitus [Arastéh et al. 2009]. In fact, GCKD
patients suffering from diabetic nephropathy (mean baseline HbA1c percentaged fraction 7.5%)
exhibited significantly higher (p-value < 2.2e−16) percentaged fractions of HbA1c in compar-
ison to GCKD patients suffering from glomerulonephritis (mean baseline HbA1c percentaged
fraction 6.0%), hereditary diseases (mean baseline HbA1c percentaged fraction 5.9%), intersti-
tial nephropathy (mean baseline HbA1c percentaged fraction 6.1%), systemic diseases (mean
baseline HbA1c percentaged fraction 5.8%), and vascular nephropathy (mean baseline HbA1c
percentaged fraction 6.2%), respectively, despite frequent administration of anti-diabetic medi-
cation in the diabetic nephropathy group (88.5% of patients received anti-diabetic medication)
in comparison to other groups (between 4 and 18%). This supports the significant up-regulation
of D-glucose in EDTA plasma specimens collected at the baseline time-point of patients suf-
fering from diabetic nephropathy in comparison to patients suffering from other leading renal
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diseases as revealed by NMR spectroscopy.
Moreover, significant higher lipid signals in EDTA plasma specimens of patients suffering from
glomerulonephritis in comparison to patients suffering from other leading renal diseases were de-
tected. Hyperlipidemia is a common characteristic of the so-called nephrotic syndrome [Arastéh
et al. 2009], which itself is one of the major pathophysiological conditions of glomerulonephri-
tis [Arastéh et al. 2009]. Therefore, the presented results are in good concordance with standard
clinical definitions of diabetic nephropathy and glomerulonephritis.
Although these various group comparisons revealed interesting NMR spectral differences be-
tween various leading renal diseases, one has to keep in mind that specific metabolic fingerprints
of these renal diseases could only be determined by comparing the respective 1D 1H NMR spec-
tra of one individual leading renal disease to 1D 1H NMR spectra of healthy individuals. Here,
one has to consider that the sample preparation procedures for the respective EDTA plasma
specimens of the healthy control group have to be exactly the same as reported for the EDTA
plasma GCKD specimens. This implies the acquisition of 1D 1H CPMG spectra without prior
ultrafiltration of the specimens. Unfortunately, appropriate NMR spectra of a suitable healthy
control group were not available for this Ph.D. thesis. A comparison between single entities
suffering from specific leading chronic renal diseases and a suitable healthy control group by
means of classification, as, e.g. realized by [Gronwald et al. 2011] for urine specimens collected
from patients suffering from ADPKD, would be able to estimate the diagnostic value of novel
biomarkers.
A comparison between the four different GFR estimation equations by means of Pearson’s
correlation coefficients and Bland-Altman plots revealed almost perfect consensus between dif-
ferent eGFR formulas based on SCr, and larger deviations between eGFR formulas either based
on SCr or SCysC. However, I was not able to make any deductions about over- or underesti-
mation of GFR by the employed eGFR values, since measured GFR values were not available
for the GCKD study.
The LASSO regression analyses for the prediction of baseline Synlab clinical chemistry param-
eters employing the complete set of 660 baseline NMR bucket intensities showed very good
performance for SCr values and slightly minor performance for SCysC values on the indepen-
dent test set. The same observations hold true for eGFR values either based on SCr and/or
SCysC. The MDRD4, CKD-EPI crea, and CKD-EPI cys formulas are all based on sex, age,
ethnicity, and either SCr or SCysC [Levey et al. 1999,Inker et al. 2012]. The CKD-EPI crea cys
formula is based on sex, age, ethnicity, and both SCr as well as SCysC [Inker et al. 2012]. NMR
buckets corresponding to plasma creatinine had always been included in the derived LASSO
models with high absolute β coefficients (data not shown). However, LASSO models derived
after the exclusions of all spectral regions corresponding to creatinine mostly showed a signifi-
cant performance drop in comparison to LASSO models including creatinine buckets especially
for baseline response variables based on SCr. Consequently, the inclusion of creatinine buckets
for multiple regression analyses seems to be very important to obtain good predictive results
with respect to baseline clinical parameters.
The reliable prediction of future kidney performance in the context of chronic kidney disease
is of crucial importance for sufficient patient treatment. Therefore, I evaluated the predictive
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performance of different regression analyses with respect to FU2 clinical parameters. Appar-
ently, simple linear regression models based on the respective baseline parameters outperformed
respective LASSO models based on baseline NMR bucket intensities for the prediction of FU2
Synlab clinical chemistry and all eGFR values in terms of both higher R2 and lower mse val-
ues on the test set. These results seem to reflect the fact that the majority of the included
patients in this cohort did not experience large changes in SCr, SCysC or eGFR values over
the investigated time period of two years. Multiple regression analyses based on baseline NMR
data with respect to future follow-up response variables might reveal different results. However,
clinical parameters of, e.g., the third follow-up time-point had not been available for this Ph.D.
thesis. Provided that sufficient numbers of GCKD patients experienced major changes in renal
function, the described regression analyses might also be performed separately within specific
CKD entities, e.g. only including patients suffering from diabetic nephropathy. Thereby, pos-
sibly different CKD progression rates in individual CKD entities might be detected and more
homogeneous metabolic profiles within one entity might improve multiple regression analyses
results based on NMR data.
The absolute quantification of metabolites in unfiltered EDTA plasma NMR spectra acquired
by utilizing the CPMG pulse sequence is going to be evaluated by Jens Wallmeier in the context
of his Ph.D. thesis. Here, one has to consider NMR signal intensity losses due to overall NMR
signal decay during the filtering period of the CPMG sequence. These signal intensity losses
result from T2 relaxation, which arises, as described in section 4.2.1, from intramolecular spin-
spin interactions. T2 relaxation consequently depends on the molecule’s size, the density of the
interacting nuclei, the viscosity of the solvent, and the temperature, as T2 relaxation is mainly
mediated by dipolar interactions which critically depend on molecular motions. Furthermore,
NMR signal intensity losses are also enhanced by increasing salt content of the solution. The
impact of these various influences on recorded NMR signal intensities with respect to metabo-
lite quantification are currently investigated by Jens Wallmeier. Analyses so far showed that
NMR signal intensities recorded with a CPMG pulse sequence seem to be considerably influ-
enced by the specific matrix composition of the investigated solution. One might be able to
account for these matrix effects in NMR based absolute quantification by determining suitable
calibration factors. This implies the experimental determination of calibration factors with the
CPMG pulse sequence in pooled unfiltered EDTA plasma specimens from the GCKD study
cohort, as currently performed by Jens Wallmeier. Provided that the matrix composition of
unfiltered EDTA plasma specimens is fairly similar within the GCKD study cohort, these newly
determined calibration factors will probably facilitate appropriate metabolite quantification in
unfiltered EDTA plasma specimens. Absolute concentrations of plasma metabolites in this
CKD cohort or entities thereof could then be compared against reference concentrations in
healthy subjects as provided, for example, by the HMDB [Wishart et al. 2007]. Moreover,
simple as well as multiple linear regression analyses based on absolute metabolite concentra-
tions determined by NMR spectroscopy at the baseline or at future follow-up time-points with
respect to baseline or future clinical parameters could be performed. Besides NMR analyses of
EDTA plasma specimens, the Institute of Functional Genomics will furthermore investigate the
composition of complementary urine specimens of the GCKD study collected at the baseline
as well as future follow-up time-points. Absolute quantification of metabolites simultaneously
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in EDTA plasma and matching urine specimens would facilitate the determination of their re-
spective fractional excretions to give further insights into renal clearance of these compounds in
this CKD cohort or entities thereof. Please note that the described statistical analyses in this
Ph.D. thesis were all performed with NMR bucket intensities relative to the reference signal
intensity of formic acid. It is obvious that the NMR signal intensity decay due to T2 relaxation
during the filtering period of the CPMG sequence also impacts bucket intensities. Since, how-
ever, statistical analyses based on Student’s t-test15 or the performance of multiple regression
models employing the LASSO method16 are invariant under shifts of log2 transformed bucket
intensities, one does not have to account for these previously discussed NMR signal decays in
these analyses, provided that unfiltered EDTA plasma specimens of the GCKD study yield
fairly similar matrix compositions.
In addition to the already discussed research opportunities within the GCKD cohort, this study
offers numerous other possibilities to derive meaningful statistical inferences about the total
population. Survival analyses with respect to overall patient survival as well as time elapsed un-
til onset of RRT by means of Cox regression [Cox 1972] with baseline or future follow-up 1D 1H
NMR EDTA plasma and/or urine spectra might reveal interesting metabolites associated with
poor survival and/or rapid need for RRT in this CKD cohort or entities thereof. Corresponding
analyses will be performed in the future at the Institute of Functional Genomics. Moreover,
correlation calculations, regression, as well as classification analyses based on metabolic profiles
derived from EDTA plasma or urine specimens collected at various time-points with respect to
numerous clinical and quality of life parameters, sociodemographic factors, comorbidities, etc.
might establish novel relationships between distinct metabolic profiles and these parameters.
The GCKD study comprises over 5000 patients suffering from a huge spectrum of various re-
nal diseases, including ADPKD. NMR fingerprinting of urine specimens, for example, already
proofed to reliably differentiate ADPKD patients from those suffering from CKD for other rea-
sons than ADPKD as well as from healthy individuals [Gronwald et al. 2011]. The urinary
metabolic profiles of GCKD patients suffering from ADPKD might be compared to both these
already investigated study cohorts as well as other GCKD entities suffering from other renal
diseases. Thereby, the ADPKD biomarkers investigated by [Gronwald et al. 2011] might be
validated in an independent study cohort. Moreover, novel EDTA plasma metabolic profiles of
patients suffering from ADPKD might be established in comparison to other GCKD entities,
which might complement the already investigated urinary profiles provided by [Gronwald et al.
2011].
Besides, this huge NMR spectral data set offers excellent opportunities to evaluate possible im-
15Consider a general shift for bucket intensity Xb → X˜b = Xb · a. For log2 transformed bucket intensities,
Student’s t statistic is now calculated as T˜b = log2(X˜b1)−log2(X˜b2)
s˜b
√
1
n1
+ 1n2
=
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i=1
log2(Xb1i·a)
n1
−
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log2(Xb2j ·a)
n2
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√
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16Consider a general shift for bucket intensity xij → x˜ij = xij · aj . For log2 transformed bucket intensities,
the linear model is now calculated as y˜i = β0 +
∑p
j=1 βj log2 x˜ij +  = β0 +
∑p
j=1 βj log2(xij · aj) +  =
β0+
∑p
j=1 βj log2 aj+
∑p
j=1 βj log2 xij+ = β˜0+
∑p
j=1 βj log2 xij+. As β0 is not included in the penalizing
term of Eq. (4.16), such a general shift does not affect regression model performance.
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provements for statistical data analysis in NMR based metabolomics. B.Sc. Sebastian Mehrl is
currently investigating the predictive performance of a newly developed regression method, i.e.
zero-sum regression [Altenbuchinger et al. 2016], employing the GCKD EDTA plasma 1D 1H
NMR spectra under the guidance of M.Sc. Helena U. Zacharias and Dr. Michael Altenbuchinger
in the context of a master thesis. Zero-sum regression is, by construction, reference point in-
sensitive. It might therefore yield improved predictive performance in comparison to standard
multiple regression methods if the response variable cannot be uniquely associated with a ref-
erence point, e.g. in the case of survival or diagnostic data.
In summary, this NMR analysis of GCKD EDTA plasma specimens collected at the baseline
time-point with respect to both baseline as well as FU2 clinical parameters can be regarded
as a pilot study for future investigations of large-scale clinical trials by means of NMR spec-
troscopy. The presented methods to compensate drawbacks from the traditional NMR reference
substance TSP in unfiltered plasma will be easily implemented for NMR data acquisition of
unfiltered EDTA plasma specimens collected at future follow-up time-points. The realization of
all discussed perspectives for statistical analyses of the GCKD study would have been beyond
the scope of this thesis. They will be performed in the future at the Institute of Functional
Genomics.
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5.3 Trial to Reduce Cardiovascular Events with Aranesp®
Therapy study
5.3.1 Introduction
Besides the investigation of baseline EDTA plasma samples from the German Chronic Kidney
Disease study cohort, I furthermore focused my research interests on a second large-scale clin-
ical study in the context of CKD and anemia, compare to section 4.1.4.
The Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) study
(ClinicalTrials.gov Identifier: NCT00093015) was designed as a randomized multicenter,
double-blind, placebo-controlled, clinical trial and sponsored by Amgen® [Pfeffer et al. 2009a)].
It should test the hypothesis that in patients with diabetes, CKD not requiring dialysis, and
concomitant anemia, increasing Hb levels by using darbepoetin alfa would reduce the rates
of death or cardiovascular morbidity and RRT [Pfeffer et al. 2009a)]. In total, 4044 patients
with type-2 diabetes mellitus, CKD defined as an eGFR of 20-60 ml/min per 1.73m2 calcu-
lated with the use of the MDRD equation, anemia (Hb level ≤11.0 g/dl), and a transferrin
saturation ≥15% have been enrolled from August 2004 until December 2007 at 623 sites in 24
countries [Pfeffer et al. 2009a)]. Patient baseline characteristics, study design procedures, and
outcomes are detailed in [Pfeffer et al. 2009a),Pfeffer et al. 2009b),Lewis et al. 2011,McMurray
et al. 2011,Mix et al. 2005,Rao and Pereira 2003,Skali et al. 2011,Skali et al. 2013,Solomon
et al. 2010]. In brief, this study could not detect a reduced risk of either primary cardio-
vascular or primary renal events for patients treated with darbepoetin alfa in comparison to
patients treated with a placebo compound [Pfeffer et al. 2009b)]. However, the patient group
treated with darbepoetin alfa seemed to suffer from an increased risk of stroke in comparison
to placebo-treated study participants [Pfeffer et al. 2009b), Skali et al. 2011]. As a conse-
quence, clinical guidelines for the treatment of anemia in CKD patients employing ESAs were
adapted [KDIGO workgroup 2013,Singh 2010], as explicitly discussed in section 4.1.4.
A subset of 1167 urine samples were measured with NMR spectroscopy and statistically ana-
lyzed in order to gain new insights into CKD progression and corresponding Hb responsiveness.
Therefore, the following three hypotheses were statistically evaluated: (1) no difference in
metabolic profiles exists between patients dying from any cause (code V), and patients not
dying (code U), under the restriction that all patients within both subcohorts do not progress
to ESRD (hypothesis 1a), (2) no difference in metabolic profiles exists between patients pro-
gressing (code P) and not progressing to ESRD (code O) under the restriction that all patients
within both subcohorts do not die (hypothesis 1b) and (3) no difference in metabolic profiles
exists between patients with various stages of Hb responsiveness, respectively, whereas four
different subcohorts treated with darbepoetin alfa with various stages of Hb responsiveness
and one subcohort treated with a placebo compound are investigated (codes A - E, hypothesis
2). This subset had been provided by Amgen® to our collaboration partners at the Univer-
sity Clinic of Erlangen-Nuremberg, who allocated corresponding specimen aliquots to us for
metabolic investigations after prior consultation with Amgen®.
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5.3.2 Materials and Methods
Table 5.8 lists the number of investigated urine specimens according to hypothesis and group
membership. Note that a number of specimens belonged to two different groups and were
equally investigated for both eligible hypotheses. For hypotheses 1a and 1b, urine samples were
collected in the last week directly before treatment randomization (W1), i.e. neither darbepo-
etin alfa nor the placebo compound had been administered to the patients yet, for hypothesis
2, two urine samples were collected from each patient at two different time-points, i.e. one in
W1 and one in the 49th week (W49) after treatment randomization. Code identities of patient
outcome for hypotheses 1a and 1b were available, whereas code identities for hypothesis 2 are
still blinded.
Hypothesis Hypothesis Hypothesis Hypothesis 2
1a 1b
Code U V P O A B C D E
Collection
time-point W1 W1 W1 W1 W1 W49 W1 W49 W1 W49 W1 W49 W1 W49
Number of
samples 129 127 113 92 90 62 87 72 87 70 84 69 83 71
Table 5.8: Number of investigated urine samples subdivided by corresponding hy-
pothesis, group membership, and collection time-point. More details are
given in the text.
Urine specimens were prepared in collaboration with Claudia Samol and 1D 1H NOESY as well
as 2D 1H-13C HSQC spectra were measured according to the standard protocols described in sec-
tion 4.2.2 employing the parameters given in section 5.1.2.2. One representative high-resolution
2D 1H-13C HSQC spectrum from a patient not progressing to ESRD (code O, collected at W1)
was acquired with 2048 × 512 data points using 44 scans per increment. For the same urine
specimen, one 2D 1H 1H TOCSY spectrum was acquired using the pulse program mlevgpphw5
(BrukerBioSpin GmbH, Rheinstetten, Germany) with 2048 × 256 data points, 56 scans per
increment, and a mixing time of 50 ms. The total acquisition times of the high-resolution 2D
1H-13C HSQC and 2D 1H 1H TOCSY spectrum amounted to approximately 19.6 h and 13 h,
respectively.
1D 1H NOESY and standard 2D 1H-13C HSQC spectra were preprocessed by Claudia Samol
following the protocols described in section 4.2.2.3 and the TSP reference signal in the standard
2D 1H-13C HSQC spectra was manually set to zero.
I evenly split the region from 9.5 - 0.5 ppm of the 1D 1H NOESY spectra, excluding the solvent
area and the area containing the broad urea peak from 6.5 - 4.5 ppm, into 701 buckets with a
bucket width of 0.01 ppm employing AMIX-Viewer 3.9.13 (Bruker BioSpin GmbH, Rheinstet-
ten, Germany). The signal intensities of each bin were summed and additionally scaled to the
reference region of creatinine from 3.06 - 3.028 ppm, as outlined in section 4.3.1.1. For further
analysis, data were imported into R (Development Core Team 2009).
In order to guide decision making for the appropriate normalization technique, the for the
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AKI project developed strategy was applied, compare to section 5.1.3.1. The respective data
for hypothesis 1a, 1b, and 2 were not normally distributed (Shapiro-Wilk normality test p-
values <2.2e−16). Consequently, only a log2 transformation was applied for minimization of
heteroscedasticity, compare to section 5.1.3.1.
Identification of discriminant compounds was performed by Welch t-tests and/or one-way
ANOVA as described in section 4.3.1.3, and classification was performed employing an RF
classifier in a leave-five-out cross-validation with feature selection based on Welch t-test and
parameter optimization, compare to section 4.3.1.3. The number of selected features was in-
creased in steps of one starting with four features and the maximum number was set to 50.
The internal parameters of the RF classifier were optimized employing a grid search procedure,
as explicitly described in section 5.1.2.6. Metabolite identification was performed as described
in section 4.3.2. Hierarchical clustering employing Euclidean distances and the average linkage
method was performed as detailed in section 4.3.1.2.
5.3.3 Results
Welch t-tests were employed for a statistical evaluation of differences between the respective
groups of the corresponding hypotheses. 283 and 247 significantly different NMR features were
identified by comparing groups U and V of hypothesis 1a and comparing groups P and O of
hypothesis 1b, respectively. These NMR features were identified and are listed in Appendix
IV Tables 7.22 and 7.23, respectively. For both t-tests, most of the significantly different buck-
ets comprised broad protein and macromolecule signals. For hypothesis 1a, some significant
buckets further comprised sugars like D-glucose, sucrose, etc.. The corresponding significant
p-values B/H-adjusted are in the range between 0.01 and 0.05, indicating only slight metabolic
differences between the investigated groups.
In total, 45 individual compounds have been identified in a representative high-resolution 2D
1H-13C HSQC spectrum of a urine sample from group O collected at W1 supported by a
corresponding 2D 1H 1H TOCSY spectrum. This annotated 2D 1H-13C HSQC spectrum is
displayed in Appendix III, Figure 7.12. Metabolite identification in 1D 1H spectra was rather
cumbersome due to massive signal overlap with broad NMR signals arising from proteins and
macromolecules.
The discriminating features indicated by a t-test comparing groups U versus V and groups
O versus P, respectively, are displayed in heat-map representations in Figure 5.8. Columns
(i.e. NMR spectra) and rows (i.e. features) of the heat-maps are ordered according to the
results of hierarchical cluster analyses performed with the respective spectra and significant
buckets, respectively, and the corresponding dendrograms are also shown in Figure 5.8. The
NMR features were split into five clusters for hypothesis 1a, and into two clusters for hypothesis
1b according to the hierarchy of the generated dendrograms. These NMR feature clusters are
driven by the respective bucket intensities. For hypothesis 1a, the clusters of NMR features
are driven by two main compounds, i.e. either broad protein signals or various sugars such as
D-glucose and sucrose. The two clusters of NMR features for hypothesis 1b comprise NMR
signals arising from proteins/macromolecules and three NMR features probably corresponding
to various metabolites in combination with proteins and/or macromolecules, respectively.
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For both hypotheses, NMR spectra were split into four distinct clusters according to the hier-
archy of the generated dendrograms. Table 5.9 lists the numbers and proportions with respect
to the total number of patients belonging to the individual group for each cluster. It is ob-
vious that the cluster formation for both hypotheses is mainly driven by the different protein
content of the individual urine samples. As can be seen in the heat-map representation for
hypothesis 1a, Figure 5.8A), urine spectra grouped in clusters 1 and 4 have a high protein and
sugar content. Urine spectra arranged in cluster 2 have the lowest protein and sugar levels
in comparison to all other spectra and cluster 3 consists of urine spectra with intermediate
protein and sugar content. Likewise for hypothesis 1b, Figure 5.8B), cluster 5 has the highest
protein/macromolecule content, whereas cluster 6 has the lowest protein/macromolecule con-
tent. The two intermediate clusters 7 and 8 can also be distinguished by their different protein
content with cluster 8 showing a higher protein content than cluster 7. Data from Table 5.9
indicates that clusters characterized by an up-regulated protein content of the urine samples
mainly comprise V and P patients. To be more precise, patients dying from any cause and
patients progressing to ESRD seem to have a higher urinary protein content in comparison to
patients not dying and patients not progressing to ESRD, respectively.
Note that this cluster analysis, in general described as an unsupervised statistical analysis
method (compare to section 4.3.1.2), was only performed with the statistically significant NMR
bins, which had been revealed by a Welch t-test representing a supervised method (compare
to section 4.3.1.3). Therefore, cluster analyses were repeated for hypotheses 1a and 1b, re-
spectively, now including all 701 NMR buckets (data not shown). Again, NMR spectra for
hypothesis 1a could be divided into four distinct clusters. NMR spectra for hypothesis 1b
could be divided into three clusters, whereas, in comparison to Figure 5.8, only one interme-
diate cluster appears. Clusters characterized by up-regulated feature intensities, dominated by
broad protein signals, again mainly consisted of patients dying from any cause and patients
progressing to ESRD.
The predictive power of the discriminating features for both hypotheses has also been assessed
by RF classification. For each hypothesis one RF run was performed in a nested leave-five-out
cross-validation procedure with parameter optimization. For hypothesis 1a, an averaged total
accuracy of 49.6% and an area under the ROC curve of 0.52 were obtained. On average, nine
features were selected by the RF classifier, mostly comprising proteins. The median of the
selected mtry parameter was two and the median of the selected number of trees ntree was 300.
For hypothesis 1b, an averaged total accuracy of 54.2% and an area under the ROC curve of 0.56
were obtained. This classification rested, on average, on 37 features, which were mainly identi-
fied with proteins and macromolecules. The median of the selected mtry parameter amounted
to four and the median of the selected number of trees ntree was 300.
This classification data indicates a rather poor predictive power of the discriminating NMR
features for both hypotheses. However, this result does not come as a surprise, since the dis-
criminating power of the NMR features employed by the RF classifier as indicated by their
respective p-values according to the performed Welch t-tests, compare to Appendix III Tables
7.22 and 7.23, had not been very prominent.
As already outlined, proteins and macromolecules, which give rise to very broad and unspecific
signals in the 1D 1H NMR spectra [Klein 2011], comprise most of the significantly differing
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NMR buckets for both hypothesis 1a and 1b. These broad signals might obscure the discrim-
inating power of distinct, underlying NMR features arising from metabolites. Therefore, the
statistical analysis described above for hypothesis 1b was repeated with a subcohort of, in total,
67 urine spectra with minor proteinuria (36 O patients and 31 P patients, respectively). This
subcohort had been selected by eye with regard to the total amount of protein signals visible in
the 1D NMR spectra. The corresponding t-test did not reveal any significant buckets (smallest
p-value B/H-adjusted = 0.34). The RF classification run obtained an averaged total accuracy
of 50.0% and an area under the ROC curve of 0.53. On average, 15.5 features were selected, still
mostly comprising proteins and macromolecules. The median of the selected mtry parameter
was 3.25 and the median of the selected number of trees ntree was 325.
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Figure 5.8: Heat-map representation of significant features according to t-test results for hypothesis 1a (A) and 1b
(B), respectively, after cluster analysis for both NMR spectra and features. Each row corresponds to one
NMR feature, each column corresponds to one urine spectrum, respectively to one patient. NMR spectra and features
are ordered according to cluster analysis results. Clusters are separated from each other by red vertical/horizontal lines
and were cut according to the hierarchy of the respective dendrograms, shown on the top and left side of the heat-maps
for NMR spectra and features, respectively. Numbers and percentaged fractions of patients belonging to individual
groups within each cluster are given in Table 5.9. Blue denotes a down-regulated feature, whereas yellow indicates an
up-regulated one.120
5.3 Trial to Reduce Cardiovascular Events with Aranesp® Therapy study
Hypothesis 1a
Cluster 1 Cluster 2 Cluster 3 Cluster 4
Number (percentaged fraction)
of patients belonging to
hypothesis 1a 4 (1.6%) 21 (8.2%) 191 (74.6%) 40 (15.6%)
Number (percentaged fraction)
of U patients 0 (0%/0%) 13 (10.1%/61.9%) 103 (79.8%/53.9%) 13 (10.1%/32.5%)
Number (percentaged fraction)
of V patients 4 (3.2%/100%) 8 (6.3%/38.1%) 88 (69.3%/46.1%) 27 (21.3%/67.5%)
Hypothesis 1b
Cluster 5 Cluster 6 Cluster 7 Cluster 8
Number (percentaged fraction)
of patients belonging to
hypothesis 1b 51 (24.9%) 15 (7.3%) 73 (35.6%) 66 (32.2%)
Number (percentaged fraction)
of O patients 15 (16.3%/29.4%) 11 (12%/73.3%) 34 (37%/46.6%) 32 (34.8%/48.5%)
Number (percentaged fraction)
of P patients 36 (31.9%/70.6%) 4 (3.5%/26.7%) 39 (34.5%/53.4%) 34 (30.1%/51.5%)
Table 5.9: Summary of cluster analyses results. The total number of patients within each
cluster is given as well as the percentaged fraction with respect to the total number of
patients belonging to one hypothesis. The numbers as well as percentaged fractions
of patients in each cluster in the heat-map representations of Figure 5.8 are given in
brackets (first percentage donates percentage fraction with respect to total number
of patients belonging to one group in this cluster, second percentage donates fraction
of patients belonging to one group representing this cluster; for illustration purposes
regard number of V patients in cluster 1: four out of, in total, 127 V patients were
clustered in cluster 1 corresponding to a percentaged fraction of 3.2% with respect
to the total number of V patients, four out of four patients forming this cluster are V
patients, i.e. 100% of the patients forming this cluster are V patients). Hypothesis
1a: no difference exists between patients dying from any cause without progression
to ESRD (code V) and patients not dying without progression to ESRD (code U).
Hypothesis 1b: no difference exists between patients progressing to ESRD without
dying (code P) and patients not progressing to ESRD without dying (code O). All
urine samples were collected in the last week directly before treatment randomization
(W1).
With regard to hypothesis 2, an ANOVA was performed including all groups and sample col-
lection time-points belonging to this hypothesis. The corresponding F -test did not obtain any
significant buckets (smallest B/H-adjusted p-value = 0.92). This result indicates a rather small
probability for the detection of a significant group difference between patients with various Hb
responsiveness at W1 or at W49.
5.3.4 Discussion
Results from the statistical data analyses of NMR spectra corresponding to hypothesis 1a and
1b, respectively, clearly reveal a statistically significant up-regulation of proteins and macro-
molecules in urine specimens collected in the week directly prior to treatment randomization
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from patients who are going to die or develop ESRD in the future, respectively. As already
outlined in sections 4.1.2 and 4.1.4, presence of proteinuria, i.e. mainly albuminuria, for more
than three months, is one of the main criteria for the diagnosis of CKD [KDIGO workgroup
2013]. Moreover, proteinuria has proven to be a significant and independent predictor of ESRD
in mass screening settings as well as in patients with type-2 diabetes mellitus and nephropa-
thy [Iseki et al. 2003,Keane et al. 2003]. Therefore, my results are in good concordance with
previous studies about ESRD.
However, the power of NMR features corresponding to broad protein signals for prediction of
future ESRD was rather negligible, as indicated by both the results of the RF classification and
the rather moderate B/H-adjusted p-values above 0.01.
The statistical analysis of hypothesis 1a revealed that patients dying from any cause without
progressing to ESRD also exhibit a higher degree of urinary protein content in comparison to
patients not dying. In general, proteinuria is also a prominent risk factor for all-cause as well
as cardiovascular mortality in patients with CKD [KDIGO workgroup 2013]. Differentiating
investigations for individual causes of death might reveal further interesting results, however,
no information about the individual cause of death for each patient enrolled in hypothesis 1a
was available.
The TREAT study had been originally designed in order to test whether the administration of
darbepoetin alfa would reduce the rates of death, cardiovascular events, and ESRD in patients
with type-2 diabetes mellitus, CKD not requiring dialysis, and anemia [Pfeffer et al. 2009a),Pf-
effer et al. 2009b)]. No reduced risk of either primary cardiovascular or primary renal events
for patients treated with darbepoetin alfa in comparison to patients treated with a placebo
compound were reported [Pfeffer et al. 2009b)]. However, an increased risk of stroke in the
patient group treated with darbepoetin alfa has been observed [Pfeffer et al. 2009b), Skali et
al. 2011]. As an additional baseline predictor for stroke, Skali et al. identified an increased
urinary protein-to-creatinine ratio, which, however, did not seem to be interconnected with the
administration of darbepoetin alfa [Skali et al. 2011]. Solomon et al. further identified a poor
initial hematopoietic response to the treatment with darbepoetin alfa as a risk factor for death
or cardiovascular events [Solomon et al. 2010]. A higher urinary protein-to-creatinine ratio has
also been identified as a significant risk factor for both the cardiovascular composite outcome,
i.e. death or nonfatal cardiovascular event, as well as development of ESRD in the TREAT
study itself [Pfeffer et al. 2009b),McMurray et al. 2011]. Investigations about the impact of
darbepoetin alfa treatment on risk of death or progression of ESRD could not be made in my
study, since for hypotheses 1a and 1b, only one urine specimen from each patient had been
collected in the last week directly before treatment randomization, i.e. patients had not yet
received darbepoetin alfa or the placebo compound. Furthermore, no information about the
subsequent treatment assignment for these four patient groups was available. For hypothesis
2, which included four different patient groups treated with varying doses of darbepoetin alfa
and one group treated with a placebo compound, two urine specimens from each patient had
been collected in the last week directly before treatment randomization and in the 49th week
after randomization. However, no information about the group identities was available for
my investigations. Moreover, the statistical analysis of hypothesis 2 itself did not reveal any
promising results. Consequently, this NMR data analysis is not able to make any statements
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about treatment effects related to darbepoetin alfa or placebo compound.
The identification of metabolites with statistical significance for hypothesis 1a, 1b, and/or 2
has not been successful. A possible explanation includes the concealment of probably differ-
entiating metabolite signals by underlying broad, unspecific protein signals in the investigated
1D 1H NOESY NMR spectra. A removal of this protein background by either prior ultrafiltra-
tion or acquisition of 1D 1H CPMG NMR spectra, compare to section 4.2.2.1 and 4.2.2.2, was
not attempted. However, statistical analysis of hypothesis 1b with a subset of specimens with
minor protein content did not reveal any group separation. Furthermore, the statistical anal-
ysis of liquid chromatography-mass spectrometry (LC-MS) measurements on the same urine
specimens corresponding to hypothesis 1b as for the NMR analysis, which was performed by
M.Sc. Franziska Vogl, showed no clear group separation in a PCA plot and therefore supports
NMR results. Hence, I would conclude that metabolic differences for hypothesis 1b are rather
unlikely to be detected in this specimen cohort.
NMR analysis of specimens collected at additional time-points, individual patient information
about treatment, specific outcome, clinical chemistry parameters, etc. might have facilitated
further statistical investigations, but that data was not available to our lab. As already dis-
cussed for the GCKD study, compare to section 5.2.4, survival analyses with respect to overall
patient survival as well as time elapsed until manifestation of ESRD by means of Cox regres-
sion [Cox 1972] with measured urinary NMR spectra of the TREAT study might have revealed
interesting metabolites associated with poor survival and/or rapid onset of ESRD in this spe-
cific CKD entity. Nevertheless, the TREAT study offered a large urinary NMR spectral data
set for patients belonging to a well defined CKD entity. After the acquisition of NMR spectra
from urine specimens collected at the baseline and/or future follow-up time-points from the
GCKD study, which will be realized in the future at the Institute of Functional Genomics, a
comparison of urinary metabolic profiles from GCKD and TREAT study participants could
be performed, e.g. for individual CKD entities. Moreover, urinary 1D 1H NMR spectra of an
apparently healthy control group, i.e. a subgroup of the German National Cohort study [Ger-
man National Cohort Consortium 2014], would be already at hand [Schlecht et al. 2016]. By
comparing urinary metabolic profiles of CKD patients of one study cohort, e.g. TREAT, and
healthy individuals from the German National Cohort employing machine learning methods,
one could determine a distinct molecular signature of CKD or entities thereof, which could be
independently validated in the second CKD study cohort, i.e. GCKD or vice versa.
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6 Conclusion and Perspectives
The main objective of this thesis was the application of NMR based metabolomics in the con-
text of nephrology. This objective was both pursued in acute as well as chronic kidney diseases
and could be subdivided in three specific aims.
The first aim was the detection of metabolic biomarkers for different kidney diseases as alterna-
tives to traditional clinical approaches. In a prospective study of 85 unselected adult patients
undergoing cardiac surgery with CPB, out of which 33 patients developed post-operative acute
kidney injury, I identified novel low-molecular-weight factors for early detection of AKI. The
most discriminative compounds included propofol-glucuronide, Mg2+, and lactate 24 h after
surgery. Elevated plasma levels of the glucuronide conjugate of propofol, an anesthetic agent
which had been administered to all patients during surgery, in patients with AKI seem to be
a surrogate marker for a general worsening of renal function even outperforming creatinine.
An elevation of Mg2+ levels in AKI patients might be explained by its use for the treatment
of cardiac arrythmias, and ischemic injury as well as systemic hypoperfusion present in AKI
patients might be linked to elevated lactate levels in this group. This study had been a follow-
up project of my master thesis [Zacharias 2012], where I statistically analyzed urine specimens
collected before and at 4 and 24 h after cardiac surgery with CPB. Here, elevated urinary levels
of tranexamic acid together with decreased urinary levels of carnitine and 2-oxoglutaric acid
had shown best overall AKI prognostication at 24 h after surgery. The novel detected EDTA
plasma biomarkers for the detection of AKI clearly outperformed these urinary biomarkers with
respect to overall prognostication accuracy.
Moreover, I aimed at a reliable prognostication of AKI after cardiac surgery based on a small
set of easily quantifiable endogenous metabolites. In this regard, a combination of plasma
creatinine, plasma Mg2+, and plasma lactate revealed overall best prognostication accuracy. I
further employed this biomarker panel to derive a new AKIN index score, which revealed that
the metabolic profiles of patients suffering from AKIN 1 disease were largely indistinguishable
from those of patients not suffering from AKI. This finding might be connected to the rather
mild nature of AKIN 1 disease. This novel biomarker panel would offer a reliable and swift di-
agnostic tool for the detection of AKI after cardiac surgery with CPB use only requiring easily
implementable point-of-care technologies. This study underscores the power of NMR spec-
troscopy in combination with bioinformatics in identifying novel biomarkers of kidney disease
and in gaining new insights into pathomechanisms. Nevertheless, larger prospective studies are
required to validate the temporal development of these novel prognostic metabolites, and to
further investigate how their temporal course relates to the onset, severity, and outcome of AKI.
Furthermore, the prognostic validity of this biomarker panel has to be directly compared to
that of other already established AKI biomarkers such as NGAL, IL-6, IL-18, KIM-1, L-FABP,
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and NAG, and a combination of novel and established biomarkers might even further improve
AKI prognostication.
In the context of chronic kidney diseases, specific metabolic fingerprints for the discrimination of
6 individual leading renal diseases were investigated in 1D 1H CPMG spectra of EDTA plasma
specimens collected at the baseline time-point of the GCKD study. This study represents the
currently worldwide largest CKD patient cohort and offers an unprecedented dimensionality in
NMR based metabolomic analyses. A significant up-regulation of plasma D-glucose concentra-
tions could be reported for patients suffering from diabetic nephropathy, as well as significantly
up-regulated plasma lipid signals for patients suffering from glomerulonephritis, respectively.
These findings are in good concordance with standard clinical pathologies of diabetic nephropa-
thy and glomerulonephritis. Further insights into pathologies of different renal diseases might
be established with this specimen cohort in comparison to suitably acquired data from healthy
individuals in the future. Comparing single CKD entities to a suitable healthy control group by
means of classification, as, e.g. realized by [Gronwald et al. 2011] for urine specimens collected
from patients suffering from ADPKD, might reveal as well as estimate the diagnostic value of
novel biomarkers.
1D 1H NOESY spectra of baseline urine specimens of a second large-scale clinical trial, the
TREAT study including CKD patients with type-2 diabetes mellitus and concomitant anemia,
have additionally been investigated to gain new insights into CKD progression and correspond-
ing Hb responsiveness. A statistically significant up-regulation of proteins in urine specimens
collected in the week directly prior to treatment start from patients who are going to die or
develop ESRD in the future, respectively, could be reported. With proteinuria being both a
diagnosis criterium for CKD and a predictor for ESRD as well as all-cause and cardiovascu-
lar mortality [KDIGO workgroup 2013, Iseki et al. 2003,Keane et al. 2003], these results are
in good agreement with established pathophysiological findings in CKD patients. In the fu-
ture, the urinary metabolic profiles of these patients suffering from CKD with type-2 diabetes
mellitus and concomitant anemia might be compared to respective profiles from other CKD
entities of the GCKD study. The acquisition of NMR spectra from urine specimens collected at
the baseline and/or future follow-up time-points from the GCKD study will be realized at the
Institute of Functional Genomics and urinary 1D 1H NMR spectra of an apparently healthy
control group [Schlecht et al. 2016] are already available. After completing the acquisition
of urinary NMR spectra from the GCKD cohort, one might, for example, try to determine
a distinct molecular signature for CKD or entities thereof in comparison to healthy controls
employing, e.g., GCKD patients suffering from diabetic nephropathy. This molecular signature
might be subsequently applied to a test set comprising urinary NMR metabolic fingerprints
from TREAT study participants. Thereby, one would be able to validate this newly generated
molecular signature of CKD patients suffering from diabetic nephropathy in an independent
patient cohort.
The second aim of my Ph.D. thesis comprised the prediction of future kidney performance based
on baseline metabolic fingerprints derived by NMR spectroscopy. The prediction of future renal
performance is essential for timely interventions and improved patient care. Multiple regression
analyses between NMR metabolic fingerprints derived from the baseline plasma specimen co-
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hort of the GCKD study with the estimated GFR and specific renal performance markers, such
as SCr and SCysC, clinically assessed both at the baseline as well as at the second follow-up
time-point were performed employing the LASSO method. Furthermore, simple linear regres-
sion analyses employing baseline clinical parameters with respect to second follow-up clinical
parameters were conducted. Considering baseline renal performance parameters, LASSO mod-
els derived from 1D 1H NMR bucket intensities showed very good predictive performances.
The prediction of renal performance markers clinically assessed at the second follow-up time-
point, however, was best achieved by simple linear regression models based on respective base-
line clinical parameters. This result might be explained by the fact that the majority of the
GCKD patients did not experience large changes in SCr, SCysC, or eGFR values over the inves-
tigated time period of two years. Additional regression analyses based on baseline NMR data
with respect to future follow-up response variables might reveal different results. In this con-
text, regression analyses might also be performed separately within specific CKD entities, e.g.
only including patients suffering from diabetic nephropathy. As specific metabolic differences
between individual leading renal disease groups do exist, such analyses might probably yield
improved multiple regression analyses results based on NMR data due to more homogeneous
metabolic profiles within one CKD entity. Moreover, possibly different CKD progression rates
in individual CKD entities could be detected in this approach.
Additionally, survival analyses with respect to overall patient survival as well as time elapsed
until onset of RRT by means of Cox regression with baseline or future follow-up 1D 1H NMR
EDTA plasma spectra might reveal interesting metabolites associated with poor survival and/or
rapid need for RRT in this study cohort. Furthermore, the predictive performance of a newly de-
veloped reference point insensitive regression method, i.e. zero-sum regression [Altenbuchinger
et al. 2016], is currently assessed at the Institute of Functional Genomics and might yield
improved results.
The third aim of this Ph.D. thesis comprised general method developments and additions for
NMR based metabolomics. While investigating novel compounds for the early detection of
AKI after cardiac surgery with CPB use, it became apparent that the application of Variance
Stabilization normalization on the EDTA plasma spectral data set yielded large intergroup
differences in CaEDTA2− abundance by means of t-test based statistical analysis. This find-
ing, however, is rather unlikely, since calcium levels are usually tightly regulated in the human
body. In contrast, simple scaling of spectral features to the TSP reference signal followed by
log2-transformation, confirmed for CaEDTA2− the absence of a significant intergroup differ-
ence. Utilizing this data preprocessing method, I could further reveal significant intergroup
differences in MgEDTA2− levels. Thus, the choice of appropriate data normalization methods
proofed to be crucial for correct data analysis and interpretation in this project and should
always be thoroughly appraised. These results could be further verified by corresponding sta-
tistical analyses of the absolute concentrations of these metal ions by NMR spectroscopy.
Finally, the acquisition of 1D 1H NMR spectra of EDTA plasma specimens collected from
GCKD study participants posed several new challenges on both NMR data acquisition as well
as analysis. To effectively suppress broad signals in 1D 1H NMR spectra arising from protons in
proteins, we preferred to utilize the CPMG pulse sequence over common protein removal strate-
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gies. This facilitated the acquisition of well resolved 1D 1H spectra in sufficiently low sample
preparation and measurement times for high-throughput studies. The common NMR reference
substance TSP proved to be inappropriate for unfiltered plasma specimens and alternatively,
the reference substance formic acid was successfully implemented. This strategy can be easily
employed for GCKD plasma specimens collected at future follow-up time-points. Moreover, a
readily implementable spectral alignment tool is presented to eliminate overall spectral shifts,
which can be also applied to other 1D NMR spectral data sets. Due to overall signal decay
during the filtering period of the CPMG pulse sequence, which seems to be significantly influ-
enced by the specific matrix composition of the investigated fluid, the absolute quantification
of metabolites in unfiltered EDTA plasma specimens by means of 1D 1H CPMG spectra is
not straightforward. These matrix effects might be compensated by suitable calibration fac-
tors, which should be experimentally determined with the CPMG pulse sequence in pooled
unfiltered EDTA plasma specimens from the GCKD study cohort. The corresponding analyses
are currently performed by Jens Wallmeier and will be part of his Ph.D. thesis. The absolute
quantification of plasma metabolites in this CKD cohort or entities thereof would facilitate
further statistical analyses, including comparisons against reference concentrations in healthy
subjects.
In summary, this Ph.D. thesis proofs the successful application of NMR-based metabolomics
in combination with advanced bioinformatics to reveal novel markers for the early detection
of renal diseases, as demonstrated in the context of acute kidney injury after cardiac surgery
with cardiopulmonary bypass use. It moreover reports important method implementations for
NMR-based investigations of large-scale clinical trials and presents first promising statistical
analyses results for two studies on chronic kidney disease, which will be further evaluated at
the Institute of Functional Genomics.
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7.1 Appendix I: General R-Code
This section provides general R commands employed for statistical data analysis of this thesis.
For each command, short commentaries are given comprising a brief description of the respective
command. Instead of containing specific names of R objects or R settings, the R commands
displayed in this R-code are illustrated using place holder variables. These variables are printed
in bold, italic type and need to be replaced by the respective R objects or settings in an
actual analysis procedure. More details and an exact documentation of the used libraries and
functions can be found on the specific help/documentary pages by either using the R commands
help(R.command) or ?(R.command), or at http://www.r-project.org/.
7.1.1 Get familiar with data
x<-read.table("bucket.table", as.is=T, header=T, row.names=1) # import bucket table
x1<-as.matrix(t(x)) # transpose bucket table, in x1, rows=buckets, columns=samples
kick.out<-apply(x1,1,function(z)all(z==0)) # collect all rows/buckets completely filled with zero
x2<-x1[!kick.out,] # eliminate all rows/buckets only containing zeros
dim(x2) # number of rows/buckets and columns/samples
colnames(x2) # sample names
rownames(x2) # bucket names
7.1.2 Choose normalization method
w3<-x2[,c(sample.IDs)] # sort samples according to comparable groups
colnames(w3) # check whether sample order is correct
areas<-apply(w3, 2, sum) # sum over all buckets for each sample=area under the curve
plot(density(areas)) # plot areas under the curve as density plot → first indication, whether data is normally distributed or
not
shapiro.test(areas) # Shapiro-Wilk test in order to find out whether the complete data set is normally distributed, H0:
data is normally distributed
# if normality does not show significant p-value, data can be either quantile or vs normalized (→ go to 7.1.3.2 or 7.1.3.3, respectively)
min(w3) # indicates whether there are values <0, be aware if log2 transformation is applied
min(w3[w3>0]) # check scale of data
max(w3[w3<0]) # check scale of data
which(w3==0) # indicates whether there are values=0, if there are values=0, then apply * before log2 transformation
# if there are values <0 in the data, take absolute values if log2 transformation is applied (compare to 7.1.3.1)
# if scale of data <10, scale data correspondingly (e.g. scale of data about 10(−8), multiply data with 108 (i.e. 10(scale))) for log2
transformation as well as quantile or vs normalization
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7.1.3 Normalization
7.1.3.1 log2 transformation
w3.abs<-abs(w3) # take absolute values in order to avoid problems with log2 transformation
w3.abs=w3.abs*10ˆ(scale) # scale data in order to avoid computing problems
* w3.abs<-w3.abs+10ˆ(- scale) # avoid values=0 for log2 transformation, only apply if which(w3==0)!=integer(0)
w3.abs.log<-log2(w3.abs) # log2 transformation, perform all following data analyses with this object
7.1.3.2 Quantile normalization
w3=w3*10ˆ(scale) # scale data in order to avoid computing problems
library(affy) # quantile normalization library
normalize.quantile<-get("normalize.quantiles",en=asNamespace("affy")) # quantile normalization function
quantile.w3<-normalize.quantile(w3) # apply quantile normalization to data and obtain quantile normalized data, perform
all following data analyses with this object
7.1.3.3 Variance Stabilization normalization
w3=w3*10ˆ(scale) # scale data in order to avoid computing problems
library(vsn) # VSN library
vsn.model<-vsn2(w3) # calculate VSN model
vsn.w3<-predict(vsn.model,w3) # apply VSN model to data and obtain VS normalized data, perform all following data anal-
yses with this object
7.1.4 Data analysis
# all data analysis is performed with the properly normalized data set (i.e. w3.abs.log, quantile.w3 or vsn.w3), which is from now
on called data.set
7.1.4.1 Unsupervised machine learning methods
Principal component analysis (PCA)
pc<-prcomp(t(data.set)) # PCA
plot(pc$x[1:first.group.IDs,PC],pc$x[1:first.group.IDs,PC],main="name",xlab="PC",
ylab="PC",pch=symbol,col="color", xlim=c(x.margins),ylim=c(y.margins)) # plot first group
points(pc$x[first.group.IDs+1:second.group.IDs,PC],
pc$x[first.group.IDs+1:second.group.IDs,PC],pch=symbol,col="color") # plot second group
# etc.
library(missMDA) # required library
pca<-PCA(t(data.set),scale.unit=FALSE,axes=c(PC,PC)) # perform same PCA plot including sample IDs, loadings plot and
information about percentages of variances
7.1.4.2 Supervised methods
t-test with "multtest"
l1<-numeric(sample.number) # define labels
for (i in first.group.IDs+1:second.group.IDs) {l1[i]=1} # set labels for second group
library(multtest) # required library
t<-mt.teststat(data.set, classlabel=l1, test="t") # calculate t-statistics
pt<-2*pt(-abs(t),df=degrees.of.freedom) # calculate p-values, set degrees of freedom df=sample.number-2
tmp<-rownames(data.set) # vector with bucket names (be aware that after quantile normalization, the object quantile.w3 has
no more bucket names, therefore use unnormalized object w3)
pt2<-data.frame(tmp,pt) # create data frame combining bucket names and p-values
pt3<-pt2[order(pt2$pt),] # order pt2 according to calculated p-values in ascending order
pAdjusted<-mt.rawp2adjp(pt,proc=c("BH")) # calculate B/H-adjusted p-values
pt4<-data.frame(pt3$tmp,pAdjusted$adjp) # create data frame with ordered bucket names, raw p-values and B/H-adjusted
p-values
pt4[1:last.significant.bucket.ID,] # list significant buckets
pt5 <- cbind(pt4, as.numeric(rownames(pt3))) # get bucket IDs
pt5[1:last.significant.bucket.ID,] # list of significant buckets with bucket IDs
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Statistical power calculation
library("pwr") # required library
library("compute.es") # required library
m.1<-vector(mode="numeric",length=number.of.sign.buckets)
m.2<-vector(mode="numeric",length=number.of.sign.buckets)
sd.1<-vector(mode="numeric",length=number.of.sign.buckets)
sd.2<-vector(mode="numeric",length=number.of.sign.buckets)
for(i in 1:number.of.sign.buckets){
m.1[i]<-mean(data.set[which(rownames(data.set)==rownames(sign.buckets)[i]),first.group.ids])
m.2[i]<-mean(data.set[which(rownames(data.set)==rownames(sign.buckets)[i]),second.group.ids])
sd.1[i]<-sd(data.set[which(rownames(data.set)==rownames(sign.buckets)[i]),first.group.ids])
sd.2[i]<-sd(data.set[which(rownames(data.set)==rownames(sign.buckets)[i]),second.group.ids])
}
n.1<-dim(data.set[,second.group.ids])[2]
n.2<-dim(data.set[,second.group.ids])[2]
d<-list()
d.d<-vector(mode="numeric",length=number.of.sign.buckets)
d.d.p<-vector(mode="numeric",length=number.of.sign.buckets)
for(i in 1:number.of.sign.buckets){
d[[i]]<-mes(m.1[i],m.2[i],sd.1[i],sd.2[i],n.1,n.2)
d.d[i]<-d[[i]]$d
d.d.p[i]<-d[[i]]$pval.d
}
p<-list()
p.p<-vector(mode="numeric",length=number.of.sign.buckets)
for(i in 1:number.of.sign.buckets){
p[[i]]<-pwr.t2n.test(n1=n.1,n2=n.2,d=d.d[i],sig.level=0.05,power=NULL,alternative="two.sided")
p.p[i]<-round(((as.numeric(p[[i]]$power))*100),digits=2)
}
Heat-map for significant buckets
as.numeric(rownames(pt3))[1:last.significant.bucket.ID] # get significant bucket IDs
w5<-data.set[c(significant.bucket.IDs separated by ","),] # obtain data object from original normalized data.set with
all desired samples and all significant buckets ordered by p-value
samples<-colnames(data.set) # sample names
samples # check sample order
bins<-rownames(w3[c(significant.bucket.IDs separated by ","),]) # obtain bucket names
bins # check bucket names and order
library(compdiagTools) # required library
geneImager(w5,cluster="FALSE",dendro="FALSE",hide.colorbar=TRUE,
annotSamples=samples,annotProbes=bins,scale=TRUE, file="filename.jpg") # plot heat-map without clustering, if cluster-
ing is desired, cluster="TRUE"
Correlation calculation for heat-map:
vx<-as.numeric(sample.number) # vector for all samples
vcor<-as.numeric(number.of.significant.buckets) # vector for all significant buckets
for (i in 1:first.group.IDs) {vx[i]=1} # labels for samples
for (i in first.group.IDs+1:second.group.IDs) {vx[i]=0} # labels for samples
for (i in 1:number.of.significant.buckets) {vcor[i]<-cor(w5[i,],vx)} # calculate correlation coefficient for significant
buckets between buckets and class labels
z1<-data.frame(w5,vcor) # create data frame consisting of sample × significant buckets and correlation coefficients
z2<-z1[order(z1$vcor),] # order data frame according to correlation coefficients
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sx<-data.frame(bins,vcor) # create data frame consisting of bucket names and correlation coefficients
sx2<-sx[order(sx$vcor),] # order data frame according to correlation coefficients
library(compdiagTools) # required library
geneImager(z2[,1:sample.number],cluster="FALSE",dendro="FALSE",
annotSamples=samples,annotProbes=sx2$bins,hide.colorbar=TRUE,scale=TRUE, file="filename.jpg") # plot heat-map with-
out clustering, if clustering is desired, cluster="TRUE"
ANOVA/t-tests with "limma"
labels<-vector(length=sample.number) # create vector for group labels
labels[1:first.group.IDs]=1 # labels for first group
labels[first.group.IDs+1:second.group.IDs]=2 # labels for second group
# etc.
data<-cbind(colnames(data.set),labels) # combine sample names and labels
data # check if labels vector is correct
library(limma) # required library for ANOVA
design<-model.matrix( 0+factor(labels)) # create design matrix
colnames(design)<-c("first.group.name","second.group.name",etc.) # assign colnames for design matrix according to
groups
design # check if design matrix/labels is correct
fit<-lmFit(data.set,design) # fit linear model for data.set with design matrix
cont<-makeContrasts("first.group.name-second.group.name", "first.group.name-third.group.name",etc., levels=design)
# create contrast matrix for all group comparisons
fit2<-contrasts.fit(fit,cont) # given a linear model, compute estimated coefficients and standard errors for a given set of
contrasts
fit3<-eBayes(fit2) # given a series of related parameter estimates and standard errors, compute moderated t-statistics, mod-
erated F-statistic, and log-odds of differential expression by empirical Bayes shrinkage of the standard errors towards a common
value
cont # check if contrast matrix is correct
ANOVA<-topTable(fit3,coef=c(1:number.of.comparisons),p.value=0.05, adjust="BH",number=755)
ANOVA # results of F-test
firstgroupname.secondgroupname<-topTable(fit3,coef=1,adjust="BH", number=number.of.significant.buckets)
firstgroupname.secondgroupname # results of t-test for first comparison
firstgroupname.thirdgroupname<-topTable(fit3,coef=2,adjust="BH", number=number.of.significant.buckets)
firstgroupname.thirdgroupname # results of t-test for second comparison
# etc.
7.1.4.3 Regression analysis with LASSO method
library(glmnet) # required library
set.seed(2014)
LASSO.model <- cv.glmnet(t(data.train),log2(response.train)) # train LASSO model
predicted.values <- predict(LASSO.model, t(data.test),s="lambda.min") # predict test data
coef <- predict(LASSO.model, s=LASSO.model$lambda.min, type="coefficients") # get coefficients of LASSO model
7.1.5 NMR bucket alignment and bucket fusion
adjust.buckets <- function(data,bucket.interval) # function for bucket alignment
{
max.bucket.list <- list()
shifts <- list()
data.temp <- matrix(NA, ncol=ncol(data),nrow=length(bucket.interval)+nrow(data))
for(j in 1:ncol(data))
{
max.bucket <- which.max(data[bucket.interval,j]) # find bucket with max. bucket intensity in bucket.interval
max.bucket.list[[j]] <- bucket.interval[max.bucket] # record bucket with max. bucket intensity in bucket.interval
data.temp[,j] <- c(rep(NA, length(bucket.interval)-max.bucket),data[,j],rep(NA, max.bucket)) # shift spectral data
of spectrum j by (length(bucket.interval)-max.bucket)
shifts[[j]] <- length(bucket.interval)-max.bucket # record shift
}
max.bucket.list.unlist <- unlist(max.bucket.list)
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names(max.bucket.list.unlist) <- colnames(data)
shifts <- unlist(shifts)
names(shifts) <- colnames(data)
feature.selected <- as.integer(names(which.max(summary(as.factor(max.bucket.list.unlist))))) # bucket number that
is mainly selected as maximum bucket
sel.samples <- names(max.bucket.list.unlist)[max.bucket.list.unlist==feature.selected] # spectra, where most abun-
dant bucket is selected
rownames(data.temp) <- c(paste("temp. feature",1:shifts[sel.samples[1]]),rownames(data),paste("temp. feature",
(1+shifts[sel.samples[1]]):(length(bucket.interval)))) # name buckets of aligned data
colnames(data.temp) <- colnames(data) # name spectra of aligned data
return(list(data.temp,highest.bucket.in.interval=max.bucket.list.unlist))
}
reduce.buckets <- function(data,start,number.of.combined.buckets) # function for bucket fusion
{
n <- number.of.combined.buckets
s <- start
pos <- s
data.temp <- NULL
temp.rownames <- list()
for(i in 1:floor((nrow(data)-s+1)/n)){
data.for <- data[pos:(pos+n-1),]
data.temp <- rbind(data.temp,apply(data.for,2,sum))
data.vec <- round(mean(as.numeric(gsub("X","",gsub("X........","",rownames(data.for))))),digits=4)
temp.rownames[[i]] <- paste("X........",data.vec,sep="")
pos <- pos+n
}
rownames(data.temp) <- unlist(temp.rownames)
return(data.temp)
}
7.2 Appendix II: Acute Kidney Injury study
7.2.1 Clinical characteristics and outcome of patients included in AKI
study
a) AKI urine study b) AKI plasma study
Non-AKI AKI P - Non-AKI AKI P -
patients patients value patients patients value
N 72 34 52 33
Age [years] 68 ± 10 73 ± 8 0.011b 68 ± 11 73 ± 8 0.008b
Sex, male 58 (80.6%) 23 (67.6%) 0.131c 43 (82.7%) 22 (66.7%) 0.11c
Weight [kg] 82.2 ± 13.2 82.6 ± 16.5 0.90b 82.8 ± 13.7 83.3 ± 16.2 0.88b
Height [cm] 171.2 ± 6.5 169.5 ± 7.4 0.25b 171.5 ± 6.5 169.2 ± 7.4 0.15b
BMI [kg/m2] 28 ± 4 29 ± 5 0.481b 28 ± 4 29 ± 5 0.404b
BSA [m2]d 1.94 ± 0.17 1.93 ± 0.20 0.75b 1.95 ± 0.17 1.9 ± 0.2 0.72b
SCr [mg/dl] 1.16 ± 0.41 1.36 ± 0.53 0.057b 1.19 ± 0.44 1.35 ± 0.53 0.15b
eGFR 13-60 ml/min
per 1.73 m2 27 23 0.006c 21 (40.4%) 22 (66.7%) 0.026c
eGFR > 60 ml/min
per 1.73 m2 45 11 0.006c 31 (59.6%) 11 (33.3%) 0.026c
Comorbid disease, n
Diabetes mellitus 26 (36.1%) 18 (52.9%) 0.139c 20 (38.5%) 18 (54.6%) 0.182c
Hypertension 70 (97.2%) 34 (100%) 1.000c 51 (98.1%) 33 (100%) 1.000c
Cardiac insufficiency 57 (79.2%) 30 (88.2%) 0.293c 38 (73.1%) 29 (87.9%) 0.172c
Atrial fibrillation 10 (13.9%) 8 (23.5%) 0.27e 9 (17.3%) 8 (24.2%) 0.579e
Cerebrovascular disease 24 (33.3%) 15 (44.1%) 0.29e 16 (30.8%) 14 (42.4%) 0.353e
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Hypercholesterolemia 67 (93.1%) 30 (88.2%) 0.464c 48 (92.3%) 29 (87.9%) 0.705c
Acute myocardial infarction 25 (34.7%) 15 (44.1%) 0.395c 20 (38.5%) 15 (45.5%) 0.652c
COPD 12 (16.7%) 7 (20.6%) 0.601c 11 (21.2%) 7 (21.2%) 1.000c
PAVD 10 (13.9%) 6 (17.7%) 0.772c 7 (13.5%) 6 (18.2%) 0.554c
Cardiovascular disease 24 (33.3%) 15 (44.1%) 0.291c 16 (30.8%) 14 (42.4%) 0.353c
CKD 17 (23.6%) 22 (64.7%) 0.00008c 12 (23.1%) 21 (63.6%) 0.0003c
Valvular heart disease 36 (50.0%) 25 (73.5%) 0.034c 24 (46.2%) 24 (72.7%) 0.024c
cardiac surgical interventions
in the past 1 (1.4%) 6 (17.7%) 0.004e 1 (1.9%) 6 (18.2%) 0.013e
AKI in the past 2 (2.8%) 3 (8.8%) 0.325c 2 (3.9%) 3 (9.1%) 0.372c
RRT in the past 2 (2.8%) 0 (0%) 1.000c 2 (3.9%) 0 (0%) 0.519c
IABP pre-op 1 (1.4%) 2 (5.9%) 0.240b 1 (1.9%) 2 (6.1%) 0.557c
Preoperative
medication, n
Statin pre-op 53 (73.6%) 25 (73.5%) 1.000c 34 (65.4%) 24 (72.7%) 0.633c
ACE inhibitor 56 (77.8%) 27 (79.4%) 1.000c 41 (78.9%) 27 (81.8%) 0.788c
Beta-blocker 53 (73.6%) 27 (79.4%) 0.631c 40 (76.9%) 26 (78.8%) 1.000c
Other antihypertensive
drugs pre-op 12 (16.7%) 11 (32.4%) 0.081c 11 (21.2%) 11 (33.3%) 0.309c
Insulin pre-op 9 (12.5%) 7 (20.6%) 0.383c 7 (13.5%) 7 (21.2%) 0.381c
Oral anti-diabetic medication 15 (20.8%) 11 (32.4%) 0.230c 11 (21.2%) 11 (33.3%) 0.309c
NSAID 1 (1.4%) 0 (0%) 1.000c 35 (67.3%) 22 (66.7%) 1.000c
Type of surgery, n
CABG 54 (75%) 16 (47.1%) 0.008c 40 (76.9%) 16 (48.5%) 0.01c
Aortic valve surgery 6 (8.3%) 7 (20.6%) 0.110c 6 (11.5%) 7 (21.2%) 0.354c
Mitral valve surgery 2 (2.8%) 2 (5.9%) 0.592c 1 (1.9%) 2 (6.1%) 0.557c
CABG + aortic valve surgery 5 (6.9%) 7 (20.6%) 0.051c 2 (3.9%) 6 (18.2%) 0.051c
CABG + mitral valve surgery 1 (1.4%) 1 (2.9%) 0.541c 0 (0%) 1 (0.03%) 0.388c
Thoracic aortic surgery 4 (5.6%) 1 (2.9%) 1.000c 3 (5.8%) 1 (3.0%) 1.000c
Surgery data
Bypass time period [min] 83.9 ± 30.2 89.9 ± 39.4 0.44b 83.8 ± 29.1 90.4 ± 39.9 0.42b
Aortic clamping time [min] 49.7 ± 22.4 54.7 ± 21.0 0.27b 48.5 ± 20.4 55.0 ± 21.3 0.19b
Reperfusion time [min] 28.1 ± 10.1 30.4 ± 20.7 0.55b 28.2 ± 10.8 30.5 ± 21.0 0.56b
RCC, n 27 (37.5%) 26 (76.5%) 0.0003e 22 (42.3%) 25 (75.8%) 0.004e
RCC [ml] 666.7 ± 336.3 715.4 ± 530.4 0.69b 695.5 ± 363.2 732.0 ± 534.4 0.78b
Thrombocyte concentrate, n 30 (41.7%) 19 (55.9%) 0.21e 22 (42.3%) 18 (54.5%) 0.373e
Thrombocyte concentrate [ml] 253.3 ± 90.0 271.1 ± 147.5 0.64b 240.9 ± 68.4 275.0 ± 150.7 0.38b
FFP, n 13 (18.1%) 15 (44.1%) 0.009e 10 (19.2%) 15 (45.5%) 0.014e
FFP [ml] 1092.3 ± 175.4 936.7 ± 405.5 0.19b 1080.0 ± 193.2 936.7 ± 405.5 0.25b
Crystalloid solution, n 72 (100%) 34 (100%) 1.0c 52 (100%) 33 (100%) 1.0c
Crystalloid solution [ml] 1405.1 ± 487.6 1344.3 ± 393.6 0.50b 1503.1 ± 465.2 1354.7 ± 394.9 0.12b
Colloid solution, n 11 (15.3%) 2 (5.9%) 0.22e 9 (17.3%) 2 (6.1%) 0.190e
Colloid solution [ml] 500.0 ± 0.0 500.0 ± 0.0 500.0 ± 0.0 500.0 ± 0.0
Minimum MAP [mmHg] 38.2 ± 7.5 36.5 ± 9.2 0.34b 38.9 ± 8.1 36.5 ± 9.3 0.24b
Lowest body temperature
during CPB [°C] 35.3 ± 0.9 35.4 ± 0.9 0.59b 35.4 ± 0.7 35.4 ± 0.9 0.96b
Intraoperative HF, n 3 (4.2%) 3 (8.8%) 0.38e 2 (3.9%) 3 (9.1%) 0.372e
Postoperative IABP, n 1 (1.4%) 9 (26.5%) 0.0001e 1 (1.9%) 9 (27.3%) 0.001e
Need for catecholamines, n 72 (100%) 32 (94.1%) 0.10e 52 (100%) 31 (94.0%) 0.148e
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Table 7.1: Previous page: Clinical characteristics and outcome of all patients included in a) AKI
urine and b) AKI plasma study. aPatients with AKI were diagnosed based on AKIN-criteria. For
this, serum samples of the second post-operative day were taken into account. bP -values calculated
using two-sided t-test assuming unequal variance with Microsoft Office EXCEL 2007. cP -values
calculated using Fisher’s exact test with Microsoft Office EXCEL 2007. dBody surface area calculated
employing the DuBois formula [DuBois 1916]. eP -values calculated using Fisher’s exact test with R
version 3.2.0. Abbreviations: ACE, angiotensin-converting-enzyme; AKI, acute kidney injury; BMI,
body mass index; BSA, body surface area; CABG, coronary artery bypass grafting; CKD, chronic
kidney disease; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; eGFR,
estimated glomerular filtration rate; FFP, fresh frozen plasma; HF, hemofiltration; IABP, intra-aortic
balloon pump; MAP, mean arterial pressure; NSAID, non-steroidal anti-inflammatory drug; PAVD,
peripheral arterial vascular disease; RCC, red cell concentrate; RRT, renal replacement therapy.
Modified from [Zacharias et al. 2013a),Zacharias et al. 2015].
7.2.2 CPB protocol
1 The CPB circuit was prefilled with 500 ml of Ringer’s solution, 500 ml of 10% Mannitol, and
500 ml of 6% Voluven supplemented with 5000 IU of Heparin and 2 g of tranexamic acid. The
CPB was conducted using normothermia, non-pulsatile blood flow, and α-stat pH management.
1The following section has been published in [Zacharias et al. 2015].
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7.2.3 Spike-In experiments for the quantification of free calcium and
magnesium levels
a) Spike-In experiments in H2O
Added 0.50mM Ca + 0.75mM Ca + 1.00mM Ca + -
1.00mM Mg 0.75mM Mg 0.50mM Mg
Measured 0.50mM Ca; 0.73mM Ca; 0.95mM Ca; -
1.04mM Mg 0.77mM Mg 0.50mM Mg
Recovery 100% Ca; 97% Ca; 95% Ca; -
104% Mg 103% Mg 100% Mg
Mean recovery 97 ± 2.5% Ca; 102 ± 2.1% Mg
b) Spike-In experiments in human plasma
Added 0.25mM Ca + 0.50mM Ca + 0.75mM Ca + 1.00mM Ca +
1.00mM Mg 0.75mM Mg 0.50mM Mg 0.25mM Mg
Measured 0.23mM Ca; 0.44mM Ca; 0.70mM Ca; 1.06mM Ca;
1.08mM Mg 0.81mM Mg 0.52mM Mg 0.24mM Mg
Recovery 92% Ca; 88% Ca; 93% Ca; 106% Ca;
108% Mg 108% Mg 104% Mg 96% Mg
Mean recovery 95 ± 6.8% Ca; 104 ± 4.9% Mg
Table 7.2: Spike-In experiments for the absolute quantification of free calcium and mag-
nesium levels in H2O and human plasma. a) For H2O spike-in experiments, 260 µl
H2O containing 2 mM EDTA were mixed with stock solutions containing Ca2+ and Mg2+
ions to give a final volume of 400 µl. The concentrations given here are the concentrations
contained in 400 µl of sample. b) For plasma spike-in experiments, 350 µl of pooled EDTA
plasma were mixed with stock solutions containing Ca2+ and Mg2+ ions to give a final
volume of 400 µl. For plasma the concentrations given below are the added amounts in 400
µl of sample. EDTA was obtained from Carl Roth GmbH and Mg-chloride-hexahydrate
and Ca-chloride-2-hydrate were purchased from Sigma-Aldrich. Modified from [Zacharias
et al. 2015].
136
7.2 Appendix II: Acute Kidney Injury study
7.2.4 Time-course development
Figure 7.1: Principal component analysis of all 318 urine specimens collected before and at 4 and 24 h after surgery.
For the time-point before surgery the data of the 72 non-AKI and 34 AKI patients are plotted in black and blue,
respectively. For the first time-point after surgery, data of the non-AKI and AKI patients are shown in yellow and
green, respectively, while at 24 h after surgery, data of the non-AKI and AKI patients are colored in red and orange,
respectively. a) All NMR features were used. PC 1 and PC 2 explain 64.72% and 17.30% of the variance, respectively.
Modified from [Zacharias et al. 2013a)]. b) Features corresponding to D-mannitol were excluded from the PCA. PC
1 and PC 2 explain 30.82% and 9.96% of the variance, respectively. The group separation is now mainly driven by
creatinine. Modified from [Zacharias et al. 2013a)]. c) Representative 1D 1H NMR spectra of urine specimens collected
0 h pre-op, 4 h post-op and 24 h post-op for one non-AKI patient (left side) and one AKI patient (right side). These
1H urinary spectra were individually scaled by eye to creatinine for each patient. The higher abundance of D-mannitol
especially at 4 h after surgery in comparison to pre-surgery urine specimens is apparent. Modified from [Zacharias
2012].
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7.2.5 Results of permutation tests
Total AUC Number of Optimized Optimized Sensitivity Specificity
accuracy [%] selected mtry ntree [%] [%]
features
55.7 ± 5.1 0.48 ± 0.08 117.1 ± 2.7 8.9 ± 1.7 270 ± 41.0 17.1 ± 7.2 80.2 ± 6.3
Table 7.3: Classification performance on randomly permuted data. Mean values ±
standard deviations of 20 nested cross-validation runs of an RF algorithm trained on
85 plasma 1D 1H NMR spectra with randomly permuted class-labels [Zacharias et
al. 2015]. Given are the total accuracy, area under the ROC curve (AUC), number
of selected features, optimal number of tried variables mtry, number of grown trees
ntree, sensitivity, and specificity.
Figure 7.2: Exemplary receiver operating characteristic (ROC) curves of the RF clas-
sifier. a) RF trained on 85 plasma 1D 1H NMR spectra with randomly permuted
class-labels. b) RF trained on 85 plasma 1D 1H NMR spectra with non-permuted
class-labels. The x-axis denotes the false positive rate (1 - specificity), the y-axis the
true positive rate (sensitivity). The area under the ROC curve is an indicator for the
power of the used classifier (an area of one represents the ideal classifier). The ROC
curves were obtained from nested cross-validation runs with inner cross-validation
for parameter calibration. Modified from [Zacharias et al. 2015].
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7.2.6 Discriminative 24 h plasma NMR features
ID Spectral P -value P -value Identified compounds
position un- B/H-
[ppm] adjusted adjusted
222 7.285 2.87e-11 2.06e-08 Propofol-glucuronide, tryptophan
361 4.305 3.24e-10 1.16e-07 Multiple compounds
223 7.275 4.56e-09 1.09e-06 Tryptophan, propofol-glucuronide
654 1.165 6.34e-09 1.14e-06 4-Hydroxy-propofol-1-OH-D-glucuronide, propofol-
glucuronide, isopropanol1
494 2.765 9.76e-09 1.40e-06 Unknown
182 7.685 1.95e-08 2.34e-06 Unknown
444 3.285 2.28e-08 2.34e-06 Myo-inositol, D-glucuronic acid (?), phenylalanine, 4-
hydroxy-propofol-4-OH-D-glucuronide
167 7.835 2.78e-08 2.49e-06 Hippuric acid
497 2.735 3.60e-08 2.87e-06 MgEDTA2−, unknown
451 3.195 4.17e-08 2.99e-06 Acetyl-L-carnitine, propionylcarnitine (?), CaEDTA2−
489 2.815 5.71e-08 3.17e-06 Unknown
506 2.645 6.01e-08 3.17e-06 Citric acid
647 1.235 6.50e-08 3.17e-06 Unknown
360 4.315 6.51e-08 3.17e-06 Multiple compounds
632 1.385 6.73e-08 3.17e-06 Tranexamic acid
362 4.295 7.07e-08 3.17e-06 Multiple compounds
504 2.665 7.58e-08 3.20e-06 Citric acid, unknown
390 4.015 8.71e-08 3.48e-06 Isopropanol1, unknown
385 4.065 1.03e-07 3.91e-06 Creatinine, myo-inositol, choline (?)
280 6.705 2.09e-07 7.52e-06 4-Hydroxy-propofol-1-OH-D-glucuronide
662 1.085 2.39e-07 8.18e-06 Tranexamic acid, propofol-glucuronide
357 4.345 2.77e-07 8.55e-06 Unknown, 3-hydroxyglutaric acid (?), glycerophospho-
choline (?)
663 1.075 2.80e-07 8.55e-06 Tranexamic acid, propofol-glucuronide
648 1.225 2.95e-07 8.55e-06 Unknown
183 7.675 3.11e-07 8.55e-06 Unknown
503 2.675 3.12e-07 8.55e-06 Citric acid, MgEDTA2−
664 1.065 3.21e-07 8.55e-06 Unknown, tranexamic acid, propofol-glucuronide
633 1.375 4.04e-07 1.01e-05 Tranexamic acid
482 2.885 4.14e-07 1.01e-05 Tranexamic acid
635 1.355 4.23e-07 1.01e-05 2-Hydroxybutyric acid, tranexamic acid
368 4.235 4.48e-07 1.02e-05 Threonine, sucrose
358 4.335 4.55e-07 1.02e-05 Multiple compounds
631 1.395 4.90e-07 1.07e-05 Tranexamic acid
587 1.835 5.70e-07 1.20e-05 Tranexamic acid
634 1.365 6.51e-07 1.34e-05 2-Hydroxybutyric acid, tranexamic acid
384 4.075 6.95e-07 1.35e-05 Myo-inositol, D-glucuronic acid (?), choline (?)
382 4.095 6.98e-07 1.35e-05 Unknown, lactic acid, D-glucuronic acid (?)
139
7 Appendix
585 1.855 8.30e-07 1.57e-05 Tranexamic acid
588 1.825 8.62e-07 1.59e-05 Tranexamic acid
586 1.845 9.56e-07 1.72e-05 Tranexamic acid
507 2.635 1.22e-06 2.08e-05 Methionine, acetyl-L-carnitine
502 2.685 1.22e-06 2.08e-05 MgEDTA2−
492 2.785 1.43e-06 2.38e-05 Unknown
412 3.755 1.69e-06 2.75e-05 D-glucose, D-mannitol
389 4.025 1.74e-06 2.77e-05 D-gluconic acid, isopropanol1
549 2.215 1.82e-06 2.84e-05 Unknown
154 7.965 1.88e-06 2.86e-05 Unknown
500 2.705 1.91e-06 2.86e-05 MgEDTA2−
418 3.695 1.96e-06 2.87e-05 D-mannitol, threitol (?), D-gluconic acid
246 7.045 2.07e-06 2.97e-05 Unknown
607 1.635 2.45e-06 3.44e-05 Tranexamic acid, unknown
417 3.705 2.50e-06 3.45e-05 D-glucose, D-mannitol, threitol, propofol-glucuronide
487 2.835 2.58e-06 3.50e-05 Methylguanidine (?)
493 2.775 2.72e-06 3.60e-05 Unknown
419 3.685 2.76e-06 3.60e-05 D-mannitol, D-gluconic acid, propofol-glucuronide
404 3.875 2.83e-06 3.61e-05 D-mannitol
465 3.055 2.87e-06 3.61e-05 Creatinine, tyrosine, unknown
405 3.865 3.49e-06 4.33e-05 D-mannitol
630 1.405 4.06e-06 4.94e-05 Tranexamic acid
410 3.815 4.20e-06 5.02e-05 D-mannitol , D-glucose, D-gluconic acid
445 3.275 4.89e-06 5.76e-05 Betaine, unknown, D-glucuronic acid (?), 4-hydroxy-
propofol-4-OH-D-glucuronide
498 2.725 5.04e-06 5.84e-05 MgEDTA2−, dimethylamine (?), unknown
566 2.045 5.15e-06 5.87e-05 N2-acetyl-L-ornithine (?), unknown, 2-hydroxyisovaleric
acid
466 3.045 5.79e-06 6.50e-05 Creatinine, creatine, phosphocreatine
166 7.845 6.24e-06 6.89e-05 Hippuric acid
387 4.045 6.37e-06 6.89e-05 D-gluconic acid
264 6.865 6.43e-06 6.89e-05 Unknown, 4-hydroxyphenylacetic acid,
4-hydroxyphenyllactic acid
388 4.035 6.64e-06 7.01e-05 D-gluconic acid, isopropanol1
359 4.325 7.21e-06 7.50e-05 Multiple compounds
369 4.225 7.86e-06 8.06e-05 Unknown
364 4.275 8.26e-06 8.35e-05 Threonine
658 1.125 8.52e-06 8.49e-05 2-Oxoisovaleric acid, 4-hydroxy-propofol-1-OH-D-
glucuronide
386 4.055 9.32e-06 9.11e-05 D-gluconic acid, creatinine, choline (?)
488 2.825 9.39e-06 9.11e-05 Unknown
483 2.875 1.02e-05 9.78e-05 Tranexamic acid
659 1.115 1.13e-05 1.07e-04 2-Oxoisovaleric acid, 4-hydroxy-propofol-1-OH-D-
glucuronide
501 2.695 1.15e-05 1.07e-04 MgEDTA2−
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495 2.755 1.23e-05 1.13e-04 Unknown
472 2.985 1.24e-05 1.13e-04 Tranexamic acid, unknown
518 2.525 1.44e-05 1.29e-04 Citric acid, CaEDTA2−
403 3.885 1.49e-05 1.31e-04 D-mannitol, paracetamol-glucuronide
575 1.955 1.49e-05 1.31e-04 Tranexamic acid, lysine
486 2.845 1.56e-05 1.35e-04 Unknown
209 7.415 1.64e-05 1.40e-04 Phenylalanine, heparin (?), unknown
395 3.965 1.71e-05 1.45e-04 Hippuric acid, isethionic acid (?), unknown
399 3.925 1.98e-05 1.65e-04 D-glucose, unknown
646 1.245 2.10e-05 1.73e-04 Unknown
363 4.285 2.39e-05 1.95e-04 Unknown, malic acid (?), pseudouridine
212 7.385 2.50e-05 2.01e-04 Unknown, phenylalanine, heparin (?)
471 2.995 2.52e-05 2.01e-04 Unknown, 2-oxoisovaleric acid
449 3.235 2.66e-05 2.10e-04 D-glucose
496 2.745 2.99e-05 2.32e-04 Unknown, MgEDTA2−
499 2.715 3.00e-05 2.32e-04 MgEDTA2−, unknown
220 7.305 3.30e-05 2.52e-04 Paracetamol-sulfate
406 3.855 3.47e-05 2.63e-04 D-glucose, D-mannitol
641 1.295 3.65e-05 2.73e-04 Unknown, L-isoleucine
517 2.535 3.97e-05 2.94e-04 CaEDTA2−, citric acid
584 1.865 4.16e-05 3.05e-04 Tranexamic acid, lysine
396 3.955 4.42e-05 3.20e-04 Unknown
576 1.945 4.97e-05 3.57e-04 Tranexamic acid, lysine
470 3.005 5.12e-05 3.64e-04 Unknown, 2-oxoisovaleric acid
394 3.975 5.26e-05 3.70e-04 Unknown
397 3.945 5.42e-05 3.77e-04 Unknown
249 7.015 5.46e-05 3.77e-04 Unknown
391 4.005 5.51e-05 3.77e-04 2-Hydroxybutyric acid, unknown, phenylalanine
684 0.865 5.74e-05 3.88e-04 Unknown
211 7.395 5.88e-05 3.94e-04 Unknown, phenylalanine, heparin (?)
195 7.555 6.41e-05 4.26e-04 Unknown
560 2.105 6.65e-05 4.37e-04 Glutamine, glutamic acid, tranexamic acid, ketoleucine,
2-oxoisocaproic acid
409 3.825 6.70e-05 4.37e-04 D-glucose, D-gluconic acid, 4-hydroxy-propofol-4-OH-D-
glucuronide
505 2.655 6.82e-05 4.41e-04 Unknown
464 3.065 7.25e-05 4.65e-04 Unknown
442 3.305 7.46e-05 4.74e-04 Phenylalanine, unknown
265 6.855 7.82e-05 4.93e-04 Unknown, 4-hydroxyphenylacetic acid,
4-hydroxyphenyllactic acid
603 1.675 9.43e-05 5.89e-04 Tranexamic acid
604 1.665 1.02e-04 6.31e-04 Tranexamic acid
636 1.345 1.04e-04 6.40e-04 Lactic acid, threonine, tranexamic acid
378 4.135 1.10e-04 6.66e-04 Lactic acid, D-gluconic acid
508 2.625 1.11e-04 6.70e-04 Ketoleucine, 2-oxoisocaproic acid
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550 2.205 1.12e-04 6.73e-04 Unknown
605 1.655 1.16e-04 6.89e-04 Tranexamic acid
401 3.905 1.24e-04 7.27e-04 D-glucose, betaine
561 2.095 1.25e-04 7.27e-04 Tranexamic acid, ketoleucine, 2-oxoisocaproic acid
339 4.525 1.56e-04 9.06e-04 Unknown
248 7.025 1.59e-04 9.15e-04 Unknown
606 1.645 1.64e-04 9.33e-04 Tranexamic acid
210 7.405 1.72e-04 9.75e-04 Heparin (?), unknown
254 6.965 1.92e-04 1.07e-03 Unknown
253 6.975 1.96e-04 1.09e-03 Unknown
639 1.315 1.99e-04 1.09e-03 Lactic acid, threonine, unknown
279 6.715 1.99e-04 1.09e-03 4-hydroxy-propofol-1-OH-D-glucuronide
252 6.985 2.11e-04 1.15e-03 Unknown
668 1.025 2.24e-04 1.21e-03 Tranexamic acid, valine
372 4.195 2.38e-04 1.27e-03 L-pyroglutamic acid
577 1.935 2.49e-04 1.33e-03 Tranexamic acid
613 1.575 2.83e-04 1.50e-03 Unknown
247 7.035 2.87e-04 1.51e-03 Unknown
592 1.785 3.18e-04 1.65e-03 Unknown
393 3.985 3.43e-04 1.77e-03 Phenylalanine, 2-hydroxybutyric acid, serine, unknown
447 3.255 3.59e-04 1.83e-03 D-glucose, unknown, 4-hydroxy-propofol-4-OH-D-
glucuronide
208 7.425 3.60e-04 1.83e-03 Phenylalanine, heparin (?), unknown, ephedrine (?)
413 3.745 3.67e-04 1.86e-03 D-glucose, D-mannitol
116 8.345 3.80e-04 1.91e-03 Unknown, S-5-adenosyl-L-homocysteine (?)
233 7.175 3.87e-04 1.93e-03 4-Hydroxyphenylacetic acid
196 7.545 3.89e-04 1.93e-03 Unknown, hippuric acid, tryptophan, heparin (?)
490 2.805 4.36e-04 2.14e-03 Unknown
567 2.035 4.39e-04 2.14e-03 Unknown, N-acetyl-L-glutamic acid (?), N-acetyl-L-
glutamine (?), 2-hydroxyisovaleric acid
221 7.295 4.61e-04 2.24e-03 Tryptophan
653 1.175 4.91e-04 2.37e-03 Propofol-glucuronide, isopropanol1
381 4.105 4.95e-04 2.37e-03 Lactic acid
591 1.795 5.49e-04 2.61e-03 Unknown
152 7.985 6.06e-04 2.86e-03 Unknown
207 7.435 6.45e-04 3.03e-03 Phenylalanine, heparin (?), unknown, ephedrine (?)
284 6.665 6.67e-04 3.11e-03 Unknown
371 4.205 6.86e-04 3.18e-03 Unknown
441 3.315 7.14e-04 3.29e-03 Unknown
407 3.845 8.66e-04 3.96e-03 D-glucose, D-gluconic acid, 2-hydroxyisovaleric acid, 4-
hydroxy-propofol-4-OH-D-glucuronide
476 2.945 9.43e-04 4.29e-03 N,N-dimethylglycine, unknown
416 3.715 9.63e-04 4.35e-03 D-glucose, threitol, propofol-glucuronide
262 6.885 1.02e-03 4.57e-03 Tyrosine
150 8.005 1.12e-03 5.01e-03 Unknown
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511 2.595 1.13e-03 5.02e-03 CaEDTA2−
392 3.995 1.16e-03 5.09e-03 2-Hydroxybutyric acid, unknown, phenylalanine
612 1.585 1.20e-03 5.26e-03 Unknown
415 3.725 1.23e-03 5.34e-03 D-glucose, leucine, threitol
443 3.295 1.24e-03 5.34e-03 Unknown, phenylalanine, myo-inositol, 4-hydroxy-
propofol-4-OH-D-glucuronide
661 1.095 1.39e-03 5.98e-03 Tranexamic acid, unknown
485 2.855 1.43e-03 6.08e-03 Unknown
614 1.565 1.43e-03 6.08e-03 Unknown
164 7.865 1.45e-03 6.14e-03 Unknown
473 2.975 1.56e-03 6.56e-03 Unknown
379 4.125 1.60e-03 6.66e-03 Lactic acid, 3-hydroxybutyric acid
652 1.185 1.74e-03 7.24e-03 Propofol-glucuronide, 4-hydroxy-propofol-4-OH-D-
glucuronide
193 7.575 1.76e-03 7.27e-03 Unknown
642 1.285 1.80e-03 7.39e-03 Unknown
491 2.795 1.83e-03 7.46e-03 Unknown, ephedrine (?)
197 7.535 1.86e-03 7.55e-03 Unknown, tryptophan, hippuric acid (?)
198 7.525 1.94e-03 7.81e-03 Unknown
380 4.115 1.95e-03 7.84e-03 Lactic acid
402 3.895 2.02e-03 8.04e-03 D-glucose
206 7.445 2.11e-03 8.35e-03 Phenylalanine, heparin (?), paracetamol-sulfate,
ephedrine (?)
590 1.805 2.17e-03 8.56e-03 Unknown
421 3.515 2.22e-03 8.72e-03 D-glucose, propofol-glucuronide, 4-hydroxy-propofol-4-
OH-D-glucuronide
408 3.835 2.24e-03 8.72e-03 D-glucose, D-gluconic acid, unknown, 4-hydroxy-
propofol-4-OH-D-glucuronide
192 7.585 2.25e-03 8.72e-03 Unknown
65 8.855 2.31e-03 8.90e-03 Unknown
671 0.995 2.42e-03 9.30e-03 Valine
334 4.575 2.52e-03 9.62e-03 4-hydroxy-propofol-4-OH-D-glucuronide, glutathione,
carnitine
565 2.055 2.56e-03 9.69e-03 Unknown, 2-oxoisocaproic acid, glutamic acid
672 0.985 2.56e-03 9.69e-03 Valine
628 1.425 2.60e-03 9.76e-03 Lysine, unknown
435 3.375 2.74e-03 1.03e-02 Unknown
189 7.615 2.76e-03 1.03e-02 Unknown
559 2.115 2.90e-03 1.07e-02 Glutamine, glutamic acid, tranexamic acid, ketoleucine,
2-oxoisocaproic acid
478 2.925 3.00e-03 1.10e-02 Unknown
370 4.215 3.07e-03 1.13e-02 Sucrose (?)
637 1.335 3.26e-03 1.19e-02 Lactic acid, tranexamic acid
640 1.305 3.55e-03 1.29e-02 Unknown, lactic acid
638 1.325 3.58e-03 1.29e-02 Lactic acid
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153 7.975 3.59e-03 1.29e-02 Unknown
251 6.995 3.63e-03 1.30e-02 Unknown
564 2.065 3.65e-03 1.30e-02 Glutamic acid, ketoleucine, 2-oxoisocaproic acid
446 3.265 3.74e-03 1.32e-02 D-glucose, betaine, 4-hydroxy-propofol-4-OH-D-
glucuronide
608 1.625 4.39e-03 1.55e-02 Tranexamic acid
267 6.835 4.54e-03 1.59e-02 Unknown
367 4.245 4.94e-03 1.72e-02 Threonine
519 2.515 5.20e-03 1.80e-02 Unknown, glutamine
563 2.075 5.21e-03 1.80e-02 Glutamic acid, ketoleucine, 2-oxoisocaproic acid
683 0.875 5.29e-03 1.82e-02 Unknown, propofol-glucuronide
509 2.615 5.41e-03 1.85e-02 Ketoleucine, 2-oxoisocaproic acid
179 7.715 5.60e-03 1.91e-02 Unknown
667 1.035 5.90e-03 2.00e-02 Valine, tranexamic acid
616 1.545 6.08e-03 2.05e-02 Unknown
558 2.125 6.34e-03 2.12e-02 Glutamine, glutamic acid, tranexamic acid, ketoleucine,
2-oxoisocaproic acid
424 3.485 6.36e-03 2.12e-02 D-glucose
353 4.385 6.37e-03 2.12e-02 Unknown
281 6.695 6.66e-03 2.20e-02 Unknown
615 1.555 6.69e-03 2.20e-02 Unknown
657 1.135 6.71e-03 2.20e-02 2-Oxoisovaleric acid, 4-hydroxy-propofol-1-OH-D-
glucuronide
202 7.485 7.19e-03 2.35e-02 Unknown
474 2.965 7.27e-03 2.36e-02 Unknown, 3-aminopropionitrilefumarate (?)
203 7.475 7.32e-03 2.37e-02 Unknown, paracetamol-sulfate
184 7.665 7.41e-03 2.39e-02 Unknown
219 7.315 7.46e-03 2.39e-02 Paracetamol-sulfate
400 3.915 7.53e-03 2.40e-02 D-glucose
414 3.735 7.56e-03 2.40e-02 D-glucose, leucine
521 2.495 7.74e-03 2.45e-02 Glutamine, unknown
194 7.565 8.08e-03 2.54e-02 Unknown
626 1.445 8.11e-03 2.54e-02 Unknown, lysine
269 6.815 8.15e-03 2.54e-02 Unknown
191 7.595 8.30e-03 2.58e-02 Unknown
298 6.525 8.35e-03 2.58e-02 Fumaric acid
263 6.875 8.41e-03 2.59e-02 4-Hydroxyphenylacetic acid, 4-hydroxyphenyllactic acid
229 7.215 8.47e-03 2.60e-02 Unknown, tyrosine
686 0.845 8.80e-03 2.69e-02 2-Hydroxyisovaleric acid, unknown
469 3.015 9.11e-03 2.77e-02 Lysine, 2-oxoisovaleric acid
365 4.265 9.14e-03 2.77e-02 Threonine
589 1.815 9.57e-03 2.89e-02 Tranexamic acid
536 2.345 1.05e-02 3.15e-02 Glutamic acid
484 2.865 1.08e-02 3.24e-02 Tranexamic acid, unknown
285 6.655 1.18e-02 3.52e-02 Unknown
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276 6.745 1.19e-02 3.52e-02 Unknown
142 8.085 1.23e-02 3.64e-02 Unknown
411 3.765 1.25e-02 3.68e-02 Glutamic acid, D-glucose, lysine, glutamine, D-mannitol
627 1.435 1.28e-02 3.76e-02 Lysine, unknown
623 1.475 1.29e-02 3.76e-02 Alanine, lysine
398 3.935 1.34e-02 3.90e-02 Creatine
242 7.085 1.41e-02 4.07e-02 Unknown
141 8.095 1.42e-02 4.08e-02 Unknown
448 3.245 1.54e-02 4.41e-02 D-glucose
687 0.835 1.56e-02 4.44e-02 2-Hydroxyisovaleric acid, unknown
429 3.435 1.56e-02 4.44e-02 D-glucose
431 3.415 1.60e-02 4.53e-02 D-glucose
148 8.025 1.60e-02 4.53e-02 Unknown
185 7.655 1.61e-02 4.53e-02 Unknown
218 7.325 1.64e-02 4.59e-02 Phenylalanine, paracetamol-sulfate
190 7.605 1.66e-02 4.63e-02 Unknown
174 7.765 1.71e-02 4.76e-02 Unknown
341 4.505 1.75e-02 4.86e-02 Unknown
534 2.365 1.78e-02 4.92e-02 Glutamic acid, proline, 3-hydroxyglutaric acid (?), malic
acid (?)
275 6.755 1.81e-02 4.98e-02 Unknown
Table 7.4: Spectral positions and P -values of plasma features that discriminated AKI
from non-AKI patients. The 85 plasma specimens studied were collected 24 hours
post-operatively. The first 24 ± 2.8 features were used by the RF classifier. A false
discovery rate (FDR) below 5% was applied. The FDR was adjusted according to
the method of Benjamini and Hochberg (B/H). In case more than one compound
contributed to one significant bin, all possibly corresponding molecules are anno-
tated. A question mark denotes ambiguous signal assignments, mostly due to severe
signal overlap. 1Probably contamination. Adapted from [Zacharias et al. 2015].
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Figure 7.3: Previous page: Heat-map representation of plasma NMR features, whose
signal intensities differed significantly between AKI and non-AKI pa-
tients at 24 hours after surgery. These features are also listed in Appendix II
section 7.2.6 Table 7.4. Each row corresponds to a significant feature (as assigned
on the right), each column corresponds to a single patient. Up-regulated features
are indicated in yellow, while down-regulated ones are marked in blue. Rows are
ordered according to increasing correlation coefficients between disease status and
feature intensities. Rows that are mostly up-regulated in AKI patients and down-
regulated in all other groups are shown at the bottom part of the heat-map and
vice versa. The 52 patients without AKI are divided into two groups, namely cor-
rectly predicted patients (n = 45) and patients who were falsely classified as "AKI
patients" (n = 7). The 33 AKI patients are listed on the right side of the heat-
map; they are divided into four groups, namely falsely predicted AKIN 1 patients
(n = 9), correctly predicted AKIN 1 patients (n = 15), correctly predicted AKIN
2 patients (n = 3) and correctly predicted AKIN 3 patients (n = 6). The different
groups are separated from each other by red vertical bars. The 27 features that
were mostly selected for Random Forest prognostication are indicated by red ar-
rows on the right. Displayed results represent prognostication outcomes obtained
in the majority of multiple RF runs. Reprinted with permission from [Zacharias et
al. 2015]. Copyright 2015 American Chemical Society.
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7.3 Appendix III: German Chronic Kidney Disease Study
7.3.1 Patient characteristics
Baseline patient characteristics Reported values Number of missing
values
Number of patients 3164 -
Age [years] 60.2 ± 11.8 (18 - 75) 1
Sex, male 1945 (61.5%) -
Smoking 12
Number of non-smokers 1265 (40.1%)
Number of current smokers 507 (16.1%)
Number of former smokers 1380 (43.8%)
Waist-hip-ratio 0.94 ± 0.09 (0.64 - 1.3) 94
BMI [kg/m2] 29.7 ± 5.8 (16.9 - 61.5) 32
Diabetes mellitus type 1 63 (2.0%) 1
Diabetes mellitus type 2 783 (24.8%) 1
Synlab baseline parameters
SCr [mg/dl]a 1.51 ± 0.48 (0.45 - 4.73) 17
SCysC [mg/l]b 1.51 ± 0.48 (0.50 - 4.95) 15
Baseline eGFR valuesc
[ml/min per 1.73m2]
eGFRmdrd4 47.28 ± 16.48 (11.90 - 145.87) 18
eGFRckdepi crea 49.70 ± 18.11 (11.52 - 136.56) 18
eGFRckdepi cys 49.93 ± 19.74 (8.83 - 154.59) 16
eGFRckdepi crea cys 48.93 ± 18.16 (11.52 - 147.68) 18
Baseline proteinuria categoriesd 51
< 30 mg/l 1488 (47.8%)
(30 - 300) mg/l 896 (28.8%)
> 300 mg/l 729 (23.4%)
Leading renal disease 1
Diabetic nephropathy 471 (14.9%)
Glomerulonephritis 587 (18.6%)
Hereditary disease 126 (4.0%)
Interstitial nephropathy 138 (4.4%)
No leading renal disease 650 (20.6%)
Other leading renal diseases 208 (6.6%)
Systemic disease 217 (6.9%)
Hypertensive nephropathy 766 (24.2%)
148
7.3 Appendix III: German Chronic Kidney Disease Study
Table 7.5: Previous page: Baseline patient characteristics of the GCKD study baseline
sample cohort. Data is expressed as number (percentage) for categorical, and mean ±
standard deviation (range) for continuous variables, respectively. The number of missing
values is reported in the last column. aIn healthy subjects, SCr values range between 0.84-
1.25mg/dl in white men and 0.66-1.09mg/dl in white women [Dörner 2013]. bIn healthy
adults, SCysC values range between 0.54-0.94mg/l in men and 0.48-0.82mg/l in women
[Dörner 2013]. cReference eGFR values in young healthy whites are about 130ml/min per
1.73m2 for men and 120 ml/min per 1.73m2 for women [Stevens and Levey 2009, Stevens
et al. 2006]. dHealthy individuals usually excrete less than 150mg of protein per day
into the urine [Dörner 2013,Arastéh et al. 2009]. Abbreviations: BMI, body mass index;
eGFR, estimated glomerular filtration rate; eGFRckdepi crea, eGFR based on CKD-EPI crea
formula; eGFRckdepi crea cys, eGFR based on CKD-EPI crea cys formula; eGFRckdepi cys,
eGFR based on CKD-EPI cys formula; eGFRmdrd4, eGFR based on MDRD4 formula; SCr,
serum creatinine; SCysC, serum cystatin C.
Baseline patient characteristics Reported values Number of missing
values
Number of patients 2697 -
Age [years] 60.2 ± 11.7 (18 - 75) 1
Sex, male 1634 (60.6%) -
Smoking 9
Number of non-smokers 1109 (41.3%)
Number of current smokers 409 (15.2%)
Number of former smokers 1170 (43.5%)
Waist-hip-ratio 0.94 ± 0.09 (0.64 - 1.3) 71
BMI [kg/m2] 29.7 ± 5.8 (16.9 - 61.5) 26
Diabetes mellitus type 1 50 (1.9%) 1
Diabetes mellitus type 2 642 (23.8%) 1
Synlab baseline parameters
SCr [mg/dl] 1.50 ± 0.46 (0.45 - 4.72) 14
SCys C [mg/l] 1.50 ± 0.46 (0.53 - 4.95) 12
Baseline eGFR values
[ml/min per 1.73m2]
eGFRmdrd4 47.36 ± 16.00 (11.91 - 145.87) 15
eGFRckdepi crea 49.82 ± 17.62 (11.96 - 131.21) 15
eGFRckdepi cys 50.37 ± 19.26 (8.83 - 141.59) 13
eGFRckdepi crea cys 49.20 ± 17.60 (11.52 - 128.14) 15
Baseline proteinuria categories 41
< 30 mg/l 1281 (48.2%)
(30 - 300) mg/l 769 (29.0%)
> 300 mg/l 606 (22.8%)
Leading renal disease 1
Diabetic nephropathy 386 (14.3%)
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Glomerulonephritis 510 (18.9%)
Hereditary disease 111 (4.1%)
Interstitial nephropathy 121 (4.5%)
No leading renal disease 562 (20.8%)
Other leading renal diseases 174 (6.5%)
Systemic disease 194 (7.2%)
Hypertensive nephropathy 639 (23.7%)
FU2 patient characteristics Reported values Number of missing
values
Number of patients 2697 -
Synlab FU2 parameters
SCr [mg/dl] 1.68 ± 0.75 (0.45 - 10.54) 193
SCys C [mg/l] 1.72 ± 0.65 (0.39 - 7.00) 191
FU2 eGFR values
[ml/min per 1.73m2]
eGFRmdrd4 43.49 ± 16.57 (5.22 - 142.13) 193
eGFRckdepi crea 45.67 ± 18.35 (5.07 - 127.50) 193
eGFRckdepi cys 43.96 ± 19.79 (5.92 - 157.85) 191
eGFRckdepi crea cys 43.82 ± 18.40 (5.79 - 130.92) 193
Table 7.6: Baseline and FU2 patient characteristics of the GCKD study FU2 sample co-
hort. Data is expressed as number (percentage) for categorical, and mean± standard devia-
tion (range) for continuous variables, respectively. The number of missing values is reported
in the last column. Abbreviations: BMI, body mass index; eGFR, estimated glomerular
filtration rate; eGFRckdepi crea, eGFR based on CKD-EPI crea formula; eGFRckdepi crea cys,
eGFR based on CKD-EPI crea cys formula; eGFRckdepi cys, eGFR based on CKD-EPI cys
formula; eGFRmdrd4, eGFR based on MDRD4 formula; FU2, second follow-up; SCr, serum
creatinine; SCysC, serum cystatin C.
Baseline patient Complete patient set Training set Test set p-value
characteristics
Number of patients 2492 1661 831 -
Age [years] 60.3 ± 11.6 (18 - 75) 60.1 ± 11.7 (18 - 75) 60.7 ± 11.4 (20 - 75) 0.26a
Sex, male 1508 (60.5%) 997 (60.0%) 511 (61.5%) 0.49b
Smoking
Number of non-smokers 1037 (41.7%) 701 (42.3%) 336 (40.6%) 0.44b
Number of current smokers 374 (15.0%) 238 (14.4%) 136 (16.4%) 0.19b
Number of former smokers 1075 (43.2%) 719 (43.4%) 356 (43.0%) 0.86b
Waist-hip-ratio 0.94 ± 0.09 (0.64 - 1.3) 0.94 ± 0.09 (0.67 - 1.22) 0.94 ± 0.09 (0.64 - 1.3) 1a
BMI [kg/m2] 29.7 ± 5.8 (16.9 - 61.5) 29.7 ± 5.7 (17.1 - 61.5) 29.7 ± 5.8 (16.9 - 56.6) 0.93a
Diabetes mellitus type 1 47 (1.9%) 29 (1.7%) 18 (2.2%) 0.53b
Diabetes mellitus type 2 591 (23.7%) 403 (24.3%) 188 (22.6%) 0.37b
Synlab baseline
parameters
SCr [mg/dl] 1.49 ± 0.46 (0.45 - 4.72) 1.50 ± 0.47 (0.45 - 4.72) 1.49 ± 0.44 (0.51 - 3.85) 0.66a
SCysC [mg/l] 1.49 ± 0.46 (0.53 - 4.95) 1.49 ± 0.46 (0.53 - 4.95) 1.49 ± 0.45 (0.57 - 3.77) 0.82a
Baseline eGFR values
[ml/min per 1.73m2]
eGFRmdrd4 47.5 ± 16.1 (11.9 - 145.9) 47.5 ± 16.3 (11.9 - 145.9) 47.5 ± 15.8 (16.5 - 124.8) 0.95a
eGFRckdepi crea 49.9 ± 17.7 (12.0 - 131.2) 50.0 ± 17.9 (12.0 - 131.21) 49.9 ± 17.3 (16.8 - 119.5) 0.93a
eGFRckdepi cys 50.5 ± 19.3 (8.8 - 141.6) 50.6 ± 19.3 (8.8 - 141.6) 50.2 ± 19.2 (12.6 - 120.0) 0.64a
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eGFRckdepi crea cys 49.3 ± 17.7 (14.5 - 128.1) 49.4 ± 17.9 (14.5 - 128.1) 49.2 ± 17.4 (14.8 - 116.1) 0.75a
Baseline proteinuria
categories
< 30 mg/l 1192 (48.4%) 787 (48.0%) 405 (49.5%) 0.52b
(30 - 300) mg/l 717 (29.2%) 478 (29.2%) 239 (29.2%) 1b
>300 mg/l 550 (22.4%) 375 (22.9%) 175 (21.4%) 0.41b
Leading renal disease
Diabetic nephropathy 352 (14.1%) 224 (13.5%) 128 (15.4%) 0.20b
Glomerulonephritis 478 (19.2%) 326 (19.6%) 152 (18.3%) 0.45b
Hereditary disease 106 (4.3%) 71 (4.3%) 35 (4.2%) 1b
Interstitial nephropathy 115 (4.6%) 76 (4.6%) 39 (4.7%) 0.92b
No leading renal disease 517 (20.8%) 348 (21.0%) 169 (20.3%) 0.75b
Other leading renal diseases 162 (6.5%) 113 (6.8%) 49 (5.9%) 0.44b
Systemic disease 178 (7.1%) 118 (7.1%) 60 (7.2%) 0.93b
Hypertensive nephropathy 584 (23.4%) 385 (23.2%) 199 (24.0%) 0.69b
FU2 patient Complete patient set Training set Test set p-value
characteristics
Number of patients 2492 1661 831 -
Synlab FU2 parameters
SCr [mg/dl] 1.68 ± 0.75 (0.45 - 10.54) 1.69 ± 0.80 (0.45 - 10.54) 1.66 ± 0.63 (0.5 - 6.54) 0.31a
SCys C [mg/l] 1.72 ± 0.65 (0.57 - 7.00) 1.72 ± 0.67 (0.57 - 7.00) 1.72 ± 0.62 (0.63 - 6.26) 0.86a
FU2 eGFR values
[ml/min per 1.73m2]
eGFRmdrd4 43.5 ± 16.6 (5.2 - 142.1) 43.6 ± 17.0 (5.2 - 142.1) 43.2 ± 15.5 (8.4 - 141.2) 0.49a
eGFRckdepi crea 45.7 ± 18.3 (5.1 - 127.5) 45.8 ± 18.8 (5.1 - 127.5) 45.3 ± 17.2 (7.6 - 126.7) 0.44a
eGFRckdepi cys 43.9 ± 19.7 (5.9 - 143.3) 44.2 ± 19.9 (5.9 - 143.3) 43.3 ± 19.1 (7.0 - 121.6) 0.24a
eGFRckdepi crea cys 43.8 ± 18.4 (5.8 - 130.9) 44.1 ± 18.8 (5.8 - 130.9) 43.3 ± 17.5 (7.4 - 128.5) 0.30a
Table 7.7: Baseline and FU2 patient characteristics of the regression sample subset cohort
taken from the original GCKD study FU2 sample cohort. Given are the baseline
patient characteristics for the complete regression cohort, as well as separately for train-
ing and test set. Data is expressed as number (percentage) for categorical, and mean ±
standard deviation (range) for continuous variables, respectively. The last column gives the
corresponding p-values for aWelch-test or bFisher’s exact tests between training and test
set calculated with R. Abbreviations: BMI, body mass index; eGFR, estimated glomerular
filtration rate; eGFRckdepi crea, eGFR based on CKD-EPI crea formula; eGFRckdepi crea cys,
eGFR based on CKD-EPI crea cys formula; eGFRckdepi cys, eGFR based on CKD-EPI cys
formula; eGFRmdrd4, eGFR based on MDRD4 formula; FU2, second follow-up; SCr, serum
creatinine; SCysC, serum cystatin C.
7.3.2 t-tests between various leading renal diseases
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
3.782 359 0.410 3.43e-108 2.26e-105 100.00 D-glucose, alanine, glutamine,
arginine
3.802 357 0.451 2.47e-107 8.14e-105 100.00 D-glucose, alanine
3.842 353 0.509 4.88e-105 1.07e-102 100.00 D-glucose, unknown
3.852 352 0.529 3.20e-103 3.74e-101 100.00 D-glucose, unknown
3.562 368 0.527 3.25e-103 3.74e-101 100.00 D-glucose
3.912 346 0.501 3.63e-103 3.74e-101 100.00 D-glucose, betaine, unknown
3.552 369 0.544 3.97e-103 3.74e-101 100.00 D-glucose, myo-inositol
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3.932 344 0.512 4.94e-102 4.07e-100 100.00 D-glucose
3.872 350 0.440 6.67e-101 4.89e-99 100.00 D-glucose, unknown
3.752 362 0.535 9.80e-101 6.47e-99 100.00 D-glucose, glutamic acid
3.572 367 0.492 3.89e-99 2.34e-97 100.00 D-glucose, glycine
3.742 363 0.535 7.08e-99 3.89e-97 100.00 D-glucose, leucine
3.412 383 0.565 1.00e-98 5.08e-97 100.00 D-glucose, carnitine, taurine, pro-
line
3.482 376 0.567 5.91e-98 2.79e-96 100.00 D-glucose
3.862 351 0.532 1.15e-97 5.04e-96 100.00 D-glucose, unknown
3.472 377 0.555 1.22e-97 5.04e-96 100.00 D-glucose
3.442 380 0.554 1.81e-97 7.01e-96 100.00 D-glucose, carnitine, taurine, pro-
line
3.512 373 0.578 2.50e-97 9.18e-96 100.00 D-glucose
3.722 365 0.452 5.51e-97 1.91e-95 100.00 D-glucose, N,N-dimethylglycine
3.432 381 0.560 1.30e-96 4.29e-95 100.00 D-glucose, carnitine, taurine, pro-
line
3.502 374 0.574 1.46e-96 4.57e-95 100.00 D-glucose
3.452 379 0.491 1.99e-95 5.98e-94 100.00 D-glucose, carnitine, proline
3.882 349 0.478 3.11e-95 8.91e-94 100.00 D-glucose, unknown
3.422 382 0.569 1.35e-94 3.72e-93 100.00 D-glucose, carnitine, taurine, pro-
line
3.762 361 0.485 2.83e-94 7.47e-93 100.00 D-glucose, arginine, glutamine,
glutamic acid
3.732 364 0.489 1.04e-91 2.63e-90 100.00 D-glucose, unknown
3.792 358 0.288 1.32e-91 3.24e-90 100.00 D-glucose, alanine
3.532 371 0.496 3.18e-91 7.48e-90 100.00 D-glucose
3.492 375 0.550 4.52e-90 1.03e-88 100.00 D-glucose
3.772 360 0.429 1.98e-85 4.35e-84 100.00 D-glucose, alanine, glutamine,
arginine
3.812 356 0.369 2.76e-75 5.88e-74 100.00 D-glucose
3.542 370 0.412 8.07e-66 1.66e-64 100.00 D-glucose, myo-inositol
3.942 343 0.439 6.80e-63 1.36e-61 100.00 D-glucose
3.522 372 0.480 2.33e-58 4.52e-57 100.00 D-glucose
3.832 354 0.241 1.73e-57 3.27e-56 100.00 Unknown
3.402 384 0.335 1.70e-52 3.12e-51 100.00 Unknown
3.922 345 0.268 1.27e-48 2.26e-47 100.00 D-glucose, unknown
3.822 355 0.232 7.20e-42 1.25e-40 100.00 Unknown
3.962 341 0.135 3.71e-35 6.28e-34 100.00 Unknown
3.892 348 0.134 2.17e-26 3.59e-25 100.00 Unknown
3.462 378 0.217 7.03e-26 1.13e-24 100.00 D-glucose
3.972 340 0.104 4.96e-21 7.80e-20 100.00 Unknown
3.372 387 -0.167 8.72e-18 1.34e-16 100.00 Methanol, proline
7.432 205 0.136 1.60e-14 2.40e-13 100.00 Phenylalanine
4.122 325 0.204 1.84e-14 2.69e-13 100.00 Proline, lactic acid
4.152 322 0.171 2.59e-14 3.72e-13 100.00 Proline, lactic acid
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4.032 334 0.130 5.67e-14 7.96e-13 100.00 Unknown
1.072 606 0.136 1.53e-13 2.11e-12 100.00 Valine
1.082 605 0.142 1.97e-13 2.65e-12 100.00 Unknown
4.142 323 0.202 9.21e-13 1.22e-11 100.00 Proline, lactic acid
3.712 366 0.116 8.66e-12 1.12e-10 100.00 Unknown
1.902 523 0.078 9.28e-12 1.18e-10 100.00 Overlap of multiple minor com-
pounds
4.052 332 0.192 1.53e-11 1.91e-10 100.00 Unknown
1.002 613 0.125 1.83e-11 2.24e-10 100.00 Valine, lipid methyl, cholesterol
(ester)
4.132 324 0.203 1.94e-11 2.33e-10 100.00 Proline, lactic acid
1.492 564 0.127 2.92e-11 3.44e-10 100.00 Alanine
1.102 603 0.133 3.58e-11 4.14e-10 100.00 Unknown
1.502 563 0.130 6.51e-11 7.41e-10 100.00 Alanine
2.382 475 0.120 6.72e-11 7.52e-10 100.00 Proline, glutamic acid
1.012 612 0.135 1.43e-10 1.55e-09 100.00 Valine, lipid methyl, cholesterol
(ester)
1.892 524 0.075 1.43e-10 1.55e-09 100.00 Overlap of multiple minor com-
pounds
4.072 330 0.164 1.45e-10 1.55e-09 99.99 Creatinine
2.392 474 0.126 1.68e-10 1.76e-09 100.00 Unknown
2.372 476 0.116 2.97e-10 3.06e-09 100.00 Proline, glutamic acid
2.552 458 0.089 3.43e-10 3.49e-09 100.00 Citric acid
1.092 604 0.126 4.48e-10 4.48e-09 100.00 Unknown
3.062 407 0.105 5.03e-10 4.96e-09 99.99 Creatinine
4.002 337 -0.071 6.02e-10 5.84e-09 100.00 Unknown
7.202 228 0.123 6.35e-10 6.08e-09 100.00 Tyrosine
1.052 608 0.181 8.22e-10 7.75e-09 100.00 Valine
7.372 211 0.091 1.19e-09 1.11e-08 99.99 Phenylalanine
3.992 338 -0.080 1.26e-09 1.15e-08 100.00 Unknown
2.362 477 0.104 1.44e-09 1.30e-08 100.00 Proline, glutamic acid
3.032 410 0.041 2.87e-09 2.56e-08 99.99 Lysine, unknown
7.382 210 0.080 3.84e-09 3.38e-08 99.99 Phenylalanine
1.912 522 0.075 8.28e-09 7.19e-08 99.99 Overlap of multiple minor com-
pounds
2.672 446 0.106 9.59e-09 8.22e-08 100.00 Citric acid
7.342 214 0.067 1.69e-08 1.43e-07 99.99 Phenylalanine
2.572 456 0.069 1.84e-08 1.54e-07 100.00 CaEDTA2−, citric acid
4.162 321 0.123 2.54e-08 2.09e-07 99.96 Proline, lactic acid
7.352 213 0.072 2.93e-08 2.39e-07 99.99 Phenylalanine
1.742 539 0.071 3.01e-08 2.42e-07 99.99 Leucine, lysine
1.132 600 0.098 3.27e-08 2.60e-07 99.96 Unknown
1.882 525 0.064 4.91e-08 3.86e-07 99.93 Overlap of multiple minor com-
pounds
1.062 607 0.113 5.17e-08 4.02e-07 99.98 Valine
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3.392 385 0.253 7.02e-08 5.39e-07 99.96 Methanol, proline
7.442 204 0.085 9.77e-08 7.41e-07 99.98 Phenylalanine
3.052 408 0.050 1.32e-07 9.91e-07 99.93 Creatinine
2.692 444 0.063 1.82e-07 1.35e-06 100.00 Citric acid
4.192 318 0.166 2.15e-07 1.57e-06 99.93 Unknown
3.952 342 0.106 2.52e-07 1.83e-06 99.88 Unknown
1.752 538 0.070 2.98e-07 2.13e-06 99.93 Leucine, lysine
1.732 540 0.062 3.71e-07 2.63e-06 99.93 Leucine, lysine
4.112 326 0.186 4.03e-07 2.83e-06 99.80 Proline, lactic acid
6.902 258 0.065 6.95e-07 4.81e-06 99.88 Tyrosine
2.352 478 0.069 7.00e-07 4.81e-06 99.68 Proline, glutamic acid
4.092 328 0.132 7.42e-07 5.03e-06 99.68 Unknown
1.512 562 0.101 7.46e-07 5.03e-06 99.80 Alanine
1.922 521 0.067 1.05e-06 6.97e-06 99.80 Overlap of multiple minor com-
pounds
7.192 229 0.074 1.46e-06 9.66e-06 99.68 Tyrosine
2.302 483 0.100 3.41e-06 2.23e-05 99.48 Lipid (methylene carbonyl)
6.922 256 0.093 3.68e-06 2.38e-05 99.68 Tyrosine
7.392 209 0.062 4.20e-06 2.69e-05 99.68 Phenylalanine
2.312 482 0.088 5.14e-06 3.26e-05 99.18 Lipid (methylene carbonyl)
6.832 265 0.077 5.51e-06 3.47e-05 99.18 Unknown
3.042 409 0.029 5.61e-06 3.49e-05 99.18 Lysine, unknown
1.872 526 0.055 6.32e-06 3.90e-05 99.18 Overlap of multiple minor com-
pounds
3.902 347 0.050 7.63e-06 4.66e-05 99.48 D-glucose, unknown
3.072 406 0.035 9.50e-06 5.75e-05 98.74 Unknown
7.402 208 0.063 1.18e-05 7.06e-05 99.48 Phenylalanine
2.292 484 0.110 1.77e-05 1.05e-04 98.74 Lipid (methylene carbonyl)
1.722 541 0.049 1.84e-05 1.08e-04 98.74 Leucine, lysine
2.402 473 0.047 2.04e-05 1.19e-04 98.11 Glutamine, carnitine
3.312 393 0.100 2.06e-05 1.20e-04 98.74 Unknown
4.062 331 0.119 2.15e-05 1.23e-04 98.74 Creatinine
1.762 537 0.056 4.25e-05 2.42e-04 98.11 Leucine, lysine
1.352 578 0.136 4.30e-05 2.43e-04 98.11 Lipid methylene, lactic acid, thre-
onine
1.702 543 0.051 4.79e-05 2.68e-04 97.23 Unknown, arginine
1.482 565 0.075 5.31e-05 2.94e-04 97.23 Alanine
1.342 579 0.132 6.10e-05 3.35e-04 98.11 Lipid methylene, lactic acid, thre-
onine
2.562 457 0.038 6.35e-05 3.46e-04 98.74 CaEDTA2−
4.312 306 0.086 7.17e-05 3.88e-04 97.23 Lipid alpha-methylene to car-
boxyl, lipid glycerine
8.092 139 0.184 7.48e-05 4.01e-04 96.03 Trigonelline
1.032 610 0.090 1.06e-04 5.65e-04 97.23 L-isoleucine, lipid methyl, choles-
terol (ester)
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2.322 481 0.069 1.08e-04 5.73e-04 96.03 Lipid (methylene carbonyl)
1.232 590 0.078 1.10e-04 5.78e-04 96.03 Lipid methylene
1.022 611 0.082 1.20e-04 6.21e-04 97.23 L-isoleucine, lipid methyl, choles-
terol (ester)
7.332 215 0.055 1.47e-04 7.56e-04 94.44 Phenylalanine
1.462 567 0.081 1.59e-04 8.13e-04 96.03 Lipid methylene
2.542 459 0.056 1.65e-04 8.38e-04 98.11 Unknown
6.822 266 0.064 1.78e-04 8.98e-04 96.03 Unknown
9.172 31 -0.357 1.88e-04 9.41e-04 96.03 Unknown
1.682 545 0.062 1.98e-04 9.82e-04 94.44 Unknown, arginine
1.242 589 0.083 2.02e-04 9.97e-04 96.03 Lipid methylene
2.282 485 0.119 2.13e-04 1.04e-03 96.03 Lipid (methylene carbonyl)
1.142 599 0.071 2.16e-04 1.05e-03 94.44 Unknown
3.152 398 0.027 2.21e-04 1.06e-03 86.62 CaEDTA2−
8.102 138 0.180 2.34e-04 1.12e-03 96.03 Trigonelline
4.102 327 0.135 2.36e-04 1.12e-03 94.44 Unknown
1.932 520 0.049 2.45e-04 1.15e-03 96.03 Acetic acid
6.842 264 0.063 2.53e-04 1.18e-03 94.44 Unknown
2.342 479 0.061 2.56e-04 1.19e-03 94.44 Proline, glutamic acid
3.172 396 0.052 3.03e-04 1.40e-03 92.39 CaEDTA2−
6.962 252 0.065 3.08e-04 1.41e-03 94.44 Unknown
7.142 234 0.072 3.27e-04 1.49e-03 94.44 Unknown
1.692 544 0.051 3.67e-04 1.66e-03 92.39 Unknown, arginine
2.112 502 0.063 4.03e-04 1.81e-03 92.39 Lipid allylic
7.182 230 0.068 4.14e-04 1.84e-03 94.44 Unknown
7.252 223 0.058 4.15e-04 1.84e-03 92.39 Unknown
1.362 577 0.126 4.46e-04 1.96e-03 94.44 Lipid methylene, lactic acid, thre-
onine
2.872 426 0.087 4.60e-04 2.01e-03 92.39 Lipid diallylic
1.712 542 0.040 4.70e-04 2.04e-03 92.39 Leucine, lysine
1.452 568 0.084 4.89e-04 2.11e-03 92.39 Lipid methylene
6.972 251 0.078 5.47e-04 2.34e-03 94.44 Unknown
8.032 145 0.116 5.56e-04 2.37e-03 92.39 Unknown
2.652 448 0.035 5.75e-04 2.43e-03 92.39 Unknown
2.662 447 0.077 6.21e-04 2.61e-03 94.44 Citric acid
1.472 566 0.069 6.25e-04 2.61e-03 89.80 Lipid methylene
6.912 257 0.068 6.76e-04 2.81e-03 92.39 Tyrosine
2.332 480 0.062 6.87e-04 2.84e-03 89.80 Proline, glutamic acid
1.862 527 0.043 6.95e-04 2.85e-03 89.80 Unknown
7.072 241 0.065 6.99e-04 2.85e-03 89.80 Unknown
7.132 235 0.065 7.23e-04 2.93e-03 92.39 Unknown
7.242 224 0.052 7.42e-04 2.99e-03 89.80 Unknown
0.992 614 0.071 8.30e-04 3.32e-03 89.80 Leucine, lipid methyl, cholesterol
(ester)
1.122 601 0.075 8.38e-04 3.33e-03 89.80 Unknown
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6.542 294 0.319 8.63e-04 3.41e-03 89.80 Unknown
0.982 615 0.069 9.17e-04 3.60e-03 89.80 Leucine, lipid methyl, cholesterol
(ester)
1.972 516 0.054 9.59e-04 3.75e-03 89.80 Lipid allylic
6.812 267 0.067 9.89e-04 3.84e-03 92.39 Unknown
7.562 192 -0.085 1.03e-03 3.99e-03 92.39 Unknown
1.982 515 0.061 1.05e-03 4.04e-03 89.80 Lipid allylic
2.422 471 0.061 1.11e-03 4.25e-03 89.80 Glutamine, carnitine
7.122 236 0.050 1.12e-03 4.26e-03 89.80 Unknown
4.182 319 0.141 1.15e-03 4.33e-03 89.80 Unknown
2.122 501 0.055 1.17e-03 4.38e-03 86.62 Lipid allylic
8.042 144 0.244 1.32e-03 4.90e-03 89.80 Unknown
4.042 333 0.085 1.37e-03 5.09e-03 89.80 Unknown
2.902 423 0.045 1.40e-03 5.16e-03 82.82 Unknown
1.522 561 0.053 1.41e-03 5.16e-03 86.62 Lipids (?)
7.232 225 0.048 1.42e-03 5.19e-03 86.62 Unknown
2.852 428 0.104 1.51e-03 5.49e-03 86.62 Lipid diallylic
7.262 222 0.053 1.55e-03 5.60e-03 86.62 Unknown
7.322 216 0.049 1.74e-03 6.24e-03 82.82 Unknown
2.492 464 -0.044 1.76e-03 6.27e-03 86.62 Glutamine
1.962 517 0.045 1.83e-03 6.48e-03 86.62 Lipid allylic
1.162 597 0.085 1.84e-03 6.50e-03 89.80 Lipid methylene
4.012 336 -0.037 1.93e-03 6.77e-03 86.62 Unknown
2.102 503 0.048 1.98e-03 6.91e-03 86.62 Lipid allylic
2.222 491 0.113 2.00e-03 6.93e-03 86.62 Lipid (methylene carbonyl)
4.342 303 0.058 2.05e-03 7.08e-03 86.62 Lipid alpha-methylene to car-
boxyl, lipid glycerine
2.212 492 0.101 2.14e-03 7.37e-03 86.62 Lipid (methylene carbonyl)
2.862 427 0.095 2.26e-03 7.74e-03 82.82 Lipid diallylic
7.862 162 0.094 2.30e-03 7.82e-03 82.82 Unknown
1.172 596 0.078 2.38e-03 8.05e-03 86.62 Lipid methylene
4.322 305 0.059 2.42e-03 8.14e-03 82.82 Lipid alpha-methylene to car-
boxyl, lipid glycerine
7.742 174 0.063 2.51e-03 8.40e-03 82.82 Unknown
4.302 307 0.072 2.55e-03 8.50e-03 82.82 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
2.432 470 0.039 2.57e-03 8.50e-03 82.82 Glutamine, carnitine
8.122 136 0.117 2.58e-03 8.50e-03 86.62 Unknown
7.872 161 0.085 2.66e-03 8.66e-03 82.82 Unknown
7.552 193 -0.084 2.66e-03 8.66e-03 86.62 Unknown
7.222 226 0.052 2.66e-03 8.66e-03 86.62 Tyrosine
3.332 391 0.200 2.73e-03 8.84e-03 86.62 Proline
1.252 588 0.074 2.82e-03 9.08e-03 82.82 Lipid methylene
7.272 221 0.047 3.02e-03 9.68e-03 78.40 Unknown
1.182 595 0.065 3.04e-03 9.69e-03 82.82 Lipid methylene
156
7.3 Appendix III: German Chronic Kidney Disease Study
2.882 425 0.059 3.11e-03 9.87e-03 78.40 Lipid diallylic
1.992 514 0.057 3.22e-03 1.02e-02 82.82 Lipid allylic
2.132 500 0.037 3.45e-03 1.09e-02 78.40 Glutamine
2.202 493 0.076 3.57e-03 1.12e-02 82.82 Lipid (methylene carbonyl)
1.442 569 0.073 3.63e-03 1.13e-02 78.40 Lipid methylene
1.152 598 0.063 3.91e-03 1.21e-02 82.82 Lipid methylene
7.112 237 0.039 3.98e-03 1.23e-02 78.40 Unknown
7.672 181 0.152 4.17e-03 1.28e-02 78.40 Unknown
4.172 320 0.097 4.39e-03 1.34e-02 78.40 Unknown
2.272 486 0.117 4.42e-03 1.35e-02 78.40 Lipid (methylene carbonyl)
2.482 465 -0.040 4.58e-03 1.39e-02 78.40 Glutamine, carnitine
2.732 440 -0.034 4.73e-03 1.43e-02 78.40 MgEDTA2−
2.092 504 0.070 4.89e-03 1.47e-02 78.40 Lipid allylic
7.052 243 0.055 5.05e-03 1.51e-02 78.40 Unknown
7.632 185 0.097 5.06e-03 1.51e-02 78.40 Unknown
0.972 616 0.057 5.44e-03 1.61e-02 78.40 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.532 560 0.057 5.55e-03 1.64e-02 73.37 Lipids (?)
8.112 137 0.146 5.76e-03 1.69e-02 73.37 Trigonelline
2.642 449 0.031 6.47e-03 1.89e-02 73.37 Unknown
8.082 140 0.103 6.64e-03 1.93e-02 78.40 Trigonelline
2.252 488 0.099 6.68e-03 1.93e-02 73.37 Lipid (methylene carbonyl), ace-
tone
2.842 429 0.094 6.84e-03 1.96e-02 73.37 Lipid diallylic
2.532 460 0.040 6.86e-03 1.96e-02 73.37 Unknown
2.452 468 0.051 6.87e-03 1.96e-02 73.37 Glutamine, carnitine
2.972 416 0.019 7.21e-03 2.05e-02 73.37 Unknown
1.432 570 0.072 8.24e-03 2.33e-02 73.37 Lipid methylene
1.852 528 0.034 8.45e-03 2.38e-02 73.37 Unknown
1.672 546 0.052 8.78e-03 2.47e-02 73.37 Unknown, arginine
1.952 518 0.034 9.03e-03 2.53e-02 73.37 Acetic acid
7.152 233 0.065 9.20e-03 2.56e-02 78.40 Unknown
1.412 572 0.109 9.32e-03 2.58e-02 73.37 Lipid methylene
7.282 220 0.038 9.70e-03 2.68e-02 67.82 Unknown
2.002 513 0.051 9.89e-03 2.72e-02 67.82 Lipid allylic
7.572 191 -0.074 1.03e-02 2.81e-02 73.37 Unknown
7.172 231 0.072 1.08e-02 2.94e-02 73.37 Unknown
1.662 547 0.059 1.12e-02 3.04e-02 67.82 Lipids (?)
4.272 310 0.044 1.13e-02 3.05e-02 67.82 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
9.142 34 0.303 1.14e-02 3.06e-02 73.37 Trigonelline
3.092 404 0.017 1.15e-02 3.09e-02 67.82 CaEDTA2−
7.302 218 0.037 1.17e-02 3.13e-02 67.82 Unknown
7.422 206 0.073 1.17e-02 3.13e-02 73.37 Phenylalanine
8.022 146 0.098 1.23e-02 3.25e-02 73.37 Unknown
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1.422 571 0.085 1.23e-02 3.25e-02 67.82 Lipid methylene
0.962 617 0.057 1.26e-02 3.32e-02 67.82 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
2.892 424 0.034 1.33e-02 3.47e-02 61.84 Lipid diallylic
2.232 490 0.094 1.33e-02 3.47e-02 67.82 Lipid (methylene carbonyl)
6.762 272 0.179 1.34e-02 3.49e-02 67.82 Unknown
8.872 61 0.297 1.36e-02 3.53e-02 67.82 Trigonelline
3.182 395 0.020 1.41e-02 3.63e-02 55.55 CaEDTA2−
7.412 207 -0.065 1.44e-02 3.71e-02 73.37 Phenylalanine
8.982 50 -0.237 1.46e-02 3.72e-02 67.82 Unknown
2.412 472 0.048 1.46e-02 3.72e-02 67.82 Glutamine, carnitine
1.402 573 0.127 1.47e-02 3.72e-02 67.82 Lipid methylene
1.542 559 0.065 1.48e-02 3.75e-02 67.82 Lipids (?)
7.992 149 0.145 1.49e-02 3.77e-02 67.82 Unknown
0.952 618 0.065 1.51e-02 3.79e-02 67.82 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
8.352 113 0.193 1.54e-02 3.84e-02 73.37 Unknown
7.292 219 0.035 1.54e-02 3.84e-02 61.84 Unknown
6.982 250 0.073 1.69e-02 4.20e-02 67.82 Unknown
1.842 529 0.030 1.70e-02 4.20e-02 61.84 Unknown
1.262 587 0.064 1.71e-02 4.21e-02 61.84 Lipid methylene
2.832 430 0.080 1.72e-02 4.21e-02 61.84 Lipid diallylic
2.192 494 0.049 1.72e-02 4.21e-02 61.84 Lipid (methylene carbonyl)
6.792 269 0.053 1.78e-02 4.34e-02 67.82 Unknown
3.142 399 0.023 1.82e-02 4.41e-02 49.13 CaEDTA2−
3.342 390 0.068 1.85e-02 4.48e-02 61.84 Proline
7.362 212 0.036 1.88e-02 4.53e-02 67.82 Phenylalanine
6.782 270 0.095 1.95e-02 4.68e-02 61.84 Unknown
7.062 242 0.050 1.96e-02 4.68e-02 61.84 Unknown
8.392 109 0.188 2.01e-02 4.79e-02 67.82 Unknown
3.122 401 0.019 2.04e-02 4.84e-02 49.13 CaEDTA2−
2.262 487 0.108 2.08e-02 4.93e-02 61.84 Lipid (methylene carbonyl)
Table 7.8: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values both
unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical power in
%, as well as correspondingly identified compounds of NMR features that dis-
criminated patients suffering from diabetic nephropathy from those suffering
from glomerulonephritis. A false discovery rate (FDR) below 5% was applied. The
FDR was adjusted according to the method of Benjamini and Hochberg (B/H). In case
that more than one compound contributed to a significant bin, all possible assignments
are given. A question mark denotes ambiguous signal assignments, mostly due to severe
signal overlap. The statistical power was calculated with a significance level of 0.05 and a
specificity of 95%.
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Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
3.802 357 0.476 2.22e-49 1.28e-46 100.00 D-glucose, alanine
3.842 353 0.542 5.22e-49 1.28e-46 100.00 D-glucose, unknown
3.782 359 0.430 5.80e-49 1.28e-46 100.00 D-glucose, alanine, glutamine,
arginine
3.882 349 0.537 8.72e-49 1.44e-46 100.00 D-glucose, unknown
3.872 350 0.472 1.12e-47 1.48e-45 100.00 D-glucose, unknown
3.862 351 0.578 4.48e-47 4.93e-45 100.00 D-glucose, unknown
3.742 363 0.576 5.53e-47 4.98e-45 100.00 D-glucose, leucine
3.442 380 0.601 6.12e-47 4.98e-45 100.00 D-glucose, carnitine, taurine, pro-
line
3.412 383 0.608 6.79e-47 4.98e-45 100.00 D-glucose, carnitine, taurine, pro-
line
3.562 368 0.553 9.41e-47 6.21e-45 100.00 D-glucose
3.912 346 0.525 1.28e-46 7.65e-45 100.00 D-glucose, betaine, unknown
3.852 352 0.553 1.39e-46 7.67e-45 100.00 D-glucose, unknown
3.552 369 0.569 2.04e-46 1.03e-44 100.00 D-glucose, myo-inositol
3.432 381 0.607 2.52e-46 1.19e-44 100.00 D-glucose, carnitine, taurine, pro-
line
3.452 379 0.534 4.13e-46 1.82e-44 100.00 D-glucose, carnitine, proline
3.502 374 0.619 5.50e-46 2.24e-44 100.00 D-glucose
3.482 376 0.607 5.76e-46 2.24e-44 100.00 D-glucose
3.762 361 0.529 7.99e-46 2.93e-44 100.00 D-glucose, arginine, glutamine,
glutamic acid
3.722 365 0.485 8.83e-46 3.07e-44 100.00 D-glucose, N,N-dimethylglycine
3.932 344 0.534 9.60e-46 3.17e-44 100.00 D-glucose
3.572 367 0.521 1.05e-45 3.32e-44 100.00 D-glucose, glycine
3.512 373 0.616 2.47e-45 7.42e-44 100.00 D-glucose
3.492 375 0.605 2.06e-44 5.93e-43 100.00 D-glucose
3.752 362 0.553 2.52e-44 6.93e-43 100.00 D-glucose, glutamic acid
3.532 371 0.537 1.32e-43 3.48e-42 100.00 D-glucose
3.472 377 0.573 5.73e-43 1.45e-41 100.00 D-glucose
3.772 360 0.477 6.71e-43 1.64e-41 100.00 D-glucose, alanine, glutamine,
arginine
3.422 382 0.584 5.12e-41 1.21e-39 100.00 D-glucose, carnitine, taurine, pro-
line
3.732 364 0.505 2.99e-40 6.81e-39 100.00 D-glucose, unknown
3.792 358 0.296 7.64e-40 1.68e-38 100.00 D-glucose, alanine
3.812 356 0.417 8.18e-39 1.74e-37 100.00 D-glucose
3.942 343 0.526 4.26e-36 8.79e-35 100.00 D-glucose
3.922 345 0.341 3.94e-31 7.88e-30 100.00 D-glucose, unknown
3.962 341 0.202 2.11e-30 4.11e-29 100.00 Unknown
3.522 372 0.514 3.29e-27 6.21e-26 100.00 D-glucose
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3.542 370 0.396 3.82e-25 7.00e-24 100.00 D-glucose, myo-inositol
3.832 354 0.246 1.26e-24 2.25e-23 100.00 Unknown
3.402 384 0.341 2.30e-22 4.00e-21 100.00 Unknown
3.972 340 0.171 1.22e-21 2.06e-20 100.00 Unknown
3.822 355 0.257 1.01e-20 1.67e-19 100.00 Unknown
3.892 348 0.177 3.25e-18 5.23e-17 100.00 Unknown
3.462 378 0.273 1.96e-16 3.07e-15 100.00 D-glucose
4.122 325 0.345 1.21e-15 1.86e-14 100.00 Proline, lactic acid
4.142 323 0.320 2.89e-12 4.33e-11 100.00 Proline, lactic acid
4.132 324 0.340 4.41e-12 6.46e-11 100.00 Proline, lactic acid
1.102 603 0.225 5.28e-12 7.58e-11 100.00 Unknown
4.152 322 0.248 8.99e-12 1.26e-10 100.00 Proline, lactic acid
1.132 600 0.188 7.76e-11 1.07e-09 100.00 Unknown
1.232 590 0.211 9.83e-11 1.32e-09 100.00 Lipid methylene
1.092 604 0.212 1.09e-10 1.44e-09 100.00 Unknown
1.082 605 0.199 1.86e-10 2.41e-09 100.00 Unknown
2.402 473 0.112 4.01e-10 5.09e-09 100.00 Glutamine, carnitine
1.152 598 0.217 8.22e-10 1.02e-08 100.00 Lipid methylene
1.692 544 0.141 1.50e-09 1.81e-08 100.00 Unknown, arginine
2.312 482 0.189 1.51e-09 1.81e-08 100.00 Lipid (methylene carbonyl)
1.002 613 0.179 2.54e-09 2.99e-08 100.00 Valine, lipid methyl, cholesterol
(ester)
1.682 545 0.160 2.83e-09 3.28e-08 100.00 Unknown, arginine
1.702 543 0.122 3.02e-09 3.44e-08 100.00 Unknown, arginine
2.382 475 0.175 4.11e-09 4.60e-08 100.00 Proline, glutamic acid
1.242 589 0.211 5.39e-09 5.93e-08 99.99 Lipid methylene
2.122 501 0.160 6.14e-09 6.65e-08 100.00 Lipid allylic
2.302 483 0.204 6.34e-09 6.75e-08 99.99 Lipid (methylene carbonyl)
1.362 577 0.338 6.80e-09 7.12e-08 99.99 Lipid methylene, lactic acid, thre-
onine
1.072 606 0.172 7.11e-09 7.33e-08 100.00 Valine
1.342 579 0.307 9.49e-09 9.63e-08 99.99 Lipid methylene, lactic acid, thre-
onine
4.312 306 0.202 9.67e-09 9.67e-08 99.99 Lipid alpha-methylene to car-
boxyl, lipid glycerine
2.362 477 0.158 1.20e-08 1.19e-07 99.99 Proline, glutamic acid
1.972 516 0.151 1.25e-08 1.21e-07 100.00 Lipid allylic
1.962 517 0.132 1.39e-08 1.33e-07 100.00 Lipid allylic
7.262 222 0.153 1.47e-08 1.38e-07 100.00 Unknown
6.832 265 0.155 1.70e-08 1.58e-07 100.00 Unknown
7.222 226 0.159 1.82e-08 1.67e-07 99.99 Tyrosine
1.142 599 0.174 1.99e-08 1.80e-07 99.98 Unknown
7.272 221 0.144 2.07e-08 1.85e-07 100.00 Unknown
2.322 481 0.162 2.52e-08 2.22e-07 99.98 Lipid (methylene carbonyl)
2.392 474 0.176 3.29e-08 2.86e-07 99.99 Unknown
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1.352 578 0.299 3.55e-08 3.04e-07 99.98 Lipid methylene, lactic acid, thre-
onine
2.652 448 0.090 4.12e-08 3.49e-07 100.00 Unknown
1.872 526 0.108 5.04e-08 4.21e-07 99.98 Overlap of multiple minor com-
pounds
1.672 546 0.175 5.26e-08 4.34e-07 99.98 Unknown, arginine
1.712 542 0.101 5.51e-08 4.49e-07 99.98 Leucine, lysine
2.292 484 0.225 6.57e-08 5.24e-07 99.97 Lipid (methylene carbonyl)
1.842 529 0.111 6.59e-08 5.24e-07 99.98 Unknown
7.252 223 0.145 6.85e-08 5.38e-07 99.99 Unknown
1.862 527 0.111 6.98e-08 5.41e-07 99.98 Unknown
2.642 449 0.101 7.05e-08 5.41e-07 99.98 Unknown
1.982 515 0.161 7.73e-08 5.86e-07 99.98 Lipid allylic
6.842 264 0.148 9.06e-08 6.79e-07 99.99 Unknown
2.372 476 0.159 1.01e-07 7.49e-07 99.97 Proline, glutamic acid
1.222 591 0.217 1.03e-07 7.59e-07 99.99 Lipid methylene
4.112 326 0.314 1.22e-07 8.81e-07 99.98 Proline, lactic acid
7.232 225 0.129 1.31e-07 9.37e-07 99.99 Unknown
7.332 215 0.123 1.38e-07 9.77e-07 99.98 Phenylalanine
7.282 220 0.125 1.39e-07 9.77e-07 99.99 Unknown
7.292 219 0.123 1.48e-07 1.03e-06 99.99 Unknown
7.202 228 0.169 1.54e-07 1.06e-06 99.95 Tyrosine
4.342 303 0.159 1.64e-07 1.12e-06 99.95 Lipid alpha-methylene to car-
boxyl, lipid glycerine
3.712 366 0.144 1.70e-07 1.14e-06 99.76 Unknown
7.322 216 0.133 1.71e-07 1.14e-06 99.99 Unknown
1.062 607 0.175 1.84e-07 1.21e-06 99.95 Valine
4.322 305 0.163 2.18e-07 1.42e-06 99.94 Lipid alpha-methylene to car-
boxyl, lipid glycerine
7.302 218 0.125 2.20e-07 1.42e-06 99.98 Unknown
1.812 532 0.108 2.30e-07 1.47e-06 99.95 Unknown
7.212 227 0.154 2.50e-07 1.59e-06 99.97 Tyrosine
1.662 547 0.195 2.59e-07 1.63e-06 99.94 Lipids (?)
2.352 478 0.115 3.17e-07 1.97e-06 99.87 Proline, glutamic acid
7.312 217 0.130 3.19e-07 1.97e-06 99.98 Unknown
1.012 612 0.173 3.41e-07 2.09e-06 99.94 Valine, lipid methyl, cholesterol
(ester)
1.882 525 0.097 3.66e-07 2.21e-06 99.94 Overlap of multiple minor com-
pounds
1.252 588 0.205 3.73e-07 2.24e-06 99.87 Lipid methylene
6.822 266 0.141 4.09e-07 2.43e-06 99.98 Unknown
1.492 564 0.157 4.16e-07 2.44e-06 99.94 Alanine
1.482 565 0.151 4.18e-07 2.44e-06 99.94 Alanine
1.852 528 0.106 4.48e-07 2.59e-06 99.91 Unknown
2.132 500 0.105 4.54e-07 2.61e-06 99.87 Glutamine
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2.282 485 0.261 5.20e-07 2.96e-06 99.91 Lipid (methylene carbonyl)
1.462 567 0.173 6.19e-07 3.49e-06 99.87 Lipid methylene
4.032 334 0.139 6.42e-07 3.59e-06 99.87 Unknown
2.332 480 0.147 6.89e-07 3.82e-06 99.87 Proline, glutamic acid
1.892 524 0.094 7.19e-07 3.93e-06 99.87 Overlap of multiple minor com-
pounds
1.512 562 0.163 7.20e-07 3.93e-06 99.87 Alanine
1.992 514 0.155 8.10e-07 4.38e-06 99.87 Lipid allylic
3.902 347 0.090 8.79e-07 4.71e-06 99.76 D-glucose, unknown
0.962 617 0.181 9.02e-07 4.80e-06 99.82 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.452 568 0.193 9.09e-07 4.80e-06 99.82 Lipid methylene
1.502 563 0.158 9.20e-07 4.82e-06 99.87 Alanine
1.902 523 0.090 9.95e-07 5.17e-06 99.87 Overlap of multiple minor com-
pounds
1.832 530 0.093 1.04e-06 5.31e-06 99.91 Unknown
1.122 601 0.179 1.04e-06 5.31e-06 99.87 Unknown
4.302 307 0.190 1.06e-06 5.38e-06 99.87 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
1.822 531 0.097 1.11e-06 5.61e-06 99.91 Unknown
2.112 502 0.140 1.14e-06 5.70e-06 99.82 Lipid allylic
1.802 533 0.112 1.26e-06 6.28e-06 99.91 Unknown
1.162 597 0.215 1.37e-06 6.77e-06 99.98 Lipid methylene
1.022 611 0.168 1.46e-06 7.13e-06 99.76 L-isoleucine, lipid methyl, choles-
terol (ester)
1.172 596 0.201 1.47e-06 7.13e-06 99.98 Lipid methylene
4.332 304 0.146 1.61e-06 7.76e-06 99.76 Lipid alpha-methylene to car-
boxyl, lipid glycerine
2.342 479 0.130 1.87e-06 8.93e-06 99.67 Proline, glutamic acid
6.922 256 0.155 1.93e-06 9.14e-06 99.76 Tyrosine
1.952 518 0.099 2.12e-06 9.92e-06 99.82 Acetic acid
1.522 561 0.127 2.12e-06 9.92e-06 99.82 Lipids (?)
0.972 616 0.159 2.17e-06 1.01e-05 99.67 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
7.372 211 0.113 3.07e-06 1.42e-05 99.67 Phenylalanine
2.272 486 0.310 3.34e-06 1.53e-05 99.67 Lipid (methylene carbonyl)
7.242 224 0.115 3.37e-06 1.53e-05 99.87 Unknown
1.472 566 0.151 3.58e-06 1.62e-05 99.67 Lipid methylene
0.952 618 0.201 3.62e-06 1.63e-05 99.56 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
4.102 327 0.276 3.81e-06 1.70e-05 99.76 Unknown
2.002 513 0.148 3.89e-06 1.72e-05 99.67 Lipid allylic
1.722 541 0.085 4.05e-06 1.78e-05 99.56 Leucine, lysine
2.102 503 0.115 4.11e-06 1.79e-05 99.67 Lipid allylic
4.162 321 0.163 5.02e-06 2.18e-05 99.56 Proline, lactic acid
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2.252 488 0.270 5.45e-06 2.34e-05 99.67 Lipid (methylene carbonyl), ace-
tone
7.382 210 0.099 5.47e-06 2.34e-05 99.56 Phenylalanine
3.372 387 -0.142 6.07e-06 2.58e-05 98.68 Methanol, proline
1.182 595 0.160 6.10e-06 2.58e-05 99.22 Lipid methylene
1.262 587 0.197 6.37e-06 2.68e-05 99.41 Lipid methylene
0.992 614 0.156 6.71e-06 2.80e-05 99.22 Leucine, lipid methyl, cholesterol
(ester)
6.912 257 0.147 7.05e-06 2.92e-05 99.56 Tyrosine
4.192 318 0.232 7.46e-06 3.08e-05 99.67 Unknown
0.982 615 0.150 7.56e-06 3.10e-05 99.22 Leucine, lipid methyl, cholesterol
(ester)
1.272 586 0.208 9.38e-06 3.82e-05 99.22 Lipid methylene
1.532 560 0.145 1.24e-05 5.03e-05 99.22 Lipids (?)
1.442 569 0.178 1.34e-05 5.40e-05 99.22 Lipid methylene
1.652 548 0.200 1.46e-05 5.82e-05 99.22 Lipids (?)
1.112 602 0.138 1.46e-05 5.82e-05 98.68 Unknown
6.852 263 0.121 1.56e-05 6.17e-05 99.41 Unknown
2.262 487 0.326 1.59e-05 6.26e-05 99.22 Lipid (methylene carbonyl)
7.142 234 0.140 1.77e-05 6.88e-05 99.22 Unknown
2.632 450 0.074 1.78e-05 6.88e-05 99.41 Unknown
6.812 267 0.142 1.78e-05 6.88e-05 97.27 Unknown
1.422 571 0.236 1.86e-05 7.15e-05 98.98 Lipid methylene
2.222 491 0.254 1.88e-05 7.18e-05 99.22 Lipid (methylene carbonyl)
4.052 332 0.196 2.14e-05 8.11e-05 97.84 Unknown
1.432 570 0.189 2.21e-05 8.33e-05 98.98 Lipid methylene
4.292 308 0.160 2.29e-05 8.59e-05 98.98 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
1.412 572 0.288 2.34e-05 8.73e-05 98.98 Lipid methylene
7.072 241 0.131 2.38e-05 8.83e-05 98.68 Unknown
7.192 229 0.103 3.39e-05 1.25e-04 99.22 Tyrosine
1.212 592 0.197 3.54e-05 1.30e-04 99.56 Lipid methylene
7.342 214 0.080 3.69e-05 1.34e-04 98.98 Phenylalanine
1.282 585 0.209 3.92e-05 1.42e-04 98.68 Lipid methylene
2.212 492 0.220 4.00e-05 1.44e-04 98.30 Lipid (methylene carbonyl)
1.752 538 0.091 4.12e-05 1.48e-04 98.30 Leucine, lysine
4.282 309 0.126 4.22e-05 1.50e-04 98.68 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
0.942 619 0.223 4.23e-05 1.50e-04 98.30 Cholesterol, lipid methyl
1.742 539 0.085 4.60e-05 1.62e-04 98.30 Leucine, lysine
4.352 302 0.129 5.66e-05 1.99e-04 97.84 Lipid alpha-methylene to car-
boxyl, lipid glycerine
1.032 610 0.152 5.84e-05 2.04e-04 97.84 L-isoleucine, lipid methyl, choles-
terol (ester)
1.402 573 0.339 6.12e-05 2.13e-04 97.84 Lipid methylene
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2.232 490 0.246 6.58e-05 2.27e-04 98.30 Lipid (methylene carbonyl)
1.302 583 0.284 7.16e-05 2.46e-04 97.84 Lipid methylene
1.732 540 0.079 7.24e-05 2.47e-04 97.84 Leucine, lysine
2.012 512 0.136 7.26e-05 2.47e-04 98.30 Lipid allylic
2.852 428 0.210 8.12e-05 2.75e-04 97.84 Lipid diallylic
1.762 537 0.087 8.70e-05 2.93e-04 97.84 Leucine, lysine
2.822 431 0.218 8.83e-05 2.95e-04 97.84 Lipid diallylic
2.622 451 0.059 8.84e-05 2.95e-04 98.68 Unknown
1.612 552 0.309 9.06e-05 3.01e-04 97.84 Lipids (?)
1.642 549 0.216 9.59e-05 3.17e-04 97.27 Lipids (?)
1.542 559 0.169 1.00e-04 3.29e-04 97.27 Lipids (?)
1.622 551 0.282 1.13e-04 3.69e-04 97.27 Lipids (?)
2.422 471 0.116 1.31e-04 4.27e-04 97.84 Glutamine, carnitine
1.392 574 0.344 1.36e-04 4.39e-04 97.27 Lipid methylene
1.602 553 0.310 1.38e-04 4.44e-04 97.27 Lipids (?)
2.412 472 0.123 1.39e-04 4.45e-04 97.27 Glutamine, carnitine
2.242 489 0.250 1.46e-04 4.64e-04 97.27 Lipid (methylene carbonyl), ace-
tone
2.202 493 0.162 1.46e-04 4.64e-04 96.58 Lipid (methylene carbonyl)
1.632 550 0.243 1.51e-04 4.77e-04 96.58 Lipids (?)
7.052 243 0.120 1.53e-04 4.81e-04 95.76 Unknown
0.852 628 0.099 1.56e-04 4.87e-04 96.58 Cholesterol, lipid methyl
2.082 505 0.146 1.61e-04 5.01e-04 97.27 Lipid allylic
0.842 629 0.100 1.63e-04 5.05e-04 96.58 Cholesterol, lipid methyl
1.382 575 0.340 1.80e-04 5.56e-04 96.58 Lipid methylene
1.552 558 0.202 1.90e-04 5.83e-04 96.58 Lipids (?)
2.832 430 0.204 1.91e-04 5.83e-04 96.58 Lipid diallylic
1.312 582 0.282 2.04e-04 6.19e-04 96.58 Lipid methylene
0.932 620 0.242 2.42e-04 7.32e-04 95.76 Cholesterol, lipid methyl
1.292 584 0.218 2.43e-04 7.32e-04 96.58 Lipid methylene
1.332 580 0.305 2.47e-04 7.41e-04 95.76 Lipid methylene
3.982 339 0.078 2.56e-04 7.63e-04 94.78 Unknown
2.842 429 0.207 2.61e-04 7.76e-04 95.76 Lipid diallylic
1.592 554 0.291 2.64e-04 7.81e-04 95.76 Lipids (?)
3.392 385 0.276 2.90e-04 8.54e-04 94.78 Methanol, proline
1.572 556 0.244 2.97e-04 8.71e-04 95.76 Lipids (?)
2.862 427 0.182 3.03e-04 8.83e-04 94.78 Lipid diallylic
1.912 522 0.076 3.04e-04 8.83e-04 96.58 Overlap of multiple minor com-
pounds
1.582 555 0.269 3.08e-04 8.90e-04 95.76 Lipids (?)
1.772 536 0.085 3.11e-04 8.96e-04 95.76 Leucine, lysine
2.022 511 0.140 3.15e-04 9.03e-04 95.76 Lipid allylic
7.362 212 0.090 3.16e-04 9.04e-04 95.76 Phenylalanine
4.092 328 0.155 3.21e-04 9.14e-04 96.58 Unknown
1.562 557 0.222 3.33e-04 9.42e-04 95.76 Lipids (?)
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2.032 510 0.157 3.34e-04 9.42e-04 95.76 Lipid allylic
1.792 534 0.099 3.39e-04 9.52e-04 96.58 Unknown
1.052 608 0.170 3.48e-04 9.73e-04 95.76 Valine
1.322 581 0.282 3.94e-04 1.10e-03 94.78 Lipid methylene
1.042 609 0.162 4.12e-04 1.14e-03 93.62 L-isoleucine, lipid methyl, choles-
terol (ester)
1.372 576 0.320 4.24e-04 1.17e-03 94.78 Lipid methylene
2.872 426 0.140 5.10e-04 1.40e-03 93.62 Lipid diallylic
2.812 432 0.192 5.53e-04 1.52e-03 94.78 Lipid diallylic
2.432 470 0.072 5.70e-04 1.55e-03 93.62 Glutamine, carnitine
4.272 310 0.097 6.44e-04 1.75e-03 92.28 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
7.152 233 0.136 7.78e-04 2.10e-03 93.62 Unknown
2.042 509 0.155 8.56e-04 2.31e-03 92.28 Lipid allylic
0.922 621 0.234 9.22e-04 2.47e-03 90.74 Cholesterol, lipid methyl
6.902 258 0.070 9.39e-04 2.51e-03 92.28 Tyrosine
7.132 235 0.103 1.04e-03 2.77e-03 90.74 Unknown
2.072 506 0.105 1.05e-03 2.77e-03 90.74 Lipid allylic
9.232 25 0.488 1.12e-03 2.95e-03 90.74 Unknown
3.952 342 0.108 1.20e-03 3.14e-03 86.99 Unknown
0.602 653 -0.489 1.44e-03 3.77e-03 88.98 Unkown
3.032 410 0.035 1.64e-03 4.27e-03 84.76 Lysine, unknown
7.122 236 0.079 1.64e-03 4.27e-03 86.99 Unknown
6.932 255 0.103 1.66e-03 4.30e-03 90.74 Tyrosine
6.742 274 -0.213 1.70e-03 4.37e-03 88.98 Unknown
7.352 213 0.065 1.89e-03 4.86e-03 88.98 Phenylalanine
2.792 434 0.137 1.98e-03 5.06e-03 88.98 Lipid diallylic
7.112 237 0.066 2.29e-03 5.84e-03 86.99 Unknown
2.802 433 0.148 2.35e-03 5.97e-03 88.98 Lipid diallylic
1.782 535 0.088 2.47e-03 6.23e-03 88.98 Unknown
2.192 494 0.100 2.66e-03 6.70e-03 84.76 Lipid (methylene carbonyl)
4.362 301 0.104 2.73e-03 6.86e-03 84.76 Unknown
6.802 268 0.103 3.00e-03 7.51e-03 84.76 Unknown
2.962 417 -0.052 3.05e-03 7.60e-03 82.30 Unknown
4.182 319 0.208 3.17e-03 7.86e-03 86.99 Unknown
4.002 337 -0.054 3.36e-03 8.30e-03 76.66 Unknown
1.192 594 0.191 3.42e-03 8.41e-03 90.74 Lipid methylene
0.832 630 0.086 3.50e-03 8.56e-03 84.76 Cholesterol, lipid methyl
1.922 521 0.065 3.50e-03 8.56e-03 84.76 Overlap of multiple minor com-
pounds
4.252 312 0.132 3.93e-03 9.57e-03 82.30 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
2.052 508 0.104 4.15e-03 1.01e-02 82.30 Lipid allylic
4.242 313 0.163 4.16e-03 1.01e-02 82.30 Unknown
9.402 8 -0.456 4.30e-03 1.04e-02 76.66 Unknown
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7.182 230 0.089 4.33e-03 1.04e-02 84.76 Unknown
2.062 507 0.065 4.50e-03 1.08e-02 82.30 Lipid allylic
4.172 320 0.155 4.89e-03 1.17e-02 82.30 Unknown
0.802 633 0.118 5.32e-03 1.26e-02 79.59 Cholesterol, lipid methyl
1.202 593 0.215 5.41e-03 1.28e-02 86.99 Lipid methylene
0.862 627 0.082 5.70e-03 1.34e-02 79.59 Cholesterol, lipid methyl
2.482 465 -0.063 5.71e-03 1.34e-02 76.66 Glutamine, carnitine
2.672 446 0.082 6.08e-03 1.42e-02 86.99 Citric acid
4.062 331 0.124 6.25e-03 1.46e-02 79.59 Creatinine
4.372 300 0.115 6.34e-03 1.47e-02 76.66 Unknown
2.782 435 0.123 6.36e-03 1.47e-02 79.59 Lipid diallylic
7.012 247 0.120 6.44e-03 1.49e-02 76.66 Unknown
1.932 520 0.059 6.56e-03 1.51e-02 79.59 Acetic acid
0.912 622 0.177 6.70e-03 1.54e-02 76.66 Cholesterol, lipid methyl
2.092 504 0.107 7.68e-03 1.75e-02 79.59 Lipid allylic
4.212 316 0.150 7.73e-03 1.76e-02 79.59 Unknown
0.812 632 0.112 7.79e-03 1.77e-02 76.66 Cholesterol, lipid methyl
7.062 242 0.092 7.91e-03 1.79e-02 73.50 Unknown
0.792 634 0.099 8.94e-03 2.01e-02 76.66 Cholesterol, lipid methyl
4.232 314 0.153 9.43e-03 2.11e-02 73.50 Unknown
0.822 631 0.095 9.45e-03 2.11e-02 73.50 Cholesterol, lipid methyl
4.222 315 0.150 9.47e-03 2.11e-02 76.66 Unknown
3.022 411 0.032 9.78e-03 2.17e-02 76.66 Lysine, unknown
4.042 333 0.110 1.05e-02 2.34e-02 73.50 Unknown
2.882 425 0.082 1.11e-02 2.45e-02 70.15 Lipid diallylic
3.012 412 0.037 1.13e-02 2.49e-02 76.66 Lysine, unknown
2.182 495 0.074 1.26e-02 2.75e-02 70.15 Glutamine
3.312 393 0.095 1.26e-02 2.75e-02 66.61 Unknown
2.702 443 0.036 1.33e-02 2.89e-02 73.50 MgEDTA2−
4.262 311 0.090 1.41e-02 3.06e-02 70.15 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
2.902 423 0.055 1.58e-02 3.41e-02 66.61 Unknown
4.202 317 0.125 1.62e-02 3.50e-02 70.15 Unknown
0.772 636 0.078 1.65e-02 3.54e-02 66.61 Cholesterol, lipid methyl
6.862 262 0.078 1.67e-02 3.57e-02 66.61 Unknown
6.672 281 -0.358 1.71e-02 3.66e-02 70.15 Unknown
0.762 637 0.077 1.78e-02 3.78e-02 66.61 Cholesterol, lipid methyl
0.592 654 -0.375 1.92e-02 4.07e-02 66.61 Unkown
6.962 252 0.068 1.93e-02 4.07e-02 62.91 Unknown
6.872 261 0.065 1.96e-02 4.11e-02 66.61 Unknown
7.392 209 0.051 1.96e-02 4.11e-02 66.61 Phenylalanine
2.612 452 0.031 1.99e-02 4.17e-02 70.15 CaEDTA2−
6.892 259 0.049 2.02e-02 4.21e-02 66.61 Unknown
7.172 231 0.105 2.06e-02 4.30e-02 62.91 Unknown
2.742 439 0.056 2.08e-02 4.31e-02 66.61 Lipid diallylic
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0.542 659 0.368 2.11e-02 4.36e-02 62.91 Unkown
8.352 113 0.294 2.32e-02 4.79e-02 66.61 Unknown
Table 7.9: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values both
unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical power in
%, as well as correspondingly identified compounds of NMR features that dis-
criminated patients suffering from diabetic nephropathy from those suffering
from hereditary diseases. A false discovery rate (FDR) below 5% was applied. The
FDR was adjusted according to the method of Benjamini and Hochberg (B/H). In case
that more than one compound contributed to a significant bin, all possible assignments
are given. A question mark denotes ambiguous signal assignments, mostly due to severe
signal overlap. The statistical power was calculated with a significance level of 0.05 and a
specificity of 95%.
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
3.872 350 0.461 1.15e-48 7.56e-46 100.00 D-glucose, unknown
3.842 353 0.507 2.76e-46 9.09e-44 100.00 D-glucose, unknown
3.552 369 0.545 7.68e-46 1.20e-43 100.00 D-glucose, myo-inositol
3.782 359 0.400 8.03e-46 1.20e-43 100.00 D-glucose, alanine, glutamine,
arginine
3.562 368 0.527 9.11e-46 1.20e-43 100.00 D-glucose
3.852 352 0.528 1.11e-45 1.23e-43 100.00 D-glucose, unknown
3.802 357 0.439 2.54e-45 2.39e-43 100.00 D-glucose, alanine
3.912 346 0.498 3.68e-45 3.03e-43 100.00 D-glucose, betaine, unknown
3.932 344 0.510 7.53e-45 5.52e-43 100.00 D-glucose
3.452 379 0.506 1.71e-44 1.13e-42 100.00 D-glucose, carnitine, proline
3.722 365 0.459 3.11e-44 1.86e-42 100.00 D-glucose, N,N-dimethylglycine
3.862 351 0.536 7.97e-44 4.38e-42 100.00 D-glucose, unknown
3.412 383 0.564 1.14e-43 5.80e-42 100.00 D-glucose, carnitine, taurine, pro-
line
3.472 377 0.555 3.87e-43 1.83e-41 100.00 D-glucose
3.442 380 0.553 4.45e-43 1.85e-41 100.00 D-glucose, carnitine, taurine, pro-
line
3.742 363 0.530 4.49e-43 1.85e-41 100.00 D-glucose, leucine
3.882 349 0.483 5.91e-43 2.30e-41 100.00 D-glucose, unknown
3.422 382 0.574 1.86e-42 6.64e-41 100.00 D-glucose, carnitine, taurine, pro-
line
3.482 376 0.561 1.98e-42 6.64e-41 100.00 D-glucose
3.752 362 0.521 2.01e-42 6.64e-41 100.00 D-glucose, glutamic acid
3.512 373 0.573 2.26e-42 7.09e-41 100.00 D-glucose
3.432 381 0.557 3.13e-42 9.40e-41 100.00 D-glucose, carnitine, taurine, pro-
line
3.572 367 0.480 5.33e-42 1.53e-40 100.00 D-glucose, glycine
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3.532 371 0.506 7.28e-42 2.00e-40 100.00 D-glucose
3.732 364 0.498 8.45e-42 2.23e-40 100.00 D-glucose, unknown
3.502 374 0.566 1.18e-41 2.99e-40 100.00 D-glucose
3.762 361 0.485 1.27e-41 3.09e-40 100.00 D-glucose, arginine, glutamine,
glutamic acid
3.492 375 0.548 1.88e-39 4.43e-38 100.00 D-glucose
3.772 360 0.410 1.06e-34 2.42e-33 100.00 D-glucose, alanine, glutamine,
arginine
3.792 358 0.265 1.17e-34 2.58e-33 100.00 D-glucose, alanine
3.402 384 0.384 1.28e-29 2.72e-28 100.00 Unknown
3.542 370 0.414 3.73e-29 7.70e-28 100.00 D-glucose, myo-inositol
3.942 343 0.449 7.85e-29 1.57e-27 100.00 D-glucose
3.812 356 0.341 1.13e-28 2.20e-27 100.00 D-glucose
3.922 345 0.297 9.00e-26 1.70e-24 100.00 D-glucose, unknown
3.832 354 0.230 3.43e-23 6.29e-22 100.00 Unknown
3.962 341 0.167 6.26e-23 1.12e-21 100.00 Unknown
3.522 372 0.424 1.92e-20 3.34e-19 100.00 D-glucose
3.462 378 0.279 3.39e-18 5.73e-17 100.00 D-glucose
3.972 340 0.147 1.64e-17 2.71e-16 100.00 Unknown
3.892 348 0.159 5.27e-16 8.49e-15 100.00 Unknown
3.822 355 0.192 3.82e-13 6.00e-12 100.00 Unknown
2.402 473 0.111 1.37e-10 2.10e-09 100.00 Glutamine, carnitine
3.712 366 0.162 9.83e-10 1.48e-08 99.98 Unknown
4.112 326 0.347 1.42e-09 2.09e-08 100.00 Proline, lactic acid
2.312 482 0.179 3.18e-09 4.56e-08 99.99 Lipid (methylene carbonyl)
1.132 600 0.161 6.87e-09 9.65e-08 99.99 Unknown
2.302 483 0.196 7.11e-09 9.78e-08 99.99 Lipid (methylene carbonyl)
2.352 478 0.125 8.00e-09 1.08e-07 99.99 Proline, glutamic acid
1.702 543 0.114 9.27e-09 1.22e-07 99.99 Unknown, arginine
2.342 479 0.149 1.40e-08 1.82e-07 99.99 Proline, glutamic acid
2.322 481 0.158 2.05e-08 2.60e-07 99.98 Lipid (methylene carbonyl)
1.072 606 0.160 2.34e-08 2.92e-07 99.98 Valine
2.362 477 0.149 2.51e-08 3.07e-07 99.99 Proline, glutamic acid
1.082 605 0.165 4.33e-08 5.19e-07 99.98 Unknown
2.332 480 0.156 4.99e-08 5.89e-07 99.98 Proline, glutamic acid
1.692 544 0.122 5.39e-08 6.18e-07 99.98 Unknown, arginine
1.002 613 0.158 5.43e-08 6.18e-07 99.97 Valine, lipid methyl, cholesterol
(ester)
1.232 590 0.171 5.58e-08 6.24e-07 99.97 Lipid methylene
2.382 475 0.153 9.57e-08 1.05e-06 99.98 Proline, glutamic acid
7.372 211 0.124 1.20e-07 1.30e-06 99.93 Phenylalanine
1.712 542 0.095 1.28e-07 1.36e-06 99.93 Leucine, lysine
1.682 545 0.136 1.48e-07 1.55e-06 99.95 Unknown, arginine
4.122 325 0.217 1.54e-07 1.59e-06 99.95 Proline, lactic acid
2.122 501 0.138 1.94e-07 1.97e-06 99.93 Lipid allylic
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1.222 591 0.203 2.55e-07 2.55e-06 99.98 Lipid methylene
2.292 484 0.206 3.08e-07 3.03e-06 99.90 Lipid (methylene carbonyl)
7.332 215 0.115 3.68e-07 3.57e-06 99.93 Phenylalanine
1.012 612 0.166 3.87e-07 3.70e-06 99.90 Valine, lipid methyl, cholesterol
(ester)
7.322 216 0.123 4.74e-07 4.47e-06 99.93 Unknown
4.092 328 0.209 4.94e-07 4.59e-06 99.95 Unknown
4.302 307 0.188 5.17e-07 4.74e-06 99.95 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
4.192 318 0.251 5.32e-07 4.81e-06 99.97 Unknown
3.982 339 0.103 5.81e-07 5.15e-06 99.86 Unknown
2.372 476 0.144 5.85e-07 5.15e-06 99.93 Proline, glutamic acid
4.312 306 0.169 6.37e-07 5.53e-06 99.93 Lipid alpha-methylene to car-
boxyl, lipid glycerine
4.282 309 0.148 6.69e-07 5.73e-06 99.93 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
1.152 598 0.169 7.16e-07 6.06e-06 99.95 Lipid methylene
1.142 599 0.146 1.04e-06 8.71e-06 99.81 Unknown
4.052 332 0.217 1.07e-06 8.82e-06 99.50 Unknown
1.962 517 0.109 1.15e-06 9.37e-06 99.86 Lipid allylic
1.212 592 0.221 1.52e-06 1.22e-05 99.97 Lipid methylene
7.242 224 0.114 1.74e-06 1.38e-05 99.86 Unknown
2.412 472 0.149 1.76e-06 1.38e-05 99.86 Glutamine, carnitine
7.262 222 0.124 1.79e-06 1.39e-05 99.86 Unknown
1.812 532 0.096 1.84e-06 1.42e-05 99.81 Unknown
7.122 236 0.115 1.89e-06 1.43e-05 99.73 Unknown
7.252 223 0.123 1.95e-06 1.45e-05 99.81 Unknown
7.312 217 0.117 1.95e-06 1.45e-05 99.81 Unknown
7.232 225 0.112 2.03e-06 1.49e-05 99.86 Unknown
4.162 321 0.163 2.17e-06 1.58e-05 99.81 Proline, lactic acid
1.102 603 0.148 2.44e-06 1.75e-05 99.63 Unknown
2.282 485 0.236 2.47e-06 1.75e-05 99.73 Lipid (methylene carbonyl)
7.292 219 0.106 2.56e-06 1.78e-05 99.81 Unknown
1.032 610 0.172 2.56e-06 1.78e-05 99.63 L-isoleucine, lipid methyl, choles-
terol (ester)
1.722 541 0.084 2.69e-06 1.85e-05 99.50 Leucine, lysine
6.842 264 0.125 2.80e-06 1.90e-05 99.81 Unknown
4.292 308 0.170 2.86e-06 1.93e-05 99.81 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
1.972 516 0.120 2.92e-06 1.94e-05 99.73 Lipid allylic
1.092 604 0.148 2.99e-06 1.97e-05 99.63 Unknown
1.122 601 0.164 3.32e-06 2.16e-05 99.73 Unknown
1.672 546 0.144 3.33e-06 2.16e-05 99.63 Unknown, arginine
2.652 448 0.073 3.40e-06 2.18e-05 99.73 Unknown
3.902 347 0.082 3.49e-06 2.21e-05 99.33 D-glucose, unknown
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4.072 330 0.185 3.52e-06 2.21e-05 99.81 Creatinine
6.822 266 0.125 3.68e-06 2.29e-05 99.73 Unknown
7.302 218 0.107 3.93e-06 2.42e-05 99.73 Unknown
2.112 502 0.128 4.16e-06 2.54e-05 99.63 Lipid allylic
4.032 334 0.124 4.31e-06 2.61e-05 99.63 Unknown
4.102 327 0.261 5.55e-06 3.33e-05 99.81 Unknown
1.662 547 0.165 6.00e-06 3.57e-05 99.50 Lipids (?)
7.272 221 0.112 6.13e-06 3.61e-05 99.63 Unknown
6.832 265 0.119 6.62e-06 3.86e-05 99.63 Unknown
1.482 565 0.130 7.17e-06 4.15e-05 99.50 Alanine
4.062 331 0.197 7.63e-06 4.38e-05 99.50 Creatinine
1.872 526 0.085 8.52e-06 4.85e-05 99.12 Overlap of multiple minor com-
pounds
2.102 503 0.107 8.77e-06 4.95e-05 99.33 Lipid allylic
2.422 471 0.130 8.87e-06 4.96e-05 99.63 Glutamine, carnitine
1.062 607 0.143 9.56e-06 5.30e-05 99.12 Valine
2.232 490 0.262 1.06e-05 5.81e-05 99.33 Lipid (methylene carbonyl)
1.892 524 0.081 1.10e-05 6.01e-05 98.84 Overlap of multiple minor com-
pounds
7.012 247 0.188 1.11e-05 6.02e-05 99.12 Unknown
4.152 322 0.153 1.16e-05 6.22e-05 99.33 Proline, lactic acid
7.282 220 0.101 1.19e-05 6.31e-05 99.50 Unknown
1.052 608 0.201 1.30e-05 6.86e-05 99.33 Valine
1.902 523 0.078 1.32e-05 6.89e-05 98.84 Overlap of multiple minor com-
pounds
2.222 491 0.249 1.36e-05 7.06e-05 99.12 Lipid (methylene carbonyl)
0.982 615 0.141 1.39e-05 7.18e-05 98.84 Leucine, lipid methyl, cholesterol
(ester)
1.882 525 0.080 1.44e-05 7.35e-05 98.48 Overlap of multiple minor com-
pounds
7.382 210 0.092 1.45e-05 7.35e-05 98.84 Phenylalanine
6.852 263 0.117 1.56e-05 7.82e-05 99.33 Unknown
1.022 611 0.145 1.57e-05 7.82e-05 98.84 L-isoleucine, lipid methyl, choles-
terol (ester)
1.982 515 0.125 1.59e-05 7.82e-05 99.12 Lipid allylic
2.242 489 0.274 1.59e-05 7.82e-05 99.33 Lipid (methylene carbonyl), ace-
tone
2.252 488 0.246 1.66e-05 8.12e-05 99.50 Lipid (methylene carbonyl), ace-
tone
0.972 616 0.139 1.78e-05 8.58e-05 98.84 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
4.272 310 0.118 1.78e-05 8.58e-05 99.33 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
1.842 529 0.084 1.96e-05 9.38e-05 98.84 Unknown
2.272 486 0.274 1.99e-05 9.39e-05 99.12 Lipid (methylene carbonyl)
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1.162 597 0.183 1.99e-05 9.39e-05 99.86 Lipid methylene
1.172 596 0.171 2.07e-05 9.68e-05 99.81 Lipid methylene
1.862 527 0.084 2.14e-05 9.96e-05 98.84 Unknown
1.242 589 0.148 2.17e-05 1.00e-04 98.84 Lipid methylene
1.462 567 0.142 2.21e-05 1.01e-04 98.84 Lipid methylene
0.992 614 0.141 2.28e-05 1.04e-04 98.48 Leucine, lipid methyl, cholesterol
(ester)
1.452 568 0.160 2.29e-05 1.04e-04 98.84 Lipid methylene
1.472 566 0.133 2.50e-05 1.12e-04 98.84 Lipid methylene
7.142 234 0.132 2.74e-05 1.22e-04 98.84 Unknown
1.182 595 0.142 2.96e-05 1.31e-04 98.04 Lipid methylene
1.442 569 0.164 3.11e-05 1.37e-04 98.48 Lipid methylene
2.132 500 0.083 3.45e-05 1.51e-04 98.48 Glutamine
2.212 492 0.213 3.71e-05 1.61e-04 98.48 Lipid (methylene carbonyl)
1.822 531 0.079 3.73e-05 1.61e-04 99.12 Unknown
1.852 528 0.083 4.04e-05 1.73e-04 98.04 Unknown
1.432 570 0.176 4.11e-05 1.75e-04 98.04 Lipid methylene
1.952 518 0.083 4.20e-05 1.78e-04 98.48 Acetic acid
2.642 449 0.074 4.38e-05 1.84e-04 98.48 Unknown
3.392 385 0.299 4.64e-05 1.94e-04 98.04 Methanol, proline
2.262 487 0.295 5.39e-05 2.24e-04 98.48 Lipid (methylene carbonyl)
7.052 243 0.124 5.52e-05 2.28e-04 97.50 Unknown
1.352 578 0.210 5.92e-05 2.43e-04 98.04 Lipid methylene, lactic acid, thre-
onine
1.832 530 0.074 6.01e-05 2.45e-04 98.04 Unknown
4.342 303 0.117 6.73e-05 2.73e-04 98.84 Lipid alpha-methylene to car-
boxyl, lipid glycerine
7.042 244 0.160 7.12e-05 2.86e-04 96.02 Unknown
0.962 617 0.141 7.17e-05 2.87e-04 97.50 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
7.132 235 0.119 7.94e-05 3.16e-04 97.50 Unknown
1.422 571 0.210 8.19e-05 3.22e-04 97.50 Lipid methylene
8.152 133 0.311 8.20e-05 3.22e-04 98.04 Unknown
4.322 305 0.119 8.79e-05 3.43e-04 98.04 Lipid alpha-methylene to car-
boxyl, lipid glycerine
1.992 514 0.119 8.82e-05 3.43e-04 97.50 Lipid allylic
1.732 540 0.075 8.99e-05 3.47e-04 96.83 Leucine, lysine
1.412 572 0.257 9.57e-05 3.67e-04 97.50 Lipid methylene
2.082 505 0.146 9.81e-05 3.74e-04 97.50 Lipid allylic
1.582 555 0.279 1.03e-04 3.90e-04 98.04 Lipids (?)
1.342 579 0.199 1.12e-04 4.24e-04 97.50 Lipid methylene, lactic acid, thre-
onine
2.202 493 0.158 1.15e-04 4.30e-04 96.83 Lipid (methylene carbonyl)
3.952 342 0.124 1.19e-04 4.43e-04 96.02 Unknown
2.002 513 0.119 1.21e-04 4.48e-04 96.83 Lipid allylic
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1.802 533 0.085 1.30e-04 4.80e-04 98.04 Unknown
4.142 323 0.168 1.35e-04 4.95e-04 96.83 Proline, lactic acid
2.432 470 0.077 1.37e-04 4.98e-04 97.50 Glutamine, carnitine
1.572 556 0.248 1.45e-04 5.27e-04 97.50 Lipids (?)
1.652 548 0.169 1.46e-04 5.27e-04 96.83 Lipids (?)
1.592 554 0.290 1.62e-04 5.83e-04 97.50 Lipids (?)
7.192 229 0.090 1.81e-04 6.45e-04 96.83 Tyrosine
1.742 539 0.074 2.07e-04 7.33e-04 96.02 Leucine, lysine
1.402 573 0.302 2.20e-04 7.75e-04 96.02 Lipid methylene
1.752 538 0.079 2.25e-04 7.89e-04 95.05 Leucine, lysine
1.602 553 0.289 2.35e-04 8.20e-04 96.83 Lipids (?)
4.182 319 0.249 2.49e-04 8.64e-04 98.04 Unknown
3.062 407 0.096 2.55e-04 8.77e-04 93.91 Creatinine
1.382 575 0.321 2.55e-04 8.77e-04 96.02 Lipid methylene
4.132 324 0.173 2.58e-04 8.83e-04 96.02 Proline, lactic acid
7.112 237 0.077 2.66e-04 9.06e-04 95.05 Unknown
2.852 428 0.187 2.72e-04 9.22e-04 96.02 Lipid diallylic
1.502 563 0.112 2.80e-04 9.44e-04 96.02 Alanine
1.612 552 0.275 2.94e-04 9.85e-04 96.02 Lipids (?)
0.952 618 0.151 3.05e-04 1.02e-03 95.05 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
2.012 512 0.118 3.56e-04 1.18e-03 95.05 Lipid allylic
1.392 574 0.310 3.61e-04 1.19e-03 95.05 Lipid methylene
1.762 537 0.076 3.72e-04 1.22e-03 93.91 Leucine, lysine
1.642 549 0.190 3.87e-04 1.27e-03 93.91 Lipids (?)
1.562 557 0.210 4.20e-04 1.37e-03 95.05 Lipids (?)
1.622 551 0.247 4.55e-04 1.47e-03 95.05 Lipids (?)
8.142 134 0.322 4.64e-04 1.49e-03 87.17 Unknown
4.352 302 0.108 4.68e-04 1.50e-03 96.02 Lipid alpha-methylene to car-
boxyl, lipid glycerine
1.292 584 0.200 4.97e-04 1.58e-03 95.05 Lipid methylene
7.342 214 0.065 5.46e-04 1.73e-03 93.91 Phenylalanine
1.632 550 0.213 5.68e-04 1.79e-03 93.91 Lipids (?)
7.022 246 0.207 5.87e-04 1.84e-03 92.56 Unknown
7.062 242 0.114 6.10e-04 1.91e-03 91.00 Unknown
1.362 577 0.192 6.21e-04 1.93e-03 93.91 Lipid methylene, lactic acid, thre-
onine
4.172 320 0.182 6.22e-04 1.93e-03 95.05 Unknown
1.522 561 0.088 6.43e-04 1.98e-03 92.56 Lipids (?)
2.072 506 0.105 6.80e-04 2.08e-03 92.56 Lipid allylic
2.482 465 -0.075 6.80e-04 2.08e-03 89.21 Glutamine, carnitine
1.532 560 0.109 7.04e-04 2.14e-03 92.56 Lipids (?)
1.372 576 0.295 7.40e-04 2.24e-03 92.56 Lipid methylene
1.282 585 0.165 7.57e-04 2.28e-03 92.56 Lipid methylene
1.302 583 0.232 7.74e-04 2.32e-03 93.91 Lipid methylene
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2.022 511 0.126 8.07e-04 2.41e-03 92.56 Lipid allylic
1.552 558 0.174 8.50e-04 2.52e-03 92.56 Lipids (?)
0.942 619 0.175 8.53e-04 2.52e-03 91.00 Cholesterol, lipid methyl
4.332 304 0.098 8.62e-04 2.54e-03 93.91 Lipid alpha-methylene to car-
boxyl, lipid glycerine
2.192 494 0.107 9.17e-04 2.69e-03 91.00 Lipid (methylene carbonyl)
2.032 510 0.139 1.05e-03 3.06e-03 92.56 Lipid allylic
1.312 582 0.239 1.07e-03 3.11e-03 92.56 Lipid methylene
1.772 536 0.074 1.14e-03 3.31e-03 91.00 Leucine, lysine
1.542 559 0.136 1.16e-03 3.33e-03 91.00 Lipids (?)
2.632 450 0.053 1.23e-03 3.53e-03 91.00 Unknown
1.322 581 0.247 1.29e-03 3.69e-03 91.00 Lipid methylene
2.052 508 0.113 1.33e-03 3.79e-03 91.00 Lipid allylic
4.082 329 0.134 1.36e-03 3.84e-03 92.56 Creatinine
1.332 580 0.256 1.45e-03 4.08e-03 91.00 Lipid methylene
6.812 267 0.101 1.46e-03 4.08e-03 93.91 Unknown
1.792 534 0.085 1.46e-03 4.08e-03 92.56 Unknown
2.862 427 0.154 1.50e-03 4.18e-03 89.21 Lipid diallylic
1.252 588 0.123 1.51e-03 4.18e-03 87.17 Lipid methylene
1.912 522 0.064 1.63e-03 4.51e-03 89.21 Overlap of multiple minor com-
pounds
6.862 262 0.099 1.67e-03 4.58e-03 87.17 Unknown
2.622 451 0.046 1.67e-03 4.58e-03 91.00 Unknown
0.842 629 0.080 1.68e-03 4.59e-03 87.17 Cholesterol, lipid methyl
8.402 108 0.407 1.79e-03 4.86e-03 87.17 Unknown
1.492 564 0.093 1.84e-03 4.98e-03 91.00 Alanine
1.112 602 0.095 1.85e-03 4.98e-03 84.88 Unknown
2.042 509 0.138 2.11e-03 5.67e-03 89.21 Lipid allylic
0.832 630 0.087 2.28e-03 6.09e-03 87.17 Cholesterol, lipid methyl
2.062 507 0.067 2.32e-03 6.18e-03 87.17 Lipid allylic
3.032 410 0.032 2.65e-03 7.01e-03 79.53 Lysine, unknown
3.372 387 -0.091 2.65e-03 7.01e-03 79.53 Methanol, proline
1.272 586 0.135 2.73e-03 7.17e-03 84.88 Lipid methylene
7.072 241 0.089 2.76e-03 7.24e-03 84.88 Unknown
0.932 620 0.189 2.95e-03 7.69e-03 84.88 Cholesterol, lipid methyl
2.392 474 0.091 3.11e-03 8.09e-03 84.88 Unknown
7.152 233 0.115 3.21e-03 8.32e-03 84.88 Unknown
8.352 113 0.365 3.46e-03 8.92e-03 89.21 Unknown
7.182 230 0.087 3.78e-03 9.70e-03 82.33 Unknown
2.822 431 0.154 4.08e-03 1.04e-02 82.33 Lipid diallylic
2.832 430 0.151 4.31e-03 1.10e-02 82.33 Lipid diallylic
2.842 429 0.155 4.49e-03 1.14e-02 82.33 Lipid diallylic
6.872 261 0.076 5.01e-03 1.27e-02 82.33 Unknown
2.562 457 0.041 5.12e-03 1.29e-02 87.17 CaEDTA2−
1.782 535 0.078 5.74e-03 1.44e-02 82.33 Unknown
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2.872 426 0.107 5.75e-03 1.44e-02 76.48 Lipid diallylic
8.022 146 0.169 5.84e-03 1.45e-02 76.48 Unknown
8.412 107 0.408 5.85e-03 1.45e-02 76.48 Unknown
6.882 260 0.070 5.97e-03 1.47e-02 79.53 Unknown
3.312 393 0.101 5.98e-03 1.47e-02 76.48 Unknown
1.042 609 0.121 6.07e-03 1.49e-02 76.48 L-isoleucine, lipid methyl, choles-
terol (ester)
1.262 587 0.114 6.89e-03 1.68e-02 76.48 Lipid methylene
2.882 425 0.084 6.97e-03 1.70e-02 73.19 Lipid diallylic
9.342 14 0.416 8.00e-03 1.94e-02 73.19 Unknown
1.202 593 0.197 8.34e-03 2.02e-02 82.33 Lipid methylene
6.732 275 -0.317 9.86e-03 2.37e-02 73.19 Unknown
0.802 633 0.105 1.03e-02 2.46e-02 73.19 Cholesterol, lipid methyl
0.922 621 0.174 1.07e-02 2.55e-02 73.19 Cholesterol, lipid methyl
1.192 594 0.161 1.08e-02 2.57e-02 79.53 Lipid methylene
7.962 152 0.276 1.08e-02 2.57e-02 73.19 Unknown
6.802 268 0.085 1.11e-02 2.63e-02 79.53 Unknown
8.392 109 0.321 1.12e-02 2.64e-02 76.48 Unknown
8.322 116 0.289 1.17e-02 2.75e-02 76.48 Unknown
2.492 464 -0.055 1.19e-02 2.77e-02 69.69 Glutamine
7.972 151 0.275 1.19e-02 2.77e-02 69.69 Unknown
2.092 504 0.097 1.23e-02 2.86e-02 69.69 Lipid allylic
8.582 90 -0.356 1.27e-02 2.95e-02 66.00 Unknown
7.352 213 0.050 1.32e-02 3.05e-02 69.69 Phenylalanine
1.512 562 0.078 1.39e-02 3.19e-02 73.19 Alanine
2.812 432 0.132 1.40e-02 3.22e-02 69.69 Lipid diallylic
3.012 412 0.034 1.41e-02 3.23e-02 69.69 Lysine, unknown
7.422 206 0.111 1.42e-02 3.23e-02 69.69 Phenylalanine
4.372 300 0.099 1.43e-02 3.25e-02 73.19 Unknown
0.822 631 0.086 1.51e-02 3.42e-02 66.00 Cholesterol, lipid methyl
0.812 632 0.098 1.65e-02 3.71e-02 66.00 Cholesterol, lipid methyl
2.182 495 0.068 1.67e-02 3.74e-02 66.00 Glutamine
8.202 128 0.145 1.75e-02 3.92e-02 66.00 Unknown
1.922 521 0.051 1.76e-02 3.92e-02 66.00 Overlap of multiple minor com-
pounds
8.592 89 -0.434 1.79e-02 3.97e-02 37.86 Unknown
7.362 212 0.057 1.79e-02 3.97e-02 66.00 Phenylalanine
8.172 131 0.167 1.80e-02 3.98e-02 62.14 Unknown
9.452 3 0.359 1.83e-02 4.02e-02 69.69 Unknown
8.262 122 0.089 1.90e-02 4.16e-02 62.14 Unknown
0.792 634 0.086 1.92e-02 4.20e-02 66.00 Cholesterol, lipid methyl
4.252 312 0.103 1.97e-02 4.29e-02 66.00 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
8.002 148 0.221 2.13e-02 4.63e-02 58.17 Unknown
6.892 259 0.047 2.18e-02 4.71e-02 66.00 Unknown
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7.902 158 0.111 2.21e-02 4.76e-02 62.14 Unknown
4.262 311 0.081 2.22e-02 4.78e-02 66.00 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
7.612 187 0.087 2.24e-02 4.81e-02 54.10 Unknown
3.022 411 0.028 2.27e-02 4.84e-02 62.14 Lysine, unknown
2.802 433 0.106 2.32e-02 4.94e-02 66.00 Lipid diallylic
Table 7.10: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values both
unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical power in
%, as well as correspondingly identified compounds of NMR features that dis-
criminated patients suffering from diabetic nephropathy from those suffering
from interstitial nephropathy. A false discovery rate (FDR) below 5% was applied.
The FDR was adjusted according to the method of Benjamini and Hochberg (B/H). In
case that more than one compound contributed to a significant bin, all possible assign-
ments are given. A question mark denotes ambiguous signal assignments, mostly due to
severe signal overlap. The statistical power was calculated with a significance level of 0.05
and a specificity of 95%.
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
3.782 359 0.446 9.04e-76 5.97e-73 100.00 D-glucose, alanine, glutamine,
arginine
3.562 368 0.586 3.09e-75 8.09e-73 100.00 D-glucose
3.552 369 0.605 3.68e-75 8.09e-73 100.00 D-glucose, myo-inositol
3.802 357 0.488 1.18e-74 1.95e-72 100.00 D-glucose, alanine
3.842 353 0.557 1.81e-74 2.38e-72 100.00 D-glucose, unknown
3.852 352 0.581 1.08e-73 1.19e-71 100.00 D-glucose, unknown
3.872 350 0.487 7.48e-73 7.06e-71 100.00 D-glucose, unknown
3.752 362 0.590 4.41e-72 3.64e-70 100.00 D-glucose, glutamic acid
3.452 379 0.556 1.31e-71 9.64e-70 100.00 D-glucose, carnitine, proline
3.572 367 0.540 1.34e-70 8.85e-69 100.00 D-glucose, glycine
3.912 346 0.537 2.21e-70 1.30e-68 100.00 D-glucose, betaine, unknown
3.862 351 0.589 2.36e-70 1.30e-68 100.00 D-glucose, unknown
3.742 363 0.587 2.75e-70 1.39e-68 100.00 D-glucose, leucine
3.442 380 0.612 4.05e-70 1.91e-68 100.00 D-glucose, carnitine, taurine, pro-
line
3.932 344 0.551 4.90e-70 2.16e-68 100.00 D-glucose
3.472 377 0.612 5.73e-70 2.36e-68 100.00 D-glucose
3.422 382 0.637 1.39e-69 5.40e-68 100.00 D-glucose, carnitine, taurine, pro-
line
3.512 373 0.635 2.21e-69 8.09e-68 100.00 D-glucose
3.482 376 0.621 3.12e-69 1.09e-67 100.00 D-glucose
3.412 383 0.615 3.70e-69 1.22e-67 100.00 D-glucose, carnitine, taurine, pro-
line
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3.432 381 0.617 4.37e-69 1.37e-67 100.00 D-glucose, carnitine, taurine, pro-
line
3.722 365 0.496 5.92e-69 1.78e-67 100.00 D-glucose, N,N-dimethylglycine
3.882 349 0.529 1.11e-68 3.20e-67 100.00 D-glucose, unknown
3.502 374 0.629 2.45e-68 6.73e-67 100.00 D-glucose
3.762 361 0.532 7.53e-67 1.99e-65 100.00 D-glucose, arginine, glutamine,
glutamic acid
3.732 364 0.540 1.27e-65 3.22e-64 100.00 D-glucose, unknown
3.772 360 0.490 4.07e-65 9.96e-64 100.00 D-glucose, alanine, glutamine,
arginine
3.492 375 0.606 2.01e-64 4.75e-63 100.00 D-glucose
3.532 371 0.538 2.15e-63 4.89e-62 100.00 D-glucose
3.792 358 0.310 1.13e-62 2.48e-61 100.00 D-glucose, alanine
3.542 370 0.482 2.78e-52 5.91e-51 100.00 D-glucose, myo-inositol
3.812 356 0.398 1.51e-51 3.11e-50 100.00 D-glucose
3.522 372 0.553 4.07e-45 8.14e-44 100.00 D-glucose
3.942 343 0.486 4.30e-45 8.34e-44 100.00 D-glucose
3.832 354 0.255 4.51e-38 8.50e-37 100.00 Unknown
3.402 384 0.364 1.82e-36 3.34e-35 100.00 Unknown
3.922 345 0.300 1.87e-35 3.34e-34 100.00 D-glucose, unknown
3.822 355 0.245 1.92e-27 3.33e-26 100.00 Unknown
3.962 341 0.155 5.55e-27 9.39e-26 100.00 Unknown
3.462 378 0.282 4.50e-25 7.43e-24 100.00 D-glucose
3.972 340 0.138 3.68e-21 5.93e-20 100.00 Unknown
1.902 523 0.142 1.32e-20 2.07e-19 100.00 Overlap of multiple minor com-
pounds
1.082 605 0.232 1.86e-19 2.85e-18 100.00 Unknown
1.072 606 0.220 1.94e-19 2.91e-18 100.00 Valine
1.002 613 0.215 3.50e-18 5.13e-17 100.00 Valine, lipid methyl, cholesterol
(ester)
1.892 524 0.132 2.56e-17 3.68e-16 100.00 Overlap of multiple minor com-
pounds
3.892 348 0.138 9.75e-17 1.37e-15 100.00 Unknown
1.012 612 0.229 2.34e-16 3.21e-15 100.00 Valine, lipid methyl, cholesterol
(ester)
1.092 604 0.221 2.43e-16 3.27e-15 100.00 Unknown
1.882 525 0.127 4.85e-16 6.41e-15 100.00 Overlap of multiple minor com-
pounds
1.102 603 0.212 2.31e-15 3.00e-14 100.00 Unknown
2.362 477 0.178 5.31e-15 6.74e-14 100.00 Proline, glutamic acid
2.382 475 0.189 9.36e-15 1.17e-13 100.00 Proline, glutamic acid
1.132 600 0.182 1.23e-14 1.50e-13 100.00 Unknown
1.912 522 0.133 1.78e-14 2.14e-13 100.00 Overlap of multiple minor com-
pounds
2.372 476 0.186 2.56e-14 3.01e-13 100.00 Proline, glutamic acid
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3.062 407 0.171 2.72e-14 3.15e-13 100.00 Creatinine
1.232 590 0.203 3.13e-14 3.56e-13 100.00 Lipid methylene
1.702 543 0.126 5.81e-14 6.50e-13 100.00 Unknown, arginine
4.032 334 0.172 8.66e-14 9.52e-13 100.00 Unknown
1.062 607 0.204 1.24e-13 1.34e-12 100.00 Valine
2.312 482 0.189 2.09e-13 2.22e-12 100.00 Lipid (methylene carbonyl)
4.092 328 0.257 3.43e-13 3.59e-12 100.00 Unknown
2.302 483 0.208 4.68e-13 4.83e-12 100.00 Lipid (methylene carbonyl)
2.352 478 0.132 5.97e-13 6.06e-12 100.00 Proline, glutamic acid
1.242 589 0.209 1.74e-12 1.74e-11 100.00 Lipid methylene
1.052 608 0.274 2.41e-12 2.37e-11 100.00 Valine
1.682 545 0.154 2.91e-12 2.83e-11 100.00 Unknown, arginine
1.692 544 0.133 3.07e-12 2.94e-11 100.00 Unknown, arginine
7.372 211 0.138 3.66e-12 3.45e-11 100.00 Phenylalanine
1.722 541 0.105 3.72e-12 3.46e-11 100.00 Leucine, lysine
6.832 265 0.156 4.40e-12 4.04e-11 100.00 Unknown
4.072 330 0.235 4.77e-12 4.32e-11 100.00 Creatinine
1.922 521 0.126 4.98e-12 4.45e-11 100.00 Overlap of multiple minor com-
pounds
1.022 611 0.196 6.33e-12 5.57e-11 100.00 L-isoleucine, lipid methyl, choles-
terol (ester)
1.742 539 0.117 7.84e-12 6.81e-11 100.00 Leucine, lysine
1.032 610 0.212 8.00e-12 6.86e-11 100.00 L-isoleucine, lipid methyl, choles-
terol (ester)
1.732 540 0.111 8.90e-12 7.47e-11 100.00 Leucine, lysine
1.482 565 0.167 8.94e-12 7.47e-11 100.00 Alanine
6.842 264 0.155 9.58e-12 7.91e-11 100.00 Unknown
2.122 501 0.154 1.02e-11 8.28e-11 100.00 Lipid allylic
1.752 538 0.122 1.95e-11 1.57e-10 100.00 Leucine, lysine
1.932 520 0.119 2.02e-11 1.60e-10 100.00 Acetic acid
2.292 484 0.227 2.67e-11 2.10e-10 100.00 Lipid (methylene carbonyl)
0.982 615 0.184 2.78e-11 2.16e-10 100.00 Leucine, lipid methyl, cholesterol
(ester)
1.712 542 0.101 3.33e-11 2.55e-10 100.00 Leucine, lysine
3.712 366 0.149 3.36e-11 2.55e-10 100.00 Unknown
1.142 599 0.168 4.10e-11 3.07e-10 100.00 Unknown
1.502 563 0.174 4.23e-11 3.13e-10 100.00 Alanine
1.872 526 0.107 5.59e-11 4.10e-10 100.00 Overlap of multiple minor com-
pounds
2.322 481 0.155 7.94e-11 5.76e-10 100.00 Lipid (methylene carbonyl)
0.992 614 0.183 1.06e-10 7.64e-10 100.00 Leucine, lipid methyl, cholesterol
(ester)
4.052 332 0.243 1.28e-10 9.05e-10 100.00 Unknown
1.122 601 0.193 1.29e-10 9.05e-10 100.00 Unknown
4.112 326 0.309 2.25e-10 1.56e-09 100.00 Proline, lactic acid
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0.972 616 0.174 2.36e-10 1.62e-09 100.00 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.162 597 0.231 2.61e-10 1.77e-09 100.00 Lipid methylene
1.152 598 0.182 3.20e-10 2.16e-09 100.00 Lipid methylene
1.172 596 0.213 4.18e-10 2.79e-09 100.00 Lipid methylene
6.822 266 0.142 4.60e-10 3.04e-09 100.00 Unknown
1.492 564 0.153 1.66e-09 1.08e-08 100.00 Alanine
1.972 516 0.131 1.73e-09 1.12e-08 100.00 Lipid allylic
2.282 485 0.256 1.78e-09 1.14e-08 100.00 Lipid (methylene carbonyl)
1.472 566 0.160 1.86e-09 1.18e-08 100.00 Lipid methylene
7.382 210 0.107 2.30e-09 1.45e-08 100.00 Phenylalanine
1.982 515 0.146 2.53e-09 1.58e-08 100.00 Lipid allylic
2.652 448 0.080 2.56e-09 1.58e-08 100.00 Unknown
7.192 229 0.121 2.88e-09 1.76e-08 100.00 Tyrosine
4.102 327 0.289 3.13e-09 1.89e-08 100.00 Unknown
1.182 595 0.171 3.16e-09 1.90e-08 99.99 Lipid methylene
7.252 223 0.128 6.59e-09 3.92e-08 99.99 Unknown
4.162 321 0.169 7.88e-09 4.64e-08 99.99 Proline, lactic acid
7.322 216 0.119 8.49e-09 4.96e-08 100.00 Unknown
7.262 222 0.127 8.61e-09 4.98e-08 99.99 Unknown
1.222 591 0.192 8.88e-09 5.09e-08 100.00 Lipid methylene
7.332 215 0.110 9.73e-09 5.53e-08 99.99 Phenylalanine
0.962 617 0.172 1.19e-08 6.69e-08 99.99 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
3.372 387 -0.146 1.22e-08 6.84e-08 99.97 Methanol, proline
1.462 567 0.162 1.34e-08 7.45e-08 99.99 Lipid methylene
7.232 225 0.113 1.59e-08 8.73e-08 99.99 Unknown
2.132 500 0.096 1.66e-08 9.06e-08 99.99 Glutamine
1.962 517 0.107 1.70e-08 9.21e-08 99.99 Lipid allylic
4.312 306 0.161 1.97e-08 1.06e-07 99.99 Lipid alpha-methylene to car-
boxyl, lipid glycerine
7.182 230 0.143 2.17e-08 1.15e-07 99.99 Unknown
2.402 473 0.082 2.17e-08 1.15e-07 99.97 Glutamine, carnitine
1.452 568 0.179 2.67e-08 1.40e-07 99.99 Lipid methylene
7.272 221 0.117 2.76e-08 1.43e-07 99.99 Unknown
1.992 514 0.143 3.10e-08 1.60e-07 99.99 Lipid allylic
2.342 479 0.123 3.49e-08 1.79e-07 99.98 Proline, glutamic acid
2.112 502 0.129 4.04e-08 2.05e-07 99.98 Lipid allylic
1.252 588 0.180 4.87e-08 2.45e-07 99.97 Lipid methylene
2.332 480 0.132 5.30e-08 2.65e-07 99.97 Proline, glutamic acid
2.552 458 0.102 5.69e-08 2.82e-07 100.00 Citric acid
2.212 492 0.235 8.53e-08 4.19e-07 99.97 Lipid (methylene carbonyl)
7.282 220 0.104 8.58e-08 4.19e-07 99.98 Unknown
2.202 493 0.186 8.90e-08 4.32e-07 99.95 Lipid (methylene carbonyl)
7.242 224 0.108 9.84e-08 4.74e-07 99.97 Unknown
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7.312 217 0.111 1.10e-07 5.25e-07 99.98 Unknown
1.672 546 0.140 1.11e-07 5.25e-07 99.97 Unknown, arginine
2.252 488 0.256 1.35e-07 6.37e-07 99.95 Lipid (methylene carbonyl), ace-
tone
7.292 219 0.101 1.36e-07 6.37e-07 99.97 Unknown
2.392 474 0.137 1.54e-07 7.17e-07 99.92 Unknown
1.952 518 0.090 1.61e-07 7.44e-07 99.97 Acetic acid
1.762 537 0.095 1.86e-07 8.50e-07 99.95 Leucine, lysine
7.302 218 0.103 1.91e-07 8.71e-07 99.97 Unknown
1.442 569 0.174 2.04e-07 9.21e-07 99.95 Lipid methylene
2.002 513 0.135 3.15e-07 1.42e-06 99.92 Lipid allylic
2.222 491 0.247 3.56e-07 1.59e-06 99.92 Lipid (methylene carbonyl)
0.842 629 0.109 4.67e-07 2.07e-06 99.82 Cholesterol, lipid methyl
1.432 570 0.183 4.87e-07 2.14e-06 99.88 Lipid methylene
0.952 618 0.177 5.76e-07 2.52e-06 99.88 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
7.342 214 0.079 5.82e-07 2.53e-06 99.82 Phenylalanine
1.522 561 0.109 5.96e-07 2.57e-06 99.92 Lipids (?)
7.032 245 0.188 6.08e-07 2.60e-06 99.82 Unknown
2.102 503 0.102 6.10e-07 2.60e-06 99.88 Lipid allylic
2.672 446 0.122 6.34e-07 2.68e-06 99.98 Citric acid
1.422 571 0.225 6.48e-07 2.73e-06 99.88 Lipid methylene
4.152 322 0.147 7.13e-07 2.98e-06 99.73 Proline, lactic acid
4.122 325 0.174 7.39e-07 3.07e-06 99.73 Proline, lactic acid
2.872 426 0.163 7.53e-07 3.11e-06 99.88 Lipid diallylic
1.412 572 0.276 7.64e-07 3.13e-06 99.88 Lipid methylene
1.212 592 0.192 7.89e-07 3.21e-06 99.98 Lipid methylene
2.272 486 0.268 8.73e-07 3.53e-06 99.88 Lipid (methylene carbonyl)
4.322 305 0.125 1.08e-06 4.35e-06 99.82 Lipid alpha-methylene to car-
boxyl, lipid glycerine
1.662 547 0.149 1.32e-06 5.27e-06 99.82 Lipids (?)
1.042 609 0.180 1.68e-06 6.66e-06 99.73 L-isoleucine, lipid methyl, choles-
terol (ester)
6.812 267 0.129 1.75e-06 6.92e-06 99.92 Unknown
2.192 494 0.130 1.95e-06 7.67e-06 99.62 Lipid (methylene carbonyl)
7.142 234 0.126 2.10e-06 8.19e-06 99.82 Unknown
1.862 527 0.080 2.11e-06 8.19e-06 99.73 Unknown
4.302 307 0.150 2.34e-06 9.04e-06 99.82 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
1.402 573 0.323 3.05e-06 1.17e-05 99.73 Lipid methylene
6.852 263 0.106 3.81e-06 1.45e-05 99.62 Unknown
3.952 342 0.126 3.92e-06 1.49e-05 99.23 Unknown
1.512 562 0.124 4.66e-06 1.76e-05 99.45 Alanine
2.232 490 0.231 4.69e-06 1.76e-05 99.62 Lipid (methylene carbonyl)
7.052 243 0.119 4.74e-06 1.77e-05 98.93 Unknown
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0.942 619 0.204 4.90e-06 1.82e-05 99.62 Cholesterol, lipid methyl
1.542 559 0.160 6.04e-06 2.23e-05 99.62 Lipids (?)
7.102 238 0.168 6.55e-06 2.40e-05 99.62 Unknown
7.132 235 0.115 7.65e-06 2.79e-05 99.45 Unknown
2.642 449 0.069 7.98e-06 2.89e-05 99.45 Unknown
2.852 428 0.194 8.25e-06 2.97e-05 99.45 Lipid diallylic
4.192 318 0.188 8.92e-06 3.20e-05 99.73 Unknown
4.342 303 0.110 1.00e-05 3.57e-05 99.45 Lipid alpha-methylene to car-
boxyl, lipid glycerine
7.352 213 0.075 1.24e-05 4.40e-05 98.53 Phenylalanine
1.532 560 0.119 1.25e-05 4.40e-05 99.23 Lipids (?)
1.552 558 0.193 1.28e-05 4.48e-05 99.23 Lipids (?)
4.042 333 0.152 1.52e-05 5.32e-05 99.23 Unknown
1.392 574 0.318 1.65e-05 5.73e-05 99.23 Lipid methylene
1.562 557 0.216 1.96e-05 6.75e-05 99.23 Lipids (?)
2.242 489 0.230 1.96e-05 6.75e-05 98.93 Lipid (methylene carbonyl), ace-
tone
4.082 329 0.151 2.09e-05 7.16e-05 99.23 Creatinine
2.082 505 0.135 2.14e-05 7.27e-05 98.93 Lipid allylic
1.352 578 0.188 2.16e-05 7.32e-05 98.93 Lipid methylene, lactic acid, thre-
onine
6.802 268 0.120 2.35e-05 7.91e-05 99.23 Unknown
2.262 487 0.261 2.36e-05 7.91e-05 98.93 Lipid (methylene carbonyl)
7.202 228 0.111 2.47e-05 8.25e-05 98.93 Tyrosine
3.992 338 -0.073 2.59e-05 8.59e-05 98.01 Unknown
2.862 427 0.173 2.64e-05 8.73e-05 98.93 Lipid diallylic
2.572 456 0.068 3.41e-05 1.12e-04 99.92 CaEDTA2−, citric acid
1.262 587 0.147 3.92e-05 1.28e-04 98.01 Lipid methylene
1.852 528 0.070 3.99e-05 1.30e-04 98.01 Unknown
1.382 575 0.305 4.10e-05 1.33e-04 98.53 Lipid methylene
7.172 231 0.153 4.25e-05 1.37e-04 98.53 Unknown
4.332 304 0.101 4.68e-05 1.50e-04 98.53 Lipid alpha-methylene to car-
boxyl, lipid glycerine
1.572 556 0.225 4.75e-05 1.51e-04 98.53 Lipids (?)
3.032 410 0.037 4.76e-05 1.51e-04 96.51 Lysine, unknown
7.152 233 0.134 4.91e-05 1.55e-04 98.53 Unknown
2.492 464 -0.076 5.14e-05 1.62e-04 97.35 Glutamine
2.012 512 0.113 5.92e-05 1.85e-04 98.01 Lipid allylic
1.342 579 0.175 5.94e-05 1.85e-04 98.01 Lipid methylene, lactic acid, thre-
onine
1.652 548 0.149 7.93e-05 2.46e-04 97.35 Lipids (?)
2.422 471 0.097 8.89e-05 2.74e-04 98.01 Glutamine, carnitine
2.842 429 0.181 9.67e-05 2.97e-04 97.35 Lipid diallylic
4.282 309 0.098 1.01e-04 3.09e-04 97.35 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
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0.852 628 0.083 1.06e-04 3.22e-04 96.51 Cholesterol, lipid methyl
0.932 620 0.208 1.11e-04 3.36e-04 97.35 Cholesterol, lipid methyl
1.622 551 0.230 1.18e-04 3.55e-04 97.35 Lipids (?)
4.142 323 0.143 1.31e-04 3.94e-04 95.46 Proline, lactic acid
1.612 552 0.246 1.33e-04 3.96e-04 97.35 Lipids (?)
1.842 529 0.064 1.37e-04 4.06e-04 96.51 Unknown
1.582 555 0.232 1.41e-04 4.16e-04 97.35 Lipids (?)
4.062 331 0.142 1.41e-04 4.16e-04 97.35 Creatinine
3.392 385 0.236 1.45e-04 4.26e-04 95.46 Methanol, proline
2.832 430 0.169 1.56e-04 4.56e-04 97.35 Lipid diallylic
1.272 586 0.145 1.60e-04 4.66e-04 96.51 Lipid methylene
7.122 236 0.077 1.68e-04 4.85e-04 96.51 Unknown
1.632 550 0.197 1.68e-04 4.85e-04 96.51 Lipids (?)
8.152 133 0.250 1.83e-04 5.25e-04 98.01 Unknown
1.642 549 0.169 1.88e-04 5.38e-04 96.51 Lipids (?)
4.292 308 0.115 1.98e-04 5.64e-04 96.51 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
2.482 465 -0.069 2.07e-04 5.86e-04 92.62 Glutamine, carnitine
1.602 553 0.246 2.11e-04 5.95e-04 96.51 Lipids (?)
2.822 431 0.167 2.31e-04 6.49e-04 96.51 Lipid diallylic
4.272 310 0.085 2.53e-04 7.08e-04 95.46 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
7.862 162 0.149 2.67e-04 7.43e-04 94.18 Unknown
7.722 176 -0.180 2.70e-04 7.49e-04 94.18 Unknown
7.432 205 0.085 2.72e-04 7.52e-04 95.46 Phenylalanine
1.372 576 0.269 2.83e-04 7.79e-04 95.46 Lipid methylene
3.052 408 0.046 2.92e-04 7.97e-04 94.18 Creatinine
1.592 554 0.236 2.92e-04 7.97e-04 95.46 Lipids (?)
7.392 209 0.065 3.01e-04 8.17e-04 94.18 Phenylalanine
1.362 577 0.172 3.11e-04 8.41e-04 95.46 Lipid methylene, lactic acid, thre-
onine
2.882 425 0.095 3.18e-04 8.56e-04 94.18 Lipid diallylic
2.412 472 0.095 3.23e-04 8.66e-04 95.46 Glutamine, carnitine
0.832 630 0.086 3.62e-04 9.66e-04 94.18 Cholesterol, lipid methyl
1.112 602 0.092 3.89e-04 1.03e-03 94.18 Unknown
4.172 320 0.157 4.67e-04 1.24e-03 95.46 Unknown
8.122 136 0.180 4.85e-04 1.28e-03 92.62 Unknown
6.862 262 0.093 4.98e-04 1.31e-03 92.62 Unknown
3.982 339 0.060 5.59e-04 1.46e-03 92.62 Unknown
6.792 269 0.102 5.79e-04 1.51e-03 94.18 Unknown
1.282 585 0.143 5.87e-04 1.52e-03 94.18 Lipid methylene
3.312 393 0.107 6.02e-04 1.56e-03 90.76 Unknown
3.362 388 0.084 6.15e-04 1.59e-03 90.76 Proline
0.742 639 0.156 6.51e-04 1.67e-03 92.62 Unkown
2.092 504 0.112 6.85e-04 1.75e-03 92.62 Lipid allylic
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2.432 470 0.058 8.22e-04 2.09e-03 90.76 Glutamine, carnitine
2.902 423 0.062 8.46e-04 2.15e-03 90.76 Unknown
2.702 443 0.040 8.61e-04 2.18e-03 90.76 MgEDTA2−
1.332 580 0.226 8.96e-04 2.26e-03 92.62 Lipid methylene
4.132 324 0.133 8.99e-04 2.26e-03 88.58 Proline, lactic acid
2.662 447 0.098 9.36e-04 2.34e-03 92.62 Citric acid
2.452 468 0.084 9.39e-04 2.34e-03 88.58 Glutamine, carnitine
2.692 444 0.053 9.68e-04 2.40e-03 98.93 Citric acid
2.542 459 0.065 1.00e-03 2.48e-03 92.62 Unknown
7.672 181 0.229 1.12e-03 2.76e-03 88.58 Unknown
2.022 511 0.103 1.19e-03 2.92e-03 90.76 Lipid allylic
3.072 406 0.034 1.21e-03 2.96e-03 86.06 Unknown
3.342 390 0.124 1.24e-03 3.01e-03 90.76 Proline
7.062 242 0.091 1.30e-03 3.14e-03 86.06 Unknown
7.362 212 0.066 1.38e-03 3.34e-03 88.58 Phenylalanine
8.172 131 0.192 1.42e-03 3.41e-03 86.06 Unknown
8.102 138 0.207 1.42e-03 3.41e-03 86.06 Trigonelline
4.352 302 0.083 1.50e-03 3.59e-03 90.76 Lipid alpha-methylene to car-
boxyl, lipid glycerine
1.322 581 0.205 1.62e-03 3.87e-03 90.76 Lipid methylene
1.812 532 0.054 1.63e-03 3.87e-03 88.58 Unknown
1.312 582 0.195 1.70e-03 4.02e-03 88.58 Lipid methylene
2.632 450 0.044 1.81e-03 4.26e-03 88.58 Unknown
7.112 237 0.055 1.83e-03 4.31e-03 86.06 Unknown
1.302 583 0.180 2.04e-03 4.78e-03 88.58 Lipid methylene
2.032 510 0.110 2.10e-03 4.91e-03 88.58 Lipid allylic
6.542 294 0.388 2.29e-03 5.32e-03 86.06 Unknown
1.942 519 0.107 2.44e-03 5.64e-03 94.18 Acetic acid
4.002 337 -0.046 2.48e-03 5.72e-03 86.06 Unknown
0.752 638 0.102 2.59e-03 5.95e-03 83.18 Cholesterol, lipid methyl
1.822 531 0.049 2.81e-03 6.43e-03 86.06 Unknown
1.192 594 0.159 2.90e-03 6.61e-03 90.76 Lipid methylene
7.752 173 0.080 3.00e-03 6.84e-03 86.06 Unknown
6.982 250 0.120 3.14e-03 7.12e-03 83.18 Unknown
7.992 149 0.234 3.16e-03 7.14e-03 83.18 Unknown
1.292 584 0.143 3.19e-03 7.18e-03 86.06 Lipid methylene
7.832 165 -0.199 3.31e-03 7.44e-03 83.18 Unknown
4.182 319 0.166 3.83e-03 8.57e-03 86.06 Unknown
0.812 632 0.098 4.45e-03 9.91e-03 79.94 Cholesterol, lipid methyl
2.072 506 0.074 4.73e-03 1.05e-02 79.94 Lipid allylic
7.692 179 0.148 4.85e-03 1.07e-02 79.94 Unknown
3.172 396 0.054 4.86e-03 1.07e-02 86.06 CaEDTA2−
0.822 631 0.084 4.87e-03 1.07e-02 79.94 Cholesterol, lipid methyl
9.382 10 0.363 4.93e-03 1.08e-02 76.35 Unknown
2.042 509 0.107 5.07e-03 1.11e-02 79.94 Lipid allylic
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3.902 347 0.042 5.25e-03 1.14e-02 76.35 D-glucose, unknown
0.732 640 0.174 5.29e-03 1.15e-02 83.18 Unkown
2.142 499 0.044 5.53e-03 1.20e-02 76.35 Glutamine
8.112 137 0.194 5.57e-03 1.20e-02 76.35 Trigonelline
0.802 633 0.096 5.58e-03 1.20e-02 79.94 Cholesterol, lipid methyl
7.072 241 0.070 5.69e-03 1.22e-02 76.35 Unknown
2.812 432 0.125 5.96e-03 1.27e-02 79.94 Lipid diallylic
6.902 258 0.048 6.02e-03 1.28e-02 76.35 Tyrosine
8.092 139 0.169 6.07e-03 1.29e-02 76.35 Trigonelline
2.622 451 0.034 6.17e-03 1.31e-02 79.94 Unknown
2.562 457 0.034 6.25e-03 1.32e-02 86.06 CaEDTA2−
8.352 113 0.287 6.64e-03 1.40e-02 86.06 Unknown
6.892 259 0.046 7.26e-03 1.52e-02 76.35 Unknown
0.922 621 0.154 7.40e-03 1.55e-02 76.35 Cholesterol, lipid methyl
3.152 398 0.026 8.58e-03 1.79e-02 86.06 CaEDTA2−
7.442 204 0.055 9.02e-03 1.87e-02 68.24 Phenylalanine
8.652 83 -0.349 9.22e-03 1.91e-02 72.44 Unknown
8.162 132 0.186 9.47e-03 1.95e-02 68.24 Unknown
0.792 634 0.080 9.54e-03 1.96e-02 76.35 Cholesterol, lipid methyl
7.222 226 0.060 9.63e-03 1.97e-02 72.44 Tyrosine
1.202 593 0.163 9.68e-03 1.98e-02 79.94 Lipid methylene
1.772 536 0.049 1.00e-02 2.04e-02 72.44 Leucine, lysine
9.142 34 0.407 1.04e-02 2.10e-02 68.24 Trigonelline
6.922 256 0.068 1.09e-02 2.20e-02 72.44 Tyrosine
8.012 147 0.175 1.14e-02 2.30e-02 72.44 Unknown
2.182 495 0.061 1.16e-02 2.33e-02 68.24 Glutamine
8.042 144 0.248 1.36e-02 2.73e-02 72.44 Unknown
2.802 433 0.098 1.37e-02 2.75e-02 72.44 Lipid diallylic
8.982 50 -0.313 1.50e-02 2.99e-02 63.78 Unknown
2.712 442 0.031 1.55e-02 3.08e-02 68.24 MgEDTA2−
0.762 637 0.064 1.56e-02 3.08e-02 68.24 Cholesterol, lipid methyl
7.402 208 0.046 1.60e-02 3.17e-02 63.78 Phenylalanine
2.052 508 0.071 1.67e-02 3.28e-02 68.24 Lipid allylic
8.182 130 0.159 1.75e-02 3.43e-02 59.13 Unknown
8.132 135 0.167 1.76e-02 3.44e-02 68.24 Unknown
6.962 252 0.056 1.83e-02 3.58e-02 63.78 Unknown
7.882 160 0.090 1.93e-02 3.75e-02 59.13 Unknown
6.742 274 -0.129 1.96e-02 3.80e-02 63.78 Unknown
2.792 434 0.084 2.02e-02 3.90e-02 63.78 Lipid diallylic
6.872 261 0.053 2.02e-02 3.90e-02 63.78 Unknown
0.672 646 0.126 2.14e-02 4.11e-02 49.50 Unkown
8.002 148 0.187 2.17e-02 4.16e-02 63.78 Unknown
1.832 530 0.036 2.20e-02 4.21e-02 63.78 Unknown
7.562 192 -0.078 2.24e-02 4.28e-02 59.13 Unknown
0.722 641 0.154 2.30e-02 4.37e-02 63.78 Unkown
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7.742 174 0.063 2.35e-02 4.46e-02 59.13 Unknown
3.332 391 0.200 2.37e-02 4.49e-02 63.78 Proline
1.802 533 0.042 2.53e-02 4.78e-02 63.78 Unknown
Table 7.11: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values both
unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical power in
%, as well as correspondingly identified compounds of NMR features that dis-
criminated patients suffering from diabetic nephropathy from those suffering
from systemic diseases. A false discovery rate (FDR) below 5% was applied. The
FDR was adjusted according to the method of Benjamini and Hochberg (B/H). In case
that more than one compound contributed to a significant bin, all possible assignments
are given. A question mark denotes ambiguous signal assignments, mostly due to severe
signal overlap. The statistical power was calculated with a significance level of 0.05 and a
specificity of 95%.
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
3.842 353 0.422 5.93e-83 3.91e-80 100.00 D-glucose, unknown
3.802 357 0.368 1.95e-82 6.42e-80 100.00 D-glucose, alanine
3.562 368 0.439 6.36e-82 1.40e-79 100.00 D-glucose
3.782 359 0.332 1.59e-81 2.12e-79 100.00 D-glucose, alanine, glutamine,
arginine
3.552 369 0.452 1.60e-81 2.12e-79 100.00 D-glucose, myo-inositol
3.872 350 0.369 3.68e-81 4.05e-79 100.00 D-glucose, unknown
3.882 349 0.413 9.59e-81 9.04e-79 100.00 D-glucose, unknown
3.412 383 0.476 2.56e-80 2.12e-78 100.00 D-glucose, carnitine, taurine, pro-
line
3.862 351 0.451 3.44e-80 2.52e-78 100.00 D-glucose, unknown
3.742 363 0.449 1.30e-79 8.59e-78 100.00 D-glucose, leucine
3.912 346 0.410 1.73e-79 1.04e-77 100.00 D-glucose, betaine, unknown
3.572 367 0.411 2.41e-79 1.32e-77 100.00 D-glucose, glycine
3.852 352 0.431 5.33e-79 2.71e-77 100.00 D-glucose, unknown
3.932 344 0.418 1.90e-78 8.97e-77 100.00 D-glucose
3.432 381 0.472 2.11e-78 9.30e-77 100.00 D-glucose, carnitine, taurine, pro-
line
3.442 380 0.464 2.97e-78 1.23e-76 100.00 D-glucose, carnitine, taurine, pro-
line
3.502 374 0.483 5.13e-78 1.99e-76 100.00 D-glucose
3.722 365 0.378 7.34e-78 2.69e-76 100.00 D-glucose, N,N-dimethylglycine
3.482 376 0.471 1.87e-77 6.36e-76 100.00 D-glucose
3.512 373 0.482 1.93e-77 6.36e-76 100.00 D-glucose
3.752 362 0.435 2.03e-76 6.37e-75 100.00 D-glucose, glutamic acid
3.762 361 0.406 1.90e-75 5.69e-74 100.00 D-glucose, arginine, glutamine,
glutamic acid
3.492 375 0.471 3.14e-75 9.02e-74 100.00 D-glucose
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3.532 371 0.416 1.72e-73 4.72e-72 100.00 D-glucose
3.452 379 0.402 2.20e-73 5.80e-72 100.00 D-glucose, carnitine, proline
3.472 377 0.445 2.43e-72 6.16e-71 100.00 D-glucose
3.422 382 0.461 1.89e-71 4.63e-70 100.00 D-glucose, carnitine, taurine, pro-
line
3.732 364 0.401 1.13e-70 2.66e-69 100.00 D-glucose, unknown
3.772 360 0.364 4.98e-70 1.13e-68 100.00 D-glucose, alanine, glutamine,
arginine
3.792 358 0.228 3.80e-66 8.35e-65 100.00 D-glucose, alanine
3.942 343 0.404 9.08e-60 1.93e-58 100.00 D-glucose
3.812 356 0.307 2.66e-59 5.49e-58 100.00 D-glucose
3.542 370 0.326 2.55e-47 5.09e-46 100.00 D-glucose, myo-inositol
3.922 345 0.244 2.60e-45 5.04e-44 100.00 D-glucose, unknown
3.522 372 0.379 6.51e-42 1.23e-40 100.00 D-glucose
3.832 354 0.190 3.15e-41 5.78e-40 100.00 Unknown
3.402 384 0.275 1.58e-40 2.82e-39 100.00 Unknown
3.962 341 0.124 2.04e-33 3.55e-32 100.00 Unknown
3.972 340 0.114 2.18e-27 3.69e-26 100.00 Unknown
3.822 355 0.173 7.00e-27 1.16e-25 100.00 Unknown
3.372 387 -0.184 2.93e-23 4.71e-22 100.00 Methanol, proline
3.892 348 0.117 1.17e-22 1.84e-21 100.00 Unknown
3.462 378 0.173 4.65e-19 7.13e-18 100.00 D-glucose
3.712 366 0.126 4.26e-15 6.40e-14 100.00 Unknown
7.372 211 0.097 9.92e-12 1.45e-10 100.00 Phenylalanine
2.402 473 0.070 2.99e-11 4.28e-10 100.00 Glutamine, carnitine
6.832 265 0.105 5.54e-11 7.78e-10 100.00 Unknown
7.382 210 0.079 5.47e-10 7.52e-09 100.00 Phenylalanine
6.842 264 0.100 6.52e-10 8.79e-09 100.00 Unknown
6.822 266 0.098 1.91e-09 2.53e-08 100.00 Unknown
7.332 215 0.081 3.79e-09 4.90e-08 100.00 Phenylalanine
7.232 225 0.084 4.56e-09 5.79e-08 100.00 Unknown
3.952 342 0.114 5.41e-09 6.73e-08 100.00 Unknown
7.302 218 0.082 7.15e-09 8.74e-08 100.00 Unknown
3.392 385 0.257 8.02e-09 9.45e-08 100.00 Methanol, proline
7.292 219 0.079 8.02e-09 9.45e-08 100.00 Unknown
7.142 234 0.110 8.27e-09 9.57e-08 99.99 Unknown
7.322 216 0.084 1.50e-08 1.71e-07 100.00 Unknown
4.032 334 0.092 1.70e-08 1.88e-07 99.99 Unknown
3.982 339 0.070 1.71e-08 1.88e-07 99.99 Unknown
7.312 217 0.082 2.87e-08 3.10e-07 100.00 Unknown
6.852 263 0.091 3.09e-08 3.29e-07 99.99 Unknown
3.992 338 -0.069 3.49e-08 3.65e-07 99.98 Unknown
7.242 224 0.079 4.50e-08 4.64e-07 99.99 Unknown
7.052 243 0.100 6.47e-08 6.57e-07 99.98 Unknown
1.812 532 0.064 1.65e-07 1.65e-06 99.98 Unknown
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7.262 222 0.082 1.78e-07 1.75e-06 99.99 Unknown
1.872 526 0.061 1.87e-07 1.81e-06 99.96 Overlap of multiple minor com-
pounds
4.122 325 0.130 1.94e-07 1.85e-06 99.96 Proline, lactic acid
7.282 220 0.072 2.54e-07 2.39e-06 99.98 Unknown
7.042 244 0.126 2.64e-07 2.46e-06 99.92 Unknown
1.892 524 0.057 3.47e-07 3.18e-06 99.92 Overlap of multiple minor com-
pounds
3.062 407 0.081 3.89e-07 3.52e-06 99.96 Creatinine
7.272 221 0.076 4.21e-07 3.76e-06 99.98 Unknown
7.252 223 0.079 5.55e-07 4.88e-06 99.96 Unknown
1.802 533 0.068 5.81e-07 5.04e-06 99.96 Unknown
7.132 235 0.091 6.51e-07 5.58e-06 99.92 Unknown
7.062 242 0.100 7.66e-07 6.48e-06 99.86 Unknown
1.902 523 0.053 8.59e-07 7.18e-06 99.86 Overlap of multiple minor com-
pounds
1.882 525 0.054 1.19e-06 9.83e-06 99.86 Overlap of multiple minor com-
pounds
1.082 605 0.088 1.54e-06 1.25e-05 99.76 Unknown
6.862 262 0.092 1.61e-06 1.29e-05 99.86 Unknown
1.092 604 0.092 1.63e-06 1.29e-05 99.76 Unknown
4.152 322 0.101 1.65e-06 1.29e-05 99.76 Proline, lactic acid
7.072 241 0.086 2.01e-06 1.56e-05 99.86 Unknown
6.812 267 0.091 2.14e-06 1.64e-05 99.92 Unknown
1.862 527 0.056 2.75e-06 2.08e-05 99.76 Unknown
2.412 472 0.088 2.80e-06 2.10e-05 99.59 Glutamine, carnitine
4.012 336 -0.052 3.31e-06 2.46e-05 99.76 Unknown
2.352 478 0.061 3.41e-06 2.50e-05 99.76 Proline, glutamic acid
6.802 268 0.094 3.71e-06 2.69e-05 99.76 Unknown
7.122 236 0.067 4.48e-06 3.21e-05 99.76 Unknown
1.822 531 0.053 5.31e-06 3.77e-05 99.76 Unknown
4.052 332 0.122 5.66e-06 3.97e-05 99.59 Unknown
6.882 260 0.070 5.84e-06 4.06e-05 99.59 Unknown
1.702 543 0.054 6.47e-06 4.45e-05 99.59 Unknown, arginine
4.192 318 0.135 7.95e-06 5.41e-05 99.59 Unknown
4.142 323 0.118 9.43e-06 6.35e-05 99.34 Proline, lactic acid
7.872 161 0.119 9.58e-06 6.39e-05 99.34 Unknown
7.192 229 0.064 1.05e-05 6.93e-05 99.59 Tyrosine
6.872 261 0.071 1.20e-05 7.87e-05 99.34 Unknown
8.352 113 0.324 1.85e-05 1.20e-04 98.95 Unknown
1.712 542 0.046 1.96e-05 1.26e-04 98.95 Leucine, lysine
1.072 606 0.074 2.01e-05 1.28e-04 98.95 Valine
1.842 529 0.051 2.12e-05 1.33e-04 98.95 Unknown
7.152 233 0.100 2.21e-05 1.37e-04 98.95 Unknown
1.102 603 0.080 2.26e-05 1.40e-04 98.95 Unknown
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1.852 528 0.052 2.41e-05 1.47e-04 98.95 Unknown
8.392 109 0.320 2.93e-05 1.77e-04 98.95 Unknown
4.162 321 0.087 3.11e-05 1.86e-04 99.34 Proline, lactic acid
2.392 474 0.077 3.39e-05 2.02e-04 98.95 Unknown
7.032 245 0.111 3.45e-05 2.03e-04 98.36 Unknown
1.692 544 0.056 3.47e-05 2.03e-04 98.95 Unknown, arginine
7.012 247 0.107 3.54e-05 2.05e-04 98.95 Unknown
6.962 252 0.070 3.97e-05 2.28e-04 97.53 Unknown
4.002 337 -0.044 4.17e-05 2.37e-04 98.36 Unknown
1.792 534 0.065 4.83e-05 2.73e-04 98.95 Unknown
7.182 230 0.074 5.00e-05 2.79e-04 98.36 Unknown
4.132 324 0.116 5.03e-05 2.79e-04 98.36 Proline, lactic acid
2.342 479 0.063 7.09e-05 3.90e-04 97.53 Proline, glutamic acid
2.642 449 0.043 8.33e-05 4.55e-04 98.36 Unknown
6.792 269 0.083 8.92e-05 4.82e-04 98.36 Unknown
3.902 347 0.041 9.61e-05 5.16e-04 97.53 D-glucose, unknown
4.112 326 0.135 1.01e-04 5.37e-04 98.36 Proline, lactic acid
7.022 246 0.141 1.02e-04 5.37e-04 97.53 Unknown
7.882 160 0.105 1.19e-04 6.24e-04 96.36 Unknown
7.992 149 0.217 1.24e-04 6.44e-04 96.36 Unknown
1.682 545 0.060 1.42e-04 7.34e-04 97.53 Unknown, arginine
7.362 212 0.056 1.48e-04 7.57e-04 97.53 Phenylalanine
7.112 237 0.048 1.56e-04 7.91e-04 97.53 Unknown
1.832 530 0.042 1.59e-04 8.00e-04 97.53 Unknown
7.342 214 0.043 1.61e-04 8.03e-04 96.36 Phenylalanine
1.722 541 0.041 1.66e-04 8.24e-04 96.36 Leucine, lysine
6.892 259 0.046 1.69e-04 8.32e-04 97.53 Unknown
1.772 536 0.051 1.94e-04 9.44e-04 96.36 Leucine, lysine
8.552 93 -0.303 1.95e-04 9.44e-04 96.36 Unknown
2.122 501 0.060 2.01e-04 9.70e-04 96.36 Lipid allylic
8.162 132 0.190 2.09e-04 9.94e-04 92.69 Unknown
1.132 600 0.062 2.09e-04 9.94e-04 96.36 Unknown
2.422 471 0.065 2.15e-04 1.02e-03 96.36 Glutamine, carnitine
1.062 607 0.072 2.23e-04 1.04e-03 96.36 Valine
2.652 448 0.035 2.62e-04 1.21e-03 96.36 Unknown
2.302 483 0.075 2.63e-04 1.21e-03 96.36 Lipid (methylene carbonyl)
2.932 420 -0.049 3.08e-04 1.41e-03 96.36 Unknown
2.332 480 0.062 3.19e-04 1.45e-03 94.78 Proline, glutamic acid
1.002 613 0.063 3.49e-04 1.58e-03 94.78 Valine, lipid methyl, cholesterol
(ester)
1.782 535 0.060 4.16e-04 1.87e-03 96.36 Unknown
1.762 537 0.046 4.21e-04 1.88e-03 94.78 Leucine, lysine
2.322 481 0.059 4.63e-04 2.05e-03 92.69 Lipid (methylene carbonyl)
1.912 522 0.043 5.17e-04 2.27e-03 94.78 Overlap of multiple minor com-
pounds
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2.312 482 0.063 5.47e-04 2.39e-03 92.69 Lipid (methylene carbonyl)
8.002 148 0.200 5.61e-04 2.44e-03 92.69 Unknown
4.092 328 0.086 6.33e-04 2.73e-03 94.78 Unknown
1.752 538 0.044 6.61e-04 2.83e-03 92.69 Leucine, lysine
1.742 539 0.041 6.73e-04 2.86e-03 92.69 Leucine, lysine
8.152 133 0.162 6.82e-04 2.88e-03 92.69 Unknown
4.342 303 0.060 7.59e-04 3.19e-03 94.78 Lipid alpha-methylene to car-
boxyl, lipid glycerine
1.732 540 0.039 7.93e-04 3.31e-03 92.69 Leucine, lysine
2.722 441 -0.036 8.16e-04 3.37e-03 92.69 MgEDTA2−
1.962 517 0.045 8.16e-04 3.37e-03 92.69 Lipid allylic
2.942 419 -0.026 8.25e-04 3.38e-03 94.78 N,N-dimethylglycine
6.972 251 0.070 9.74e-04 3.97e-03 92.69 Unknown
2.432 470 0.040 1.01e-03 4.08e-03 90.01 Glutamine, carnitine
1.672 546 0.060 1.27e-03 5.12e-03 90.01 Unknown, arginine
7.172 231 0.085 1.44e-03 5.76e-03 90.01 Unknown
8.192 129 0.153 1.47e-03 5.83e-03 86.69 Unknown
2.362 477 0.051 1.50e-03 5.95e-03 90.01 Proline, glutamic acid
8.282 120 0.134 1.60e-03 6.29e-03 92.69 Unknown
1.972 516 0.049 1.65e-03 6.45e-03 90.01 Lipid allylic
1.122 601 0.066 1.85e-03 7.19e-03 86.69 Unknown
7.972 151 0.205 1.94e-03 7.47e-03 86.69 Unknown
2.382 475 0.054 2.00e-03 7.68e-03 86.69 Proline, glutamic acid
7.982 150 0.187 2.04e-03 7.78e-03 86.69 Unknown
1.022 611 0.062 2.26e-03 8.58e-03 86.69 L-isoleucine, lipid methyl, choles-
terol (ester)
2.632 450 0.031 2.31e-03 8.69e-03 86.69 Unknown
6.782 270 0.116 2.47e-03 9.27e-03 86.69 Unknown
7.862 162 0.088 2.73e-03 1.02e-02 82.67 Unknown
4.312 306 0.061 2.82e-03 1.05e-02 86.69 Lipid alpha-methylene to car-
boxyl, lipid glycerine
1.512 562 0.057 2.89e-03 1.06e-02 86.69 Alanine
7.102 238 0.079 2.93e-03 1.07e-02 82.67 Unknown
2.112 502 0.050 2.94e-03 1.07e-02 86.69 Lipid allylic
8.012 147 0.146 2.98e-03 1.08e-02 82.67 Unknown
8.092 139 0.130 2.99e-03 1.08e-02 82.67 Trigonelline
8.122 136 0.109 3.16e-03 1.13e-02 82.67 Unknown
1.952 518 0.036 3.30e-03 1.17e-02 86.69 Acetic acid
8.172 131 0.126 3.30e-03 1.17e-02 82.67 Unknown
6.902 258 0.036 3.41e-03 1.20e-02 82.67 Tyrosine
1.152 598 0.060 3.54e-03 1.24e-02 82.67 Lipid methylene
1.012 612 0.058 3.56e-03 1.24e-02 82.67 Valine, lipid methyl, cholesterol
(ester)
1.142 599 0.053 3.65e-03 1.27e-02 82.67 Unknown
8.342 114 0.202 3.71e-03 1.28e-02 82.67 Unknown
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1.662 547 0.063 4.02e-03 1.38e-02 82.67 Lipids (?)
2.102 503 0.042 4.04e-03 1.38e-02 82.67 Lipid allylic
8.222 126 0.063 4.42e-03 1.50e-02 77.95 Unknown
4.182 319 0.117 4.46e-03 1.51e-02 82.67 Unknown
1.922 521 0.037 4.48e-03 1.51e-02 82.67 Overlap of multiple minor com-
pounds
1.232 590 0.054 4.75e-03 1.59e-02 82.67 Lipid methylene
4.072 330 0.068 4.79e-03 1.60e-02 86.69 Creatinine
7.352 213 0.034 4.95e-03 1.64e-02 82.67 Phenylalanine
4.282 309 0.050 5.02e-03 1.65e-02 82.67 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
8.202 128 0.104 5.02e-03 1.65e-02 77.95 Unknown
1.982 515 0.049 5.12e-03 1.67e-02 82.67 Lipid allylic
1.032 610 0.061 5.48e-03 1.78e-02 82.67 L-isoleucine, lipid methyl, choles-
terol (ester)
2.132 500 0.033 5.63e-03 1.82e-02 82.67 Glutamine
2.372 476 0.048 5.81e-03 1.87e-02 77.95 Proline, glutamic acid
1.492 564 0.050 5.93e-03 1.90e-02 82.67 Alanine
4.102 327 0.096 5.97e-03 1.90e-02 82.67 Unknown
8.082 140 0.099 6.22e-03 1.97e-02 77.95 Trigonelline
4.062 331 0.073 6.24e-03 1.97e-02 77.95 Creatinine
2.922 421 -0.047 6.29e-03 1.98e-02 82.67 Unknown
4.172 320 0.087 6.56e-03 2.05e-02 77.95 Unknown
7.852 163 0.112 6.62e-03 2.06e-02 77.95 Unknown
4.082 329 0.069 6.74e-03 2.09e-02 82.67 Creatinine
9.232 25 0.236 6.89e-03 2.12e-02 77.95 Unknown
1.502 563 0.050 7.29e-03 2.24e-02 77.95 Alanine
3.032 410 0.017 7.40e-03 2.26e-02 77.95 Lysine, unknown
2.912 422 -0.036 7.88e-03 2.40e-02 77.95 Unknown
2.002 513 0.050 8.23e-03 2.49e-02 77.95 Lipid allylic
6.742 274 -0.104 8.71e-03 2.62e-02 72.57 Unknown
8.302 118 0.170 9.56e-03 2.87e-02 77.95 Unknown
8.232 125 0.056 1.01e-02 3.01e-02 72.57 Unknown
8.372 111 0.196 1.04e-02 3.08e-02 72.57 Unknown
8.292 119 0.142 1.13e-02 3.33e-02 72.57 Unknown
2.292 484 0.061 1.16e-02 3.40e-02 72.57 Lipid (methylene carbonyl)
4.302 307 0.057 1.18e-02 3.47e-02 72.57 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
8.102 138 0.116 1.24e-02 3.63e-02 72.57 Trigonelline
1.992 514 0.046 1.28e-02 3.71e-02 72.57 Lipid allylic
2.012 512 0.050 1.34e-02 3.87e-02 72.57 Lipid allylic
1.482 565 0.043 1.42e-02 4.10e-02 72.57 Alanine
4.322 305 0.045 1.47e-02 4.22e-02 72.57 Lipid alpha-methylene to car-
boxyl, lipid glycerine
3.332 391 0.154 1.50e-02 4.29e-02 66.61 Proline
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3.072 406 0.018 1.75e-02 4.95e-02 66.61 Unknown
8.422 106 0.201 1.75e-02 4.95e-02 60.20 Unknown
8.262 122 0.054 1.76e-02 4.97e-02 66.61 Unknown
Table 7.12: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values both
unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical power in
%, as well as correspondingly identified compounds of NMR features that dis-
criminated patients suffering from diabetic nephropathy from those suffering
from hypertensive nephropathy. A false discovery rate (FDR) below 5% was applied.
The FDR was adjusted according to the method of Benjamini and Hochberg (B/H). In
case that more than one compound contributed to a significant bin, all possible assign-
ments are given. A question mark denotes ambiguous signal assignments, mostly due to
severe signal overlap. The statistical power was calculated with a significance level of 0.05
and a specificity of 95%.
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
1.152 598 0.154 7.84e-06 0.00284 99.21 Lipid methylene
1.832 530 0.083 8.60e-06 0.00284 98.96 Unknown
1.232 590 0.134 2.78e-05 0.00419 98.25 Lipid methylene
1.222 591 0.163 4.59e-05 0.00419 98.65 Lipid methylene
1.802 533 0.092 4.77e-05 0.00419 96.43 Unknown
1.842 529 0.080 5.72e-05 0.00419 97.76 Unknown
1.822 531 0.078 6.13e-05 0.00419 96.43 Unknown
7.212 227 0.116 7.52e-05 0.00419 97.16 Tyrosine
1.692 544 0.090 7.99e-05 0.00419 96.43 Unknown, arginine
3.962 341 0.067 8.08e-05 0.00419 97.76 Unknown
1.812 532 0.080 8.33e-05 0.00419 95.56 Unknown
1.672 546 0.123 8.90e-05 0.00419 96.43 Unknown, arginine
2.122 501 0.105 9.41e-05 0.00419 96.43 Lipid allylic
7.272 221 0.097 1.09e-04 0.00419 94.52 Unknown
7.222 226 0.107 1.09e-04 0.00419 97.16 Tyrosine
3.972 340 0.067 1.10e-04 0.00419 96.43 Unknown
7.292 219 0.088 1.18e-04 0.00419 94.52 Unknown
7.312 217 0.096 1.20e-04 0.00419 94.52 Unknown
1.962 517 0.087 1.21e-04 0.00419 95.56 Lipid allylic
7.262 222 0.100 1.42e-04 0.00454 94.52 Unknown
2.642 449 0.070 1.44e-04 0.00454 95.56 Unknown
1.792 534 0.102 1.57e-04 0.00470 93.30 Unknown
7.282 220 0.087 1.70e-04 0.00479 94.52 Unknown
1.972 516 0.097 1.79e-04 0.00479 94.52 Lipid allylic
1.682 545 0.098 1.85e-04 0.00479 94.52 Unknown, arginine
1.362 577 0.212 1.98e-04 0.00479 95.56 Lipid methylene, lactic acid, thre-
onine
2.402 473 0.065 1.99e-04 0.00479 94.52 Glutamine, carnitine
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7.302 218 0.088 2.03e-04 0.00479 93.30 Unknown
1.662 547 0.136 2.40e-04 0.00543 94.52 Lipids (?)
1.112 602 0.114 2.47e-04 0.00543 94.52 Unknown
3.062 407 -0.097 2.75e-04 0.00579 93.30 Creatinine
1.242 589 0.129 2.81e-04 0.00579 94.52 Lipid methylene
0.852 628 0.091 3.77e-04 0.00754 94.52 Cholesterol, lipid methyl
3.042 409 -0.036 4.08e-04 0.00772 93.30 Lysine, unknown
0.842 629 0.091 4.22e-04 0.00772 94.52 Cholesterol, lipid methyl
1.702 543 0.070 4.47e-04 0.00772 91.87 Unknown, arginine
4.332 304 0.104 4.55e-04 0.00772 90.23 Lipid alpha-methylene to car-
boxyl, lipid glycerine
0.832 630 0.101 4.55e-04 0.00772 93.30 Cholesterol, lipid methyl
1.852 528 0.072 4.56e-04 0.00772 93.30 Unknown
0.962 617 0.125 5.53e-04 0.00912 91.87 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
2.652 448 0.055 5.70e-04 0.00918 93.30 Unknown
1.982 515 0.101 5.91e-04 0.00927 90.23 Lipid allylic
7.432 205 -0.096 6.04e-04 0.00927 90.23 Phenylalanine
4.342 303 0.101 6.35e-04 0.00937 88.36 Lipid alpha-methylene to car-
boxyl, lipid glycerine
1.142 599 0.104 6.39e-04 0.00937 91.87 Unknown
4.322 305 0.104 6.91e-04 0.00971 88.36 Lipid alpha-methylene to car-
boxyl, lipid glycerine
7.232 225 0.081 6.95e-04 0.00971 86.25 Unknown
1.862 527 0.068 7.21e-04 0.00971 90.23 Unknown
7.322 216 0.084 7.31e-04 0.00971 88.36 Unknown
4.312 306 0.116 7.49e-04 0.00971 88.36 Lipid alpha-methylene to car-
boxyl, lipid glycerine
4.122 325 0.141 7.50e-04 0.00971 91.87 Proline, lactic acid
1.712 542 0.061 7.84e-04 0.00995 90.23 Leucine, lysine
1.342 579 0.175 8.08e-04 0.01010 90.23 Lipid methylene, lactic acid, thre-
onine
2.132 500 0.067 9.02e-04 0.01080 88.36 Glutamine
1.252 588 0.131 9.04e-04 0.01080 90.23 Lipid methylene
2.312 482 0.101 9.17e-04 0.01080 90.23 Lipid (methylene carbonyl)
1.782 535 0.095 9.30e-04 0.01080 88.36 Unknown
7.252 223 0.087 9.76e-04 0.01110 86.25 Unknown
2.322 481 0.093 1.10e-03 0.01230 90.23 Lipid (methylene carbonyl)
1.652 548 0.147 1.16e-03 0.01270 88.36 Lipids (?)
0.822 631 0.116 1.25e-03 0.01360 88.36 Cholesterol, lipid methyl
0.952 618 0.136 1.34e-03 0.01410 88.36 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.952 518 0.066 1.35e-03 0.01410 88.36 Acetic acid
2.632 450 0.054 1.37e-03 0.01410 86.25 Unknown
2.742 439 0.076 1.39e-03 0.01410 86.25 Lipid diallylic
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1.992 514 0.098 1.42e-03 0.01420 86.25 Lipid allylic
1.132 600 0.089 1.48e-03 0.01460 88.36 Unknown
6.842 264 0.086 1.56e-03 0.01510 83.88 Unknown
0.862 627 0.092 1.59e-03 0.01520 86.25 Cholesterol, lipid methyl
1.272 586 0.143 1.83e-03 0.01720 86.25 Lipid methylene
1.262 587 0.133 1.84e-03 0.01720 86.25 Lipid methylene
0.892 624 0.127 1.89e-03 0.01730 83.88 Cholesterol, lipid methyl
2.002 513 0.097 1.95e-03 0.01750 83.88 Lipid allylic
0.972 616 0.102 1.97e-03 0.01750 83.88 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
4.302 307 0.118 1.99e-03 0.01750 83.88 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
1.302 583 0.216 2.04e-03 0.01770 83.88 Lipid methylene
1.212 592 0.143 2.08e-03 0.01780 88.36 Lipid methylene
3.052 408 -0.046 2.12e-03 0.01800 86.25 Creatinine
1.352 578 0.162 2.18e-03 0.01820 86.25 Lipid methylene, lactic acid, thre-
onine
2.012 512 0.103 2.23e-03 0.01840 83.88 Lipid allylic
4.292 308 0.113 2.28e-03 0.01860 81.27 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
1.282 585 0.151 2.35e-03 0.01890 83.88 Lipid methylene
2.302 483 0.103 2.54e-03 0.02020 83.88 Lipid (methylene carbonyl)
1.172 596 0.123 2.59e-03 0.02040 83.88 Lipid methylene
6.852 263 0.082 2.67e-03 0.02070 83.88 Unknown
7.332 215 0.068 2.71e-03 0.02080 81.27 Phenylalanine
0.882 625 0.106 2.80e-03 0.02130 81.27 Cholesterol, lipid methyl
2.022 511 0.114 2.88e-03 0.02150 81.27 Lipid allylic
1.162 597 0.130 2.90e-03 0.02150 86.25 Lipid methylene
2.032 510 0.127 3.03e-03 0.02190 81.27 Lipid allylic
9.232 25 0.435 3.05e-03 0.02190 83.88 Unknown
2.272 486 0.193 3.05e-03 0.02190 81.27 Lipid (methylene carbonyl)
2.262 487 0.219 3.10e-03 0.02200 81.27 Lipid (methylene carbonyl)
2.622 451 0.043 3.15e-03 0.02210 78.41 Unknown
2.252 488 0.171 3.26e-03 0.02230 78.41 Lipid (methylene carbonyl), ace-
tone
2.332 480 0.085 3.27e-03 0.02230 81.27 Proline, glutamic acid
0.802 633 0.122 3.28e-03 0.02230 81.27 Cholesterol, lipid methyl
1.292 584 0.171 3.37e-03 0.02270 78.41 Lipid methylene
0.812 632 0.121 3.52e-03 0.02350 81.27 Cholesterol, lipid methyl
6.742 274 -0.193 3.62e-03 0.02370 81.27 Unknown
6.832 265 0.078 3.63e-03 0.02370 78.41 Unknown
1.122 601 0.104 3.81e-03 0.02430 81.27 Unknown
1.642 549 0.157 3.82e-03 0.02430 81.27 Lipids (?)
1.102 603 0.092 3.87e-03 0.02430 81.27 Unknown
6.672 281 -0.425 3.89e-03 0.02430 81.27 Unknown
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2.782 435 0.127 3.94e-03 0.02430 78.41 Lipid diallylic
1.312 582 0.214 3.99e-03 0.02430 78.41 Lipid methylene
0.902 623 0.150 4.01e-03 0.02430 78.41 Cholesterol, lipid methyl
0.872 626 0.097 4.03e-03 0.02430 78.41 Cholesterol, lipid methyl
0.792 634 0.107 4.05e-03 0.02430 78.41 Cholesterol, lipid methyl
2.042 509 0.130 4.17e-03 0.02480 78.41 Lipid allylic
4.352 302 0.089 4.22e-03 0.02480 75.32 Lipid alpha-methylene to car-
boxyl, lipid glycerine
4.132 324 0.137 4.26e-03 0.02490 81.27 Proline, lactic acid
0.922 621 0.196 4.47e-03 0.02550 78.41 Cholesterol, lipid methyl
2.792 434 0.124 4.48e-03 0.02550 78.41 Lipid diallylic
0.912 622 0.182 4.48e-03 0.02550 75.32 Cholesterol, lipid methyl
1.522 561 0.074 4.53e-03 0.02550 78.41 Lipids (?)
2.752 438 0.093 4.58e-03 0.02560 75.32 Lipid diallylic
6.932 255 0.091 4.64e-03 0.02570 75.32 Tyrosine
1.452 568 0.108 4.70e-03 0.02580 78.41 Lipid methylene
2.292 484 0.115 4.74e-03 0.02590 78.41 Lipid (methylene carbonyl)
6.822 266 0.077 4.79e-03 0.02590 75.32 Unknown
4.072 330 -0.114 4.85e-03 0.02600 68.48 Creatinine
1.612 552 0.216 5.01e-03 0.02670 75.32 Lipids (?)
2.282 485 0.142 5.07e-03 0.02670 78.41 Lipid (methylene carbonyl)
1.422 571 0.151 5.09e-03 0.02670 78.41 Lipid methylene
4.282 309 0.084 5.23e-03 0.02710 75.32 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
2.972 416 -0.032 5.26e-03 0.02710 78.41 Unknown
1.622 551 0.199 5.37e-03 0.02750 78.41 Lipids (?)
1.632 550 0.174 5.60e-03 0.02840 78.41 Lipids (?)
2.102 503 0.068 5.73e-03 0.02870 78.41 Lipid allylic
1.182 595 0.095 5.79e-03 0.02870 78.41 Lipid methylene
1.332 580 0.225 5.83e-03 0.02870 75.32 Lipid methylene
0.942 619 0.147 5.85e-03 0.02870 78.41 Cholesterol, lipid methyl
7.442 204 -0.069 5.86e-03 0.02870 81.27 Phenylalanine
1.322 581 0.214 5.97e-03 0.02880 75.32 Lipid methylene
2.112 502 0.077 5.98e-03 0.02880 75.32 Lipid allylic
1.602 553 0.217 6.29e-03 0.02990 72.00 Lipids (?)
1.872 526 0.053 6.30e-03 0.02990 75.32 Overlap of multiple minor com-
pounds
1.532 560 0.088 6.47e-03 0.03050 75.32 Lipids (?)
1.462 567 0.092 6.51e-03 0.03050 75.32 Lipid methylene
2.812 432 0.147 6.86e-03 0.03190 72.00 Lipid diallylic
1.412 572 0.179 7.20e-03 0.03320 75.32 Lipid methylene
2.772 436 0.115 7.34e-03 0.03360 72.00 Lipid diallylic
1.432 570 0.116 7.49e-03 0.03380 75.32 Lipid methylene
1.092 604 0.086 7.49e-03 0.03380 75.32 Unknown
2.072 506 0.083 7.69e-03 0.03450 72.00 Lipid allylic
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1.202 593 0.201 7.78e-03 0.03470 78.41 Lipid methylene
0.932 620 0.171 7.87e-03 0.03490 72.00 Cholesterol, lipid methyl
4.142 323 0.118 8.18e-03 0.03600 75.32 Proline, lactic acid
1.192 594 0.168 8.42e-03 0.03650 78.41 Lipid methylene
1.482 565 0.077 8.52e-03 0.03650 72.00 Alanine
1.772 536 0.060 8.55e-03 0.03650 72.00 Leucine, lysine
2.562 457 -0.039 8.58e-03 0.03650 75.32 CaEDTA2−
7.242 224 0.064 8.59e-03 0.03650 68.48 Unknown
2.762 437 0.103 8.62e-03 0.03650 68.48 Lipid diallylic
4.362 301 0.089 8.67e-03 0.03650 68.48 Unknown
1.442 569 0.105 8.80e-03 0.03670 72.00 Lipid methylene
1.592 554 0.203 9.23e-03 0.03830 68.48 Lipids (?)
2.822 431 0.141 9.31e-03 0.03840 68.48 Lipid diallylic
2.552 458 -0.058 9.55e-03 0.03920 86.25 Citric acid
1.472 566 0.082 9.72e-03 0.03960 68.48 Lipid methylene
6.772 271 -0.270 9.85e-03 0.03990 75.32 Unknown
0.602 653 -0.387 9.96e-03 0.04010 78.41 Unkown
3.922 345 0.073 1.00e-02 0.04010 83.88 D-glucose, unknown
2.342 479 0.068 1.01e-02 0.04010 72.00 Proline, glutamic acid
1.382 575 0.228 1.04e-02 0.04090 68.48 Lipid methylene
1.402 573 0.212 1.04e-02 0.04090 68.48 Lipid methylene
2.802 433 0.122 1.05e-02 0.04090 68.48 Lipid diallylic
1.392 574 0.225 1.06e-02 0.04130 68.48 Lipid methylene
2.542 459 -0.060 1.07e-02 0.04140 78.41 Unknown
2.062 507 0.057 1.10e-02 0.04230 72.00 Lipid allylic
9.452 3 0.391 1.12e-02 0.04260 72.00 Unknown
1.372 576 0.225 1.13e-02 0.04300 68.48 Lipid methylene
1.042 609 0.113 1.16e-02 0.04380 68.48 L-isoleucine, lipid methyl, choles-
terol (ester)
2.232 490 0.152 1.17e-02 0.04380 68.48 Lipid (methylene carbonyl)
2.082 505 0.095 1.21e-02 0.04530 68.48 Lipid allylic
1.022 611 0.085 1.23e-02 0.04570 72.00 L-isoleucine, lipid methyl, choles-
terol (ester)
0.992 614 0.084 1.24e-02 0.04580 68.48 Leucine, lipid methyl, cholesterol
(ester)
0.652 648 -0.283 1.26e-02 0.04610 72.00 Unkown
0.982 615 0.082 1.27e-02 0.04630 68.48 Leucine, lipid methyl, cholesterol
(ester)
2.242 489 0.160 1.28e-02 0.04630 64.78 Lipid (methylene carbonyl), ace-
tone
1.582 555 0.181 1.29e-02 0.04640 64.78 Lipids (?)
2.052 508 0.088 1.32e-02 0.04730 64.78 Lipid allylic
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Table 7.13: Previous page: Spectral positions given in ppm, IDs, log(Fold-change)
(log(FC)), p-values both unadjusted and Benjamini and Hochberg (B/H)-
adjusted, statistical power in %, as well as correspondingly identified com-
pounds of NMR features that discriminated patients suffering from glomeru-
lonephritis from those suffering from hereditary diseases. A false discovery rate
(FDR) below 5% was applied. The FDR was adjusted according to the method of Ben-
jamini and Hochberg (B/H). In case that more than one compound contributed to a signif-
icant bin, all possible assignments are given. A question mark denotes ambiguous signal
assignments, mostly due to severe signal overlap. The statistical power was calculated
with a significance level of 0.05 and a specificity of 95%.
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
1.222 591 0.149 0.000113 0.0318 97.42 Lipid methylene
2.402 473 0.064 0.000144 0.0318 95.86 Glutamine, carnitine
1.212 592 0.167 0.000189 0.0318 97.42 Lipid methylene
0.832 630 0.102 0.000248 0.0318 94.84 Cholesterol, lipid methyl
4.282 309 0.106 0.000268 0.0318 93.62 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
3.982 339 0.073 0.000289 0.0318 93.62 Unknown
1.832 530 0.063 0.000395 0.0332 92.19 Unknown
3.992 338 0.071 0.000439 0.0332 95.86 Unknown
1.812 532 0.068 0.000506 0.0332 90.53 Unknown
4.292 308 0.123 0.000525 0.0332 92.19 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
7.312 217 0.082 0.000582 0.0332 86.46 Unknown
2.342 479 0.088 0.000612 0.0332 92.19 Proline, glutamic acid
1.792 534 0.088 0.000724 0.0332 88.63 Unknown
7.562 192 0.133 0.000747 0.0332 93.62 Unknown
2.332 480 0.094 0.000754 0.0332 92.19 Proline, glutamic acid
8.142 134 0.301 0.000832 0.0343 93.62 Unknown
2.972 416 -0.036 0.000894 0.0347 88.63 Unknown
2.412 472 0.100 0.000963 0.0353 90.53 Glutamine, carnitine
1.692 544 0.071 0.001170 0.0357 84.03 Unknown, arginine
7.292 219 0.071 0.001220 0.0357 84.03 Unknown
1.702 543 0.062 0.001240 0.0357 86.46 Unknown, arginine
2.322 481 0.088 0.001290 0.0357 88.63 Lipid (methylene carbonyl)
1.822 531 0.060 0.001310 0.0357 86.46 Unknown
2.122 501 0.083 0.001320 0.0357 86.46 Lipid allylic
7.012 247 0.133 0.001390 0.0357 86.46 Unknown
1.152 598 0.106 0.001410 0.0357 88.63 Lipid methylene
4.302 307 0.116 0.001510 0.0370 86.46 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
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1.712 542 0.055 0.001770 0.0397 84.03 Leucine, lysine
7.322 216 0.074 0.001840 0.0397 81.33 Unknown
2.312 482 0.091 0.001990 0.0397 86.46 Lipid (methylene carbonyl)
0.822 631 0.107 0.002050 0.0397 86.46 Cholesterol, lipid methyl
7.302 218 0.070 0.002060 0.0397 78.37 Unknown
3.342 390 -0.137 0.002090 0.0397 84.03 Proline
7.552 193 0.131 0.002110 0.0397 88.63 Unknown
8.862 62 -0.587 0.002210 0.0397 88.63 Trigonelline
7.432 205 -0.082 0.002230 0.0397 84.03 Phenylalanine
1.782 535 0.084 0.002270 0.0397 81.33 Unknown
1.672 546 0.092 0.002290 0.0397 81.33 Unknown, arginine
1.232 590 0.093 0.002360 0.0400 84.03 Lipid methylene
8.152 133 0.233 0.002520 0.0416 84.03 Unknown
1.802 533 0.065 0.002730 0.0440 81.33 Unknown
1.662 547 0.106 0.002890 0.0449 81.33 Lipids (?)
2.242 489 0.185 0.002930 0.0449 81.33 Lipid (methylene carbonyl), ace-
tone
6.852 263 0.078 0.003100 0.0461 81.33 Unknown
1.682 545 0.075 0.003150 0.0461 78.37 Unknown, arginine
1.962 517 0.065 0.003210 0.0461 78.37 Lipid allylic
3.042 409 -0.029 0.003330 0.0467 78.37 Lysine, unknown
Table 7.14: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values
both unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical
power in %, as well as correspondingly identified compounds of NMR features
that discriminated patients suffering from glomerulonephritis from those suf-
fering from interstitial nephropathy. A false discovery rate (FDR) below 5% was
applied. The FDR was adjusted according to the method of Benjamini and Hochberg
(B/H). In case that more than one compound contributed to a significant bin, all possible
assignments are given. A question mark denotes ambiguous signal assignments, mostly
due to severe signal overlap. The statistical power was calculated with a significance level
of 0.05 and a specificity of 95%.
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
1.232 590 0.126 1.16e-06 0.000517 99.76 Lipid methylene
0.842 629 0.101 1.57e-06 0.000517 99.76 Cholesterol, lipid methyl
1.702 543 0.075 3.77e-06 0.000830 99.27 Unknown, arginine
2.122 501 0.099 6.15e-06 0.000954 99.27 Lipid allylic
1.692 544 0.082 8.46e-06 0.000954 98.57 Unknown, arginine
1.242 589 0.127 1.00e-05 0.000954 99.27 Lipid methylene
0.972 616 0.117 1.10e-05 0.000954 98.97 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.902 523 0.064 1.31e-05 0.000954 98.97 Overlap of multiple minor com-
pounds
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1.682 545 0.092 1.44e-05 0.000954 98.57 Unknown, arginine
0.832 630 0.101 1.51e-05 0.000954 98.97 Cholesterol, lipid methyl
0.982 615 0.115 1.59e-05 0.000954 98.97 Leucine, lipid methyl, cholesterol
(ester)
7.032 245 0.156 1.82e-05 0.000963 98.97 Unknown
1.152 598 0.119 2.00e-05 0.000963 98.97 Lipid methylene
1.222 591 0.138 2.04e-05 0.000963 99.27 Lipid methylene
6.842 264 0.092 2.56e-05 0.001130 97.36 Unknown
1.882 525 0.063 3.02e-05 0.001250 98.04 Overlap of multiple minor com-
pounds
1.712 542 0.061 3.38e-05 0.001310 98.04 Leucine, lysine
1.022 611 0.114 3.70e-05 0.001310 98.57 L-isoleucine, lipid methyl, choles-
terol (ester)
1.162 597 0.145 3.78e-05 0.001310 98.97 Lipid methylene
1.172 596 0.135 4.08e-05 0.001310 98.57 Lipid methylene
1.932 520 0.070 4.30e-05 0.001310 98.04 Acetic acid
0.992 614 0.112 4.39e-05 0.001310 98.04 Leucine, lipid methyl, cholesterol
(ester)
1.032 610 0.122 4.75e-05 0.001310 98.04 L-isoleucine, lipid methyl, choles-
terol (ester)
2.312 482 0.101 4.85e-05 0.001310 98.04 Lipid (methylene carbonyl)
1.122 601 0.118 4.96e-05 0.001310 98.04 Unknown
0.962 617 0.116 7.53e-05 0.001850 97.36 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.142 599 0.097 7.58e-05 0.001850 97.36 Unknown
1.482 565 0.093 8.77e-05 0.002070 96.50 Alanine
2.302 483 0.108 1.03e-04 0.002350 96.50 Lipid (methylene carbonyl)
1.722 541 0.056 1.12e-04 0.002460 97.36 Leucine, lysine
1.182 595 0.107 1.31e-04 0.002790 96.50 Lipid methylene
1.002 613 0.090 1.51e-04 0.003000 96.50 Valine, lipid methyl, cholesterol
(ester)
1.892 524 0.057 1.51e-04 0.003000 95.41 Overlap of multiple minor com-
pounds
7.312 217 0.076 1.54e-04 0.003000 92.43 Unknown
2.322 481 0.086 1.99e-04 0.003740 95.41 Lipid (methylene carbonyl)
1.132 600 0.084 2.20e-04 0.003950 95.41 Unknown
4.092 328 0.126 2.26e-04 0.003950 92.43 Unknown
1.212 592 0.139 2.28e-04 0.003950 96.50 Lipid methylene
1.972 516 0.077 2.49e-04 0.004220 94.06 Lipid allylic
1.092 604 0.095 2.65e-04 0.004350 95.41 Unknown
1.082 605 0.090 2.76e-04 0.004350 94.06 Unknown
6.832 265 0.079 2.77e-04 0.004350 90.47 Unknown
0.852 628 0.075 2.91e-04 0.004360 94.06 Cholesterol, lipid methyl
1.982 515 0.086 2.95e-04 0.004360 94.06 Lipid allylic
0.822 631 0.105 2.97e-04 0.004360 94.06 Cholesterol, lipid methyl
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1.042 609 0.131 3.08e-04 0.004370 94.06 L-isoleucine, lipid methyl, choles-
terol (ester)
1.072 606 0.085 3.12e-04 0.004370 95.41 Valine
2.352 478 0.064 3.18e-04 0.004370 92.43 Proline, glutamic acid
4.082 329 0.123 3.46e-04 0.004640 90.47 Creatinine
7.292 219 0.066 3.61e-04 0.004640 90.47 Unknown
2.132 500 0.059 3.64e-04 0.004640 92.43 Glutamine
2.292 484 0.117 3.69e-04 0.004640 94.06 Lipid (methylene carbonyl)
1.472 566 0.092 3.72e-04 0.004640 94.06 Lipid methylene
6.822 266 0.078 4.07e-04 0.004980 90.47 Unknown
7.282 220 0.066 4.21e-04 0.005040 90.47 Unknown
7.322 216 0.071 4.27e-04 0.005040 88.16 Unknown
1.012 612 0.094 4.42e-04 0.005110 92.43 Valine, lipid methyl, cholesterol
(ester)
7.262 222 0.075 4.75e-04 0.005410 88.16 Unknown
2.652 448 0.045 4.88e-04 0.005460 90.47 Unknown
1.912 522 0.058 5.42e-04 0.005960 92.43 Overlap of multiple minor com-
pounds
1.672 546 0.088 5.55e-04 0.006010 90.47 Unknown, arginine
1.062 607 0.091 5.75e-04 0.006060 94.06 Valine
7.272 221 0.070 5.78e-04 0.006060 88.16 Unknown
1.992 514 0.086 5.91e-04 0.006090 90.47 Lipid allylic
7.302 218 0.065 6.13e-04 0.006220 88.16 Unknown
1.962 517 0.063 6.49e-04 0.006490 90.47 Lipid allylic
2.362 477 0.074 6.87e-04 0.006770 90.47 Proline, glutamic acid
1.952 518 0.056 7.03e-04 0.006830 90.47 Acetic acid
7.232 225 0.065 7.62e-04 0.007290 85.48 Unknown
1.922 521 0.059 7.99e-04 0.007530 90.47 Overlap of multiple minor com-
pounds
2.282 485 0.138 8.19e-04 0.007600 90.47 Lipid (methylene carbonyl)
2.252 488 0.157 8.29e-04 0.007600 88.16 Lipid (methylene carbonyl), ace-
tone
1.252 588 0.106 8.97e-04 0.008110 90.47 Lipid methylene
2.002 513 0.084 1.03e-03 0.009160 88.16 Lipid allylic
0.952 618 0.112 1.04e-03 0.009160 90.47 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.872 526 0.051 1.06e-03 0.009200 88.16 Overlap of multiple minor com-
pounds
4.102 327 0.154 1.07e-03 0.009200 85.48 Unknown
2.202 493 0.110 1.09e-03 0.009260 88.16 Lipid (methylene carbonyl)
7.252 223 0.069 1.13e-03 0.009430 85.48 Unknown
1.422 571 0.140 1.38e-03 0.011400 88.16 Lipid methylene
0.812 632 0.107 1.45e-03 0.011800 88.16 Cholesterol, lipid methyl
2.212 492 0.134 1.62e-03 0.013000 88.16 Lipid (methylene carbonyl)
1.432 570 0.111 1.64e-03 0.013100 88.16 Lipid methylene
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1.442 569 0.101 1.86e-03 0.014500 85.48 Lipid methylene
1.732 540 0.049 1.87e-03 0.014500 88.16 Leucine, lysine
1.412 572 0.167 2.00e-03 0.015300 85.48 Lipid methylene
7.102 238 0.111 2.07e-03 0.015700 88.16 Unknown
7.722 176 -0.147 2.13e-03 0.016000 88.16 Unknown
2.192 494 0.081 2.16e-03 0.016000 82.42 Lipid (methylene carbonyl)
1.102 603 0.079 2.25e-03 0.016500 85.48 Unknown
3.062 407 0.066 2.33e-03 0.016700 82.42 Creatinine
7.182 230 0.075 2.33e-03 0.016700 82.42 Unknown
1.452 568 0.094 2.35e-03 0.016700 85.48 Lipid methylene
6.852 263 0.067 2.43e-03 0.017100 82.42 Unknown
1.662 547 0.090 2.46e-03 0.017100 82.42 Lipids (?)
2.372 476 0.070 2.81e-03 0.019100 82.42 Proline, glutamic acid
2.332 480 0.070 2.81e-03 0.019100 82.42 Proline, glutamic acid
7.332 215 0.055 2.88e-03 0.019400 78.98 Phenylalanine
0.802 633 0.100 2.91e-03 0.019400 82.42 Cholesterol, lipid methyl
1.752 538 0.052 3.09e-03 0.020300 85.48 Leucine, lysine
0.942 619 0.127 3.11e-03 0.020300 82.42 Cholesterol, lipid methyl
2.382 475 0.069 3.23e-03 0.020900 82.42 Proline, glutamic acid
1.462 567 0.081 3.29e-03 0.021100 82.42 Lipid methylene
0.792 634 0.088 3.40e-03 0.021400 78.98 Cholesterol, lipid methyl
1.402 573 0.196 3.42e-03 0.021400 82.42 Lipid methylene
2.112 502 0.067 3.44e-03 0.021400 82.42 Lipid allylic
2.012 512 0.079 3.54e-03 0.021800 78.98 Lipid allylic
7.732 175 -0.121 3.61e-03 0.022100 82.42 Unknown
1.942 519 0.099 3.86e-03 0.023200 82.42 Acetic acid
7.242 224 0.057 3.87e-03 0.023200 75.18 Unknown
0.742 639 0.127 4.01e-03 0.023800 82.42 Unkown
2.272 486 0.151 4.08e-03 0.024100 78.98 Lipid (methylene carbonyl)
2.222 491 0.134 4.23e-03 0.024500 78.98 Lipid (methylene carbonyl)
2.342 479 0.062 4.23e-03 0.024500 78.98 Proline, glutamic acid
2.232 490 0.137 5.00e-03 0.028700 78.98 Lipid (methylene carbonyl)
1.392 574 0.199 5.28e-03 0.030000 78.98 Lipid methylene
1.542 559 0.095 5.39e-03 0.030400 75.18 Lipids (?)
1.742 539 0.046 5.60e-03 0.031300 78.98 Leucine, lysine
2.102 503 0.055 5.93e-03 0.032900 75.18 Lipid allylic
1.552 558 0.117 6.41e-03 0.035000 75.18 Lipids (?)
2.082 505 0.084 6.42e-03 0.035000 75.18 Lipid allylic
1.112 602 0.068 6.53e-03 0.035200 78.98 Unknown
4.312 306 0.075 6.55e-03 0.035200 75.18 Lipid alpha-methylene to car-
boxyl, lipid glycerine
2.242 489 0.140 7.09e-03 0.037800 71.04 Lipid (methylene carbonyl), ace-
tone
4.322 305 0.067 7.31e-03 0.038600 71.04 Lipid alpha-methylene to car-
boxyl, lipid glycerine
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1.522 561 0.057 7.39e-03 0.038700 71.04 Lipids (?)
1.382 575 0.192 7.45e-03 0.038700 75.18 Lipid methylene
1.562 557 0.130 7.64e-03 0.039200 71.04 Lipids (?)
0.752 638 0.087 7.66e-03 0.039200 75.18 Cholesterol, lipid methyl
8.152 133 0.172 7.77e-03 0.039500 78.98 Unknown
0.932 620 0.138 8.23e-03 0.041500 75.18 Cholesterol, lipid methyl
1.192 594 0.136 8.39e-03 0.041900 78.98 Lipid methylene
4.112 326 0.123 8.77e-03 0.043500 66.59 Proline, lactic acid
1.652 548 0.096 8.87e-03 0.043700 71.04 Lipids (?)
6.802 268 0.071 9.47e-03 0.046300 71.04 Unknown
2.262 487 0.154 1.01e-02 0.049100 71.04 Lipid (methylene carbonyl)
Table 7.15: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values both
unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical power in
%, as well as correspondingly identified compounds of NMR features that
discriminated patients suffering from glomerulonephritis from those suffering
from systemic diseases. A false discovery rate (FDR) below 5% was applied. The
FDR was adjusted according to the method of Benjamini and Hochberg (B/H). In case
that more than one compound contributed to a significant bin, all possible assignments
are given. A question mark denotes ambiguous signal assignments, mostly due to severe
signal overlap. The statistical power was calculated with a significance level of 0.05 and a
specificity of 95%.
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
7.432 205 -0.111 1.23e-12 8.09e-10 100.00 Phenylalanine
3.042 409 -0.035 4.51e-10 1.49e-07 100.00 Lysine, unknown
7.202 228 -0.097 3.64e-08 8.01e-06 99.99 Tyrosine
2.552 458 -0.067 1.08e-07 1.79e-05 99.73 Citric acid
2.902 423 -0.063 4.37e-07 4.21e-05 99.85 Unknown
3.782 359 -0.079 4.80e-07 4.21e-05 99.99 D-glucose, alanine, glutamine,
arginine
2.572 456 -0.055 4.86e-07 4.21e-05 99.53 CaEDTA2−, citric acid
3.052 408 -0.042 5.24e-07 4.21e-05 99.92 Creatinine
3.792 358 -0.060 5.75e-07 4.21e-05 99.99 D-glucose, alanine
2.972 416 -0.031 7.78e-07 5.14e-05 99.85 Unknown
3.472 377 -0.110 8.84e-07 5.30e-05 99.99 D-glucose
3.802 357 -0.083 1.69e-06 9.32e-05 99.98 D-glucose, alanine
2.892 424 -0.058 1.97e-06 9.81e-05 99.73 Lipid diallylic
3.752 362 -0.101 2.08e-06 9.81e-05 99.96 D-glucose, glutamic acid
6.922 256 -0.084 2.33e-06 9.82e-05 99.73 Tyrosine
3.852 352 -0.098 2.42e-06 9.82e-05 99.96 D-glucose, unknown
7.442 204 -0.066 2.53e-06 9.82e-05 99.85 Phenylalanine
3.912 346 -0.091 3.54e-06 1.27e-04 99.96 D-glucose, betaine, unknown
200
7.3 Appendix III: German Chronic Kidney Disease Study
3.932 344 -0.093 3.65e-06 1.27e-04 99.96 D-glucose
3.422 382 -0.108 3.89e-06 1.28e-04 99.92 D-glucose, carnitine, taurine, pro-
line
1.492 564 -0.078 4.51e-06 1.42e-04 99.53 Alanine
1.052 608 -0.119 4.78e-06 1.43e-04 99.53 Valine
7.562 192 0.104 5.11e-06 1.43e-04 99.85 Unknown
1.792 534 0.069 5.36e-06 1.43e-04 99.53 Unknown
2.932 420 -0.058 5.41e-06 1.43e-04 99.53 Unknown
1.502 563 -0.079 6.08e-06 1.54e-04 99.53 Alanine
2.692 444 -0.048 8.10e-06 1.98e-04 97.97 Citric acid
3.452 379 -0.089 8.78e-06 2.07e-04 99.92 D-glucose, carnitine, proline
2.942 419 -0.032 1.01e-05 2.31e-04 99.21 N,N-dimethylglycine
3.842 353 -0.087 1.09e-05 2.41e-04 99.85 D-glucose, unknown
3.552 369 -0.092 1.44e-05 3.06e-04 99.85 D-glucose, myo-inositol
3.732 364 -0.088 1.57e-05 3.23e-04 99.73 D-glucose, unknown
3.562 368 -0.089 1.76e-05 3.53e-04 99.85 D-glucose
2.672 446 -0.070 2.01e-05 3.89e-04 97.97 Citric acid
4.072 330 -0.096 2.24e-05 4.23e-04 98.71 Creatinine
3.482 376 -0.096 2.64e-05 4.84e-04 99.73 D-glucose
2.372 476 -0.068 2.90e-05 5.18e-04 98.71 Proline, glutamic acid
3.542 370 -0.086 3.06e-05 5.31e-04 98.71 D-glucose, myo-inositol
1.782 535 0.066 3.23e-05 5.46e-04 98.71 Unknown
1.012 612 -0.077 3.44e-05 5.68e-04 98.71 Valine, lipid methyl, cholesterol
(ester)
3.512 373 -0.096 3.86e-05 6.22e-04 99.73 D-glucose
3.572 367 -0.081 4.24e-05 6.67e-04 99.53 D-glucose, glycine
2.382 475 -0.066 4.40e-05 6.76e-04 97.97 Proline, glutamic acid
3.872 350 -0.071 4.51e-05 6.76e-04 99.53 D-glucose, unknown
3.742 363 -0.086 5.86e-05 8.46e-04 99.53 D-glucose, leucine
3.442 380 -0.090 5.89e-05 8.46e-04 99.53 D-glucose, carnitine, taurine, pro-
line
3.722 365 -0.073 6.19e-05 8.69e-04 99.53 D-glucose, N,N-dimethylglycine
3.822 355 -0.060 6.65e-05 9.15e-04 98.71 Unknown
2.542 459 -0.052 6.89e-05 9.17e-04 96.90 Unknown
2.502 463 0.069 7.04e-05 9.17e-04 97.97 Unknown
3.762 361 -0.079 7.09e-05 9.17e-04 99.53 D-glucose, arginine, glutamine,
glutamic acid
7.572 191 0.101 7.53e-05 9.55e-04 98.71 Unknown
3.502 374 -0.091 8.75e-05 1.09e-03 99.21 D-glucose
3.522 372 -0.100 9.36e-05 1.14e-03 98.71 D-glucose
3.412 383 -0.088 9.81e-05 1.18e-03 99.21 D-glucose, carnitine, taurine, pro-
line
3.832 354 -0.051 1.02e-04 1.20e-03 97.97 Unknown
3.432 381 -0.088 1.07e-04 1.24e-03 99.21 D-glucose, carnitine, taurine, pro-
line
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3.032 410 -0.023 1.16e-04 1.31e-03 97.97 Lysine, unknown
7.402 208 -0.049 1.24e-04 1.38e-03 97.97 Phenylalanine
3.532 371 -0.079 1.31e-04 1.45e-03 99.21 D-glucose
1.072 606 -0.062 1.38e-04 1.47e-03 96.90 Valine
7.412 207 0.090 1.38e-04 1.47e-03 97.97 Phenylalanine
1.002 613 -0.062 1.53e-04 1.61e-03 96.90 Valine, lipid methyl, cholesterol
(ester)
2.872 426 -0.083 1.56e-04 1.61e-03 95.39 Lipid diallylic
3.862 351 -0.081 1.67e-04 1.70e-03 99.21 D-glucose, unknown
1.802 533 0.047 1.74e-04 1.74e-03 95.39 Unknown
3.812 356 -0.063 2.75e-04 2.71e-03 97.97 D-glucose
2.662 447 -0.071 3.27e-04 3.18e-03 93.34 Citric acid
0.882 625 0.071 3.32e-04 3.18e-03 95.39 Cholesterol, lipid methyl
7.552 193 0.088 4.03e-04 3.80e-03 96.90 Unknown
4.152 322 -0.069 4.46e-04 4.11e-03 95.39 Proline, lactic acid
6.882 260 0.050 4.48e-04 4.11e-03 93.34 Unknown
3.772 360 -0.065 4.76e-04 4.30e-03 96.90 D-glucose, alanine, glutamine,
arginine
0.892 624 0.079 4.84e-04 4.32e-03 93.34 Cholesterol, lipid methyl
7.312 217 0.048 5.36e-04 4.71e-03 93.34 Unknown
2.362 477 -0.052 5.51e-04 4.73e-03 93.34 Proline, glutamic acid
3.982 339 0.040 5.52e-04 4.73e-03 93.34 Unknown
7.292 219 0.044 5.79e-04 4.90e-03 93.34 Unknown
2.562 457 -0.029 6.29e-04 5.19e-03 90.64 CaEDTA2−
2.862 427 -0.094 6.30e-04 5.19e-03 93.34 Lipid diallylic
6.912 257 -0.061 6.37e-04 5.19e-03 93.34 Tyrosine
3.492 375 -0.079 6.82e-04 5.49e-03 96.90 D-glucose
6.852 263 0.052 6.94e-04 5.52e-03 93.34 Unknown
4.142 323 -0.084 7.91e-04 6.22e-03 93.34 Proline, lactic acid
7.302 218 0.044 8.01e-04 6.22e-03 90.64 Unknown
3.882 349 -0.065 8.47e-04 6.50e-03 96.90 D-glucose, unknown
3.152 398 -0.022 9.37e-04 7.11e-03 87.22 CaEDTA2−
7.352 213 -0.037 1.08e-03 8.09e-03 90.64 Phenylalanine
4.132 324 -0.087 1.09e-03 8.11e-03 90.64 Proline, lactic acid
7.582 190 0.080 1.24e-03 9.10e-03 90.64 Unknown
1.082 605 -0.054 1.41e-03 1.03e-02 87.22 Unknown
1.812 532 0.036 1.53e-03 1.09e-02 87.22 Unknown
3.312 393 -0.066 1.53e-03 1.09e-02 90.64 Unknown
7.032 245 0.080 1.56e-03 1.09e-02 90.64 Unknown
8.492 99 -0.246 1.57e-03 1.09e-02 90.64 Formic acid
3.402 384 -0.059 1.75e-03 1.21e-02 90.64 Unknown
1.822 531 0.034 1.78e-03 1.21e-02 87.22 Unknown
4.122 325 -0.073 1.81e-03 1.22e-02 87.22 Proline, lactic acid
2.982 415 -0.019 2.05e-03 1.37e-02 87.22 Unknown
2.912 422 -0.039 2.08e-03 1.37e-02 87.22 Unknown
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1.832 530 0.032 2.20e-03 1.44e-02 87.22 Unknown
2.882 425 -0.054 2.29e-03 1.48e-02 87.22 Lipid diallylic
7.042 244 0.070 2.31e-03 1.48e-02 87.22 Unknown
3.122 401 -0.022 2.42e-03 1.54e-02 78.01 CaEDTA2−
1.102 603 -0.053 3.01e-03 1.89e-02 83.01 Unknown
8.162 132 0.139 3.82e-03 2.38e-02 83.01 Unknown
2.682 445 -0.031 4.01e-03 2.47e-02 78.01 Citric acid
8.382 110 0.217 4.25e-03 2.60e-02 78.01 Unknown
8.452 103 0.214 4.29e-03 2.60e-02 83.01 Unknown
7.022 246 0.097 4.44e-03 2.66e-02 83.01 Unknown
7.392 209 -0.034 4.48e-03 2.67e-02 83.01 Phenylalanine
2.742 439 0.038 4.74e-03 2.79e-02 78.01 Lipid diallylic
1.912 522 -0.032 4.97e-03 2.90e-02 78.01 Overlap of multiple minor com-
pounds
2.392 474 -0.049 5.11e-03 2.94e-02 83.01 Unknown
2.852 428 -0.081 5.13e-03 2.94e-02 78.01 Lipid diallylic
4.052 332 -0.070 5.34e-03 3.04e-02 83.01 Unknown
7.592 189 0.065 5.46e-03 3.08e-02 83.01 Unknown
8.732 75 -0.243 5.71e-03 3.19e-02 78.01 Unknown
8.212 127 0.081 5.81e-03 3.22e-02 83.01 Unknown
7.232 225 0.036 7.41e-03 4.06e-02 72.25 Unknown
8.252 123 0.052 7.43e-03 4.06e-02 78.01 Unknown
7.062 242 0.050 7.92e-03 4.29e-02 78.01 Unknown
8.232 125 0.053 8.25e-03 4.43e-02 78.01 Unknown
1.742 539 -0.030 8.46e-03 4.50e-02 72.25 Leucine, lysine
4.002 337 0.027 8.65e-03 4.57e-02 78.01 Unknown
7.052 243 0.045 8.75e-03 4.58e-02 78.01 Unknown
6.862 262 0.047 8.87e-03 4.61e-02 72.25 Unknown
2.722 441 -0.026 9.30e-03 4.80e-02 72.25 MgEDTA2−
7.282 220 0.034 9.39e-03 4.80e-02 72.25 Unknown
2.492 464 0.032 9.45e-03 4.80e-02 78.01 Glutamine
Table 7.16: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values both
unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical power in
%, as well as correspondingly identified compounds of NMR features that
discriminated patients suffering from glomerulonephritis from those suffering
from hypertensive nephropathy. A false discovery rate (FDR) below 5% was applied.
The FDR was adjusted according to the method of Benjamini and Hochberg (B/H). In case
that more than one compound contributed to a significant bin, all possible assignments
are given. A question mark denotes ambiguous signal assignments, mostly due to severe
signal overlap. The statistical power was calculated with a significance level of 0.05 and a
specificity of 95%.
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Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
6.922 256 -0.149 0.000192 0.0487 95.34 Tyrosine
7.222 226 -0.129 0.000198 0.0487 94.50 Tyrosine
6.912 257 -0.148 0.000221 0.0487 95.34 Tyrosine
Table 7.17: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values both
unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical power in
%, as well as correspondingly identified compounds of NMR features that
discriminated patients suffering from hereditary diseases from those suffering
from interstitial nephropathy. A false discovery rate (FDR) below 5% was applied.
The FDR was adjusted according to the method of Benjamini and Hochberg (B/H). In case
that more than one compound contributed to a significant bin, all possible assignments
are given. A question mark denotes ambiguous signal assignments, mostly due to severe
signal overlap. The statistical power was calculated with a significance level of 0.05 and a
specificity of 95%.
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
3.062 407 0.163 9.34e-08 6.17e-05 99.96 Tyrosine
4.072 330 0.185 6.38e-05 2.11e-02 98.69 Tyrosine
4.132 324 -0.207 1.50e-04 3.30e-02 94.53 Tyrosine
Table 7.18: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values both
unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical power in
%, as well as correspondingly identified compounds of NMR features that
discriminated patients suffering from hereditary diseases from those suffering
from systemic diseases. A false discovery rate (FDR) below 5% was applied. The
FDR was adjusted according to the method of Benjamini and Hochberg (B/H). In case
that more than one compound contributed to a significant bin, all possible assignments
are given. A question mark denotes ambiguous signal assignments, mostly due to severe
signal overlap. The statistical power was calculated with a significance level of 0.05 and a
specificity of 95%.
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
4.122 325 -0.215 1.86e-07 0.000123 99.96 Proline, lactic acid
1.232 590 -0.158 4.53e-07 0.000150 99.94 Lipid methylene
1.112 602 -0.148 1.14e-06 0.000173 99.88 Unknown
7.222 226 -0.132 1.17e-06 0.000173 99.83 Tyrosine
1.242 589 -0.168 1.31e-06 0.000173 99.88 Lipid methylene
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4.132 324 -0.224 1.79e-06 0.000190 99.76 Proline, lactic acid
6.922 256 -0.146 2.81e-06 0.000190 99.76 Tyrosine
3.962 341 -0.078 3.12e-06 0.000190 99.76 Unknown
1.342 579 -0.238 3.25e-06 0.000190 99.67 Lipid methylene, lactic acid, thre-
onine
1.152 598 -0.157 3.42e-06 0.000190 99.39 Lipid methylene
7.202 228 -0.143 3.49e-06 0.000190 99.67 Tyrosine
1.102 603 -0.145 3.53e-06 0.000190 99.67 Unknown
1.362 577 -0.258 3.94e-06 0.000190 99.67 Lipid methylene, lactic acid, thre-
onine
4.142 323 -0.202 4.03e-06 0.000190 99.67 Proline, lactic acid
1.132 600 -0.125 5.46e-06 0.000240 99.67 Unknown
1.352 578 -0.232 7.58e-06 0.000313 99.39 Lipid methylene, lactic acid, thre-
onine
6.912 257 -0.139 8.64e-06 0.000335 99.39 Tyrosine
1.222 591 -0.173 9.92e-06 0.000364 98.60 Lipid methylene
1.252 588 -0.169 1.19e-05 0.000414 99.39 Lipid methylene
7.212 227 -0.125 1.32e-05 0.000434 99.39 Tyrosine
1.162 597 -0.182 1.97e-05 0.000600 97.03 Lipid methylene
2.382 475 -0.121 2.00e-05 0.000600 98.93 Proline, glutamic acid
4.152 322 -0.146 2.46e-05 0.000663 99.19 Proline, lactic acid
1.172 596 -0.168 2.49e-05 0.000663 97.03 Lipid methylene
2.312 482 -0.126 2.51e-05 0.000663 99.19 Lipid (methylene carbonyl)
4.312 306 -0.140 2.95e-05 0.000748 98.93 Lipid alpha-methylene to car-
boxyl, lipid glycerine
2.282 485 -0.206 3.61e-05 0.000883 98.60 Lipid (methylene carbonyl)
2.292 484 -0.164 4.00e-05 0.000943 98.60 Lipid (methylene carbonyl)
1.142 599 -0.122 4.20e-05 0.000957 98.60 Unknown
1.002 613 -0.117 5.06e-05 0.001110 98.60 Valine, lipid methyl, cholesterol
(ester)
1.972 516 -0.102 5.47e-05 0.001160 98.93 Lipid allylic
2.362 477 -0.107 5.71e-05 0.001180 98.60 Proline, glutamic acid
0.852 628 -0.101 6.67e-05 0.001320 98.60 Cholesterol, lipid methyl
1.462 567 -0.133 6.79e-05 0.001320 98.18 Lipid methylene
2.272 486 -0.253 7.32e-05 0.001380 98.18 Lipid (methylene carbonyl)
1.452 568 -0.148 7.96e-05 0.001460 98.18 Lipid methylene
4.322 305 -0.118 8.49e-05 0.001510 98.18 Lipid alpha-methylene to car-
boxyl, lipid glycerine
0.842 629 -0.100 8.77e-05 0.001520 98.18 Cholesterol, lipid methyl
1.982 515 -0.112 9.20e-05 0.001560 98.18 Lipid allylic
1.682 545 -0.100 9.82e-05 0.001590 98.60 Unknown, arginine
1.962 517 -0.087 9.89e-05 0.001590 98.18 Lipid allylic
2.372 476 -0.111 1.02e-04 0.001610 97.66 Proline, glutamic acid
2.302 483 -0.129 1.19e-04 0.001780 97.66 Lipid (methylene carbonyl)
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0.962 617 -0.136 1.19e-04 0.001780 97.66 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.092 604 -0.120 1.28e-04 0.001850 97.03 Unknown
1.262 587 -0.160 1.29e-04 0.001850 97.66 Lipid methylene
0.952 618 -0.159 1.33e-04 0.001860 97.03 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
2.122 501 -0.101 1.37e-04 0.001890 97.66 Lipid allylic
1.692 544 -0.085 1.45e-04 0.001960 98.18 Unknown, arginine
1.482 565 -0.109 1.48e-04 0.001960 97.66 Alanine
2.822 431 -0.201 1.63e-04 0.002080 97.03 Lipid diallylic
1.412 572 -0.246 1.64e-04 0.002080 97.03 Lipid methylene
1.402 573 -0.305 1.69e-04 0.002080 97.03 Lipid methylene
3.452 379 -0.132 1.71e-04 0.002080 98.60 D-glucose, carnitine, proline
2.862 427 -0.181 1.73e-04 0.002080 97.03 Lipid diallylic
1.082 605 -0.112 1.86e-04 0.002190 97.03 Unknown
0.942 619 -0.195 1.89e-04 0.002190 96.25 Cholesterol, lipid methyl
1.672 546 -0.115 1.95e-04 0.002210 97.03 Unknown, arginine
1.422 571 -0.197 2.02e-04 0.002260 96.25 Lipid methylene
2.322 481 -0.103 2.23e-04 0.002450 97.03 Lipid (methylene carbonyl)
2.262 487 -0.267 2.28e-04 0.002460 96.25 Lipid (methylene carbonyl)
0.972 616 -0.118 2.39e-04 0.002520 97.03 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.522 561 -0.094 2.41e-04 0.002520 97.03 Lipids (?)
2.852 428 -0.187 2.45e-04 0.002520 96.25 Lipid diallylic
3.812 356 -0.110 2.49e-04 0.002530 97.03 D-glucose
1.472 566 -0.114 2.60e-04 0.002590 96.25 Lipid methylene
4.332 304 -0.106 2.63e-04 0.002590 96.25 Lipid alpha-methylene to car-
boxyl, lipid glycerine
2.252 488 -0.207 2.70e-04 0.002620 96.25 Lipid (methylene carbonyl), ace-
tone
1.992 514 -0.110 2.76e-04 0.002640 97.03 Lipid allylic
1.662 547 -0.131 2.83e-04 0.002650 96.25 Lipids (?)
1.392 574 -0.313 2.85e-04 0.002650 95.32 Lipid methylene
3.882 349 -0.124 3.02e-04 0.002710 97.66 D-glucose, unknown
1.492 564 -0.107 3.03e-04 0.002710 96.25 Alanine
0.932 620 -0.228 3.04e-04 0.002710 95.32 Cholesterol, lipid methyl
2.832 430 -0.189 3.29e-04 0.002890 95.32 Lipid diallylic
2.132 500 -0.071 3.37e-04 0.002890 97.03 Glutamine
1.212 592 -0.163 3.38e-04 0.002890 91.39 Lipid methylene
3.782 359 -0.098 3.44e-04 0.002900 97.66 D-glucose, alanine, glutamine,
arginine
3.802 357 -0.108 3.47e-04 0.002900 97.66 D-glucose, alanine
1.272 586 -0.160 3.61e-04 0.002960 95.32 Lipid methylene
4.302 307 -0.133 3.63e-04 0.002960 95.32 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
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1.012 612 -0.116 3.81e-04 0.003070 95.32 Valine, lipid methyl, cholesterol
(ester)
1.442 569 -0.138 4.03e-04 0.003190 95.32 Lipid methylene
3.762 361 -0.124 4.12e-04 0.003190 97.03 D-glucose, arginine, glutamine,
glutamic acid
0.992 614 -0.117 4.13e-04 0.003190 95.32 Leucine, lipid methyl, cholesterol
(ester)
2.872 426 -0.136 4.16e-04 0.003190 95.32 Lipid diallylic
1.432 570 -0.150 4.27e-04 0.003240 95.32 Lipid methylene
2.652 448 -0.055 4.47e-04 0.003350 95.32 Unknown
1.622 551 -0.245 4.62e-04 0.003400 94.21 Lipids (?)
1.612 552 -0.264 4.64e-04 0.003400 94.21 Lipids (?)
3.442 380 -0.137 4.73e-04 0.003410 97.03 D-glucose, carnitine, taurine, pro-
line
1.502 563 -0.107 4.76e-04 0.003410 94.21 Alanine
2.842 429 -0.189 4.88e-04 0.003440 95.32 Lipid diallylic
3.922 345 -0.097 4.89e-04 0.003440 96.25 D-glucose, unknown
3.842 353 -0.120 5.18e-04 0.003600 97.03 D-glucose, unknown
3.772 360 -0.113 5.27e-04 0.003620 95.32 D-glucose, alanine, glutamine,
arginine
1.182 595 -0.117 5.39e-04 0.003660 94.21 Lipid methylene
1.072 606 -0.098 5.51e-04 0.003660 94.21 Valine
1.382 575 -0.301 5.53e-04 0.003660 94.21 Lipid methylene
1.702 543 -0.068 5.54e-04 0.003660 95.32 Unknown, arginine
1.532 560 -0.110 5.70e-04 0.003720 94.21 Lipids (?)
2.812 432 -0.183 5.86e-04 0.003790 94.21 Lipid diallylic
4.342 303 -0.100 6.23e-04 0.003990 94.21 Lipid alpha-methylene to car-
boxyl, lipid glycerine
0.982 615 -0.110 6.54e-04 0.004150 94.21 Leucine, lipid methyl, cholesterol
(ester)
3.742 363 -0.127 6.98e-04 0.004370 96.25 D-glucose, leucine
3.482 376 -0.136 7.01e-04 0.004370 96.25 D-glucose
3.872 350 -0.103 7.12e-04 0.004390 95.32 D-glucose, unknown
1.632 550 -0.207 7.32e-04 0.004440 92.91 Lipids (?)
3.972 340 -0.057 7.33e-04 0.004440 94.21 Unknown
3.432 381 -0.134 7.41e-04 0.004440 96.25 D-glucose, carnitine, taurine, pro-
line
3.852 352 -0.122 7.51e-04 0.004470 95.32 D-glucose, unknown
1.512 562 -0.106 7.69e-04 0.004530 94.21 Alanine
3.862 351 -0.126 7.83e-04 0.004560 95.32 D-glucose, unknown
1.332 580 -0.268 7.88e-04 0.004560 92.91 Lipid methylene
2.902 423 -0.073 8.11e-04 0.004650 94.21 Unknown
3.502 374 -0.137 8.21e-04 0.004670 95.32 D-glucose
3.912 346 -0.115 8.49e-04 0.004760 95.32 D-glucose, betaine, unknown
1.652 548 -0.148 8.52e-04 0.004760 92.91 Lipids (?)
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3.722 365 -0.106 8.94e-04 0.004920 95.32 D-glucose, N,N-dimethylglycine
1.602 553 -0.259 9.00e-04 0.004920 92.91 Lipids (?)
1.552 558 -0.172 9.03e-04 0.004920 92.91 Lipids (?)
3.412 383 -0.132 9.12e-04 0.004920 95.32 D-glucose, carnitine, taurine, pro-
line
2.222 491 -0.188 9.17e-04 0.004920 92.91 Lipid (methylene carbonyl)
3.532 371 -0.120 9.75e-04 0.005150 95.32 D-glucose
3.492 375 -0.134 9.79e-04 0.005150 95.32 D-glucose
1.642 549 -0.175 9.84e-04 0.005150 91.39 Lipids (?)
1.372 576 -0.286 1.01e-03 0.005230 91.39 Lipid methylene
0.922 621 -0.222 1.04e-03 0.005330 91.39 Cholesterol, lipid methyl
3.472 377 -0.129 1.04e-03 0.005330 95.32 D-glucose
3.512 373 -0.134 1.05e-03 0.005330 95.32 D-glucose
0.832 630 -0.092 1.06e-03 0.005330 91.39 Cholesterol, lipid methyl
2.112 502 -0.090 1.07e-03 0.005330 91.39 Lipid allylic
3.932 344 -0.115 1.09e-03 0.005400 94.21 D-glucose
1.302 583 -0.223 1.13e-03 0.005570 91.39 Lipid methylene
1.542 559 -0.135 1.14e-03 0.005570 91.39 Lipids (?)
2.392 474 -0.099 1.15e-03 0.005590 91.39 Unknown
2.642 449 -0.058 1.21e-03 0.005800 92.91 Unknown
3.792 358 -0.068 1.21e-03 0.005800 95.32 D-glucose, alanine
2.002 513 -0.099 1.31e-03 0.006210 91.39 Lipid allylic
1.312 582 -0.233 1.32e-03 0.006210 89.64 Lipid methylene
1.122 601 -0.112 1.34e-03 0.006230 89.64 Unknown
3.822 355 -0.084 1.34e-03 0.006230 92.91 Unknown
2.792 434 -0.136 1.35e-03 0.006230 91.39 Lipid diallylic
1.062 607 -0.103 1.37e-03 0.006260 89.64 Valine
3.572 367 -0.110 1.45e-03 0.006600 94.21 D-glucose, glycine
3.752 362 -0.118 1.47e-03 0.006650 92.91 D-glucose, glutamic acid
1.022 611 -0.106 1.51e-03 0.006790 89.64 L-isoleucine, lipid methyl, choles-
terol (ester)
1.322 581 -0.241 1.55e-03 0.006870 89.64 Lipid methylene
1.952 518 -0.064 1.55e-03 0.006870 89.64 Acetic acid
4.112 326 -0.180 1.57e-03 0.006870 91.39 Proline, lactic acid
3.462 378 -0.100 1.58e-03 0.006870 91.39 D-glucose
3.562 368 -0.114 1.58e-03 0.006870 92.91 D-glucose
4.102 327 -0.180 1.61e-03 0.006960 91.39 Unknown
4.292 308 -0.114 1.63e-03 0.007010 89.64 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
2.232 490 -0.185 1.70e-03 0.007230 89.64 Lipid (methylene carbonyl)
3.552 369 -0.117 1.73e-03 0.007330 92.91 D-glucose, myo-inositol
3.892 348 -0.060 1.80e-03 0.007560 89.64 Unknown
2.212 492 -0.160 1.86e-03 0.007760 89.64 Lipid (methylene carbonyl)
9.402 8 0.476 1.87e-03 0.007760 85.39 Unknown
1.562 557 -0.184 1.91e-03 0.007880 89.64 Lipids (?)
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3.942 343 -0.122 2.03e-03 0.008260 91.39 D-glucose
1.282 585 -0.150 2.03e-03 0.008260 87.64 Lipid methylene
1.712 542 -0.055 2.08e-03 0.008420 89.64 Leucine, lysine
2.242 489 -0.194 2.14e-03 0.008610 87.64 Lipid (methylene carbonyl), ace-
tone
1.592 554 -0.234 2.17e-03 0.008680 87.64 Lipids (?)
2.102 503 -0.073 2.21e-03 0.008780 87.64 Lipid allylic
1.842 529 -0.060 2.25e-03 0.008870 89.64 Unknown
2.082 505 -0.113 2.38e-03 0.009340 87.64 Lipid allylic
0.822 631 -0.105 2.74e-03 0.010600 85.39 Cholesterol, lipid methyl
2.332 480 -0.085 2.74e-03 0.010600 85.39 Proline, glutamic acid
1.572 556 -0.194 2.75e-03 0.010600 87.64 Lipids (?)
3.422 382 -0.123 2.77e-03 0.010600 89.64 D-glucose, carnitine, taurine, pro-
line
3.522 372 -0.134 2.85e-03 0.010900 87.64 D-glucose
4.242 313 -0.163 2.88e-03 0.010900 87.64 Unknown
2.802 433 -0.138 2.99e-03 0.011300 87.64 Lipid diallylic
1.582 555 -0.211 3.09e-03 0.011600 85.39 Lipids (?)
4.252 312 -0.128 3.55e-03 0.013200 85.39 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
3.732 364 -0.104 3.56e-03 0.013200 89.64 D-glucose, unknown
0.862 627 -0.083 3.81e-03 0.014000 87.64 Cholesterol, lipid methyl
4.352 302 -0.088 4.17e-03 0.015300 82.88 Lipid alpha-methylene to car-
boxyl, lipid glycerine
1.832 530 -0.051 5.06e-03 0.018500 85.39 Unknown
3.062 407 0.073 5.11e-03 0.018500 85.39 Creatinine
2.782 435 -0.121 5.15e-03 0.018600 82.88 Lipid diallylic
1.192 594 -0.175 5.24e-03 0.018800 73.82 Lipid methylene
1.862 527 -0.055 5.47e-03 0.019500 82.88 Unknown
7.272 221 -0.068 5.50e-03 0.019500 85.39 Unknown
2.622 451 -0.040 5.66e-03 0.020000 82.88 Unknown
3.902 347 -0.048 5.75e-03 0.020200 80.11 D-glucose, unknown
7.262 222 -0.071 6.15e-03 0.021500 85.39 Unknown
1.292 584 -0.156 6.29e-03 0.021900 80.11 Lipid methylene
0.812 632 -0.110 6.49e-03 0.022400 77.08 Cholesterol, lipid methyl
4.232 314 -0.154 6.54e-03 0.022500 80.11 Unknown
2.912 422 -0.061 6.85e-03 0.023400 82.88 Unknown
1.202 593 -0.200 6.91e-03 0.023400 70.33 Lipid methylene
1.852 528 -0.054 6.91e-03 0.023400 80.11 Unknown
6.772 271 0.273 7.56e-03 0.025500 77.08 Unknown
4.362 301 -0.088 7.90e-03 0.026500 77.08 Unknown
2.042 509 -0.118 8.11e-03 0.027000 77.08 Lipid allylic
2.012 512 -0.087 8.38e-03 0.027800 77.08 Lipid allylic
2.202 493 -0.107 8.54e-03 0.028200 77.08 Lipid (methylene carbonyl)
2.632 450 -0.043 8.65e-03 0.028400 77.08 Unknown
209
7 Appendix
2.032 510 -0.109 9.61e-03 0.031400 77.08 Lipid allylic
7.252 223 -0.066 9.68e-03 0.031500 80.11 Unknown
4.282 309 -0.076 1.02e-02 0.033100 73.82 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
2.342 479 -0.067 1.05e-02 0.033700 73.82 Proline, glutamic acid
0.912 622 -0.160 1.09e-02 0.034800 73.82 Cholesterol, lipid methyl
0.602 653 0.371 1.15e-02 0.036700 70.33 Unkown
1.722 541 -0.044 1.17e-02 0.037200 73.82 Leucine, lysine
1.872 526 -0.048 1.18e-02 0.037200 77.08 Overlap of multiple minor com-
pounds
4.222 315 -0.140 1.19e-02 0.037300 70.33 Unknown
6.782 270 0.158 1.19e-02 0.037300 73.82 Unknown
2.352 478 -0.054 1.20e-02 0.037400 77.08 Proline, glutamic acid
1.032 610 -0.091 1.22e-02 0.037900 73.82 L-isoleucine, lipid methyl, choles-
terol (ester)
2.072 506 -0.077 1.24e-02 0.038200 73.82 Lipid allylic
4.262 311 -0.087 1.26e-02 0.038600 73.82 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
2.882 425 -0.077 1.29e-02 0.039400 70.33 Lipid diallylic
0.802 633 -0.101 1.30e-02 0.039500 70.33 Cholesterol, lipid methyl
2.402 473 -0.043 1.31e-02 0.039500 77.08 Glutamine, carnitine
2.022 511 -0.092 1.38e-02 0.041500 73.82 Lipid allylic
3.832 354 -0.056 1.41e-02 0.042400 73.82 Unknown
8.002 148 0.231 1.54e-02 0.045900 70.33 Unknown
4.372 300 -0.097 1.57e-02 0.046800 66.64 Unknown
8.822 66 -0.366 1.63e-02 0.048200 66.64 Unknown
Table 7.19: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values both
unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical power in
%, as well as correspondingly identified compounds of NMR features that
discriminated patients suffering from hereditary diseases from those suffering
from hypertensive nephropathy. A false discovery rate (FDR) below 5% was applied.
The FDR was adjusted according to the method of Benjamini and Hochberg (B/H). In case
that more than one compound contributed to a significant bin, all possible assignments
are given. A question mark denotes ambiguous signal assignments, mostly due to severe
signal overlap. The statistical power was calculated with a significance level of 0.05 and a
specificity of 95%.
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
1.212 592 -0.187 1.91e-05 0.00817 97.92 Lipid methylene
1.222 591 -0.159 2.47e-05 0.00817 97.92 Lipid methylene
2.312 482 -0.116 5.72e-05 0.01240 98.40 Lipid (methylene carbonyl)
1.232 590 -0.117 9.31e-05 0.01240 98.40 Lipid methylene
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4.112 326 -0.213 1.01e-04 0.01240 98.40 Proline, lactic acid
2.362 477 -0.098 1.26e-04 0.01240 97.31 Proline, glutamic acid
2.282 485 -0.181 1.56e-04 0.01240 97.31 Lipid (methylene carbonyl)
2.292 484 -0.144 1.65e-04 0.01240 96.57 Lipid (methylene carbonyl)
2.302 483 -0.121 1.69e-04 0.01240 97.31 Lipid (methylene carbonyl)
1.132 600 -0.099 1.91e-04 0.01240 96.57 Unknown
4.302 307 -0.131 2.44e-04 0.01240 96.57 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
2.322 481 -0.098 2.48e-04 0.01240 96.57 Lipid (methylene carbonyl)
1.162 597 -0.150 2.49e-04 0.01240 91.75 Lipid methylene
2.382 475 -0.100 2.75e-04 0.01240 95.66 Proline, glutamic acid
1.112 602 -0.106 2.97e-04 0.01240 95.66 Unknown
1.172 596 -0.139 3.01e-04 0.01240 91.75 Lipid methylene
2.242 489 -0.218 3.29e-04 0.01250 95.66 Lipid (methylene carbonyl), ace-
tone
4.292 308 -0.125 3.41e-04 0.01250 95.66 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
2.232 490 -0.201 3.91e-04 0.01300 95.66 Lipid (methylene carbonyl)
2.272 486 -0.218 3.93e-04 0.01300 95.66 Lipid (methylene carbonyl)
2.372 476 -0.096 4.81e-04 0.01370 94.57 Proline, glutamic acid
3.462 378 -0.106 5.06e-04 0.01370 96.57 D-glucose
1.012 612 -0.109 5.10e-04 0.01370 94.57 Valine, lipid methyl, cholesterol
(ester)
2.332 480 -0.094 5.86e-04 0.01370 94.57 Proline, glutamic acid
1.002 613 -0.095 5.88e-04 0.01370 93.28 Valine, lipid methyl, cholesterol
(ester)
2.342 479 -0.086 5.94e-04 0.01370 94.57 Proline, glutamic acid
4.282 309 -0.097 5.95e-04 0.01370 94.57 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
1.402 573 -0.268 6.02e-04 0.01370 93.28 Lipid methylene
0.832 630 -0.093 6.03e-04 0.01370 93.28 Cholesterol, lipid methyl
1.412 572 -0.215 6.40e-04 0.01370 93.28 Lipid methylene
3.402 384 -0.108 7.06e-04 0.01370 94.57 Unknown
2.262 487 -0.235 7.30e-04 0.01370 93.28 Lipid (methylene carbonyl)
1.392 574 -0.280 7.58e-04 0.01370 93.28 Lipid methylene
2.252 488 -0.184 7.74e-04 0.01370 94.57 Lipid (methylene carbonyl), ace-
tone
2.222 491 -0.183 7.81e-04 0.01370 91.75 Lipid (methylene carbonyl)
1.382 575 -0.281 7.90e-04 0.01370 93.28 Lipid methylene
1.432 570 -0.137 7.99e-04 0.01370 91.75 Lipid methylene
1.152 598 -0.109 8.08e-04 0.01370 89.98 Lipid methylene
2.852 428 -0.164 8.11e-04 0.01370 93.28 Lipid diallylic
1.422 571 -0.170 8.28e-04 0.01370 91.75 Lipid methylene
4.312 306 -0.108 8.71e-04 0.01400 93.28 Lipid alpha-methylene to car-
boxyl, lipid glycerine
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1.442 569 -0.125 9.13e-04 0.01400 91.75 Lipid methylene
2.912 422 -0.071 9.14e-04 0.01400 94.57 Unknown
2.862 427 -0.154 9.38e-04 0.01410 91.75 Lipid diallylic
1.142 599 -0.094 1.04e-03 0.01510 91.75 Unknown
0.842 629 -0.080 1.05e-03 0.01510 91.75 Cholesterol, lipid methyl
0.982 615 -0.100 1.22e-03 0.01680 91.75 Leucine, lipid methyl, cholesterol
(ester)
1.582 555 -0.221 1.25e-03 0.01680 91.75 Lipids (?)
0.992 614 -0.103 1.28e-03 0.01680 89.98 Leucine, lipid methyl, cholesterol
(ester)
3.372 387 -0.093 1.34e-03 0.01680 89.98 Methanol, proline
1.452 568 -0.116 1.35e-03 0.01680 89.98 Lipid methylene
1.612 552 -0.231 1.46e-03 0.01680 89.98 Lipids (?)
1.472 566 -0.095 1.47e-03 0.01680 89.98 Lipid methylene
1.592 554 -0.234 1.48e-03 0.01680 89.98 Lipids (?)
1.462 567 -0.102 1.51e-03 0.01680 89.98 Lipid methylene
0.972 616 -0.098 1.52e-03 0.01680 89.98 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.032 610 -0.110 1.52e-03 0.01680 89.98 L-isoleucine, lipid methyl, choles-
terol (ester)
1.702 543 -0.060 1.54e-03 0.01680 89.98 Unknown, arginine
1.602 553 -0.237 1.54e-03 0.01680 89.98 Lipids (?)
1.572 556 -0.197 1.55e-03 0.01680 89.98 Lipids (?)
1.052 608 -0.139 1.55e-03 0.01680 89.98 Valine
1.072 606 -0.086 1.59e-03 0.01700 87.95 Valine
1.482 565 -0.087 1.62e-03 0.01700 89.98 Alanine
2.082 505 -0.112 1.67e-03 0.01710 89.98 Lipid allylic
1.242 589 -0.105 1.68e-03 0.01710 89.98 Lipid methylene
3.872 350 -0.092 1.73e-03 0.01730 91.75 D-glucose, unknown
1.372 576 -0.262 1.76e-03 0.01730 89.98 Lipid methylene
1.622 551 -0.210 1.79e-03 0.01740 87.95 Lipids (?)
2.352 478 -0.064 1.88e-03 0.01770 91.75 Proline, glutamic acid
4.092 328 -0.123 1.88e-03 0.01770 91.75 Unknown
2.122 501 -0.079 1.91e-03 0.01770 89.98 Lipid allylic
1.682 545 -0.077 1.93e-03 0.01770 89.98 Unknown, arginine
2.212 492 -0.153 1.96e-03 0.01770 87.95 Lipid (methylene carbonyl)
1.692 544 -0.066 2.06e-03 0.01840 89.98 Unknown, arginine
4.072 330 -0.117 2.10e-03 0.01850 93.28 Creatinine
3.452 379 -0.104 2.17e-03 0.01880 91.75 D-glucose, carnitine, proline
1.182 595 -0.100 2.20e-03 0.01880 87.95 Lipid methylene
4.272 310 -0.080 2.36e-03 0.02000 89.98 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
1.562 557 -0.172 2.48e-03 0.02060 87.95 Lipids (?)
3.992 338 -0.059 2.50e-03 0.02060 89.98 Unknown
4.102 327 -0.166 2.53e-03 0.02060 89.98 Unknown
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1.632 550 -0.178 2.63e-03 0.02110 85.65 Lipids (?)
1.962 517 -0.064 2.89e-03 0.02300 85.65 Lipid allylic
4.062 331 -0.124 3.09e-03 0.02430 85.65 Creatinine
2.112 502 -0.078 3.26e-03 0.02530 85.65 Lipid allylic
0.942 619 -0.147 3.39e-03 0.02600 83.06 Cholesterol, lipid methyl
1.662 547 -0.102 3.47e-03 0.02630 85.65 Lipids (?)
8.142 134 -0.257 3.52e-03 0.02630 80.19 Unknown
3.472 377 -0.110 3.61e-03 0.02630 89.98 D-glucose
1.972 516 -0.071 3.62e-03 0.02630 85.65 Lipid allylic
1.642 549 -0.148 3.63e-03 0.02630 83.06 Lipids (?)
1.122 601 -0.098 3.70e-03 0.02650 83.06 Unknown
1.552 558 -0.144 3.79e-03 0.02690 85.65 Lipids (?)
0.932 620 -0.175 3.90e-03 0.02740 83.06 Cholesterol, lipid methyl
1.352 578 -0.143 4.05e-03 0.02810 83.06 Lipid methylene, lactic acid, thre-
onine
3.422 382 -0.113 4.18e-03 0.02880 87.95 D-glucose, carnitine, taurine, pro-
line
1.332 580 -0.219 4.39e-03 0.02990 83.06 Lipid methylene
0.822 631 -0.096 4.47e-03 0.03010 83.06 Cholesterol, lipid methyl
2.102 503 -0.065 4.53e-03 0.03020 83.06 Lipid allylic
1.712 542 -0.048 4.60e-03 0.03020 83.06 Leucine, lysine
1.672 546 -0.084 4.62e-03 0.03020 83.06 Unknown, arginine
0.962 617 -0.096 4.70e-03 0.03040 83.06 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.322 581 -0.207 4.87e-03 0.03120 83.06 Lipid methylene
3.732 364 -0.097 4.93e-03 0.03130 87.95 D-glucose, unknown
2.892 424 -0.057 5.15e-03 0.03240 83.06 Lipid diallylic
2.872 426 -0.103 5.26e-03 0.03270 80.19 Lipid diallylic
3.852 352 -0.097 5.30e-03 0.03270 85.65 D-glucose, unknown
1.982 515 -0.076 5.94e-03 0.03630 80.19 Lipid allylic
1.652 548 -0.117 6.14e-03 0.03720 80.19 Lipids (?)
1.312 582 -0.191 6.24e-03 0.03750 80.19 Lipid methylene
0.952 618 -0.109 6.40e-03 0.03810 80.19 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
8.792 69 -0.407 6.79e-03 0.04000 77.05 Unknown
1.082 605 -0.078 6.97e-03 0.04070 80.19 Unknown
3.932 344 -0.091 7.23e-03 0.04190 83.06 D-glucose
2.922 421 -0.072 7.38e-03 0.04210 80.19 Unknown
3.962 341 -0.043 7.39e-03 0.04210 77.05 Unknown
2.832 430 -0.135 7.48e-03 0.04210 77.05 Lipid diallylic
2.822 431 -0.137 7.52e-03 0.04210 77.05 Lipid diallylic
2.902 423 -0.056 7.69e-03 0.04270 80.19 Unknown
2.882 425 -0.079 7.91e-03 0.04320 77.05 Lipid diallylic
2.202 493 -0.104 7.98e-03 0.04320 77.05 Lipid (methylene carbonyl)
3.912 346 -0.088 7.99e-03 0.04320 83.06 D-glucose, betaine, unknown
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1.342 579 -0.130 8.06e-03 0.04320 77.05 Lipid methylene, lactic acid, thre-
onine
2.842 429 -0.138 8.31e-03 0.04420 77.05 Lipid diallylic
3.722 365 -0.081 8.67e-03 0.04580 83.06 D-glucose, N,N-dimethylglycine
2.072 506 -0.077 9.30e-03 0.04830 77.05 Lipid allylic
3.552 369 -0.093 9.31e-03 0.04830 80.19 D-glucose, myo-inositol
3.782 359 -0.068 9.41e-03 0.04830 80.19 D-glucose, alanine, glutamine,
arginine
1.302 583 -0.171 9.44e-03 0.04830 77.05 Lipid methylene
1.022 611 -0.083 9.54e-03 0.04850 73.65 L-isoleucine, lipid methyl, choles-
terol (ester)
8.862 62 0.485 9.64e-03 0.04850 73.65 Trigonelline
2.132 500 -0.049 9.70e-03 0.04850 80.19 Glutamine
2.052 508 -0.086 1.00e-02 0.04960 77.05 Lipid allylic
3.352 389 -0.064 1.01e-02 0.04960 73.65 Proline
3.532 371 -0.090 1.01e-02 0.04960 80.19 D-glucose
Table 7.20: Spectral positions given in ppm, IDs, log(Fold-change) (log(FC)), p-values both
unadjusted and Benjamini and Hochberg (B/H)-adjusted, statistical power in
%, as well as correspondingly identified compounds of NMR features that
discriminated patients suffering from interstitial nephropathy from those suf-
fering from hypertensive nephropathy. A false discovery rate (FDR) below 5% was
applied. The FDR was adjusted according to the method of Benjamini and Hochberg
(B/H). In case that more than one compound contributed to a significant bin, all possible
assignments are given. A question mark denotes ambiguous signal assignments, mostly
due to severe signal overlap. The statistical power was calculated with a significance level
of 0.05 and a specificity of 95%.
Spectral ID log(FC) P -value P -value Statist- Identified compounds
position un- B/H- ical
[ppm] adjusted adjusted power
1.002 613 -0.152 4.27e-11 1.73e-08 100.00 Valine, lipid methyl, cholesterol
(ester)
1.012 612 -0.171 5.23e-11 1.73e-08 100.00 Valine, lipid methyl, cholesterol
(ester)
1.072 606 -0.147 1.33e-10 2.92e-08 100.00 Valine
1.902 523 -0.088 4.38e-10 7.23e-08 100.00 Overlap of multiple minor com-
pounds
2.372 476 -0.139 1.41e-09 1.86e-07 100.00 Proline, glutamic acid
1.082 605 -0.144 1.77e-09 1.86e-07 100.00 Unknown
1.232 590 -0.150 2.28e-09 1.86e-07 100.00 Lipid methylene
1.242 589 -0.166 2.39e-09 1.86e-07 100.00 Lipid methylene
2.362 477 -0.127 2.59e-09 1.86e-07 100.00 Proline, glutamic acid
2.382 475 -0.135 2.82e-09 1.86e-07 99.99 Proline, glutamic acid
1.052 608 -0.213 6.38e-09 3.83e-07 99.99 Valine
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1.162 597 -0.198 7.30e-09 4.02e-07 99.96 Lipid methylene
1.172 596 -0.181 1.54e-08 7.82e-07 99.96 Lipid methylene
1.912 522 -0.090 2.63e-08 1.24e-06 99.99 Overlap of multiple minor com-
pounds
0.982 615 -0.143 3.15e-08 1.39e-06 99.99 Leucine, lipid methyl, cholesterol
(ester)
1.932 520 -0.091 4.14e-08 1.71e-06 99.99 Acetic acid
3.452 379 -0.154 4.96e-08 1.85e-06 100.00 D-glucose, carnitine, proline
0.992 614 -0.144 5.37e-08 1.85e-06 99.99 Leucine, lipid methyl, cholesterol
(ester)
1.132 600 -0.120 5.40e-08 1.85e-06 99.99 Unknown
1.482 565 -0.125 5.61e-08 1.85e-06 99.99 Alanine
3.542 370 -0.156 7.54e-08 2.37e-06 99.99 D-glucose, myo-inositol
0.842 629 -0.109 8.28e-08 2.48e-06 99.96 Cholesterol, lipid methyl
3.422 382 -0.176 8.65e-08 2.48e-06 99.99 D-glucose, carnitine, taurine, pro-
line
3.472 377 -0.167 1.06e-07 2.92e-06 99.99 D-glucose
1.102 603 -0.131 1.42e-07 3.75e-06 99.96 Unknown
4.072 330 -0.167 1.54e-07 3.92e-06 99.99 Creatinine
2.312 482 -0.126 1.70e-07 3.98e-06 99.96 Lipid (methylene carbonyl)
1.922 521 -0.089 1.75e-07 3.98e-06 99.96 Overlap of multiple minor com-
pounds
3.782 359 -0.115 1.75e-07 3.98e-06 99.99 D-glucose, alanine, glutamine,
arginine
2.292 484 -0.166 1.95e-07 4.08e-06 99.96 Lipid (methylene carbonyl)
3.752 362 -0.155 1.95e-07 4.08e-06 99.99 D-glucose, glutamic acid
1.032 610 -0.151 1.98e-07 4.08e-06 99.96 L-isoleucine, lipid methyl, choles-
terol (ester)
1.892 524 -0.076 2.04e-07 4.08e-06 99.96 Overlap of multiple minor com-
pounds
4.092 328 -0.172 2.13e-07 4.14e-06 99.98 Unknown
0.972 616 -0.133 2.22e-07 4.15e-06 99.98 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
3.852 352 -0.150 2.26e-07 4.15e-06 99.99 D-glucose, unknown
2.872 426 -0.159 2.51e-07 4.47e-06 99.96 Lipid diallylic
1.092 604 -0.129 2.79e-07 4.78e-06 99.94 Unknown
3.552 369 -0.154 2.82e-07 4.78e-06 99.99 D-glucose, myo-inositol
1.062 607 -0.132 2.95e-07 4.87e-06 99.94 Valine
3.562 368 -0.148 3.31e-07 5.32e-06 99.99 D-glucose
2.282 485 -0.201 4.65e-07 7.31e-06 99.94 Lipid (methylene carbonyl)
1.022 611 -0.134 4.95e-07 7.59e-06 99.91 L-isoleucine, lipid methyl, choles-
terol (ester)
1.502 563 -0.123 5.38e-07 8.07e-06 99.91 Alanine
1.882 525 -0.073 5.76e-07 8.45e-06 99.94 Overlap of multiple minor com-
pounds
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3.802 357 -0.120 6.81e-07 9.60e-06 99.98 D-glucose, alanine
2.302 483 -0.133 6.84e-07 9.60e-06 99.94 Lipid (methylene carbonyl)
1.472 566 -0.123 7.92e-07 1.09e-05 99.91 Lipid methylene
3.842 353 -0.135 1.02e-06 1.38e-05 99.96 D-glucose, unknown
3.792 358 -0.082 1.19e-06 1.57e-05 99.96 D-glucose, alanine
1.142 599 -0.115 1.25e-06 1.62e-05 99.85 Unknown
3.872 350 -0.118 1.38e-06 1.73e-05 99.96 D-glucose, unknown
3.732 364 -0.139 1.39e-06 1.73e-05 99.96 D-glucose, unknown
3.522 372 -0.174 1.45e-06 1.75e-05 99.91 D-glucose
3.772 360 -0.126 1.46e-06 1.75e-05 99.94 D-glucose, alanine, glutamine,
arginine
1.182 595 -0.129 2.02e-06 2.39e-05 99.85 Lipid methylene
1.732 540 -0.072 2.06e-06 2.39e-05 99.78 Leucine, lysine
1.742 539 -0.075 2.22e-06 2.52e-05 99.78 Leucine, lysine
1.222 591 -0.148 2.34e-06 2.62e-05 99.52 Lipid methylene
3.442 380 -0.148 2.40e-06 2.64e-05 99.94 D-glucose, carnitine, taurine, pro-
line
3.512 373 -0.154 2.75e-06 2.98e-05 99.94 D-glucose
3.932 344 -0.132 2.82e-06 3.01e-05 99.94 D-glucose
3.572 367 -0.129 2.93e-06 3.07e-05 99.91 D-glucose, glycine
1.252 588 -0.144 3.05e-06 3.15e-05 99.78 Lipid methylene
3.482 376 -0.149 3.10e-06 3.15e-05 99.94 D-glucose
3.912 346 -0.127 3.69e-06 3.69e-05 99.91 D-glucose, betaine, unknown
1.702 543 -0.072 4.00e-06 3.94e-05 99.78 Unknown, arginine
3.742 363 -0.138 4.20e-06 4.08e-05 99.91 D-glucose, leucine
2.902 423 -0.080 4.31e-06 4.13e-05 99.78 Unknown
1.752 538 -0.078 4.49e-06 4.24e-05 99.67 Leucine, lysine
3.722 365 -0.117 4.67e-06 4.32e-05 99.91 D-glucose, N,N-dimethylglycine
1.682 545 -0.094 4.72e-06 4.32e-05 99.78 Unknown, arginine
1.722 541 -0.065 4.90e-06 4.43e-05 99.67 Leucine, lysine
3.862 351 -0.137 5.32e-06 4.75e-05 99.91 D-glucose, unknown
3.432 381 -0.145 5.54e-06 4.87e-05 99.85 D-glucose, carnitine, taurine, pro-
line
1.462 567 -0.121 5.60e-06 4.87e-05 99.67 Lipid methylene
2.552 458 -0.080 5.92e-06 5.08e-05 96.47 Citric acid
3.762 361 -0.126 6.56e-06 5.46e-05 99.85 D-glucose, arginine, glutamine,
glutamic acid
1.122 601 -0.126 6.59e-06 5.46e-05 99.52 Unknown
1.152 598 -0.122 6.62e-06 5.46e-05 99.30 Lipid methylene
0.962 617 -0.127 7.10e-06 5.79e-05 99.67 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
1.412 572 -0.234 7.76e-06 6.25e-05 99.52 Lipid methylene
3.502 374 -0.146 7.89e-06 6.25e-05 99.85 D-glucose
2.862 427 -0.172 8.00e-06 6.25e-05 99.52 Lipid diallylic
1.452 568 -0.134 8.05e-06 6.25e-05 99.52 Lipid methylene
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1.402 573 -0.289 8.41e-06 6.46e-05 99.52 Lipid methylene
2.122 501 -0.094 8.52e-06 6.47e-05 99.52 Lipid allylic
1.422 571 -0.185 1.22e-05 9.18e-05 99.30 Lipid methylene
1.212 592 -0.159 1.32e-05 9.71e-05 98.06 Lipid methylene
3.412 383 -0.138 1.32e-05 9.71e-05 99.78 D-glucose, carnitine, taurine, pro-
line
1.492 564 -0.103 1.35e-05 9.81e-05 99.30 Alanine
1.692 544 -0.077 1.61e-05 1.15e-04 99.52 Unknown, arginine
3.462 378 -0.109 1.68e-05 1.19e-04 99.67 D-glucose
1.442 569 -0.134 1.78e-05 1.24e-04 99.30 Lipid methylene
2.322 481 -0.096 1.78e-05 1.24e-04 99.30 Lipid (methylene carbonyl)
3.062 407 -0.090 1.80e-05 1.24e-04 99.67 Creatinine
2.212 492 -0.175 2.14e-05 1.44e-04 99.00 Lipid (methylene carbonyl)
2.252 488 -0.193 2.14e-05 1.44e-04 99.00 Lipid (methylene carbonyl), ace-
tone
4.102 327 -0.194 2.22e-05 1.45e-04 99.00 Unknown
1.982 515 -0.098 2.22e-05 1.45e-04 99.30 Lipid allylic
1.432 570 -0.145 2.24e-05 1.45e-04 99.00 Lipid methylene
3.882 349 -0.116 2.25e-05 1.45e-04 99.67 D-glucose, unknown
1.112 602 -0.103 2.48e-05 1.59e-04 99.30 Unknown
2.852 428 -0.172 2.64e-05 1.66e-04 99.00 Lipid diallylic
0.942 619 -0.176 2.65e-05 1.66e-04 99.00 Cholesterol, lipid methyl
0.852 628 -0.084 2.81e-05 1.75e-04 99.00 Cholesterol, lipid methyl
2.352 478 -0.072 3.00e-05 1.84e-04 99.30 Proline, glutamic acid
3.532 371 -0.122 3.01e-05 1.84e-04 99.52 D-glucose
1.392 574 -0.287 3.24e-05 1.96e-04 99.00 Lipid methylene
3.492 375 -0.135 3.31e-05 1.99e-04 99.52 D-glucose
2.272 486 -0.212 3.44e-05 2.05e-04 99.00 Lipid (methylene carbonyl)
0.832 630 -0.092 4.34e-05 2.56e-04 98.60 Cholesterol, lipid methyl
0.952 618 -0.135 4.69e-05 2.74e-04 98.60 Leucine, L-isoleucine, lipid
methyl, cholesterol (ester)
2.202 493 -0.132 5.21e-05 3.02e-04 98.60 Lipid (methylene carbonyl)
1.972 516 -0.082 5.27e-05 3.02e-04 98.60 Lipid allylic
1.992 514 -0.097 5.79e-05 3.29e-04 98.60 Lipid allylic
2.222 491 -0.182 6.40e-05 3.61e-04 98.06 Lipid (methylene carbonyl)
1.552 558 -0.163 8.17e-05 4.57e-04 98.06 Lipids (?)
2.132 500 -0.062 8.63e-05 4.79e-04 98.60 Glutamine
2.502 463 0.095 1.02e-04 5.61e-04 98.06 Unknown
0.932 620 -0.195 1.17e-04 6.38e-04 97.36 Cholesterol, lipid methyl
1.712 542 -0.055 1.21e-04 6.52e-04 98.06 Leucine, lysine
4.112 326 -0.174 1.30e-04 6.96e-04 97.36 Proline, lactic acid
1.542 559 -0.127 1.32e-04 7.04e-04 97.36 Lipids (?)
1.382 575 -0.265 1.39e-04 7.35e-04 97.36 Lipid methylene
3.812 356 -0.091 1.51e-04 7.91e-04 98.06 D-glucose
2.842 429 -0.163 1.72e-04 8.90e-04 97.36 Lipid diallylic
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1.562 557 -0.178 1.73e-04 8.90e-04 97.36 Lipids (?)
2.672 446 -0.086 1.85e-04 9.49e-04 90.11 Citric acid
1.522 561 -0.076 1.89e-04 9.60e-04 97.36 Lipids (?)
4.312 306 -0.100 1.93e-04 9.71e-04 96.47 Lipid alpha-methylene to car-
boxyl, lipid glycerine
4.032 334 -0.079 2.22e-04 1.11e-03 96.47 Unknown
4.042 333 -0.122 2.25e-04 1.11e-03 96.47 Unknown
2.892 424 -0.063 2.27e-04 1.12e-03 97.36 Lipid diallylic
2.832 430 -0.154 2.54e-04 1.24e-03 96.47 Lipid diallylic
2.492 464 0.064 2.56e-04 1.24e-03 96.47 Glutamine
2.192 494 -0.093 2.73e-04 1.31e-03 96.47 Lipid (methylene carbonyl)
2.882 425 -0.090 2.74e-04 1.31e-03 96.47 Lipid diallylic
2.232 490 -0.170 3.13e-04 1.48e-03 95.33 Lipid (methylene carbonyl)
2.112 502 -0.079 3.14e-04 1.48e-03 95.33 Lipid allylic
2.652 448 -0.045 3.28e-04 1.53e-03 95.33 Unknown
0.742 639 -0.153 3.33e-04 1.55e-03 95.33 Unkown
3.832 354 -0.065 3.62e-04 1.67e-03 96.47 Unknown
2.822 431 -0.150 4.18e-04 1.91e-03 95.33 Lipid diallylic
2.912 422 -0.063 4.33e-04 1.97e-03 95.33 Unknown
2.262 487 -0.202 4.83e-04 2.18e-03 95.33 Lipid (methylene carbonyl)
2.572 456 -0.053 4.96e-04 2.22e-03 87.65 CaEDTA2−, citric acid
1.962 517 -0.062 4.99e-04 2.22e-03 95.33 Lipid allylic
1.042 609 -0.122 5.09e-04 2.25e-03 95.33 L-isoleucine, lipid methyl, choles-
terol (ester)
2.002 513 -0.085 5.53e-04 2.43e-03 93.91 Lipid allylic
7.202 228 -0.085 5.56e-04 2.43e-03 93.91 Tyrosine
1.622 551 -0.193 5.59e-04 2.43e-03 93.91 Lipids (?)
3.822 355 -0.072 5.65e-04 2.44e-03 95.33 Unknown
2.242 489 -0.174 5.82e-04 2.49e-03 93.91 Lipid (methylene carbonyl), ace-
tone
4.052 332 -0.121 6.20e-04 2.64e-03 95.33 Unknown
2.082 505 -0.101 6.46e-04 2.73e-03 93.91 Lipid allylic
1.372 576 -0.236 7.07e-04 2.97e-03 93.91 Lipid methylene
1.942 519 -0.112 7.33e-04 3.06e-03 90.11 Acetic acid
1.572 556 -0.174 7.64e-04 3.16e-03 93.91 Lipids (?)
0.822 631 -0.095 7.69e-04 3.16e-03 92.19 Cholesterol, lipid methyl
1.952 518 -0.054 7.71e-04 3.16e-03 93.91 Acetic acid
4.322 305 -0.081 8.00e-04 3.26e-03 93.91 Lipid alpha-methylene to car-
boxyl, lipid glycerine
1.612 552 -0.202 8.15e-04 3.30e-03 92.19 Lipids (?)
2.662 447 -0.093 8.36e-04 3.36e-03 87.65 Citric acid
3.402 384 -0.089 8.39e-04 3.36e-03 92.19 Unknown
2.542 459 -0.061 9.04e-04 3.60e-03 87.65 Unknown
1.632 550 -0.162 9.89e-04 3.91e-03 92.19 Lipids (?)
1.262 587 -0.110 1.02e-03 4.02e-03 92.19 Lipid methylene
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3.342 390 -0.118 1.05e-03 4.10e-03 90.11 Proline
2.712 442 -0.039 1.08e-03 4.17e-03 92.19 MgEDTA2−
1.532 560 -0.083 1.08e-03 4.17e-03 92.19 Lipids (?)
3.362 388 -0.075 1.12e-03 4.28e-03 90.11 Proline
7.832 165 0.206 1.17e-03 4.48e-03 90.11 Unknown
1.672 546 -0.079 1.28e-03 4.84e-03 92.19 Unknown, arginine
3.052 408 -0.038 1.38e-03 5.20e-03 90.11 Creatinine
0.732 640 -0.185 1.53e-03 5.72e-03 90.11 Unkown
2.922 421 -0.071 1.54e-03 5.75e-03 90.11 Unknown
2.102 503 -0.060 1.68e-03 6.23e-03 90.11 Lipid allylic
1.602 553 -0.195 1.73e-03 6.40e-03 90.11 Lipids (?)
4.302 307 -0.093 1.76e-03 6.45e-03 90.11 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
2.332 480 -0.070 2.10e-03 7.65e-03 87.65 Proline, glutamic acid
0.752 638 -0.097 2.24e-03 8.11e-03 87.65 Cholesterol, lipid methyl
1.582 555 -0.174 2.26e-03 8.15e-03 87.65 Lipids (?)
7.562 192 0.098 2.27e-03 8.16e-03 84.80 Unknown
1.872 526 -0.046 2.35e-03 8.38e-03 87.65 Overlap of multiple minor com-
pounds
0.882 625 0.084 2.37e-03 8.43e-03 90.11 Cholesterol, lipid methyl
1.642 549 -0.128 2.57e-03 9.05e-03 84.80 Lipids (?)
4.162 321 -0.082 2.71e-03 9.52e-03 87.65 Proline, lactic acid
7.722 176 0.138 2.73e-03 9.53e-03 84.80 Unknown
7.192 229 -0.057 2.75e-03 9.55e-03 84.80 Tyrosine
7.692 179 -0.147 2.82e-03 9.74e-03 84.80 Unknown
1.662 547 -0.086 2.90e-03 9.97e-03 84.80 Lipids (?)
0.812 632 -0.096 3.01e-03 1.03e-02 84.80 Cholesterol, lipid methyl
1.332 580 -0.189 3.08e-03 1.05e-02 84.80 Lipid methylene
2.702 443 -0.033 3.14e-03 1.06e-02 81.54 MgEDTA2−
1.592 554 -0.180 3.30e-03 1.11e-02 84.80 Lipids (?)
1.352 578 -0.122 3.35e-03 1.12e-02 84.80 Lipid methylene, lactic acid, thre-
onine
7.182 230 -0.069 3.77e-03 1.26e-02 81.54 Unknown
1.762 537 -0.049 3.89e-03 1.29e-02 84.80 Leucine, lysine
2.142 499 -0.042 4.03e-03 1.32e-02 84.80 Glutamine
8.262 122 0.086 4.03e-03 1.32e-02 81.54 Unknown
2.342 479 -0.060 4.10e-03 1.34e-02 84.80 Proline, glutamic acid
7.732 175 0.115 4.20e-03 1.37e-02 84.80 Unknown
1.192 594 -0.143 4.38e-03 1.42e-02 73.83 Lipid methylene
2.682 445 -0.043 5.13e-03 1.65e-02 77.88 Citric acid
7.432 205 -0.060 5.71e-03 1.83e-02 77.88 Phenylalanine
0.672 646 -0.141 6.01e-03 1.92e-02 84.80 Unkown
2.812 432 -0.116 6.38e-03 2.02e-02 81.54 Lipid diallylic
1.652 548 -0.096 6.42e-03 2.03e-02 77.88 Lipids (?)
1.272 586 -0.097 6.83e-03 2.15e-02 77.88 Lipid methylene
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1.322 581 -0.165 7.00e-03 2.19e-02 77.88 Lipid methylene
3.042 409 -0.021 7.56e-03 2.35e-02 77.88 Lysine, unknown
0.722 641 -0.169 7.65e-03 2.37e-02 77.88 Unkown
4.332 304 -0.062 8.15e-03 2.51e-02 77.88 Lipid alpha-methylene to car-
boxyl, lipid glycerine
2.452 468 -0.063 8.21e-03 2.52e-02 77.88 Glutamine, carnitine
0.922 621 -0.142 8.37e-03 2.56e-02 77.88 Cholesterol, lipid methyl
1.512 562 -0.066 8.68e-03 2.64e-02 77.88 Alanine
1.342 579 -0.107 9.08e-03 2.75e-02 73.83 Lipid methylene, lactic acid, thre-
onine
2.932 420 -0.047 9.55e-03 2.88e-02 77.88 Unknown
6.842 264 -0.055 9.87e-03 2.95e-02 77.88 Unknown
3.942 343 -0.082 9.89e-03 2.95e-02 77.88 D-glucose
7.102 238 -0.089 1.07e-02 3.19e-02 73.83 Unknown
7.082 240 -0.211 1.09e-02 3.23e-02 69.44 Unknown
7.962 152 0.219 1.10e-02 3.25e-02 69.44 Unknown
7.352 213 -0.041 1.15e-02 3.36e-02 69.44 Phenylalanine
1.312 582 -0.146 1.18e-02 3.44e-02 73.83 Lipid methylene
1.792 534 0.053 1.20e-02 3.48e-02 73.83 Unknown
1.202 593 -0.149 1.21e-02 3.50e-02 64.74 Lipid methylene
2.692 444 -0.037 1.23e-02 3.54e-02 54.72 Citric acid
3.312 393 -0.073 1.26e-02 3.63e-02 73.83 Unknown
3.922 345 -0.055 1.28e-02 3.66e-02 73.83 D-glucose, unknown
7.572 191 0.089 1.29e-02 3.66e-02 69.44 Unknown
4.082 329 -0.083 1.31e-02 3.70e-02 73.83 Creatinine
7.342 214 -0.037 1.37e-02 3.85e-02 64.74 Phenylalanine
8.232 125 0.070 1.38e-02 3.87e-02 69.44 Unknown
6.592 289 -0.284 1.38e-02 3.87e-02 69.44 Unknown
2.392 474 -0.060 1.42e-02 3.96e-02 69.44 Unknown
2.792 434 -0.083 1.43e-02 3.96e-02 69.44 Lipid diallylic
0.802 633 -0.079 1.52e-02 4.19e-02 69.44 Cholesterol, lipid methyl
2.482 465 0.043 1.53e-02 4.19e-02 64.74 Glutamine, carnitine
8.222 126 0.070 1.53e-02 4.20e-02 69.44 Unknown
3.352 389 -0.050 1.54e-02 4.21e-02 69.44 Proline
8.722 76 0.294 1.56e-02 4.23e-02 64.74 Unknown
6.832 265 -0.051 1.60e-02 4.33e-02 69.44 Unknown
2.012 512 -0.063 1.62e-02 4.35e-02 69.44 Lipid allylic
7.952 153 0.165 1.67e-02 4.49e-02 64.74 Unknown
7.252 223 -0.049 1.69e-02 4.53e-02 69.44 Unknown
4.292 308 -0.069 1.72e-02 4.56e-02 69.44 Lipid alpha-methylene to car-
boxyl, lipid glycerine, threonine
9.392 9 -0.292 1.72e-02 4.56e-02 69.44 Unknown
2.802 433 -0.088 1.76e-02 4.66e-02 69.44 Lipid diallylic
6.922 256 -0.059 1.82e-02 4.77e-02 64.74 Tyrosine
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Table 7.21: Previous page: Spectral positions given in ppm, IDs, log(Fold-change)
(log(FC)), p-values both unadjusted and Benjamini and Hochberg (B/H)-
adjusted, statistical power in %, as well as correspondingly identified com-
pounds of NMR features that discriminated patients suffering from systemic
diseases from those suffering from hypertensive nephropathy. A false discovery
rate (FDR) below 5% was applied. The FDR was adjusted according to the method of
Benjamini and Hochberg (B/H). In case that more than one compound contributed to a
significant bin, all possible assignments are given. A question mark denotes ambiguous sig-
nal assignments, mostly due to severe signal overlap. The statistical power was calculated
with a significance level of 0.05 and a specificity of 95%.
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7.3.3 Prediction of present and future kidney performance
222
7.3 Appendix III: German Chronic Kidney Disease Study
223
7 Appendix
224
7.3 Appendix III: German Chronic Kidney Disease Study
225
7 Appendix
Figure 7.4: Previous pages: Method comparison of different GFR estimation equa-
tions for baseline and FU2 eGFR values, respectively. x − y scatter plots
of the compared eGFR values including equations of the fitted simple linear re-
gression lines, Pearson’s correlation coefficients r and coefficients of determination
R2 = r2, as well as Bland-Altman plots are displayed, compare to section 5.2.3.3
Table 5.5. All displayed values are given in ml/min per 1.73m2. Abbreviations:
eGFR, estimated glomerular filtration rate; eGFRckdepi crea, eGFR based on CKD-
EPI crea formula; eGFRckdepi crea cys, eGFR based on CKD-EPI crea cys formula;
eGFRckdepi cys, eGFR based on CKD-EPI cys formula; eGFRmdrd4, eGFR based on
MDRD4 formula; FU2, second follow-up.
Figure 7.5: Comparison of Synlab SCr and SCysC values at the baseline and FU2
time-point, respectively. x − y scatter plots of the compared eGFR values in-
cluding equations of the fitted simple linear regression lines, Pearson’s correlation
coefficients r and coefficients of determination R2 = r2. Abbreviations: FU2, second
follow-up; SCr, serum creatinine; SCysC, serum cystatin C.
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Figure 7.6: Previous page: Results of LASSO regression analysis for prediction of
baseline SCr, SCysC, and eGFR values including all 660 NMR bins. Dis-
played are scatter plots of the not log2 transformed true and inversely log2 trans-
formed predicted response variables of the test set, including a linear model fitted
between these true and predicted response variables and the corresponding coef-
ficients of determination R2 between these variables. Abbreviations: eGFR, esti-
mated glomerular filtration rate; eGFRckdepi crea, eGFR based on CKD-EPI crea for-
mula; eGFRckdepi crea cys, eGFR based on CKD-EPI crea cys formula; eGFRckdepi cys,
eGFR based on CKD-EPI cys formula; eGFRmdrd4, eGFR based on MDRD4 for-
mula; SCr, serum creatinine; SCysC, serum cystatin C.
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Figure 7.7: Previous page: Results of LASSO regression analysis for prediction of
baseline SCr, SCysC, and eGFR values after exclusion of all NMR buck-
ets corresponding to creatinine. Displayed are scatter plots of the not log2
transformed true and inversely log2 transformed predicted response variables of the
test set, including a linear model fitted between these true and predicted response
variables and the corresponding coefficients of determination R2 between these vari-
ables. Abbreviations: eGFR, estimated glomerular filtration rate; eGFRckdepi crea,
eGFR based on CKD-EPI crea formula; eGFRckdepi crea cys, eGFR based on CKD-
EPI crea cys formula; eGFRckdepi cys, eGFR based on CKD-EPI cys formula;
eGFRmdrd4, eGFR based on MDRD4 formula; SCr, serum creatinine; SCysC, serum
cystatin C.
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Figure 7.8: Previous page: Results of LASSO regression analysis for prediction of
FU2 SCr, SCysC, and eGFR values. Displayed are scatter plots of the
not log2 transformed true and inversely log2 transformed predicted response vari-
ables of the test set, including a linear model fitted between these true and pre-
dicted response variables and the corresponding coefficients of determination R2 be-
tween these variables. Abbreviations: eGFR, estimated glomerular filtration rate;
eGFRckdepi crea, eGFR based on CKD-EPI crea formula; eGFRckdepi crea cys, eGFR
based on CKD-EPI crea cys formula; eGFRckdepi cys, eGFR based on CKD-EPI cys
formula; eGFRmdrd4, eGFR based on MDRD4 formula; FU2, second follow-up; SCr,
serum creatinine; SCysC, serum cystatin C.
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Figure 7.9: Previous page: Results of LASSO regression analysis for prediction of
FU2 SCr, SCysC, and eGFR values after exclusion of all NMR buck-
ets corresponding to creatinine. Displayed are scatter plots of the not log2
transformed true and inversely log2 transformed predicted response variables of the
test set, including a linear model fitted between these true and predicted response
variables and the corresponding coefficients of determination R2 between these vari-
ables. Abbreviations: eGFR, estimated glomerular filtration rate; eGFRckdepi crea,
eGFR based on CKD-EPI crea formula; eGFRckdepi crea cys, eGFR based on CKD-
EPI crea cys formula; eGFRckdepi cys, eGFR based on CKD-EPI cys formula;
eGFRmdrd4, eGFR based on MDRD4 formula; FU2, second follow-up; SCr, serum
creatinine; SCysC, serum cystatin C.
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Figure 7.10: Previous page: Results of simple linear regression analysis for predic-
tion of FU2 SCr, SCysC, and eGFR values based on corresponding
baseline values. Displayed are scatter plots of the originally not log2 trans-
formed true and predicted response variables of the test set, including a linear
model fitted between these true and predicted response variables and the corre-
sponding coefficients of determination R2 between these variables. Abbreviations:
eGFR, estimated glomerular filtration rate; eGFRckdepi crea, eGFR based on CKD-
EPI crea formula; eGFRckdepi crea cys, eGFR based on CKD-EPI crea cys formula;
eGFRckdepi cys, eGFR based on CKD-EPI cys formula; eGFRmdrd4, eGFR based on
MDRD4 formula; FU2, second follow-up; SCr, serum creatinine; SCysC, serum
cystatin C.
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Figure 7.11: Previous page: Histograms of (FU2 - baseline) kidney performance clin-
ical parameters. Abbreviations: eGFR, estimated glomerular filtration rate;
eGFRckdepi crea, eGFR based on CKD-EPI crea formula; eGFRckdepi crea cys, eGFR
based on CKD-EPI crea cys formula; eGFRckdepi cys, eGFR based on CKD-EPI
cys formula; eGFRmdrd4, eGFR based on MDRD4 formula; FU2, second follow-up;
SCr, serum creatinine; SCysC, serum cystatin C.
7.4 Appendix IV: Trial to Reduce Cardiovascular Events with
Aranesp® Therapy study
Spectral P -value P -value ID Identified compounds
position un- B/H-
[ppm] adjusted adjusted
2.845 6.46e-05 0.0135 467 Proteins
2.855 6.76e-05 0.0135 466 Proteins, unknown
2.045 9.45e-05 0.0135 547 Proteins, N-acetylglycine, proline, L-pyroglutamic acid,
N-acetyl-L-glutamine (?)
3.995 9.88e-05 0.0135 352 Proteins, unknown
1.885 1.09e-04 0.0135 563 Proteins, quinic acid
1.875 1.75e-04 0.0135 564 Proteins, quinic acid
2.065 1.90e-04 0.0135 545 Proteins, quinic acid, proline, L-pyroglutamic acid
3.755 2.00e-04 0.0135 376 Proteins, D-glucose, D-mannitol, leucine, sucrose, pseu-
douridine
4.325 2.29e-04 0.0135 319 Proteins
4.495 2.47e-04 0.0135 302 Proteins
3.685 2.59e-04 0.0135 383 Proteins, D-mannitol, L-isoleucine (?), sucrose
3.505 2.89e-04 0.0135 401 D-glucose, sucrose
3.345 3.29e-04 0.0135 417 Proteins, proline
2.055 3.54e-04 0.0135 546 Proteins, proline, quinic acid, L-pyroglutamic acid
1.675 3.79e-04 0.0135 584 Proteins, leucine, agmatine
2.085 3.91e-04 0.0135 543 Proteins, proline, N-acetyl-L-glutamine (?), N-methyl-L-
proline
4.275 4.09e-04 0.0135 324 Proteins, threonine
3.865 4.21e-04 0.0135 365 D-glucose, D-mannitol, pseudouridine, sucrose
1.175 4.25e-04 0.0135 634 Proteins
2.995 4.48e-04 0.0135 452 Proteins
2.075 4.51e-04 0.0135 544 Proteins, proline, N-methyl-L-proline
2.755 4.77e-04 0.0135 476 Proteins
1.895 4.85e-04 0.0135 562 Proteins, N-acetyl-L-glutamine
4.155 5.42e-04 0.0135 336 Proteins, proline, pseudouridine, N-acetyl-L-glutamine
4.255 5.43e-04 0.0135 326 Proteins, threonine
8.465 5.60e-04 0.0135 104 Proteins, formic acid
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2.015 5.66e-04 0.0135 550 Proteins, proline, L-pyroglutamic acid, L-isoleucine
4.315 5.74e-04 0.0135 320 Proteins, unknown
3.775 5.95e-04 0.0135 374 D-glucose, D-mannitol, sucrose
3.665 6.03e-04 0.0135 385 Unknown, proteins, D-mannitol, paracetamol-
glucuronide
2.745 6.17e-04 0.0135 477 Proteins
1.685 6.19e-04 0.0135 583 Proteins, leucine, agmatine
2.865 6.34e-04 0.0135 465 Proteins, asparagine (?)
3.585 6.69e-04 0.0138 393 Unknown, sucrose
4.165 7.01e-04 0.0139 335 Proteins, L-pyroglutamic acid, pseudouridine, N-acetyl-
L-glutamine
2.025 7.13e-04 0.0139 549 Proteins, proline, L-pyroglutamic acid, N-methyl-L-
proline (?)
1.835 7.69e-04 0.0144 568 Proteins
4.455 8.02e-04 0.0144 306 Proteins, trigonelline, D-lactose (?), unknown
0.975 8.13e-04 0.0144 654 Proteins, leucine, 2-aminobutyric acid
4.425 8.42e-04 0.0144 309 Proteins, unknown
8.005 8.43e-04 0.0144 150 Proteins, unknown
3.085 8.85e-04 0.0146 443 Proteins, unknown
3.765 8.96e-04 0.0146 375 D-glucose, D-mannitol
1.905 9.37e-04 0.0149 561 Proteins, N-acetyl-L-glutamine, unknown
2.645 9.89e-04 0.0152 487 Proteins, unknown
3.855 1.02e-03 0.0152 366 D-glucose, D-mannitol, sucrose, pseudouridine
0.925 1.04e-03 0.0152 659 Proteins
4.475 1.04e-03 0.0152 304 Proteins, D-lactose
4.145 1.08e-03 0.0155 337 Proteins, proline, pseudouridine, quinic acid
1.965 1.10e-03 0.0155 555 Proteins, quinic acid, L-isoleucine, N-acetyl-L-glutamine
4.305 1.16e-03 0.0156 321 Proteins, pseudouridine, unknown
4.005 1.16e-03 0.0156 351 Proteins, quinic acid, phosphoethanolamine, ascorbic
acid, unknown (?)
2.885 1.26e-03 0.0158 463 Proteins, unknown
0.985 1.29e-03 0.0158 653 Proteins, valine, 2-aminobutyric acid
3.785 1.31e-03 0.0158 373 D-glucose, sucrose, glutamine
2.975 1.31e-03 0.0158 454 Proteins, unknown
4.355 1.32e-03 0.0158 316 Proteins, cis-4-hydroxy-D-proline
4.135 1.32e-03 0.0158 338 Proline, proteins, unknown
1.825 1.34e-03 0.0158 569 Proteins
8.235 1.38e-03 0.0158 127 Proteins
4.415 1.44e-03 0.0158 310 Proteins, unknown
8.325 1.45e-03 0.0158 118 Proteins, unknown
2.805 1.46e-03 0.0158 471 Proteins, unknown
3.675 1.46e-03 0.0158 384 Proteins, D-mannitol, L-isoleucine
2.395 1.51e-03 0.0158 512 Proteins, L-pyroglutamic acid, unknown
2.035 1.51e-03 0.0158 548 Proteins, proline, L-pyroglutamic acid, N-acetyl-L-
glutamine (?)
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3.515 1.59e-03 0.0158 400 D-glucose
3.525 1.59e-03 0.0158 399 Proteins, D-glucose
2.765 1.63e-03 0.0158 475 Proteins, unknown
3.335 1.63e-03 0.0158 418 Proline, proteins, unknown
0.945 1.63e-03 0.0158 657 L-isoleucine, proteins
0.825 1.68e-03 0.0158 669 Proteins
0.845 1.68e-03 0.0158 667 Proteins
4.225 1.72e-03 0.0158 329 Sucrose, proteins
1.695 1.77e-03 0.0158 582 Proteins, leucine, agmatine
0.725 1.78e-03 0.0158 679 Proteins
8.695 1.78e-03 0.0158 81 Proteins
4.375 1.80e-03 0.0158 314 Proteins, cis-4-hydroxy-D-proline
4.245 1.80e-03 0.0158 327 Proteins, threonine
2.005 1.81e-03 0.0158 551 Proteins, proline, L-pyroglutamic acid, L-isoleucine
1.665 1.84e-03 0.0159 585 Proteins, leucine, agmatine
2.385 1.90e-03 0.0162 513 Proline, proteins, pyruvic acid (?)
8.245 1.94e-03 0.0163 126 Proteins
3.535 1.95e-03 0.0163 398 D-glucose
3.065 2.06e-03 0.0170 445 Unknown, proteins
4.235 2.10e-03 0.0171 328 Sucrose, proteins
1.815 2.15e-03 0.0173 570 Proteins
8.175 2.18e-03 0.0174 133 Proteins
4.335 2.21e-03 0.0174 318 Proteins, cis-4-hydroxy-D-proline
6.655 2.30e-03 0.0178 285 Proteins
4.085 2.31e-03 0.0178 343 Proteins, unknown
1.955 2.37e-03 0.0181 556 Proteins, N-acetyl-L-glutamine, L-isoleucine, quinic acid
0.815 2.41e-03 0.0182 670 Proteins
2.235 2.49e-03 0.0182 528 Acetone, proteins
8.765 2.49e-03 0.0182 74 Proteins
1.865 2.53e-03 0.0182 565 Proteins, unknown
2.225 2.53e-03 0.0182 529 Proteins
8.195 2.56e-03 0.0182 131 Proteins
8.165 2.59e-03 0.0182 134 Proteins
0.935 2.65e-03 0.0182 658 L-isoleucine, proteins, 2-oxoisocaproic acid (?)
3.815 2.67e-03 0.0182 370 D-mannitol
2.815 2.68e-03 0.0182 470 Proteins
8.185 2.68e-03 0.0182 132 Proteins
4.295 2.74e-03 0.0182 322 Pseudouridine, proteins, unknown
4.285 2.74e-03 0.0182 323 Proteins, threonine, pseudouridine
1.645 2.75e-03 0.0182 587 Proteins
2.875 2.82e-03 0.0183 464 Proteins, unknown
2.985 2.83e-03 0.0183 453 Proteins, macromolecules
1.975 2.90e-03 0.0184 554 Proteins, proline, L-isoleucine
4.385 2.90e-03 0.0184 313 Proteins, unknown
1.655 2.93e-03 0.0184 586 Proteins, leucine, unknown
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0.805 2.96e-03 0.0184 671 Proteins
8.945 2.97e-03 0.0184 56 Proteins
3.445 3.03e-03 0.0185 407 D-glucose, proline
2.915 3.03e-03 0.0185 460 Proteins
0.835 3.09e-03 0.0187 668 Proteins
1.635 3.19e-03 0.0191 588 Proteins
4.265 3.27e-03 0.0194 325 Proteins, threonine
0.965 3.38e-03 0.0198 655 Proteins, leucine
3.875 3.39e-03 0.0198 364 D-mannitol
1.405 3.42e-03 0.0198 611 Proteins, macromolecules
1.525 3.49e-03 0.0200 599 Proteins, propanol
3.705 3.53e-03 0.0200 381 D-glucose
4.015 3.60e-03 0.0200 350 Pseudouridine, proteins, unknown
3.985 3.61e-03 0.0200 353 Proteins, unknown
7.595 3.64e-03 0.0200 191 Proteins
3.645 3.66e-03 0.0200 387 Paracetamol-glucuronide, myo-inositol, unknown (?)
1.185 3.67e-03 0.0200 633 Proteins
2.375 3.68e-03 0.0200 514 Proline, proteins
3.655 3.70e-03 0.0200 386 Paracetamol-glucuronide, unknown
0.855 3.79e-03 0.0203 666 Proteins
2.315 4.01e-03 0.0212 520 Proteins, valine, N-acetyl-L-glutamine
1.845 4.04e-03 0.0212 567 Proteins
3.325 4.11e-03 0.0212 419 Proline, proteins
3.925 4.11e-03 0.0212 359 D-glucose
2.245 4.14e-03 0.0212 527 Proteins, valine, acetone
0.995 4.15e-03 0.0212 652 Valine, proteins, 2-aminobutyric acid
8.285 4.17e-03 0.0212 122 Proteins
1.915 4.26e-03 0.0214 560 Proteins, N-acetyl-L-glutamine, 2-aminobutyric acid (?)
4.365 4.27e-03 0.0214 315 Proteins, cis-4-hydroxy-D-proline
0.715 4.34e-03 0.0216 680 Proteins
3.365 4.43e-03 0.0216 415 Methanol, proline, proteins, cis-4-hydroxy-D-proline, un-
known
1.585 4.47e-03 0.0216 593 Proteins, propanol
6.585 4.49e-03 0.0216 292 Proteins, unknown
1.085 4.52e-03 0.0216 643 Proteins, unknown
0.785 4.53e-03 0.0216 673 Proteins
3.795 4.53e-03 0.0216 372 D-glucose, sucrose, guanidinoacetic acid, D-mannitol
2.965 4.59e-03 0.0217 455 Proteins, macromolecules
4.025 4.65e-03 0.0217 349 Pseudouridine, quinic acid, ascorbic acid, proteins
0.795 4.66e-03 0.0217 672 Proteins
8.205 4.70e-03 0.0217 130 Proteins
6.625 4.71e-03 0.0217 288 Proteins
2.325 4.80e-03 0.0218 519 Proteins, proline, N-acetyl-L-glutamine, unknown
1.215 4.85e-03 0.0218 630 Proteins, 3-hydroxybutyric acid (?)
8.255 4.85e-03 0.0218 125 Proteins, unknown
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1.005 4.86e-03 0.0218 651 Proteins, valine, L-isoleucine
0.735 4.95e-03 0.0220 678 Proteins, macromolecules
3.075 4.95e-03 0.0220 444 Unknown, proteins
3.555 5.06e-03 0.0223 396 D-glucose, sucrose, myo-inositol, quinic acid (?)
2.095 5.23e-03 0.0227 542 Proline, proteins, N-acetyl-L-glutamine, N-methyl-L-
proline (?)
3.175 5.24e-03 0.0227 434 Isethionic acid, proteins, N-methyl-L-proline (?), un-
known
2.825 5.25e-03 0.0227 469 Methylguanidine (?), proteins
1.595 5.31e-03 0.0228 592 Proteins, unknown
0.875 5.41e-03 0.0231 664 Proteins, ibuprofen (?)
1.995 5.45e-03 0.0232 552 Proline, proteins, L-isoleucine, N-methyl-L-proline (?)
4.125 5.59e-03 0.0236 339 Proline, proteins, unknown
3.355 5.77e-03 0.0242 416 Proline, scyllo-inositol, proteins
3.825 5.84e-03 0.0244 369 D-glucose, sucrose
4.035 5.89e-03 0.0244 348 Pseudouridine, proteins
0.865 5.94e-03 0.0244 665 Proteins
4.175 5.98e-03 0.0244 334 L-pyroglutamic acid, N-acetyl-L-glutamine, proteins
0.955 5.99e-03 0.0244 656 Proteins, leucine, L-isoleucine
3.895 6.02e-03 0.0244 362 D-glucose, paracetamol-glucuronide, sucrose
4.395 6.14e-03 0.0244 312 Proteins, unknown
1.415 6.15e-03 0.0244 610 Proteins, macromolecules
1.345 6.16e-03 0.0244 617 Proteins, threonine, lactic acid (?)
4.465 6.18e-03 0.0244 305 Proteins, D-lactose
7.675 6.20e-03 0.0244 183 Pseudouridine, proteins, unknown
3.915 6.44e-03 0.0251 360 D-glucose, sucrose
2.425 6.44e-03 0.0251 509 L-pyroglutamic acid, glutamine (?), proteins, unknown
0.775 6.58e-03 0.0254 674 Proteins
2.635 6.61e-03 0.0254 488 Proteins, unknown
3.375 6.63e-03 0.0254 414 Proteins, unknown
1.205 6.68e-03 0.0254 631 Proteins, 3-hydroxybutyric acid (?), 3-aminoisobutyric
acid (?), unknown
3.385 6.70e-03 0.0254 413 Proteins, unknown
8.705 6.74e-03 0.0254 80 Proteins, macromolecules
1.435 6.78e-03 0.0254 608 Proteins, unknown
2.795 6.97e-03 0.0260 472 Proteins, unknown
3.845 7.02e-03 0.0260 367 D-glucose, sucrose, pseudouridine
2.135 7.24e-03 0.0265 538 N-acetyl-L-glutamine, proteins, glutamine
1.575 7.25e-03 0.0265 594 Proteins, propanol
3.695 7.26e-03 0.0265 382 D-mannitol, proteins, unknown
1.625 7.50e-03 0.0272 589 Proteins
0.695 7.80e-03 0.0282 682 Proteins
3.475 7.92e-03 0.0285 404 D-glucose
8.145 7.97e-03 0.0285 136 Proteins
0.915 8.36e-03 0.0297 660 Proteins, propanol
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2.655 8.42e-03 0.0297 486 Proteins, citric acid
8.935 8.43e-03 0.0297 57 Proteins
4.205 8.68e-03 0.0303 331 Proteins, unknown
1.705 8.68e-03 0.0303 581 Proteins, leucine, agmatine
1.285 8.88e-03 0.0308 623 Proteins, L-isoleucine
1.425 9.02e-03 0.0309 609 Proteins, unknown (?)
2.105 9.03e-03 0.0309 541 Proline, N-acetyl-L-glutamine, proteins
3.455 9.04e-03 0.0309 406 D-glucose, 4-hydroxyphenylacetic acid, unknown
1.015 9.19e-03 0.0312 650 L-isoleucine, proteins
2.895 9.24e-03 0.0312 462 Proteins, unknown
3.545 9.30e-03 0.0312 397 D-glucose, myo-inositol
1.535 9.31e-03 0.0312 598 Propanol, proteins
3.745 9.50e-03 0.0317 377 D-glucose, D-mannitol, pseudouridine, ascorbic acid (?),
unknown
4.215 9.67e-03 0.0321 330 Sucrose, proteins
2.355 9.76e-03 0.0323 516 Proline, proteins, unknown (?)
8.585 9.90e-03 0.0326 92 Proteins, unknown
4.095 9.95e-03 0.0326 342 Proteins, unknown
2.405 9.98e-03 0.0326 511 L-pyroglutamic acid, proteins, succinic acid
1.235 1.01e-02 0.0328 628 L-isoleucine, proteins
1.225 1.02e-02 0.0328 629 Proteins, unknown
8.295 1.02e-02 0.0328 121 Proteins
0.705 1.03e-02 0.0328 681 Proteins
9.175 1.03e-02 0.0328 33 Proteins
8.135 1.04e-02 0.0328 137 Proteins, unknown (?)
3.495 1.04e-02 0.0328 402 D-glucose, sucrose
1.715 1.07e-02 0.0335 580 Proteins, leucine, agmatine
3.835 1.08e-02 0.0337 368 D-glucose, sucrose, pseudouridine
2.115 1.09e-02 0.0340 540 N-acetyl-L-glutamine, proteins, glutamine
7.995 1.10e-02 0.0340 151 Proteins
1.245 1.11e-02 0.0343 627 L-isoleucine, proteins, unknown
1.295 1.13e-02 0.0348 622 L-isoleucine, proteins, unknown
3.575 1.16e-02 0.0353 394 Sucrose, propanol, unknown
8.155 1.16e-02 0.0353 135 Proteins, macromolecules
3.245 1.17e-02 0.0353 427 D-glucose, agmatine
2.725 1.17e-02 0.0353 479 Dimethylamine
0.655 1.18e-02 0.0353 686 Proteins
2.945 1.18e-02 0.0353 457 N-methyl-L-proline (?), proteins, unknown
8.415 1.19e-02 0.0355 109 Proteins
8.895 1.21e-02 0.0360 61 Proteins
1.935 1.23e-02 0.0362 558 N-acetyl-L-glutamine, proteins
2.515 1.23e-02 0.0362 500 L-pyroglutamic acid, proteins
1.395 1.24e-02 0.0364 612 Proteins, macromolecules
3.395 1.28e-02 0.0373 412 D-glucose
0.905 1.30e-02 0.0376 661 Proteins, propanol
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2.785 1.30e-02 0.0376 473 Proteins, unknown
9.265 1.36e-02 0.0393 24 Proteins
1.795 1.37e-02 0.0393 572 Proteins
8.915 1.39e-02 0.0396 59 Proteins
8.865 1.39e-02 0.0396 64 Proteins
1.455 1.40e-02 0.0397 606 L-isoleucine, proteins
3.255 1.41e-02 0.0399 426 D-glucose, agmatine
7.585 1.42e-02 0.0399 192 Proteins
6.685 1.44e-02 0.0405 282 Proteins, unknown
6.535 1.45e-02 0.0405 297 Proteins
1.025 1.48e-02 0.0412 649 L-isoleucine, proteins
3.805 1.49e-02 0.0412 371 D-mannitol, proteins
0.665 1.50e-02 0.0412 685 Proteins
1.615 1.50e-02 0.0412 590 Proteins
6.695 1.52e-02 0.0416 281 Proteins
1.145 1.54e-02 0.0420 637 Proteins
6.675 1.55e-02 0.0422 283 Proteins, unknown
3.025 1.57e-02 0.0425 449 Agmatine, 2-oxoglutaric acid, 3-aminoisobutyric acid
3.725 1.60e-02 0.0430 379 D-glucose, leucine, pseudouridine
1.195 1.61e-02 0.0430 632 Proteins, 3-aminoisobutyric acid
8.125 1.61e-02 0.0430 138 Proteins, macromolecules
0.625 1.68e-02 0.0447 689 Proteins
1.725 1.68e-02 0.0447 579 Proteins, leucine, agmatine
1.565 1.69e-02 0.0448 595 Proteins, propanol
9.095 1.70e-02 0.0448 41 Proteins
1.135 1.72e-02 0.0450 638 Proteins, unknown
1.805 1.76e-02 0.0461 571 Proteins
2.335 1.79e-02 0.0468 518 Proline, N-acetyl-L-glutamine, proteins
3.485 1.81e-02 0.0468 403 D-glucose, sucrose
4.435 1.82e-02 0.0468 308 Proteins, unknown
0.645 1.82e-02 0.0468 687 Proteins
2.415 1.82e-02 0.0468 510 L-pyroglutamic acid, succinic acid, proteins
8.715 1.86e-02 0.0473 79 Proteins, macromolecules
4.485 1.87e-02 0.0473 303 Proteins, unknown
3.465 1.87e-02 0.0473 405 D-glucose, sucrose
1.545 1.88e-02 0.0473 597 Propanol, proteins
0.685 1.88e-02 0.0473 683 Proteins
9.105 1.89e-02 0.0473 40 Proteins
0.765 1.89e-02 0.0473 675 Proteins
3.735 1.93e-02 0.0481 378 D-glucose, leucine
3.955 1.96e-02 0.0486 356 Isethionic acid, proteins, unknown
4.115 2.01e-02 0.0498 340 Proteins, unknown
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Table 7.22: Previous page: Spectral positions given in ppm, p-values both unadjusted and
Benjamini and Hochberg (B/H)-adjusted, NMR IDs, as well as correspond-
ingly identified compounds of NMR features that discriminated groups U and
V of hypothesis 1a, i.e. patients dying from any cause versus patients not dy-
ing from any cause under the restriction that both groups do not progress to
end-stage renal disease (ESRD). The 256 urine specimens studied were collected in
the last week directly before treatment randomization (W1). A false discovery rate (FDR)
below 5% was applied. The FDR was adjusted according to the method of Benjamini and
Hochberg (B/H). In case that more than one compound contributed to a significant bin, all
possible assignments are given. A question mark denotes ambiguous signal assignments,
mostly due to severe signal overlap.
Spectral P -value P -value ID Identified compounds
position un- B/H-
[ppm] adjusted adjusted
0.955 1.19e-04 0.0178 656 Proteins, leucine (?)
8.585 1.44e-04 0.0178 92 Macromolecules, proteins, unknown (only visible in single
spectra)
8.875 1.99e-04 0.0178 63 Macromolecules, proteins, 1-methylnicotinamide
0.965 2.30e-04 0.0178 655 Proteins, leucine (?)
9.315 2.58e-04 0.0178 19 Macromolecules, proteins
1.175 2.97e-04 0.0178 634 Proteins
0.945 2.97e-04 0.0178 657 Proteins, unknown
1.035 3.16e-04 0.0178 648 Proteins, valine
9.305 3.59e-04 0.0178 20 Macromolecules, proteins
9.265 3.99e-04 0.0178 24 Macromolecules, proteins
0.935 4.42e-04 0.0178 658 Proteins, unknown
1.025 4.45e-04 0.0178 649 Proteins, unknown
8.105 5.37e-04 0.0178 140 Macromolecules/proteins
9.235 5.48e-04 0.0178 27 Macromolecules/proteins
9.295 5.60e-04 0.0178 21 Macromolecules/proteins
8.665 5.65e-04 0.0178 84 Macromolecules/proteins
8.655 5.87e-04 0.0178 85 Macromolecules/proteins
9.355 5.97e-04 0.0178 15 Macromolecules/proteins
0.775 6.01e-04 0.0178 674 Proteins
8.595 6.49e-04 0.0178 91 Macromolecules/proteins
9.165 6.60e-04 0.0178 34 Macromolecules/proteins
0.535 7.06e-04 0.0178 698 Proteins
8.755 7.11e-04 0.0178 75 Macromolecules/proteins
9.405 7.97e-04 0.0178 10 Macromolecules/proteins
0.785 8.42e-04 0.0178 673 Proteins
9.005 8.65e-04 0.0178 50 Macromolecules/proteins
8.375 8.72e-04 0.0178 113 Macromolecules/proteins, unknown
0.545 8.74e-04 0.0178 697 Proteins
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1.015 9.18e-04 0.0178 650 Proteins, unknown
9.455 9.28e-04 0.0178 5 Macromolecules/proteins
9.015 9.38e-04 0.0178 49 Macromolecules/proteins
9.345 9.77e-04 0.0178 16 Macromolecules/proteins
8.135 9.82e-04 0.0178 137 Macromolecules/proteins
8.605 9.84e-04 0.0178 90 Macromolecules/proteins
0.795 9.88e-04 0.0178 672 Proteins
1.005 1.01e-03 0.0178 651 Proteins, valine
7.865 1.01e-03 0.0178 164 Macromolecules/proteins
1.045 1.05e-03 0.0178 647 Proteins, unknown
0.555 1.15e-03 0.0178 696 Proteins
8.865 1.16e-03 0.0178 64 Macromolecules/proteins
0.765 1.19e-03 0.0178 675 Proteins, unknown
8.615 1.25e-03 0.0178 89 Macromolecules/proteins
0.615 1.26e-03 0.0178 690 Proteins
9.195 1.32e-03 0.0178 31 Macromolecules/proteins
0.515 1.34e-03 0.0178 700 Proteins
0.525 1.36e-03 0.0178 699 Proteins
8.645 1.37e-03 0.0178 86 Macromolecules/proteins
9.215 1.37e-03 0.0178 29 Macromolecules/proteins
0.925 1.45e-03 0.0178 659 Proteins, 3-methylglutaric acid (?)
9.145 1.47e-03 0.0178 36 Macromolecules/proteins
0.595 1.50e-03 0.0178 692 Proteins
1.695 1.55e-03 0.0178 582 Proteins
0.565 1.58e-03 0.0178 695 Proteins
0.655 1.58e-03 0.0178 686 Proteins
0.845 1.59e-03 0.0178 667 Proteins, unknown
0.605 1.59e-03 0.0178 691 Proteins
8.765 1.59e-03 0.0178 74 Macromolecules/proteins
1.165 1.62e-03 0.0178 635 Proteins
1.635 1.69e-03 0.0178 588 Proteins
0.825 1.70e-03 0.0178 669 Proteins, unknown
0.715 1.71e-03 0.0178 680 Proteins
8.695 1.72e-03 0.0178 81 Macromolecules/proteins
4.355 1.72e-03 0.0178 316 Proteins
1.645 1.73e-03 0.0178 587 Proteins
0.645 1.74e-03 0.0178 687 Proteins
1.085 1.74e-03 0.0178 643 Proteins
0.835 1.81e-03 0.0178 668 Proteins, unknown
9.105 1.84e-03 0.0178 40 Macromolecules/proteins
8.625 1.84e-03 0.0178 88 Macromolecules/proteins
8.635 1.85e-03 0.0178 87 Macromolecules/proteins
9.375 1.86e-03 0.0178 13 Macromolecules/proteins
0.625 1.86e-03 0.0178 689 Proteins
0.505 1.86e-03 0.0178 701 Proteins
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8.745 1.89e-03 0.0178 76 Macromolecules/proteins
9.185 1.90e-03 0.0178 32 Macromolecules/proteins
9.175 2.02e-03 0.0185 33 Macromolecules/proteins
0.665 2.04e-03 0.0185 685 Proteins
0.805 2.06e-03 0.0185 671 Proteins
8.675 2.16e-03 0.0191 83 Macromolecules/proteins
0.585 2.22e-03 0.0195 693 Proteins
0.695 2.30e-03 0.0196 682 Proteins
0.685 2.31e-03 0.0196 683 Proteins
0.725 2.32e-03 0.0196 679 Proteins
0.705 2.35e-03 0.0196 681 Proteins
8.935 2.38e-03 0.0197 57 Macromolecules/proteins
3.065 2.53e-03 0.0206 445 Proteins
1.685 2.57e-03 0.0206 583 Proteins
9.435 2.61e-03 0.0206 7 Macromolecules/proteins
0.995 2.62e-03 0.0206 652 Proteins
9.085 2.73e-03 0.0209 42 Proteins
0.815 2.76e-03 0.0209 670 Proteins
8.115 2.84e-03 0.0209 139 Macromolecules/proteins
1.705 2.85e-03 0.0209 581 Proteins
7.785 2.85e-03 0.0209 172 Macromolecules/proteins
1.655 2.86e-03 0.0209 586 Proteins
0.635 2.90e-03 0.0209 688 Proteins
0.675 2.93e-03 0.0209 684 Proteins
1.595 2.94e-03 0.0209 592 Proteins
8.095 2.95e-03 0.0209 141 Macromolecules/proteins
1.885 3.01e-03 0.0210 563 Proteins
9.255 3.03e-03 0.0210 25 Macromolecules/proteins
9.415 3.10e-03 0.0211 9 Macromolecules/proteins
1.125 3.10e-03 0.0211 639 Proteins
8.125 3.26e-03 0.0219 138 Macromolecules/proteins
8.145 3.31e-03 0.0219 136 Macromolecules/proteins
0.975 3.33e-03 0.0219 654 Proteins, leucine (?)
0.855 3.37e-03 0.0219 666 Proteins
7.875 3.38e-03 0.0219 163 Macromolecules/proteins
1.345 3.43e-03 0.0219 617 Proteins, unknown
1.585 3.44e-03 0.0219 593 Proteins
8.235 3.49e-03 0.0220 127 Macromolecules/proteins
1.055 3.52e-03 0.0220 646 Proteins, valine
9.205 3.61e-03 0.0224 30 Macromolecules/proteins
0.735 3.67e-03 0.0226 678 Proteins
1.615 3.72e-03 0.0227 590 Proteins
0.985 3.87e-03 0.0230 653 Proteins, valine
4.345 3.89e-03 0.0230 317 Proteins, unknown
3.205 3.91e-03 0.0230 431 Unknown
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4.075 3.91e-03 0.0230 344 Unknown
1.755 4.11e-03 0.0234 576 Proteins, leucine (?)
8.915 4.24e-03 0.0234 59 Macromolecules/proteins
1.605 4.24e-03 0.0234 591 Proteins
2.955 4.25e-03 0.0234 456 Proteins
0.915 4.27e-03 0.0234 660 Proteins, unknown
9.095 4.33e-03 0.0234 41 Macromolecules/proteins
1.245 4.33e-03 0.0234 627 Proteins
1.725 4.33e-03 0.0234 579 Proteins
9.075 4.35e-03 0.0234 43 Macromolecules/proteins
8.685 4.36e-03 0.0234 82 Macromolecules/proteins
1.135 4.37e-03 0.0234 638 Proteins
8.565 4.41e-03 0.0234 94 Macromolecules/proteins
1.715 4.42e-03 0.0234 580 Proteins, leucine (?)
8.945 4.62e-03 0.0241 56 Macromolecules/proteins
1.895 4.66e-03 0.0241 562 Proteins
9.225 4.67e-03 0.0241 28 Macromolecules/proteins
9.025 4.67e-03 0.0241 48 Macromolecules/proteins
1.095 4.76e-03 0.0243 642 Proteins
8.245 4.89e-03 0.0249 126 Macromolecules/proteins
8.215 4.96e-03 0.0250 129 Macromolecules/proteins
9.245 5.05e-03 0.0252 26 Macromolecules/proteins
0.865 5.12e-03 0.0252 665 Proteins
9.475 5.12e-03 0.0252 3 Macromolecules/proteins
9.335 5.14e-03 0.0252 17 Macromolecules/proteins
1.875 5.28e-03 0.0256 564 Proteins
1.765 5.33e-03 0.0256 575 Proteins
8.735 5.34e-03 0.0256 77 Macromolecules/proteins
8.435 5.41e-03 0.0256 107 Macromolecules/proteins
4.365 5.41e-03 0.0256 315 Proteins
9.465 5.47e-03 0.0258 4 Macromolecules/proteins
1.625 5.68e-03 0.0264 589 Proteins
8.985 5.69e-03 0.0264 52 Macromolecules/proteins
9.395 5.92e-03 0.0273 11 Macromolecules/proteins
4.255 5.95e-03 0.0273 326 Proteins, unknown
6.515 6.03e-03 0.0275 299 Macromolecules/proteins
8.475 6.10e-03 0.0275 103 Macromolecules/proteins
3.075 6.15e-03 0.0275 444 Proteins
9.495 6.15e-03 0.0275 1 Macromolecules/proteins
8.465 6.21e-03 0.0275 104 Macromolecules/proteins
8.205 6.34e-03 0.0278 130 Macromolecules/proteins
8.805 6.38e-03 0.0278 70 Macromolecules/proteins
4.135 6.40e-03 0.0278 338 Proteins, unknown
0.575 6.49e-03 0.0281 694 Proteins
1.575 6.58e-03 0.0283 594 Proteins, unknown
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1.075 6.61e-03 0.0283 644 Proteins, unknown
0.755 6.69e-03 0.0284 676 Proteins
7.775 6.73e-03 0.0284 173 Macromolecules/proteins, unknown
8.295 6.77e-03 0.0284 121 Macromolecules/proteins
1.675 6.98e-03 0.0290 584 Proteins
8.155 6.99e-03 0.0290 135 Macromolecules/proteins
9.055 7.09e-03 0.0292 45 Macromolecules/proteins
9.445 7.25e-03 0.0297 6 Macromolecules/proteins
2.975 7.45e-03 0.0301 454 Proteins, unknown
9.035 7.46e-03 0.0301 47 Macromolecules/proteins
4.375 7.49e-03 0.0301 314 Proteins
1.565 7.54e-03 0.0301 595 Proteins, unknown
4.245 7.55e-03 0.0301 327 Proteins
9.485 7.68e-03 0.0303 2 Macromolecules/proteins
1.115 7.71e-03 0.0303 640 Proteins, unknown
0.905 7.80e-03 0.0306 661 Proteins, unknown
1.235 7.88e-03 0.0307 628 Proteins
7.885 8.19e-03 0.0317 162 Macromolecules/proteins
1.735 8.29e-03 0.0319 578 Proteins, leucine (?)
1.255 8.38e-03 0.0321 626 Proteins
1.275 8.51e-03 0.0324 624 Proteins, unknown
9.385 8.64e-03 0.0327 12 Macromolecules/proteins
4.235 8.81e-03 0.0332 328 Proteins
1.185 8.88e-03 0.0333 633 Proteins
1.265 9.00e-03 0.0335 625 Proteins, unknown
8.955 9.03e-03 0.0335 55 Macromolecules/proteins
1.805 9.16e-03 0.0336 571 Proteins
1.425 9.16e-03 0.0336 609 Proteins
8.575 9.63e-03 0.0352 93 Macromolecules/proteins
2.345 9.72e-03 0.0352 517 Proteins, unknown
6.595 9.77e-03 0.0352 291 Macromolecules/proteins, unknown
2.945 9.83e-03 0.0352 457 Proteins
9.325 9.88e-03 0.0352 18 Macromolecules/proteins
9.425 9.88e-03 0.0352 8 Macromolecules/proteins
8.445 9.97e-03 0.0352 106 Macromolecules/proteins
9.155 1.00e-02 0.0352 35 Macromolecules/proteins
2.245 1.01e-02 0.0355 527 Proteins, unknown
7.205 1.02e-02 0.0357 230 Proteins, unknown
8.705 1.03e-02 0.0357 80 Macromolecules/proteins
9.065 1.03e-02 0.0357 44 Macromolecules/proteins
0.745 1.07e-02 0.0365 677 Proteins
9.365 1.07e-02 0.0365 14 Macromolecules/proteins
6.895 1.08e-02 0.0365 261 Proteins, unknown
1.065 1.08e-02 0.0365 645 Proteins, unknown
1.905 1.09e-02 0.0365 561 Proteins, unknown
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1.795 1.09e-02 0.0365 572 Proteins
6.505 1.12e-02 0.0373 300 Macromolecules/proteins
8.365 1.18e-02 0.0391 114 Macromolecules/proteins, unknown
6.525 1.18e-02 0.0391 298 Macromolecules/proteins, unknown
6.535 1.20e-02 0.0393 297 Macromolecules/proteins, unknown
6.585 1.22e-02 0.0398 292 Macromolecules/proteins
6.735 1.23e-02 0.0398 277 Macromolecules/proteins
8.815 1.23e-02 0.0398 69 Macromolecules/proteins
8.355 1.27e-02 0.0410 115 Macromolecules/proteins
6.935 1.30e-02 0.0419 257 Macromolecules/proteins
7.105 1.35e-02 0.0434 240 Macromolecules/proteins, unknown
8.925 1.37e-02 0.0435 58 Macromolecules/proteins
8.455 1.38e-02 0.0437 105 Macromolecules/proteins, unknown
6.875 1.39e-02 0.0439 263 Macromolecules/proteins
3.085 1.41e-02 0.0442 443 Proteins
6.825 1.41e-02 0.0442 268 Macromolecules/proteins
8.395 1.42e-02 0.0443 111 Macromolecules/proteins
1.535 1.43e-02 0.0443 598 Proteins, unknown
7.275 1.44e-02 0.0446 223 Unknown, macromolecules/proteins
2.075 1.45e-02 0.0447 544 Proteins, unknown
8.195 1.49e-02 0.0450 131 Macromolecules/proteins
2.985 1.49e-02 0.0450 453 Proteins
1.195 1.49e-02 0.0450 632 Proteins, unknown
3.095 1.49e-02 0.0450 442 Proteins
9.135 1.50e-02 0.0450 37 Unknown, macromolecules/proteins
2.315 1.52e-02 0.0454 520 Proteins, unknown
1.225 1.55e-02 0.0461 629 Proteins, unknown
1.775 1.56e-02 0.0463 574 Proteins
9.045 1.57e-02 0.0464 46 Macromolecules/proteins
8.715 1.58e-02 0.0465 79 Macromolecules/proteins
7.925 1.59e-02 0.0465 158 Macromolecules/proteins
7.095 1.59e-02 0.0465 241 Macromolecules/proteins, unknown
1.105 1.60e-02 0.0466 641 Proteins, unknown
1.435 1.62e-02 0.0469 608 Proteins, unknown
1.325 1.63e-02 0.0470 619 Proteins, unknown
6.865 1.63e-02 0.0470 264 Macromolecules/proteins, unknown
4.225 1.67e-02 0.0478 329 Proteins, unknown
1.555 1.70e-02 0.0485 596 Proteins, unknown
6.565 1.74e-02 0.0495 294 Macromolecules/proteins
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Table 7.23: Previous page: Spectral positions given in ppm, p-values both unadjusted and
Benjamini and Hochberg (B/H)-adjusted, NMR IDs, as well as correspond-
ingly identified compounds of NMR features that discriminated groups P and
O of hypothesis 1b, i.e. patients progressing to ESRD without dying and pa-
tients not progressing to ESRD without dying. The 205 urine specimens studied
were collected in the last week directly before treatment randomization (W1). A false dis-
covery rate (FDR) below 5% was applied. The FDR was adjusted according to the method
of Benjamini and Hochberg (B/H). In case that more than one compound contributed to
a significant bin, all possible assignments are given. A question mark denotes ambiguous
signal assignments, mostly due to severe signal overlap.
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Figure 7.12: A representative high-resolution 2D 1H-13C HSQC spectrum of a urine specimen from a study partici-
pant of the TREAT study. The spectrum was recorded with 2048 × 512 data points using 44 scans per increment.
The following compounds were identified supported by a corresponding 2D 1H 1H TOCSY spectrum, which was
recorded with 2048 × 256 data points, 56 scans per increment: 2,5-furandicarboxylic acid (?), 2-hydroxyisobutyric
acid, 2-oxoglutaric acid, 3-aminoisobutyric acid, 3-hydroxyisovaleric acid, 4-hydroxyphenylacetic acid (?), acetic acid,
acetone, agmatine, allantoin, ascorbic acid, citric acid, creatine, creatinine, D-glucose, dimethylamine, D-mannitol
(?), glutamine, glycine, guanidinoacetic acid, hippuric acid, indoxyl sulfate, isethionic acid, L-pyroglutamic acid,
lactic acid, leucine, methanol, methylguanidine, myo-inositol, N2-acetyl-L-ornithine (?), N-acetylglycine, N-acetyl-L-
glutamine, N-methyl-L-proline (?), N,N-dimethylglycine, phosphoethanolamine (?), propanol, pseudouridine, quinic
acid (?), scyllo-inositol, succinic acid, sucrose (?), TSP, trigonelline, trimethylamine-N-oxide, valine. The crowded
sugar region from 3.10 - 4.55 ppm in the 1H direction and from 50.0 - 84.5 ppm in the 13C direction has been enlarged
and is displayed below. A question mark denotes ambiguous signal assignments, mostly due to signal overlap. Note
that due to the fact that some signal intensities for few compounds, e.g. trigonelline, were below detection limit, not
all peaks could be annotated.252
8 About the author
8.1 Curriculum Vitae
Name Helena Ursula Zacharias
Date of birth January, 22nd 1988
Place of birth Regensburg, Germany
Nationality German
Education
2012 - present Ph.D. student at the biology faculty of the University of Regensburg,
Regensburg, Germany, Institute of Functional Genomics
2010 - 2012 studied physics (M.Sc.) at the University of Regensburg, Regensburg,
Germany, master thesis Investigation of Acute Kidney Injury after
Cardiac Surgery by NMR Spectroscopy and Machine Learning Methods
at the Institute of Functional Genomics (Advisor: Prof. Dr. Elmar Lang)
2007 - 2010 studied physics (B.Sc.) at the University of Regensburg, Regensburg,
Germany
1998 - 2007 attended Albrecht-Altdorfer-Gymnasium, Regensburg, Germany
8.2 Publications
Zacharias, H. U., Investigation of Acute Kidney Injury after Cardiac Surgery by NMR Spectroscopy
and Machine Learning Methods, M.Sc. thesis in physics, Institute of Functional Genomics, University
of Regensburg, March 2012.
Hochrein, J., Klein, M. S., Zacharias, H. U., Li, J., Wijffels, G., Schirra, H. J., Spang, R.,
Oefner, P. J., Gronwald, W., Performance Evaluation of Algorithms for the Classification of
Metabolic 1H NMR Fingerprints, Journal of Proteome Research, 2012, 11:6242-6251.
Zacharias, H. U., Schley, G., Hochrein, J., Klein, M. S., Köberle, C., Eckardt, K.-U., Willam,
C., Oefner, P. J., Gronwald, W., Analysis of human urine reveals metabolic changes related to the
development of acute kidney injury following cardiac surgery, Metabolomics, 2013, 9(3):697-707.
253
8 About the author
Zacharias, H. U., Hochrein, J., Klein, M. S., Samol, C., Oefner, P. J., Gronwald, W., Current
Experimental, Bioinformatic and Statistical Methods used in NMR Based Metabolomics, Current
Metabolomics, 2013, 1(3):253-268(16).
Zacharias, H. U., Hochrein, J., Vogl, F. C., Schley, G., Mayer, F., Jeleazcov, C., Eckardt, K.-
U., Willam, C., Oefner, P. J., Gronwald, W., Identification of Plasma Metabolites Prognostic of Acute
Kidney Injury after Cardiac Surgery with Cardiopulmonary Bypass, Journal of Proteome Research,
2015, 14(7):2897-2905.
Hochrein, J., Zacharias, H. U., Taruttis, F., Samol, C., Engelmann, J., Spang, R., Oefner, P.
J., Gronwald, W., Data Normalization of 1H-NMR Metabolite Fingerprinting Datasets in the
Presence of Unbalanced Metabolite Regulation, Journal of Proteome Research, 2015, 14(8):3217-3228.
Schlecht, I., Gronwald, W., Behrens, G., Baumeister, S., Hertel, J., Hochrein, J., Zacharias,
H. U., Fischer, B., Oefner, P. J., Leitzmann, M. F., Visceral adipose tissue but not subcutaneous
adipose tissue is associated with urine and serum metabolites, 2016, submitted to Int. J. of Obesity.
8.3 Poster Presentations
FGMR Discussion Meeting & Joint Conference of the German, Italian and Slovenian Magnetic
Resonance Societies, Frauenchiemsee, Germany, 2013, NMR analysis of human biofluids reveals
metabolic changes related to the development of acute kidney injury following cardiac surgery.
Discussion Meeting of the GDCh-Division of "Magnetic Resonance", Berlin, Germany, 2014,
Prediction of Acute Kidney Injury after cardiac surgery with cardiopulmonary bypass use employing
NMR urine and plasma fingerprints.
Associate seminar of the Regensburg International Graduate School of Life Sciences - RIGeL,
section Cellular Biochemistry and Biophysics, Kostenz, Germany, 2014, Prediction of Acute Kidney
Injury after cardiac surgery with cardiopulmonary bypass use employing NMR urine and plasma
fingerprints.
8.4 Conference Talks
Associate seminar of the Bavarian Genome Research Network (BayGene), Grosshadern/ Martinsried,
Germany, 2013, Analysis of human urine reveals metabolic changes related to the development of
acute kidney injury following cardiac surgery.
Associate seminar of the Regensburg International Graduate School of Life Sciences - RIGeL,
section Cellular Biochemistry and Biophysics, Sulzbürg, Germany, 2013, Analysis of human urine
reveals metabolic changes related to the development of acute kidney injury following cardiac surgery.
254
9 Bibliography
[Abdi and Williams 2010] Abdi, H., Williams, L. J., Principal Component Analysis, Wiley Interdisci-
plinary Reviews: Computational Statistics, 2010, 2(4):433-459.
[Agresti 1990] Agresti, A., Categorical data analysis, New York: Wiley, 1990, pp. 59-66.
[Agresti 2002] Agresti, A., Categorical data analysis, New York: Wiley, second edition, pp. 91-101.
[Al-Shabanah et al. 2010] Al-Shabanah, O. A., Aleisa, A. M., Al-Yahya, A. A., Al-Rejaie, S. S.,
Bakheet, S. A., Fatani, A. G., Sayed-Ahmed, M. M., Increased urinary losses of carnitine
and decreased intramitochondrial coenzyme A in gentamicin-induced acute renal failure in rats,
Nephrology Dialysis Transplantation, 2010, 25:69-76.
[Altenbuchinger et al. 2016] Altenbuchinger, M., Rehberg, T., Zacharias, H. U., Stämmler, F.,
Dettmer, K., Weber, D., Hiergeist, A., Gessner, A., Holler, E., Oefner, P. J., Spang, R., Reference
point insensitive molecular data analysis, 2016, in preparation.
[Arastéh et al. 2009] Arastéh, K., Baenkler, H.-W., Bieber, C., Brandt, R., Chatterjee, T., Dill, T.,
Ditting, T., Eich, W., Ernst, S., Fritze, D., Füeßl, H. S., Goeckenjan, G., Hahn, J.-M., Hamm,
C. W., Harenberg, J., Hengstmann, J. H., Herzog, W., Hofmann, T., Holzapfel, N., Huck, K.,
Kähler, J., Keller, M., Klingmüller, D., Köster, R., Kowol, S., Kuck, K.-H., Löwe, B., Matzdorff,
A., Müller-Tasch, T., Nienaber, C. A., Nikendei, C., Pausch, J., Petzsch, M., Rösch, W., Sauer,
N., Schlehofer, B., Schmidt, M., Schneider, H., Schuchert, A., Schwab, M., Schweikert, H.-U.,
Stern, H., Teschner, A., Träder, C., Usadel, K.-H., Veelken, R., Wahl, P., Zastrow, A., Ziegler,
R., Zipfel, S., Duale Reihe Innere Medizin, Thieme Press, Stuttgart 2009 (2nd edition).
[Arduini et al. 2008] Arduini, A., Bonomini, M., Savica, V., Amato, A., Zammit, V., Carnitine in
metabolic disease: Potential for pharmacological intervention, Pharmacology & Therapeutics,
2008, 120:149-156.
[Barker and Rayens 2003] Barker, M., Rayens, W., Partial Least Squares for Discrimination, J.
Chemometrics, 2003, 17:166-173.
[Barton et al. 2010] Barton, R. H., Waterman, D., Bonner, F. W., Holmes, E., Clarke, R., Nicholson,
J. K., Lindon, J. C., The influence of EDTA and citrate anticoagulant addition to human plasma
on information recovery from NMR-based metabolic profiling studies, Mol.BioSyst., 2010, 6:215-
224.
[Becker et al. 1988] Becker, R. A., Chambers, J. M., Wilks, A. R., The New S Language, Wadsworth
& Brooks/Cole, 1988.
[Beckonert et al. 2007] Beckonert, O., Keun, H. C., Ebbels, T. M., Bundy, J., Holmes, E., Lindon,
J. C., Nicholson, J. K., Metabolic profiling, metabolomic and metabonomic procedures for NMR
spectroscopy of urine, plasma, serum and tissue extracts, Nature Protocols, 2007, 2(11):2692-703.
255
9 Bibliography
[Bedford et al. 2014] Bedford, M., Stevens, P. E., Wheeler, T. W. K., Farmer, C. K. T., What is the
real impact of acute kidney injury?, BMC nephrology., 2014, 15:95.
[Beger et al. 2008] Beger, R. D., Holland, R. D., Sun, J., Schnackenberg, L. K., Moore, P. C., Dent,
C. L., Devarajan, P., Portilla, D., Metabonomics of acute kidney injury in children after cardiac
surgery, Pediatr. Nephrol., 2008, 23:977-984.
[Bellomo et al. 2004] Bellomo, R., Ronco, C., Kellum, J. A., Mehta, R. L., Palevsky, P., ADQI work-
group, Acute renal failure - definition, outcome measures, animal models, fluid therapy and infor-
mation technology needs: the Second International Consensus Conference of the Acute Dialysis
Quality Initiative (ADQI) Group, Critical Care, 2004, 8:R204-R212.
[Benjamini and Hochberg 1995] Benjamini, Y., Hochberg, Y., Controlling the False Discovery Rate:
a Practical and Powerful Approach to Multiple Testing, Journal of the Royal Statistical Society.
Series B (Methodological), 1995, 57(1):289-300.
[Berger and Braun 2004] Berger, S., Braun, S., 200 and More NMR Experiments, Wiley-VCH, Wein-
heim, 2004.
[Bertram et al. 2011] Bertram, H. C., Yde, C. C., Zhang, X., Kristensen, N. B., Effect of Dietary
Nitrogen Content on the Urine Metabolite Profile of Dairy Cows Assessed by Nuclear Magnetic
Resonance (NMR)-Based Metabolomics, J. Agric. Food Chem., 2011, 59:12499-12505.
[Bland and Altman 1986] Bland, J. M., Altman, D. G., Statistical methods for assessing agreement
between two methods of clinical measurement, Lancet, 1986, 1:307-10.
[Bland and Altman 1999] Bland, J. M., Altman, D. G., Measuring agreement in method comparison
studies, Stat Methods Med Res., 1999, 8:135-60.
[Bloch 1946] Bloch, F., Nuclear Induction, Physical Review, 1946, 70(7-8):460-474.
[Bolstad et al. 2003] Bolstad, B. M., Irizarry, R. A., Astrand, M., Speed, T. P., A Comparison of
Normalization Methods for High Density Oligonucleotide Array Data Based on Variance and
Bias, Bioinformatics, 2003, 19:185-193.
[Bouatra et al. 2013] Bouatra, S., Aziat, F., Mandal, R., Guo, A. C., Wilson, M. R., Knox, C.,
Bjorndahl, T. C., Krishnamurthy, R., Saleem, F., Liu, P., Dame, Z. T., Poelzer, J., Huynh, J.,
Yallou, F. S., Psychogios, N., Dong, E., Bogumil, R., Roehring, C., Wishart, D. S., The Human
Urine Metabolome, PLoS One, 2013, 8(9):e73076.
[Bragadottir et al. 2013] Bragadottir, G., Redfors, B., Ricksten, S.-E., Assessing glomerular filtration
rate (GFR) in critically ill patients with acute kidney injury - true GFR versus urinary creatinine
clearance and estimating equations, Critical Care, 2013, 17:R108.
[Breiman 2001] Breiman, L., Random Forests, Mach. Learn., 2001, 45(1):5-32.
[Breiman 2002] Breiman, L., Manual on setting up, using, and understanding random forests v3.1,
2002, http://oz.berkely.edu/users/breiman/Using_random_forests_V3.1.pdf.
[Bryan et al. 2008] Bryan, K., Brennan, L., Cunningham, P., MetaFIND: a feature analysis tool for
metabolomics data, BMC Bioinformatics, 2008, 9:470.
256
[Burges 1998] Burges, C. J. C., A Tutorial on Support Vector Machines for Pattern Recognition, Data
Mining and Knowledge Discovery, 1998, 2:121-167.
[Butler 2002] Butler, E., AVANCE SGU Based Frequency Generation Beginners Guide, Bruker
BioSpin, Rheinstetten, 2002, version 001.
[Carr and Purcell 1954] Carr, H. Y., Purcell, E. M., Effects of Diffusion on Free Precession in Nuclear
Magnetic Resonance Experiments, Physical Review, 1954, 94(3):630-638.
[Carstensen et al. 2015] Carstensen, B., Gurrin, L., Ekstrom, C., Figurski, M., MethComp: Functions
for Analysis of Agreement in Method Comparison Studies, 2015, R package version 1.22.2, http:
//CRAN.R-project.org/package=MethComp.
[Casella and Berger 2002] Casella, G., Berger, R. L., Statistical Inference, Duxbury Press, 2002, Pa-
cific Grove, USA, 2nd edition.
[Cavanagh et al. 1996] Cavanagh, J., Fairbrother, W. J., Palmer, A. G. III, Skelton, N. J., Protein
NMR Spectroscopy, Academic Press, San Diego, 1996.
[Chambers 1992] Chambers, J. M., Linear models, chapter 4 of Statistical Models in S, eds J. M.
Chambers and T. J. Hastie, Wadsworth & Brooks/Cole, 1992.
[Champely 2015] Champely, S., pwr: Basic Functions for Power Analysis, 2015, R package version
1.1-3, http://CRAN.R-project.org/package=pwr.
[Chawla et al. 2014] Chawla, L. S., Eggers, P. W., Star, R. A., Kimmel, P. L., Acute Kidney Injury
and Chronic Kidney Disease as Interconnected Syndromes, N. Engl. J. Med., 2014, 371:58-66.
[Ciba-Geigy 1983] Ciba-Geigy, Wissenschaftliche Tabellen Geigy, Basel: Ciba-Geigy, 1983.
[Clarkson et al. 1993] Clarkson, D. B., Fan, Y., Joe, H., A Remark on Algorithm 643: FEXACT: An
Algorithm for Performing Fisher’s Exact Test in r × c Contingency Tables, ACM Transactions
on Mathematical Software, 1993, 19:484-488.
[Concato 2013] Concato, J., Study Design and "Evidence" in Patient-oriented Research, Am. J. Respir.
Crit. Care Med., 2013, 187(11):1167-1172.
[Cox 1972] Cox, D. R., Regression Models and Life-Tables, Journal of the Royal Statistical Society
Series B, 1972, 34(2):187-220.
[Cravedi and Remuzzi 2013] Cravedi, P., Remuzzi, G., Pathophysiology of proteinuria and its value as
an outcome measure in chronic kidney disease, British Journal of Clinical Pharmacology, 2013,
76(4):516-523.
[Cruz et al. 2009] Cruz, D. N., Ricci, Z., Ronco, C., Clinical review: RIFLE and AKIN - time for
reappraisal, Critical Care, 2009, 13(3):211.
[Curhan 2005] Curhan, G., Cystatin C: A Marker of Renal Function or Something More?, Clinical
Chemistry, 2005, 51(2):293-294.
[Dalgaard 2008] Dalgaard, P., Introductory Statistics with R, Springer Statistics and Computing, New
York, USA, 2008.
257
9 Bibliography
[Dawiskiba et al. 2014] Dawiskiba, T., Deja, S., Mulak, A., Ząbek, A., Jawień, E., Pawełka, D., Ba-
nasik, M., Mastalerz-Migas, A., Balcerzak, W., Kaliszewski, K., Skóra, J., Barć, P., Korta, K.,
Pormańczuk, K., Szyber, P., Litarski, A., Młynarz, P., Serum and urine metabolomic finger-
printing in diagnostics of inflammatory bowel diseases, World Journal of Gastroenterology, 2014,
20(1):163-174.
[Deja et al. 2013] Deja, S., Dawiskiba, T., Balcerzak, W., Orczyk-Pawiłowicz, M., Głód, M., Pawełka,
D., Młynarz, P., Follicular Adenomas Exhibit a Unique Metabolic Profile. 1H NMR Studies of
Thyroid Lesions, PLoS One, 2013, 8(12):e84637.
[Del Palacio et al. 2012] Del Palacio, M., Romero, S., Casado, J. L., Proximal Tubular Renal Dys-
function or Damage in HIV-Infected Patients, AIDS Rev., 2012, 14:179-87.
[Del Re 2013] Del Re, A. C., compute.es: Compute Effect Sizes, 2013, R package version 0.2-2, http:
//cran.r-project.org/web/packages/compute.es.
[Dettmer and Hammock 2004] Dettmer, K., Hammock, B. D., Metabolomics - A New Exciting Field
within the "omics" Sciences, Environmental Health Perspectives, 2004, 112(7):A396-A397.
[Dettmer et al. 2013] Dettmer, K., Vogl, F. C., Ritter, A. P., Zhu, W., Nürnberger, N., Kreutz, M.,
Oefner, P. J., Gronwald, W., Gottfried, E., Distinct metabolic differences between various human
cancer and primary cells, Electrophoresis, 2013, 34:2836-2847.
[Diao et al. 2010] Diao, L., Ekins, S., Polli, J. E., Quantitative structure activity relationship for in-
hibition of human organic cation/carnitine transporter, Molecular Pharmaceutics, 2010, 7:2120-
2131.
[Dieterle et al. 2011] Dieterle, F., Riefke, B., Schlotterbeck, G., Ross, A., Senn, H., Amberg, A., NMR
and MS Methods for Metabonomics, in Drug Safety Evaluation: Methods and Protocols, Gautier,
J.-C. (ed.), Springer (Methods in Molecular Biology), 2011, pp. 385-415.
[Dimitriadou et al. 2011] Dimitriadou, E., Hornik, K., Leisch, F., Meyer, D., Weingessel, A., e1071:
Misc Functions for the Department of Statistics (e1071), TU Wien, 2011.
[Dörner 2013] Dörner, K., Niere in Dörner, K. (Ed.), Klinische Chemie und Hämatologie, Thieme
Press, Stuttgart 2013 (8th edition).
[Drüeke et al. 2006] Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I.C.,
Tsakiris, D., Burger, H.-U., Scherhag, A., for the CREATE Investigators, Normalization of
Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia, N. Engl. J. Med., 2006,
355(20):2071-2084.
[Druml et al. 1994] Druml, W., Fischer, M., Liebisch, B., Lenz, K., Roth, E., Elimination of amino
acids in renal failure, Am. J. Clin. Nutr., 1994, 60:418-423.
[DuBois 1916] DuBois, E., A formula to estimate the approximate surface area if height and weight
be known, Arch. Int. Med. 1916, 17:863-871.
[Dudoit et al. 2002] Dudoit, S., Fridlyand, J., Speed, T. P., Comparison of Discrimination Methods
for the Classification of Tumors Using Gene Expression Data, J. Am. Stat. Assoc., 2002, 97:77-
87.
258
[Dzúrik et al. 2001] Dzúrik, R., Spustová, V., Krivosíková, Z., Gazdíková, K., Hippurate participates
in the correction of metabolic acidosis, Kidney International Supplement, 2001, 78:S278-S281.
[Eckardt et al. 2012] Eckardt, K.-U., Bärthlein, B., Baid-Agrawal, S., Beck, A., Busch, M., Eitner,
F., Ekici, A. B., Floege, J., Gefeller, O., Haller, H., Hilge, R., Hilgers, K. F., Kielstein, J. T.,
Krane, V., Köttgen, A., Kronenberg, F., Oefner, P., Prokosch, H.-U., Reis, A., Schmid, M.,
Schaeffner, E., Schultheiss, U. T., Seuchter, S. A., Sitter, T., Sommerer, C., Walz, G., Wanner,
C., Wolf, G., Zeier, M., Titze, S., The German Chronic Kidney Disease (GCKD) study: design
and methods, Nephrol Dial Transplant, 2012, 27:1454-1460.
[Eckardt et al. 2013] Eckardt, K.-U., Coresh, J., Devuyst, O., Johnson, R. J., Köttgen, A., Levey, A.
S., Levin, A., Evolving importance of kidney disease: from subspecialty to global health burden,
Lancet, 2013, 382:158-169.
[Efron et al. 2004] Efron, B., Hastie, T., Johnstone, I., Tibshirani, R., Least Angle Regression, The
Annals of Statistics, 2004, 32(2):407-499.
[Eisen et al. 1998] Eisen, M. B., Spellman, P. T., Brown, P. O., Botstein, D., Cluster analysis and
display of genome-wide expression patterns, PNAS, 1998, 95:14863-14868.
[Elliott et al. 2015] Elliott, P., Posma, J. M., Chan, Q., Garcia-Perez, I., Wijeyesekera, A., Bictash,
M., Ebbels, T. M. D., Ueshima, H., Zhao, L., van Horn, L., Daviglus, M., Stamler, J., Holmes,
E., Nicholson, J. K., Urinary metabolic signatures of human adiposity, Science Translational
Medicine, 2015, 7(285):285ra62.
[Emwas et al. 2014] Emwas, A.-H., Luchinat, C., Turano, P., Tenori, L., Roy, R., Salek, R. M., Ryan,
D., Merzaban, J. S., Kaddurah-Daouk, R., Zeri, A. C., Gowda, G. A. N., Raftery, D., Wang, Y.,
Brennan, L., Wishart, D. S., Standardizing the experimental conditions for using urine in NMR-
based metabolomic studies with a particular focus on diagnostic studies: a review, Metabolomics,
2014, DOI: 10.1007/s11306-014-0746-7.
[Endre et al. 2011] Endre, Z. H., Pickering, J. W., Walker, R. J., Devarajan, P., Edelstein, C. L.,
Bonventre, J. V., Frampton, C. M., Bennett, M. R., Ma, Q., Sabbisetti, V. S., Vaidya, V.
S., Walcher, A. M., Shaw, G. M., Henderson, S. J., Nejat, M., Schollum, J. B. W., George,
P. M., Improved performance of urinary biomarkers of acute kidney injury in the critically ill
by stratification for injury duration and baseline renal function, Kidney International, 2011,
79:1119-1130.
[Engoren et al. 2014] Engoren, M., Habib, R. H., Arslanian-Engoren, C., Kheterpal, S., Schwann, T.
A., The Effect of Acute Kidney Injury and Discharge Creatinine Level on Mortality Following
Cardiac Surgery, Critical Care Medicine, 2014, 42(9):2069-2074.
[Ernst et al. 1987] Ernst, R. R., Bodenhausen, G., Wokaun, A., Principles of Nuclear Magnetic Res-
onance in One and Two Dimensions, Oxford University Press, Oxford, 1987.
[Eriksson et al. 1974] Eriksson, O., Kjellman, H., Pilbrant, A., Schannong, M., Pharmacokinetics of
tranexamic acid after intravenous administration to normal volunteers, European Journal of
Clinical Pharmacology, 1974, 7:375-380.
259
9 Bibliography
[Fassett et al. 2011] Fassett, R. G., Venuthurupalli, S. K., Gobe, G. C., Coombes, J. S., Cooper, M.
A., Hoy, W. E., Biomarkers in chronic kidney disease: a review, Kidney International, 2011,
80:806-821.
[Faul et al. 2007] Faul, F., Erdfelder, E., Lang, A.-G., Buchner, A., G*Power 3: A flexible statistical
power analysis program for the social, behavioral, and biomedical sciences, Behavior Research
Methods, 2007, 39:175-191.
[Feldman et al. 2003] Feldman, H. I., Appel, L. J., Chertow, G. M., Cifelli, D., Cizman, B., Daugirdas,
J., Fink, J. C., Franklin-Becker, E. D., Go, A. S., Hamm, L. L., He, J., Hostetter, T., Hsu, C.-Y.,
Jamerson, K., Joffe, M., Kusek, J. W., Landis, J. R., Lash, J. P., Miller, E. R., Mohler, E. R.
III, Muntner, P., Ojo, A. O., Rahman, M., Townsend, R. R., Wright, J. T., and the Chronic
Renal Insufficiency Cohort (CRIC) Study Investigators, The Chronic Renal Insufficiency Cohort
(CRIC) Study: Design and Methods, J. Am. Soc. Nephrol., 2003, 14(suppl 2):S148-S153.
[Felsenfeld et al. 2013] Felsenfeld, A., Rodriguez, M., Levine, B., New insights into regulation of cal-
cium homeostasis, Curr. Opin. Nephrol. Hypertens., 2013, 22:371-376.
[Fisher 1935] Fisher, R. A., The logic of inductive inference, Journal of the Royal Statistical Society
Series A, 1935, 98(1):39-54.
[Fisher 1962] Fisher, R. A., Confidence limits for a cross-product ratio, Australian Journal of Statis-
tics, 1962, 4(1):41.
[Fisher 1970] Fisher, R. A., Statistical Methods for Research Workers, Oliver & Boyd, 1970.
[Fisher and Wood 2007] Fisher, C. G., Wood, K. B., Introduction to and Techniques of Evidence-
Based Medicine, SPINE, 2007, 32(19S):S66-S72.
[Friedman et al. 2010] Friedman, J., Hastie, T., Tibshirani, R., Regularization Paths for Generalized
Linear Models via Coordinate Descent, Journal of Statistical Software, 2010, 33(1):1-22.
[Fukui et al. 2009] Fukui, Y., Kato, M., Inoue, Y., Matsubara, A., Itoh, K., A metabonomic approach
identifies human urinary phenylacetylglutamine as a novel marker of interstitial cystitis, Journal
of Chromatography B, 2009, 877:3806-3812.
[Ganapathy et al. 2000] Ganapathy, M. E., Huang, W., Rajan, D. P., Carter, A. L., Sugawara, M.,
Iseki, K., Leibach, F. H., Ganapathy, V., Beta-lactam antibiotics as substrates for OCTN2, an
organic cation/carnitine transporter, Journal of Biological Chemistry, 2000, 275:1699-1707.
[Gautier et al. 2004] Gautier, L., Cope, L., Bolstad, B. M., Irizarry, R. A., affy — analysis of
Affymetrix GeneChip data at the probe level, Bioinformatics, 2004, 20(3):307-315.
[Geng and Pang 1999] Geng, W., Pang, K. S., Differences in excretion of hippurate, as a metabolite of
benzoate and as an administered species, in the single-pass isolated perfused rat kidney explained,
Journal of Pharmacology and Experimental Therapeutics, 1999, 288:597-606.
[German National Cohort Consortium 2014] German National Cohort (GNC) Consortium, The Ger-
man National Cohort: aims, study design and organization, Eur. J. Epidemiol., 2014, 29:371-382.
260
[Gillies et al. 2005] Gillies, M., Bellomo, R., Doolan, L., Buxton, B., Bench-to-bedside review: In-
otropic drug therapy after adult cardiac surgery – a systematic literature review, Crit Care.,
2005, 9:266-279.
[Gronwald et al. 2008] Gronwald, W., Klein, M. S., Kaspar, H., Fagerer, S. R., Nürnberger, N.,
Dettmer, K., Bertsch, T., Oefner, P. J., Urinary Metabolite Quantification employing 2D NMR
spectroscopy, Analytical Chemistry, 2008, 80(23):9288-9297.
[Gronwald et al. 2011] Gronwald, W., Klein, M. S., Zeltner, R., Schulze, B.-D., Reinhold, S. W.,
Deutschmann, M., Immervoll, A.-K., Böger, C. A., Banas, B., Eckardt, K.-U., Oefner, P. J.,
Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting
of urine, Kidney International, 2011, 79:1244-1253.
[Haase et al. 2009] Haase, M., Bellomo, R., Devarajan, P., Schlattmann, P., Haase-Fielitz, A., Accu-
racy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Diagnosis and Prognosis in Acute
Kidney Injury: A Systematic Review and Meta-analysis, American Journal of Kidney Diseases,
2009, 54(6):1012-1024.
[Haase et al. 2010a)] Haase, M., Bellomo, R., Haase-Fielitz, A., Neutrophil gelatinase-associated
lipocalin, Current Opinion in Critical Care, 2010, 16:526-632.
[Haase et al. 2010b)] Haase, M., Bellomo, R., Haase-Fielitz, A., Novel Biomarkers, Oxidative Stress,
and the Role of Labile Iron Toxicity in Cardiopulmonary Bypass-Associated Acute Kidney Injury,
Journal of the American College of Cardiology, 2010, 55(19):2024-2033.
[Haase-Fielitz et al. 2009] Haase-Fielitz, A., Bellomo, R., Devarajan, P., Story, D., Matalanis, G.,
Dragun, D., Haase, M., Novel and conventional serum biomarkers predicting acute kidney injury
in adult cardiac surgery - A prospective cohort study, Crit. Care Med., 2009, 37(2):553-560.
[Haase-Fielitz et al. 2011] Haase-Fielitz, A., Mertens, P. R., Plaß, M., Kuppe, H., Hetzer, R., Wester-
man, M., Ostland, V., Prowle, J. R., Bellomo, R., Haase, M., Urine hepcidin has additive value
in ruling out cardiopulmonarybypass-associated acute kidney injury: An observational cohort
study, Critical Care, 2011, 15(4):R186.
[Han et al. 2002] Han, W. K., Bailly, V., Abichandani, R., Thadhani, R., Bonventre, J. V., Kidney
Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury, Kidney
international, 2002, 62(1):237-244.
[Han et al. 2009] Han, W. K., Wagener, G., Zhu, Y., Wang, S., Lee, H. T., Urinary biomarkers in the
early detection of acute kidney injury after cardiac surgery, Clinical Journal of the American
Society of Nephrology, 2009, 4(5):873-882.
[Harvey and Everett 2004] Harvey, P. W., Everett, D. J., Significance of the detection of esters of P-
hydroxybenzoic acid (parabens) in human breast tumours, Journal of Applied Toxicology, 2004,
24:1-4.
[Hastie et al. 2001] Hastie, T., Tibshirani, R., Friedman, J., The Elements of Statistical Learning,
Springer (Series in Statistics), New York 2001.
261
9 Bibliography
[Hastings et al. 2013] Hastings, J., Matos, P. de, Dekker, A., Ennis, M., Marsha, B., Kale, N.,
Muthukrishnan, V., Owen, G., Turner, S., Williams, M., Steinbeck, C., The ChEBI reference
database and ontology for biologically relevant chemistry: enhancements for 2013, Nucleic Acids
Res., 2013, 41:D456-63.
[Held et al. 2012] Held, M., Bentink, S., Kostka, D., Lottaz, C., Scheid, S., Jaeger, J., Kohler, C.,
compdiagTools: Toolbox for performing and illustrating microarray data analyses, R package
version 1.8.2, 2012.
[Hobson et al. 2009] Hobson, C. E., Yavas, S., Segal, M. S., Schold, J. D., Tribble, C. G., Layon, A.
J., Bihorac, A., Acute Kidney Injury Is Associated With Increased Long-Term Mortality After
Cardiothoracic Surgery, Circulation, 2009, 119:2444-2453.
[Hochrein 2011] Hochrein, J., Klassifikatoren in der Metabolomik und Proteomik, diploma thesis, In-
stitute of Functional Genomics, University of Regensburg, April 2011.
[Hochrein et al. 2012] Hochrein, J., Klein, M. S., Zacharias, H. U., Li, J., Wijffels, G., Schirra, H.
J., Spang, R., Oefner, P. J., Gronwald, W., Performance Evaluation of Algorithms for the
Classification of Metabolic 1H NMR Fingerprints, Journal of Proteome Research, 2012, 11:6242-
6251.
[Hochrein et al. 2015] Hochrein, J., Zacharias, H. U., Taruttis, F., Samol, C., Engelmann, J., Spang,
R., Oefner, P. J., Gronwald, W., Data Normalization of 1H-NMR Metabolite Fingerprinting
Datasets in the Presence of Unbalanced Metabolite Regulation, Journal of Proteome Research,
2015, 14(8):3217-3228.
[Hochrein 2016] Hochrein, J., Ph.D. thesis in preparation, Ph.D. thesis, Fakultät für Biologie und
Vorklinische Medizin, University of Regensburg, 2016.
[Hoerl and Kennard 1970] Hoerl, A. E., Kennard, R. W., Ridge regression: Biased estimation for
nonorthogonal problems, Technometrics, 1970, 12(1):55-67.
[Holmes et al. 1997] Holmes, E., Foxall, P. J. D., Spraul, M., Farrant, R. D., Nicholson, J. K., Lindon,
J. C., 750 MHz 1H NMR spectroscopy characterisation of the complex metabolic pattern of urine
from patients with inborn errors of metabolism: 2-hydroxyglutaric aciduria and maple syrup
urine disease, Journal of Pharmaceutical and Biomedical Analysis, 1997, 15:1647-1659.
[Homans 1995] Homans, S. W., A Dictionary of Concepts in NMR, Oxford Science Publications,
Oxford 1995.
[Huber et al. 2002] Huber, W., Heydebreck, A. V., Sültmann, H., Poustka, A., Vingron, M., Variance
Stabilisation Applied to Microarray Data Calibration and to the Quantification of Differential
Expression, Bioinformatics, 2002, 18:S96-S104.
[Hummel et al. 2006] Hummel, M., Bentink, S., Berger, H., Klapper, W., Wessendorf, S., Barth, T.
F., Bernd, H.-W., Cogliatti, S. B., Dierlamm, J., Feller, A. C., Hansmann, M.-L., Haralambieva,
E., Harder, L., Hasenclever, D., Kühn, M., Lenze, D., Lichter, P., Martin-Subero, J. I., Möller,
P., Müller-Hermelink, H.-K., Ott, G., Parwaresch, R. M., Pott, C., Rosenwald, A., Rosolowski,
M., Schwaenen, C., Stürzenhofecker, B., Szczepanowski, M., Trautmann, H., Wacker, H.-H.,
Spang, R., Loeﬄer, M., Trümper, L., Stein, H., Siebert, R., A biologic definition of Burkitt’s
lymphoma from transcriptional and genomic profiling, N. Engl. J. Med., 2006, 354:2419-2430.
262
[Husson and Josse 2013] Husson, F., Josse, J., missMDA: Handling missing values with/in multivari-
ate data analysis (principal component methods), 2013, http://CRAN.R-project.org/package=
missMDA.
[Ideker et al. 2001] Ideker, T., Galitski, T., Hood, L., A New Approach to Decoding Life: Systems
Biology, Annu. Rev. Genomics Hum. Genet., 2001, 2:343-72.
[Idrovo et al. 2012] Idrovo, J.-P., Yang, W.-L., Matsuda, A., Nicastro, J., Coppa, G. F., Wang, P.,
Post-treatment with the combination of 5-aminoimidazole-4-carboxyamide ribonucleoside and
carnitine improves renal function after ischemia/reperfusion injury, Shock, 2012, 37:39-46.
[Imai et al. 2010] Imai, E., Matsuo, S., Makino, H., Watanabe, T., Akizawa, T., Nitta, K., Iimuro, S.,
Ohashi, Y., Hishida, A., Chronic Kidney Disease Japan Cohort study: baseline characteristics
and factors associated with causative diseases and renal function, Clin. Exp. Nephrol., 2010,
14:558-570.
[Inker et al. 2012] Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene,
T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., Coresh, J., Levey, A., S., Estimating
Glomerular Filtration Rate from Serum Creatinine and Cystatin C, New England Journal of
Medicine, 2012, 367(1):20-29.
[Iseki et al. 2003] Iseki, K., Ikemiya, Y., Iseki, C., Takishita, S., Proteinuria and the risk of developing
end-stage renal disease, Kidney International, 2003, 63:1468-1474.
[Itoh et al. 2012] Itoh, Y., Ezawa, A., Kikuchi, K., Tsuruta, Y., Niwa, T., Protein-bound uremic
toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry
and their effects on endothelial ROS production, Analytical and Bioanalytical Chemistry, 2012,
403:1841-1850.
[Jager et al. 2007] Jager, K. J., Stel, V. S., Wanner, C., Zoccali, C., Dekker, F. W., The valuable
contribution of observational studies to nephrology, Kidney International, 2007, 72:671-675.
[James et al. 1972] James, M. O., Smith, R. L., Williams, R. T., Reidenberg, M., The conjugation of
phenylacetic acid in man, sub-human primates and some non-primate species, Proceedings of
the Royal Society of London B: Biological Sciences, 1972, 182:25-35.
[James et al. 2013] James, G., Witten, D., Hastie, T., Tibshirani, R., An Introduction to Statistical
Learning, Springer, New York 2013.
[Jha et al. 2013] Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R.,
Wang, A. Y.-M., Yang, C.-W., Chronic kidney disease: global dimension and perspectives,
Lancet, 2013, 382:260-272.
[Joyce and Palsson 2006] Joyce, A. R., Palsson, B. Ø., The model organism as a system: integrating
‘omics’ data sets, Nature Reviews | Molecular Cell Biology, 2006, 7:198-210.
[Kang et al. 2011] Kang, S. M., Park, J. C., Shin, M. J., Lee, H., Oh, J., Hwang, G. S., Chung, J. H.,
1H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart
failure, Clinical Biochemistry, 2011, 44(4):293-299.
263
9 Bibliography
[KDIGO workgroup 2012] Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney In-
jury Work Group, KDIGO Clinical Practice Guideline for Acute Kidney Injury, Kidney Inter-
national, Suppl. 2012, 2:1-138.
[KDIGO workgroup 2013] Kidney Disease: Improving Global Outcomes (KDIGO) CKDWork Group,
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney
Disease, Kidney International, Suppl. 2013, 3:1-150.
[Keane et al. 2003] Keane, W. F., Brenner, B. M., de Zeeuw, D., Grunfeld, J.-P., McGill, J., Mitch,
W. E., Ribeiro, A. B., Shahinfar, S., Simpson, R. L., Snapinn, S. M., Toto, R., for the RENAAL
Study Investigators, The risk of developing end-stage renal disease in patients with type 2 diabetes
and nephropathy: The RENAAL Study, Kidney International, 2003, 63:1499-1507.
[Kidher et al. 2014] Kidher, E., Harling, L., Ashrafian, H., Naase, H., Chukwuemeka, A., Ander-
son, J., Francis, D. P., Athanasiou, T., Pulse wave velocity and neutrophil gelatinase-associated
lipocalin as predictors of acute kidney injury following aortic valve replacement, J Cardiothorac
Surg, 2014, 9(1):89.
[Klein et al. 2010] Klein, M. S., Almstetter, M. F., Schlamberger, G., Nürnberger, N., Dettmer, K.,
Oefner, P. J., Meyer, H. H. D., Wiedemann, S., Gronwald, W., Nuclear magnetic resonance
and mass spectrometry-based milk metabolomics in dairy cows during early and late lactation, J
Dairy Sci, 2010, 93:1539-1550.
[Klein 2011] Klein, M. S., Analysis of Metabolic Disorders of Dairy Cows employing multidimensional
and multinuclear NMR Spectroscopy, Ph.D. thesis, Fakultät für Biologie und Vorklinische Medi-
zin, University of Regensburg, 2011.
[Klein et al. 2011] Klein, M. S., Dorn, C., Saugspier, M., Hellerbrand, C., Oefner, P. J., Gronwald, W.,
Discrimination of steatosis and NASH in mice using nuclear magnetic resonance spectroscopy,
Metabolomics, 2011, 7(2):237-246.
[Klein et al. 2012] Klein, M. S., Buttchereit, N., Miemczyk, S., Immervoll, A.-K., Louis, C., Wiede-
mann, S., Junge, W., Thaller, G., Oefner, P. J., Gronwald, W., NMR Metabolic Analysis of Dairy
Cows Reveals Milk Glycerophosphocholine to Phosphocholine Ratio as Prognostic Biomarker for
Risk of Ketosis, J Prot Res., 2012, 11(2):1373-1381.
[Klein et al. 2013] Klein, M. S., Oefner, P. J., Gronwald, W., MetaboQuant: a tool combining indi-
vidual peak calibration and outlier detection for accurate metabolite quantification in 1D 1H and
1H-13C HSQC NMR spectra, BioTechniques, 2013, 54:251-256.
[Kohl et al. 2012] Kohl, S. M., Klein, M. S., Hochrein, J., Oefner, P. J., Spang, R., Gronwald,
W., State-of-the art data normalization methods improve NMR-based metabolomic analysis,
Metabolomics, 2012, 8(1):146-160.
[Kosmides et al. 2013] Kosmides, A. K., Kamisoglu, K., Calvano, S. E., Corbett, S. A., Androulakis,
O. P., Metabolomic Fingerprinting: Challenges and Opportunities, Crit Rev Biomed Eng., 2013,
41(3):205-221.
[Kuhlmann et al. 2003] Kuhlmann, U., Walb, D., Luft, F. D., (Ed.), Nephrologie, Thieme Publisher,
Stuttgart 2003, 4th edition.
264
[Kumar et al. 1980] Kumar, A., Ernst, R. R., Wüthrich, K., A two-dimensional Nuclear Over-
hauser Enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-
relaxation networks in biological macromolecules, Biochemical and Biophysical Research Com-
munications, 1980, 95(1):1-6.
[Lameire et al. 2011] Lameire, N. H., Vanholder, R. C., Van Biesen, W. A., How to use biomarkers
efficiently in acute kidney injury, Kidney International, 2011, 79:1047-1050.
[Lameire et al. 2013] Lameire, N. H., Bagga, A., Cruz, D., De Maeseneer, J., Endre, Z., Kellum, J.
A., Liu, K. D., Mehta, R. L., Pannu, N., Van Biesen, W., Vanholder, R., Acute kidney injury:
an increasing global concern, Lancet, 2013, 382:170-179.
[Lassnigg et al. 2004] Lassnigg, A., Schmidlin, D., Mouhieddine, M., Bachmann, L. M., Druml, W.,
Bauer, P., Hiesmayr, M., Minimal changes of serum creatinine predict prognosis in patients after
cardiothoracic surgery: a prospective cohort study, J Am Soc Nephrol., 2004, 15:1597-1605.
[Levey et al. 1999] Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., for
MDRD Study Group, A More Accurate Method to Estimate Glomerular Filtration Rate from
Serum Creatinine: A New Prediction Equation, Ann. Intern. Med., 1999, 130(6):461-470.
[Levey et al. 2009] Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y., Castro, A. F., Feldman,
H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., Coresh, J., for the Chronic Kid-
ney Disease Epidemiology Collaboration (CKD-EPI), A New Equation to Estimate Glomerular
Filtration Rate, Ann. Intern. Med., 2009, 150(9):604-612.
[Lewis et al. 2011] Lewis, E. F., Pfeffer, M. A., Feng, A., Uno, H., McMurray, J. J. V., Toto, R.,
Gandra, S. R., Solomon, S. D., Moustafa, M., Macdougall, I. C., Locatelli, F., Parfrey, P. S. for
the TREAT Investigators, Darbepoetin Alfa Impact on Health Status in Diabetes Patients with
Kidney Disease: A Randomized Trial, Clin. J. Am. Soc. Nephrol. 2011, 6:845-855.
[Liaw and Wiener 2002] Liaw, A., Wiener, M., Classification and Regression by randomForest, R.
News, 2002, 2(3):18-22.
[Linstrom and Mallard 2016] P.J. Linstrom and W.G. Mallard (eds.), NIST Chemistry WebBook,
NIST Standard Reference Database Number 69, National Institute of Standards and Technology,
Gaithersburg MD, 20899, http://webbook.nist.gov, (retrieved March 8, 2016).
[Liu et al. 2012] Liu, Y., Yan, S., Ji, C., Dai, W., Hu, W., Zhang, W., Mei, C., Metabolomic changes
and protective effect of (L)-carnitine in rat kidney ischemia/reperfusion injury, Kidney and
Blood Pressure Research, 2012, 35:373-381.
[Livingston 2004] Livingston, E. H., Who Was Student and Why Do We Care So Much about His
t-Test?, Journal of Surgical Research, 2004, 118:58-65.
[Livingston and Cassidy 2005] Livingston, E. H., Cassidy, L., Statistical Power and Estimation of the
Number of Required Subjects for a Study Based on the t-Test: A Surgeon’s Primer, Journal of
Surgical Research, 2005, 126:149-159.
[Lohninger et al. 2005] Lohninger, A., Pittner, G., Pittner, F., L-Carnitine: New aspects of a known
compound-a brief survey, Monatshefte Chemie, 2005, 136:1255-1268.
265
9 Bibliography
[Lottaz et al. 2008] Lottaz, C., Kostka, D., Markowetz, F., Spang, R., Computational Diagnostics with
Gene Expression Profiles, in Keith, Jonathan M. (ed.), Bioinformatics: Structure, Function and
Applications, Humana Press, Totowa, NJ, USA, 2008, pp. 281-296.
[Macedo et al. 2011] Macedo, E., Malhotra, R., Claure-Del Granado, R., Fedullo, P., Mehta, R. L.,
Defining urine output criterion for acute kidney injury in critically ill patients, Nephrol. Dial.
Transplant., 2011, 26:509-515.
[Macedo and Mehta 2013] Macedo, E., Mehta, R. L., Measuring renal function in critically ill pa-
tients: tools and strategies for assessing glomerular filtration rate, Curr. Opin. Crit. Care, 2013,
19:560-566.
[Maher et al. 2007] Maher, A. D., Zirak, S. F. M., Holmes, E., Nicholson, J. K., Experimental and
Analytical Variation in Human Urine in 1H NMR Spectroscopy-Based Metabolic Phenotyping
Studies, Anal. Chem., 2007, 79:5204-5211.
[Mardia et al. 1979] Mardia, K. V., Kent, J. T., Bibby, J. M., Multivariate Analysis, Academic Press,
London 1979.
[Mariscalco et al. 2011] Mariscalco, G., Lorusso, R., Dominici, C., Renzulli, A., Sala, A., Acute Kidney
Injury: A Relevant Complication after Cardiac Surgery, Society of Thoracic Surgeons, 2011,
92(4):1539-1547.
[McKay 2011] McKay, R. T. How the 1D-NOESY suppresses solvent signal in metabonomics NMR
spectroscopy: An examination of the pulse sequence components and evolution, Concepts Magn.
Reson., 2011, 38A:197-220.
[McMurray et al. 2011] McMurray, J. J. V., Uno, H., Jarolim, P., Desai, A. S., de Zeeuw, D., Eckardt,
K.-U., Ivanovich, P., Levey, A. S., Lewis, E. F., McGill, J. B., Parfrey, P., Parving, H.-H., Toto,
R. M., Solomon, S. D., Pfeffer, M. A., Predictors of fatal and nonfatal cardiovascular events in
patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the
Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT), Am.
Heart J., 2011, 162:748-755.e3.
[Mehta and Patel 1986] Mehta, C. R., Patel, N. R., Algorithm 643. FEXACT: A Fortran subroutine
for Fisher’s exact test on unordered r*c contingency tables, ACM Transactions on Mathematical
Software, 1986, 12:154-161.
[Mehta et al. 2007] Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock,
D. G., Levin, A., Acute Kidney Injury Network, Acute Kidney Injury Network: report of an
initiative to improve outcomes in acute kidney injury, Critical Care, 2007, 11(2):43-51.
[Meiboom and Gill 1958] Meiboom, S., Gill, D., Modified Spin-Echo Method for Measuring Nuclear
Relaxation Times, The Review of Scientific Instruments, 1958, 29(8):688-691.
[Menze et al. 2009] Menze, B. H., Kelm, B. M., Masuch, R., Himmelreich, U., Bachert, P., Petrich,
W., Hamprecht, F. A., A comparison of random forest and its Gini importance with standard
chemometric methods for the feature selection and classification of spectral data, BMC Bioinfor-
matics, 2009, 10:213.
266
[Merziger et al. 2004] Merziger, G., Mühlbach, G., Wille, D., Wirth, T., Formeln + Hilfen zur höheren
Mathematik, Binomi Press, Hannover 2004.
[Mix et al. 2005] Mix, T.-C. H., Brenner, R. M., Cooper, M. E., de Zeeuw, D., Ivanovich, P., Levey,
A. S., McGill, J. B., McMurray, J. J. V., Parfrey, P. S., Parving, H.-H., Pereira, B. J. G.,
Remuzzi, G., Singh, A. K., Solomon, S. D., Stehman-Breen, C., Toto, R. D., Pfeffer, M. A.,
Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving
the management of cardiovascular risk in patients with chronic kidney disease, Am. Heart J.,
2005, 149:408-413.
[Motulsky 1995] Motulsky, H., Intuitive Biostatistics, Oxford University Press, New York, Oxford,
1995.
[Mukherjee et al. 2003] Mukherjee, S., Golland, P., Panchenko, P., Permutation tests for classifica-
tion, Cambridge: Massachusetts Institute of Technology, 2003, Al-Memo, 2003-19.
[Musso et al. 2009] Musso, C. G., Michelángelo, H., Vilas, M, Reynaldi, J., Martinez, B., Algranati,
L., Nún˜ez, J. F. M., Creatinine reabsorption by the aged kidney, Int. Urol. Nephrol., 2009,
41(3):727-731.
[Neild et al. 1997] Neild, G. H., Foxall, P. J. D., Lindon, J. C., Holmes, E. C., Nicholson, J. K.,
Uroscopy in the 21st Century: high-field NMR spectroscopy, Nephrol. Dial. Transplant., 1997,
12:404-417.
[Nicholson et al. 1983] Nicholson, J. K., Buckingham, M. J., Sadler, P. J., High resolution 1H n.m.r.
studies of vertebrate blood and plasma, Biochem. J., 1983, 211:605-615.
[Nicholson 2006] Nicholson, J. K., Global systems biology, personalized medicine and molecular epi-
demiology, Molecular Systems Biology, 2006, 2:52, doi:10.1038/msb4100095.
[Nicholson and Lindon 2008] Nicholson, J. K., Lindon, J. C., Metabonomics, Nature, 2008,
455(23):1054-1056.
[Ostermann 2014] Ostermann, M., Diagnosis of acute kidney injury: Kidney Disease Improving Global
Outcomes criteria and beyond, Curr. Opin. Crit. Care, 2014, 20:581-587.
[O’Toole and Sedor 2014] O’Toole, J. F., Sedor, J. R., Kidney disease: new technologies translate
mechanisms to cure, J. Clin. Invest., 2014, 124(6):2294-2298.
[Palmer et al. 2011] Palmer, S. C., Sciancalepore, M., Strippoli, G. F. M., Trial Quality in Nephrology:
How Are We Measuring Up?, AM. J. Kidney Dis., 2011, 58(3):335-337.
[Parikh et al. 2005] Parikh, C. R., Abraham, E., Ancukiewicz, M., Edelstein, C. L., Urine IL-18 is
an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care
unit, Journal of the American Society of Nephrology, 2005, 16(10):3046-3052.
[Parikh et al. 2011] Parikh, C. R., Devarajan, P., Zappitelli, M., Sint, K., Thiessen-Philbrook, H.,
Li, S., Kim, R. W., Koyner, J. L., Coca, S. G., Edelstein, C. L., Shlipak, M. G., Garg, A. X.,
Krawczeski, C. D., Postoperative Biomarkers Predict Acute Kidney Injury and Poor Outcomes
after Pediatric Cardiac Surgery, Journal of the American Society of Nephrology, 2011, 22:1737-
1747.
267
9 Bibliography
[Patefield 1981] Patefield, W. M., Algorithm AS159. An efficient method of generating r × c tables
with given row and column totals, Applied Statistics, 1981, 30:91-97.
[Pfeffer et al. 2009a)] Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D.,
Eckardt, K.-U., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J., McMur-
ray, J. J. V., Parfrey, P., Parving, H.-H., Remuzzi, G., Singh, A. K., Solomon, S. D., Toto, R.,
Uno, H., on behalf of the TREAT investigators, Baseline Characteristics in the Trial to Reduce
Cardiovascular Events With Aranesp Therapy (TREAT), American Journal of Kidney Diseases,
2009, 54(1):59-69.
[Pfeffer et al. 2009b)] Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D.,
Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill,
J. B., McMurray, J. J. V., Parfrey, P., Parving, H.-H., Remuzzi, G., Singh, A. K., Solomon, S. D.,
Toto, R., on behalf of the TREAT investigators, A Trial of Darbepoetin Alfa in Type 2 Diabetes
and Chronic Kidney Disease, New England Journal of Medicine, 2009, 361(21):2019-2032.
[Phrommintikul et al. 2007] Phrommintikul, A., Haas, S. J., Elsik, M., Krum, H., Mortality and
target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with
erythropoietin: a meta-analysis, Lancet, 2007, 369(9559):381-388.
[Pollard et al. 2005] Pollard, K. S., Dudoit, S., van der Laan, M. J., Multiple Testing Procedures: R
multtest Package and Applications to Genomics, in Bioinformatics and Computational Biology
Solutions Using R and Bioconductor, Gentleman, R., Carey, V., Huber, W., Irizarry, R., Dudoit,
S. (ed.), Springer (Statistics for Biology and Health Series), 2005, pp. 251-272.
[Psychogios et al. 2011] Psychogios, N., Hau, D. D., Peng, J., Guo, A. C., Mandal, R., Bouatra,
S., Sinelnikov, I., Krishnamurthy, R., Eisner, R., Gautam, B., Young, N., Xia, J., Knox, C.,
Dong, E., Huang, P., Hollander, Z., Pedersen, T. L., Smith, S. R., Bamforth, F., Greiner, R.,
McManus, B., Newman, J. W., Goodfriend, T., Wishart, D. S., The Human Serum Metabolome,
PLoS ONE, 2011, 6(2):e16957.
[Purnell et al. 2013] Purnell, T. S., Auguste, P., Crews, D. C., Lamprea-Montealegre, J., Olufade, T.,
Greer, R., Ephraim, P., Sheu, J., Kostecki, D., Powe, N. R., Rabb, H., Jaar, B., Boulware, L. E.,
Comparison of Life Participation Activities Among Adults Treated by Hemodialysis, Peritoneal
Dialysis, and Kidney Transplantation: A Systematic Review, Am J Kidney Dis, 2013, 62(5):953-
973.
[Rao and Pereira 2003] Rao, M., Pereira, B. J. G., Prospective trials on anemia of chronic disease:
The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT), Kidney Interna-
tional, 2003, 64(Supplement 87):S12-S19.
[R Core Team 2014] R Core Team, R: A language and environment for statistical computing, R Foun-
dation for Statistical Computing, Vienna, Austria, 2014, http://www.R-project.org.
[Rosner and Okusa 2006] Rosner, M. H., Okusa, M. D., Acute Kidney Injury Associated with Cardiac
Surgery, Clin. J. Am. Soc. Nephrol., 2006, 1:19-32.
[Ross et al. 2007] Ross, A., Schlotterbeck, G., Dieterle, F., Senn, H., NMR Spectroscopy Techniques
for Application to Metabonomics, in Lindon, J. C., Nicholson, J. K., Holmes, E., (eds.),
268
NMR Spectroscopy Techniques for Application to Metabonomics, Elsevier BV: Amsterdam, The
Netherlands, 2007, pp. 55-112.
[Schlecht et al. 2016] Schlecht, I., Gronwald, W., Behrens, G., Baumeister, S., Hertel, J., Hochrein,
J., Zacharias, H. U., Fischer, B., Oefner, P. J., Leitzmann, M. F., Visceral adipose tissue but not
subcutaneous adipose tissue is associated with urine and serum metabolites, 2016, submitted to
Int. J. of Obesity.
[Selma et al. 2009] Selma, M. V., Espín, J. C., Tomás-Barberán, F. A., Interaction between phenolics
and gut microbiota: Role in human health, Journal of Agricultural and Food Chemistry, 2009,
57:6485-6501.
[Shapiro and Wilk 1965] Shapiro, S. S., Wilk, M. B., An Analysis of Variance Test for Normality
(Complete Samples), Biometrika, 1965, 52(3/4):591-611.
[Shaw 2012] Shaw, A., Update on acute kidney injury after cardiac surgery, The Journal of Thoracic
and Cardiovascular Surgery, 2012, 143:676-681.
[Siew and Davenport 2015] Siew, E. D., Davenport, A., The growth of acute kidney injury: a rising
tide or just closer attention to detail?, Kidney International, 2015, 87:46-61.
[Sing et al. 2005] Sing, T., Sander, O., Beerenwinkel, N., Lengauer, T., ROCR: visualizing classifier
performance in R, Bioinformatics, 2005, 21(20):7881.
[Singh et al. 2006] Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., Donal
Reddan, D., for the CHOIR Investigators, Correction of Anemia with Epoetin Alfa in Chronic
Kidney Disease, N. Engl. J. Med., 2006, 355:2085-2098.
[Singh 2010] Singh, A. K., Does TREAT Give the Boots to ESAs in the Treatment of CKD Anemia?,
J. Am. Soc. Nephrol., 2010, 21:2-6.
[Skali et al. 2011] Skali, H., Parving, H.-H., Parfrey, P. S., Burdmann, E. A., Lewis, E. F., Ivanovich,
P., Keithi-Reddy, S. R., McGill, J. B., McMurray, J. J. V., Singh, A. K., Solomon, S. D., Uno, H.,
Pfeffer, M. A., on behalf of the TREAT Investigators, Stroke in Patients With Type 2 Diabetes
Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa, Circulation,
2011, 124:2903-2908.
[Skali et al. 2013] Skali, H., Lin, J., Pfeffer, M. A., Chen, C.-Y., Cooper, M. E., McMurray, J. J. V.,
Nissenson, A. R., Remuzzi, G., Rossert, J., Parfrey, P. S., Scott-Douglas, N. W., Singh, A. K.,
Toto, R., Uno, H., Ivanovich, P., Hemoglobin Stability in Patients With Anemia, CKD, and Type
2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events with Aranesp
Therapy) Placebo Arm, Am. J. Kidney Dis., 2013, 61(2):238-46.
[Smith et al. 2005] Smith, C. A., O’Maille, G., Want, E. J., Qin, C., Trauger, S. A., Brandon, T.
R., Custodio, D. E., Abagyan, R., Siuzdak, G., METLIN: a metabolite mass spectral database,
Ther. Drug. Monit., 2005, 27:747-751.
[Smyth 2005] Smyth, G. K., Limma: Linear models for microarray data, in Gentleman, R., Carey, V.,
Dudoit, S., Irizarry, R., Huber, W. (eds) Bioinformatics and Computational Biology Solutions
using R and Bioconductor, Springer, New York, 2005, pp. 397-420.
269
9 Bibliography
[Snoeijs et al. 2011] Snoeijs, M. G. J., Vaahtera, L., de Vries, E. E., Schurink, G. W. H, Haenen,
G. R. M. M., Peutz-Kootstra, C. J., Buurman, W. A., van Heurn, L. W. E., Parkkinen, J.,
Addition of a water-soluble propofol formulation to preservation solution in experimental kidney
transplantation, Transplantation, 2011, 92:296-302.
[Solomon 1955] Solomon, I., Relaxation processes in a system of two spins, Physical Review, 1955,
99(2): 559.
[Solomon et al. 2010] Solomon, S. D., Uno, H., Lewis, E. F., Eckardt, K.-U., Lin, J., Burdmann, E.
A., de Zeeuw, D., Ivanovich, P., Levey, A. S., Parfrey, P., Remuzzi, G., Singh, A. K., Toto, R.,
Huang, F., Rossert, J., McMurray, J. J., Pfeffer, M. A., for the Trial to Reduce Cardiovascular
Events with Aranesp Therapy (TREAT) Investigators, Erythropoietic Response and Outcomes
in Kidney Disease and Type 2 Diabetes, N. Engl. J. Med., 2010, 363(12):1146-55.
[Somashekar et al. 2006] Somashekar, B. S., Ijare, O. B., Nagana Gowda, G. A., Ramesh, V., Gupta,
S., Khetrapal, C. L., Simple pulse-acquire NMR methods for the quantitative analysis of calcium,
magnesium and sodium in human serum, Spectrochim. Acta A Mol. Biomol. Spectrosc., 2006,
65:254-260.
[Star 1998] Star, R. A., Treatment of acute renal failure, Kidney International, 1998, 54:1817-1831.
[Stevens et al. 2006] Stevens, L. A., Coresh, J., Greene, T., Levey, A. S., Assessing Kidney Function
- Measured and Estimated Glomerular Filtration Rate, New England Journal of Medicine, 2006,
354(23):2473-2483.
[Stevens and Levey 2009] Stevens, L. A., Levey, A. S., Measured GFR as a Confirmatory Test for
Estimated GFR, J. Am. Soc. Nephrol., 2009, 20:2305-2313.
[Strippoli et al. 2007] Strippoli, G. F. M., Tognoni, G., Navaneethan, S. D., Nicolucci, A., Craig, J.
C., Haemoglobin targets: we were wrong, time to move on, Lancet, 2007, 369(9559):346-50.
[Sun et al. 2012] Sun, J., Shannon, M., Ando, Y., Schnackenberg, L. K., Khan, N. A., Portilla, D.,
Beger, R. D., Serum Metabolomic Profiles from Patients with Acute Kidney Injury: A Pilot
Study, J.Chromatogr.B., 2012, 893:107-113.
[Thiese 2014] Thiese, M. S., Observational and interventional study design types; an overview, Bio-
chemia Medica, 2014, 24(2):199-210.
[Tibshirani 1996] Tibshirani, R., Regression Shrinkage and Selection via the LASSO, Journal Royal
Statistical Society B, 1996, 58(1):267-288.
[Titze et al. 2015] Titze, S., Schmid, M., Köttgen, A., Busch, M., Floege, J., Wanner, C., Kronenberg,
F., Eckardt, K. U., Zacharias, H., Gronwald, W., Oefner, P. J., et al., Disease burden and risk
profile in referred patients with moderate chronic kidney disease: composition of the German
Chronic Kidney Disease (GCKD) cohort, Nephrol. Dial. Transplant., 2015, 30:441-451.
[Tonelli et al. 2011] Tonelli, M., Wiebe, N., Knoll, G., Bello, A., Browne, S., Jadhav, D., Klarenbach,
S., Gill, J., Systematic Review: Kidney Transplantation Compared With Dialysis in Clinically
Relevant Outcomes, American Journal of Transplantation, 2011, 11:2093-2109.
270
[Treuting and Kowalewska 2012] Treuting, P. M., Kowalewska, J., Urinary System in Treuting, P. M.,
Dintzis, S. M., (Ed.), Comparative Anatomy and Histology, Academic Press Elsevier, London,
Waltham, San Diego, 2012 (1st edition).
[Trygg and Wold 2002] Trygg, J., Wold, S., Orthogonal Projections to Latent Structures, J. Chemo-
metrics, 2002, 16:119-128.
[Tzoulaki et al. 2014] Tzoulaki, I., Ebbels, T. M. D., Valdes, A., Elliott, P., Ioannidis, J. P. A., Design
and Analysis of Metabolomics Studies in Epidemiologic Research: A Primer on -Omic Tech-
nologies, American Journal of Epidemiology, 2014, 180(2): 129-139.
[van den Berg et al. 2006] van den Berg, R. A., Hoefsloot, H. C. J., Westerhuis, J. A., Smilde, A. K.,
van der Werf, M. J., Centering, scaling, and transformations: improving the biological informa-
tion content of metabolomics data, BMC Genomics, 2006, 7:142.
[van de Poll et al. 2004] van de Poll, M. C. G., Soeters, P. B., Deutz, N. E. P., Fearon, K. C. H.,
Dejong, C. H. C., Renal metabolism of amino acids: Its role in interorgan amino acid exchange,
American Journal of Clinical Nutrition, 2004, 79:185-197.
[Varma and Simon 2006] Varma, S., Simon, R., Bias in Error Estimation when Using Cross-
Validation for Model Selection, BMC-Bioinformatics, 2006, 7:91.
[Vaz and Wanders 2002] Vaz, F. M., Wanders, R. J. A., Carnitine biosynthesis in mammals, Bio-
chemical Journal, 2002, 361:417-429.
[Venables and Ripley 2002] Venables, W. N., Ripley, B. D., Modern Applied Statistics with S,
Springer-Verlag, 2002.
[Wagener et al. 2006] Wagener, G., Jan, M., Kim, M., Mori, K., Barasch, J. M., Sladen, R. N., Lee,
H. T., Association between increases in urinary neutrophil gelatinase-associated lipocalin and
acute renal dysfunction after adult cardiac surgery, The Journal of the American Society of
Anesthesiologists, 2006, 105(3):485-491.
[Warrack et al. 2008] Warrack, B. M., Hnatyshyn, S., Ott, K.-H., Reily, M. D., Sanders, M., Zhang,
H., Drexler, D. M., Normalization strategies for metabonomic analysis of urine samples, Journal
of Chromatography B, 2009, 877:547-552.
[Weiss et al. 2011] Weiss, R. H., Kim, K., Metabolomics in the study of kidney diseases, Nature Re-
views | Nephrology, 2011, 8(1):22-33.
[Weitz et al. 2006] Weitz, J., Koch, M., Mehrabi, A., Schemmer, P., Zeier, M., Beimler, J., Büch-
ler, M., Schmidt, J., Living-donor kidney transplantation: risks of the donor - benefits of the
recipient, Clin Transplant, 2006, 20(Suppl. 17):13-16.
[Westhuyzen et al. 2003] Westhuyzen, J., Endre, Z. H., Reece, G., Reith, D. M., Saltissi, D., Morgan,
T. J., Measurement of tubular enzymuria facilitates early detection of acute renal impairment
in the intensive care unit, Nephrology Dialysis Transplantation, 2003, 18(3):543-551.
[Wilkinson and Rogers 1973] Wilkinson, G. N. and Rogers, C. E., Symbolic descriptions of factorial
models for analysis of variance, Applied Statistics, 1973,*22*:392-9.
271
9 Bibliography
[Wishart et al. 2007] Wishart, D. S., Tzur, D., Knox, C., Querengesser, L., HMDB: The Human
Metabolome Database, Nucl. Acids Res., 2007, 35, D521.
[Wishart 2008] Wishart, D. S., Metabolomics: A Complementary Tool in Renal Transplantation, in
Thongboonkerd, V. (ed.), Proteomics in Nephrology - Towards Clinical Applications, Contrib.
Nephrol., Karger Press, Basel, 2008, vol. 160:76-87.
[Workman et al. 2002] Workman, C., Jensen, L. J., Jarmer, H., Berka, R., Gautier, L., Nielser, H. B.,
Saxild, H. H., Nielsen, C., Brunak, S., Knudsen, S., A New Non-Linear Normalization Method
for Reducing Variability in DNA Microarray Experiments, Genome Biol., 2002, 3, research0048.
[Wyckoff and Augoustides 2012] Wyckoff, T., Augoustides, J. G. T., Advances in Acute Kidney In-
jury Associated with Cardiac Surgery: The Unfolding Revolution in Early Detection, Journal of
Cardiothoracic and Vascular Anesthesia, 2012, 26(2): 340-345.
[Zacharias 2012] Zacharias, H. U., Investigation of Acute Kidney Injury after Cardiac Surgery by NMR
Spectroscopy and Machine Learning Methods, M.Sc. thesis in physics, Institute of Functional
Genomics, University of Regensburg, March 2012.
[Zacharias et al. 2013a)] Zacharias, H. U., Schley, G., Hochrein, J., Klein, M. S., Köberle, C.,
Eckardt, K.-U., Willam, C., Oefner, P. J., Gronwald, W., Analysis of human urine reveals
metabolic changes related to the development of acute kidney injury following cardiac surgery,
Metabolomics, 2013, 9(3):697-707.
[Zacharias et al. 2013b)] Zacharias, H. U., Hochrein, J., Klein, M. S., Samol, C., Oefner, P. J., Gron-
wald, W., Current Experimental, Bioinformatic and Statistical Methods used in NMR Based
Metabolomics, Current Metabolomics, 2013, 1(3):253-268(16).
[Zacharias et al. 2015] Zacharias, H. U., Hochrein, J., Vogl, F. C., Schley, G., Mayer, F., Jeleazcov, C.,
Eckardt, K.-U., Willam, C., Oefner, P. J., Gronwald, W., Identification of Plasma Metabolites
Prognostic of Acute Kidney Injury after Cardiac Surgery with Cardiopulmonary Bypass, Journal
of Proteome Research, 2015, 14(7):2897-2905.
[Zhang et al. 2014] Zhang, A., Sun, H., Qiu, S., Wang, X., Metabolomics insights into pathophysio-
logical mechanisms of nephrology, Int. Urol. Nephrol., 2014, 46:1025-1030.
[Zuckerman and Assimos 2009] Zuckerman, J. M., Assimos, D. G., Hypocitraturia: pathophysiology
and medical management, Rev Urol., 2009, 11:134-144.
272
